<!doctype html>
<html>
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover">
  <title>APEX & Trust Prototype</title>
  <link rel="stylesheet" href="../../apex_trust_panel.css">
  <style>
    @keyframes ticker {
      0% { transform: translateX(0); }
      100% { transform: translateX(-50%); }
    }
    @media (max-width: 768px) {
      #scorecard-ticker { animation: ticker 15s linear infinite; }
    }
  </style>
</head>
<body>
  <!-- CONSOLIDATED STICKY HEADER BLOCK -->
  <div style="position: sticky; top: 0; z-index: 9999; margin: 0; padding: 0; width: 100%; overflow: hidden;">
    
    <!-- Page Header -->
    <div style="background: rgb(26, 35, 54); padding: 0.3rem 1.5rem; margin: 0; border-bottom: 1px solid rgba(10, 132, 255, 0.2);">
      <div style="display: flex; align-items: center; gap: 16px;">
        <div style="font-size: 18px; font-weight: 700; color: white;">üî•APEX Intelligence Terminal</div>
      </div>
    </div>

    <!-- Stock Info Header -->
    <div id="stock-info-header" style="margin: 0; padding: 0;">
      <!-- COMPANY INFO HEADER -->
      <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.75rem; background: rgb(26, 35, 54); box-shadow: 0 2px 8px rgba(0,0,0,0.3); border-bottom: 1px solid rgba(10, 132, 255, 0.4); padding: 0.6rem 1.5rem; margin: 0; width: 100%; position: relative; border-radius: 8px 8px 0 0;">
        <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.6rem; width: 100%; overflow: hidden;">
          <!-- Ticker & Company Name (Left) -->
          <div style="flex: 1 1 auto; min-width: 100px; max-width: 180px;">
            <div id="header-ticker" style="color: white; font-size: 0.95rem; font-weight: 800; letter-spacing: 0.5px;">--</div>
            <div id="header-company" style="color: rgba(255,255,255,0.6); font-size: 0.65rem; line-height: 1; margin-top: 1px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</div>
          </div>
          
          <!-- Key Metrics (Center) - 3 columns -->
          <div style="display: flex; gap: 0.5rem; align-items: center; flex: 2 1 auto; overflow: hidden;">
            <!-- Current Price (with currency) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">
                Price <span id="header-currency" style="color: #f59e0b; font-size: 0.5rem; font-weight: 600;">--</span>
              </div>
              <div id="header-price" style="color: white; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Market Cap -->
            <div style="text-align: center; min-width: 55px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Cap</div>
              <div id="header-mcap" style="color: #10b981; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Exchange (combined Market + Exchange) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Exchange</div>
              <div id="header-exchange" style="font-size: 0.75rem; font-weight: 700; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
          </div>
        </div>
      </div>
      
      <!-- Details Row -->
      <div style="display: flex; gap: 1.5rem; font-size: 0.65rem; background: rgb(26, 35, 54); box-shadow: 0 2px 6px rgba(0,0,0,0.2); border-bottom: 1px solid rgba(10, 132, 255, 0.2); padding: 0.35rem 1.5rem 0.4rem 1.5rem; margin: 0; text-align: left; border-radius: 0 0 8px 8px;">
        <div style="display: flex; align-items: center; gap: 0.4rem; min-width: 100px;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Sector:</span>
          <span id="header-sector" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
        <div style="display: flex; align-items: center; gap: 0.4rem; flex: 1; overflow: hidden;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Ind:</span>
          <span id="header-industry" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
      </div>
    </div>

    <!-- Bloomberg Scorecard Ticker -->
    <div style="background: rgb(26, 35, 54); border-left: 3px solid #0a84ff; padding: 0.5rem 0; margin: 0; font-family: 'Courier New', monospace; font-size: 13px; letter-spacing: 0.5px; box-shadow: 0 2px 4px rgba(0,0,0,0.2); overflow: hidden; width: 100%;">
      <div id="scorecard-ticker" style="display: flex; white-space: nowrap; animation: ticker 20s linear infinite; width: max-content;">
        <div class="ticker-content" style="display: flex; align-items: center; gap: 1.5rem; padding: 0 1.5rem; flex-shrink: 0;">
          <span style="color: rgba(255,255,255,0.6); font-size: 11px; text-transform: uppercase; font-weight: 600;">SCORECARD</span>
          <span id="scorecard-apex" style="background: #10b981; color: white; padding: 6px 12px; border-radius: 6px; font-weight: 700; font-size: 13px;">APEX SCORE:--</span>
          <span id="scorecard-setup" style="color: #3B82F6; font-weight: 700;">SETUP:--</span>
          <span id="scorecard-trust" style="color: #8B5CF6; font-weight: 700;">TRUST:--</span>
          <span id="scorecard-panic" style="color: #EF4444; font-weight: 700;">PANIC:--</span>
          <span id="scorecard-comp" style="color: #F59E0B; font-weight: 700;">COMPRESSION:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-timing" style="color: #3b82f6; font-weight: 700;">TIMING:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-action" style="color: #ef4444; font-weight: 700;">ACTION:--</span>
        </div>
      </div>
    </div>
  </div>

  <div class="container">
    <!-- Narrative Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="4" width="16" height="12" stroke="#10B981" stroke-width="1.5" fill="none" rx="2"/>
        <line x1="5" y1="4" x2="5" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="15" y1="4" x2="15" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="2" y1="7" x2="18" y2="7" stroke="#10B981" stroke-width="1.5"/>
        <circle cx="8" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="12" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="16" cy="11" r="1.2" fill="#10B981"/>
      </svg>
      <span style="color: #10B981; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Company in 30 Seconds</span>
    </div>

    <!-- Narrative Card Stack -->
    <div class="card-stack" id="narrative-stack" style="position: relative; min-height: 180px; overflow: visible; touch-action: pan-y; user-select: none; margin-bottom: 30px;">
      <!-- Card 1: What They Do -->
      <div class="card component-card stack-card narrative-card" data-index="0" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(0%) scale(1); opacity: 1; pointer-events: auto; z-index: 10;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <rect x="3" y="3" width="10" height="10" stroke="#10B981" stroke-width="1.5" fill="none" rx="1"/>
            <path d="M6 3 L6 1 M10 3 L10 1 M3 6 L13 6" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
            <circle cx="8" cy="9" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">What They Do <span class="info-icon" data-field="what" data-tooltip="Company business model and core operations" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Company business model and core operations')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-what" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 2: Why It Matters -->
      <div class="card component-card stack-card narrative-card" data-index="1" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <circle cx="8" cy="8" r="6" stroke="#10B981" stroke-width="1.5" fill="none"/>
            <circle cx="8" cy="8" r="2" fill="#10B981"/>
            <path d="M8 2 L8 6 M8 10 L8 14 M2 8 L6 8 M10 8 L14 8" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Why It Matters <span class="info-icon" data-field="why" data-tooltip="Market significance and investment thesis" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Market significance and investment thesis')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-why" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 3: Current State -->
      <div class="card component-card stack-card narrative-card" data-index="2" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <path d="M2 12 L5 9 L8 11 L14 4" stroke="#10B981" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
            <circle cx="5" cy="9" r="1.5" fill="#10B981"/>
            <circle cx="8" cy="11" r="1.5" fill="#10B981"/>
            <circle cx="14" cy="4" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Current State <span class="info-icon" data-field="state" data-tooltip="Latest company situation and metrics" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Latest company situation and metrics')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-state" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Narrative Stack Navigation -->
      <div class="stack-nav" style="bottom: -35px;">
        <div class="stack-dots">
          <span class="stack-dot narrative-dot" data-index="0"></span>
          <span class="stack-dot narrative-dot" data-index="1"></span>
          <span class="stack-dot narrative-dot" data-index="2"></span>
        </div>
        <div class="stack-label" style="color: #10B981;">Company</div>
      </div>
    </div>

    <!-- Scorecard Breakdown Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="6" width="3" height="12" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="7" y="3" width="3" height="15" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="12" y="8" width="3" height="10" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="17" y="5" width="1" height="13" rx="0.5" stroke="#fff" stroke-width="1.5" fill="none"/>
        <circle cx="10" cy="1" r="1.5" fill="#fff"/>
      </svg>
      <span style="color: #fff; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Scorecard Breakdown</span>
    </div>

    <!-- Main swipeable cards -->
    <div id="component-grid"></div>

    <!-- Bloomberg Phase 2: Collapsible Sections -->
    <div class="bloomberg-sections" style="margin-top: 20px;">
      <!-- CrashDash Intelligence -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('crashdash')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(59, 130, 246, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="crashdash-arrow" style="color: #3b82f6; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px;">CrashDash Intelligence</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">INDUSTRY PATTERNS ¬∑ RECOVERY PATHS</span>
        </div>
        <div id="crashdash-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="crashdash-data">Loading...</div>
        </div>
      </div>

      <!-- Catalyst Pipeline -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('catalyst')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(16, 185, 129, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="catalyst-arrow" style="color: #10b981; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #10b981; text-transform: uppercase; letter-spacing: 0.5px;">Catalyst Pipeline</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">UPCOMING EVENTS ¬∑ TIMELINE</span>
        </div>
        <div id="catalyst-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="catalyst-data">Loading...</div>
        </div>
      </div>

      <!-- Market Tape -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('market')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(245, 158, 11, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="market-arrow" style="color: #f59e0b; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #f59e0b; text-transform: uppercase; letter-spacing: 0.5px;">Market Tape</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">SOCIAL SENTIMENT ¬∑ TRENDS</span>
        </div>
        <div id="market-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="market-data">Loading...</div>
        </div>
      </div>

      <!-- Investment Decision -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('decision')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(239, 68, 68, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="decision-arrow" style="color: #ef4444; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #ef4444; text-transform: uppercase; letter-spacing: 0.5px;">Investment Decision</span>
          </div>
          <span id="decision-status" style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">ANALYSIS ¬∑ ACTION</span>
        </div>
        <div id="decision-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="decision-data">Loading...</div>
        </div>
      </div>

      <!-- Top 5 Recent RNS -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('rns')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(6, 182, 212, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="rns-arrow" style="color: #06b6d4; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #06b6d4; text-transform: uppercase; letter-spacing: 0.5px;">Top 5 Recent RNS</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">REGULATORY NEWS ¬∑ ANNOUNCEMENTS</span>
        </div>
        <div id="rns-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="rns-data">Loading...</div>
        </div>
      </div>
    </div>

    <!-- Bloomberg Terminal Footer (Collapsible) -->
    <div id="footer-container" style="margin-top: 40px; background: linear-gradient(180deg, #0a1628 0%, #020617 100%); border: 1px solid #1e293b; border-radius: 12px; overflow: hidden; box-shadow: 0 20px 50px rgba(0,0,0,0.5);">
        <!-- Header Bar (Always Visible) -->
        <div style="background: rgba(59, 130, 246, 0.08); border-bottom: 1px solid rgba(59, 130, 246, 0.2); padding: 12px 16px; cursor: pointer;" onclick="toggleFooter()">
            <div style="display: flex; align-items: center; justify-content: space-between; gap: 8px; width: 100%;">
                <div style="display: flex; align-items: center; gap: 8px; flex: 1; min-width: 0; overflow: hidden;">
                    <div style="width: 8px; height: 8px; background: #3b82f6; border-radius: 50%; box-shadow: 0 0 12px rgba(59, 130, 246, 0.6); flex-shrink: 0;"></div>
                    <span style="font-family: 'Courier New', monospace; font-size: 12px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">APEX Intelligence Terminal</span>
                    <span id="footer-toggle-icon" style="font-size: 14px; color: #3b82f6; transition: transform 0.3s ease; flex-shrink: 0; margin-left: auto;">‚ñº</span>
                </div>
            </div>
            <div style="font-family: 'Courier New', monospace; font-size: 9px; color: rgba(255, 255, 255, 0.4); letter-spacing: 0.3px; margin-top: 6px; overflow: hidden;">
                GENERATED: <span style="color: #06b6d4;" id="footerDate"></span> ‚Ä¢ SESSION: <span style="color: #10b981;">LIVE</span>
            </div>
        </div>
        
        <!-- Collapsible Content Section -->
        <div id="footer-content" style="display: none;">
            <!-- Content Grid -->
            <div style="padding: 24px; display: grid; grid-template-columns: 1fr 1fr; gap: 24px;">
                <!-- Left Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- System Information -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #3b82f6; margin-bottom: 8px; text-transform: uppercase; letter-spacing: 1px;">System Information</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.7); display: flex; gap: 16px; flex-wrap: wrap; align-items: center;">
                            <span><span style="color: rgba(255, 255, 255, 0.4);">VERSION:</span> <span style="color: #06b6d4; font-weight: 700;">APEX v5.0</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">ENGINE:</span> <span style="color: #10b981;">CrashDash Intelligence</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">COVERAGE:</span> <span style="color: #a855f7;">LSE AIM Micro-Caps</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">SOURCES:</span> <span style="color: #ef4444;">RNS ‚Ä¢ Social ‚Ä¢ Trends</span></span>
                        </div>
                    </div>
                    
                    <!-- Risk Disclosure -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #ef4444; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Risk Disclosure</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.5); line-height: 1.6;">
                            This analysis is provided for informational purposes only and does not constitute financial advice. AIM micro-cap securities carry significant volatility and liquidity risks. Past performance does not guarantee future results. Always conduct your own due diligence and consult with a qualified financial advisor before making investment decisions.
                        </div>
                    </div>
                </div>
                
                <!-- Right Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- Platform Overview -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #10b981; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Platform Overview</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.7); line-height: 1.6;">
                            APEX Intelligence Terminal combines technical analysis, sentiment tracking, and regulatory news monitoring to identify high-probability contrarian setups in distressed micro-cap equities. Our proprietary scoring system evaluates setup quality, panic intensity, and compression patterns to surface opportunities before institutional recognition.
                        </div>
                    </div>
                    
                    <!-- Target Users -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #a855f7; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Target Users</div>
                        <div style="display: flex; flex-wrap: wrap; gap: 8px;">
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(168, 85, 247, 0.1); border: 1px solid rgba(168, 85, 247, 0.3); border-radius: 4px; color: #a855f7; font-weight: 600;">PROP TRADERS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(59, 130, 246, 0.1); border: 1px solid rgba(59, 130, 246, 0.3); border-radius: 4px; color: #3b82f6; font-weight: 600;">HEDGE FUNDS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(16, 185, 129, 0.1); border: 1px solid rgba(16, 185, 129, 0.3); border-radius: 4px; color: #10b981; font-weight: 600;">QUANT TEAMS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(239, 68, 68, 0.1); border: 1px solid rgba(239, 68, 68, 0.3); border-radius: 4px; color: #ef4444; font-weight: 600;">RESEARCH DESKS</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Bottom Bar -->
            <div style="background: rgba(2, 6, 23, 0.6); border-top: 1px solid rgba(59, 130, 246, 0.15); padding: 12px 24px;">
                <div style="display: flex; align-items: center; justify-content: space-between; flex-wrap: wrap; gap: 12px; font-family: 'Courier New', monospace; font-size: 10px;">
                    <div style="color: rgba(255, 255, 255, 0.4);">¬© 2026 APEX Intelligence ‚Ä¢ All Rights Reserved</div>
                    <div style="display: flex; align-items: center; gap: 20px; color: rgba(255, 255, 255, 0.5);">
                        <span>STATUS: <span style="color: #10b981; font-weight: 700;">‚óè OPERATIONAL</span></span>
                        <span>LATENCY: <span style="color: #06b6d4; font-weight: 700;">12ms</span></span>
                        <span>BUILD: <span style="color: #a855f7; font-weight: 700;">5.0.2</span></span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function toggleFooter() {
            const content = document.getElementById('footer-content');
            const icon = document.getElementById('footer-toggle-icon');
            
            if (content.style.display === 'none') {
                content.style.display = 'block';
                icon.style.transform = 'rotate(180deg)';
            } else {
                content.style.display = 'none';
                icon.style.transform = 'rotate(0deg)';
            }
        }

        // Mobile-friendly tooltip popover
        function showTooltipPopover(event, tooltipText) {
            event.stopPropagation();
            
            // Close any existing popover
            const existing = document.getElementById('tooltip-popover');
            if (existing) existing.remove();
            
            // Create popover
            const popover = document.createElement('div');
            popover.id = 'tooltip-popover';
            popover.style.cssText = 'position:fixed;background:rgba(20,25,40,0.98);color:#e5e7eb;padding:10px 14px;border-radius:6px;font-size:12px;line-height:1.4;max-width:250px;border:1px solid rgba(16,185,129,0.3);z-index:10000;box-shadow:0 4px 12px rgba(0,0,0,0.4);backdrop-filter:blur(8px);word-wrap:break-word';
            popover.textContent = tooltipText;
            document.body.appendChild(popover);
            
            // Position near clicked element
            const rect = event.target.getBoundingClientRect();
            popover.style.left = Math.min(rect.left, window.innerWidth - 270) + 'px';
            popover.style.top = (rect.bottom + 8) + 'px';
            
            // Close on outside click
            setTimeout(() => {
                document.addEventListener('click', closeTooltip, { once: true });
            }, 0);
        }

        function closeTooltip() {
            const popover = document.getElementById('tooltip-popover');
            if (popover) popover.remove();
        }
    </script>
  </div>
  
  <!-- Mobile Responsive Styles -->
  <style>
    @media(max-width:768px){
        body{padding:10px!important}
        .container{max-width:100%!important}
        #footer-container{margin-top:20px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:12px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:repeat(2,1fr)!important;gap:10px!important}
        div[style*="padding: 24px"]{padding:16px!important}
        div[style*="padding: 12px 16px"]{padding:10px 12px!important}
        div[style*="gap: 20px"]{gap:14px!important}
        div[style*="font-size: 11px"]{font-size:10px!important}
        div[style*="font-size: 12px"]{font-size:11px!important}
        div[style*="font-size: 13px"]{font-size:12px!important}
    }
    @media(max-width:480px){
        body{padding:6px!important}
        .container{padding:0!important;margin:0!important}
        #footer-container{margin-top:16px!important;margin-left:6px!important;margin-right:6px!important}
        #footer-container > div:first-child{padding:8px 10px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:8px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:1fr!important;gap:6px!important;padding:8px 10px!important}
        div[style*="grid-template-columns: repeat(2"]{grid-template-columns:1fr!important;gap:6px!important}
        div[style*="padding: 24px"]{padding:10px!important}
        div[style*="padding: 12px 16px"]{padding:8px 10px!important}
        div[style*="padding: 14px 16px"]{padding:8px 10px!important}
        div[style*="padding: 18px"]{padding:10px!important}
        div[style*="gap: 20px"]{gap:8px!important}
        div[style*="gap: 30px"]{gap:10px!important}
        div[style*="gap: 24px"]{gap:10px!important}
        div[style*="gap: 16px"]{gap:6px!important}
        div[style*="gap: 12px"]{gap:6px!important}
        div[style*="gap: 8px"]{gap:4px!important}
        div[style*="font-size: 9px"]{font-size:8px!important}
        div[style*="font-size: 10px"]{font-size:8px!important}
        div[style*="font-size: 11px"]{font-size:9px!important}
        div[style*="font-size: 12px"]{font-size:10px!important}
        div[style*="font-size: 13px"]{font-size:11px!important}
        div[style*="padding: 6px 12px"]{padding:4px 6px!important;font-size:7px!important}
        div[style*="line-height: 1.8"]{line-height:1.4!important}
        div[style*="line-height: 1.6"]{line-height:1.3!important}
        div[style*="line-height: 1.5"]{line-height:1.2!important}
        /* Footer system info on mobile - stack vertically and shrink */
        div[style*="display: flex; gap: 16px; flex-wrap: wrap; align-items: center"] {
          flex-direction: column!important;
          align-items: flex-start!important;
          gap: 4px!important;
          font-size: 7px!important;
        }
    }
  </style>
  
  <script>window.__APEX_PROFILE = {
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "RENX.L",
  "generated_at": "2026-02-11T23:06:44.481174Z",
  "top_card": {
    "ticker": "RENX.L",
    "company_name": "Renalytix Plc",
    "sector": "Healthcare",
    "market_cap_gbp": 18027020,
    "days_active": 440,
    "apex_score_100": 57,
    "confidence_score_100": 40,
    "ai_final_score_25": 16,
    "ai_strength": "STRONG",
    "timing_regime": "TOO_EARLY",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - TOO_EARLY timing with 57/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Renalytix Plc",
      "sector": "Healthcare",
      "industry": "Health Information Services",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 18027020,
      "current_close_price": 4.125
    },
    "basics": {
      "ticker": "RENX.L",
      "current_price": 4.125,
      "ath": 1220.0,
      "atl": 3.735,
      "ath_date": "2021-05-27",
      "atl_date": "2026-02-11",
      "week_52_high": 15.5,
      "week_52_low": 3.735,
      "week_52_high_date": "2025-09-15",
      "week_52_low_date": "2026-02-11",
      "drawdown_from_ath_pct": 99.66,
      "data_start": "2020-01-02",
      "data_end": "2026-02-11",
      "total_bars": 1544
    },
    "latest_signal": {
      "date": "2024-11-28",
      "scan_date": "2026-01-26",
      "signal_type": "EXTREME CRASH BOTTOM",
      "signal_color": "ORANGE",
      "price": 6.75,
      "drawdown_pct": 90.99,
      "ai_score": 13.0,
      "rsi": 0.0,
      "cycle_position": 0.0833,
      "holding_period_days": 440,
      "current_pnl_pct": -38.89,
      "rally_state": "accumulating",
      "distance_from_high_pct": -51.8,
      "Rally_Count": 2,
      "days_since_last_high": 7,
      "last_high_date": "2026-01-19",
      "lock_in_reached": true,
      "lock_in_date": "2025-01-06",
      "best_rally_pct": 85.19
    },
    "best_historical_signal": {
      "signal_date": "2024-01-19",
      "signal_type": "DEEP CRASH BOTTOM",
      "signal_color": "GREEN",
      "entry_price": 11.25,
      "peak_price": 74.9,
      "peak_date": "2024-02-13",
      "rally_pct": 565.78,
      "days_to_peak": 25,
      "ai_score": 10.0
    },
    "all_historical_signals": [
      {
        "signal_id": "RENX.L_2022-05-12",
        "signal_date": "2022-05-12",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 170.0,
        "current_price": 6.025,
        "current_return_pct": -96.46,
        "best_rally_pct": 7.65,
        "best_rally_date": "2022-06-09",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -96.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1355,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-05-13",
        "signal_date": "2022-05-13",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 170.0,
        "current_price": 6.025,
        "current_return_pct": -96.46,
        "best_rally_pct": 7.65,
        "best_rally_date": "2022-06-09",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -96.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1354,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-05-16",
        "signal_date": "2022-05-16",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 160.0,
        "current_price": 6.025,
        "current_return_pct": -96.23,
        "best_rally_pct": 14.37,
        "best_rally_date": "2022-06-09",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -96.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1351,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-05-17",
        "signal_date": "2022-05-17",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 160.0,
        "current_price": 6.025,
        "current_return_pct": -96.23,
        "best_rally_pct": 14.37,
        "best_rally_date": "2022-06-09",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -96.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1350,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-05-19",
        "signal_date": "2022-05-19",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 160.0,
        "current_price": 6.025,
        "current_return_pct": -96.23,
        "best_rally_pct": 14.37,
        "best_rally_date": "2022-06-09",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -96.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1348,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-05-24",
        "signal_date": "2022-05-24",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 142.5,
        "current_price": 6.025,
        "current_return_pct": -95.77,
        "best_rally_pct": 28.42,
        "best_rally_date": "2022-06-09",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -96.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1343,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-05-26",
        "signal_date": "2022-05-26",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 140.0,
        "current_price": 6.025,
        "current_return_pct": -95.7,
        "best_rally_pct": 30.71,
        "best_rally_date": "2022-06-09",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -96.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1341,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-05-27",
        "signal_date": "2022-05-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 140.0,
        "current_price": 6.025,
        "current_return_pct": -95.7,
        "best_rally_pct": 30.71,
        "best_rally_date": "2022-06-09",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -96.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1340,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-05-30",
        "signal_date": "2022-05-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 148.0,
        "current_price": 6.025,
        "current_return_pct": -95.93,
        "best_rally_pct": 23.65,
        "best_rally_date": "2022-06-09",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -96.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1337,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-05-31",
        "signal_date": "2022-05-31",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 147.5,
        "current_price": 6.025,
        "current_return_pct": -95.92,
        "best_rally_pct": 24.07,
        "best_rally_date": "2022-06-09",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -96.71,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1336,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-06-30",
        "signal_date": "2022-06-30",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 105.0,
        "current_price": 6.025,
        "current_return_pct": -94.26,
        "best_rally_pct": 42.86,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1306,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-07-06",
        "signal_date": "2022-07-06",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 112.5,
        "current_price": 6.025,
        "current_return_pct": -94.64,
        "best_rally_pct": 33.33,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1300,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-07-08",
        "signal_date": "2022-07-08",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 107.5,
        "current_price": 6.025,
        "current_return_pct": -94.4,
        "best_rally_pct": 39.53,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1298,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-08-31",
        "signal_date": "2022-08-31",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 92.5,
        "current_price": 6.025,
        "current_return_pct": -93.49,
        "best_rally_pct": 62.16,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1244,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-09-01",
        "signal_date": "2022-09-01",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 87.5,
        "current_price": 6.025,
        "current_return_pct": -93.11,
        "best_rally_pct": 71.43,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1243,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-09-02",
        "signal_date": "2022-09-02",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 83.0,
        "current_price": 6.025,
        "current_return_pct": -92.74,
        "best_rally_pct": 80.72,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1242,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-09-05",
        "signal_date": "2022-09-05",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 80.0,
        "current_price": 6.025,
        "current_return_pct": -92.47,
        "best_rally_pct": 87.5,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1239,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-09-07",
        "signal_date": "2022-09-07",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 77.5,
        "current_price": 6.025,
        "current_return_pct": -92.23,
        "best_rally_pct": 93.55,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1237,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-09-12",
        "signal_date": "2022-09-12",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 72.5,
        "current_price": 6.025,
        "current_return_pct": -91.69,
        "best_rally_pct": 106.9,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1232,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-09-14",
        "signal_date": "2022-09-14",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 62.5,
        "current_price": 6.025,
        "current_return_pct": -90.36,
        "best_rally_pct": 140.0,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1230,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-09-15",
        "signal_date": "2022-09-15",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 62.5,
        "current_price": 6.025,
        "current_return_pct": -90.36,
        "best_rally_pct": 140.0,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1229,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-09-16",
        "signal_date": "2022-09-16",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 62.5,
        "current_price": 6.025,
        "current_return_pct": -90.36,
        "best_rally_pct": 140.0,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1228,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-10-05",
        "signal_date": "2022-10-05",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 52.5,
        "current_price": 6.025,
        "current_return_pct": -88.52,
        "best_rally_pct": 185.71,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1209,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-10-06",
        "signal_date": "2022-10-06",
        "signal_type": "ENHANCED EXTREME CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 51.0,
        "current_price": 6.025,
        "current_return_pct": -88.19,
        "best_rally_pct": 194.12,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1208,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-10-10",
        "signal_date": "2022-10-10",
        "signal_type": "ENHANCED EXTREME CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 51.5,
        "current_price": 6.025,
        "current_return_pct": -88.3,
        "best_rally_pct": 191.26,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1204,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-10-14",
        "signal_date": "2022-10-14",
        "signal_type": "ENHANCED EXTREME CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 47.5,
        "current_price": 6.025,
        "current_return_pct": -87.32,
        "best_rally_pct": 215.79,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1200,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-10-17",
        "signal_date": "2022-10-17",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 50.0,
        "current_price": 6.025,
        "current_return_pct": -87.95,
        "best_rally_pct": 200.0,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1197,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-10-18",
        "signal_date": "2022-10-18",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 50.0,
        "current_price": 6.025,
        "current_return_pct": -87.95,
        "best_rally_pct": 200.0,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1196,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2022-10-19",
        "signal_date": "2022-10-19",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 50.0,
        "current_price": 6.025,
        "current_return_pct": -87.95,
        "best_rally_pct": 200.0,
        "best_rally_date": "2023-03-01",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.98,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 1195,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2023-11-14",
        "signal_date": "2023-11-14",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 27.5,
        "current_price": 6.025,
        "current_return_pct": -78.09,
        "best_rally_pct": 83.27,
        "best_rally_date": "2024-03-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -88.05,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 804,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2023-11-15",
        "signal_date": "2023-11-15",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 23.0,
        "current_price": 6.025,
        "current_return_pct": -73.8,
        "best_rally_pct": 119.13,
        "best_rally_date": "2024-03-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -88.05,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 803,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2023-12-13",
        "signal_date": "2023-12-13",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 15.5,
        "current_price": 6.025,
        "current_return_pct": -61.13,
        "best_rally_pct": 225.16,
        "best_rally_date": "2024-03-04",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -88.05,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 775,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2023-12-22",
        "signal_date": "2023-12-22",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 14.7,
        "current_price": 6.025,
        "current_return_pct": -59.01,
        "best_rally_pct": 242.86,
        "best_rally_date": "2024-03-04",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -88.05,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 766,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-01-10",
        "signal_date": "2024-01-10",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 13.5,
        "current_price": 6.025,
        "current_return_pct": -55.37,
        "best_rally_pct": 273.33,
        "best_rally_date": "2024-03-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -88.05,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 747,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-01-19",
        "signal_date": "2024-01-19",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 11.25,
        "current_price": 6.025,
        "current_return_pct": -46.44,
        "best_rally_pct": 348.0,
        "best_rally_date": "2024-03-04",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -88.05,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 738,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-04-30",
        "signal_date": "2024-04-30",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 21.5,
        "current_price": 6.025,
        "current_return_pct": -71.98,
        "best_rally_pct": 30.23,
        "best_rally_date": "2024-05-02",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -78.48,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 636,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-05-01",
        "signal_date": "2024-05-01",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 24.0,
        "current_price": 6.025,
        "current_return_pct": -74.9,
        "best_rally_pct": 16.67,
        "best_rally_date": "2024-05-02",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -78.48,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 635,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-05-31",
        "signal_date": "2024-05-31",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 16.5,
        "current_price": 6.025,
        "current_return_pct": -63.48,
        "best_rally_pct": 16.67,
        "best_rally_date": "2024-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -68.7,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 605,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-06-03",
        "signal_date": "2024-06-03",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 16.0,
        "current_price": 6.025,
        "current_return_pct": -62.34,
        "best_rally_pct": 20.31,
        "best_rally_date": "2024-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -68.7,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 602,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-06-06",
        "signal_date": "2024-06-06",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 16.5,
        "current_price": 6.025,
        "current_return_pct": -63.48,
        "best_rally_pct": 16.67,
        "best_rally_date": "2024-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -68.7,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 599,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-06-25",
        "signal_date": "2024-06-25",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 14.5,
        "current_price": 6.025,
        "current_return_pct": -58.45,
        "best_rally_pct": 20.69,
        "best_rally_date": "2024-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -65.57,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 580,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-06-26",
        "signal_date": "2024-06-26",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 12.75,
        "current_price": 6.025,
        "current_return_pct": -52.75,
        "best_rally_pct": 37.25,
        "best_rally_date": "2024-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -65.57,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 579,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-06-27",
        "signal_date": "2024-06-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 11.5,
        "current_price": 6.025,
        "current_return_pct": -47.61,
        "best_rally_pct": 52.17,
        "best_rally_date": "2024-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -65.57,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 578,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-06-28",
        "signal_date": "2024-06-28",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 11.0,
        "current_price": 6.025,
        "current_return_pct": -45.23,
        "best_rally_pct": 59.09,
        "best_rally_date": "2024-07-29",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -65.57,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 577,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-08-20",
        "signal_date": "2024-08-20",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 11.5,
        "current_price": 6.025,
        "current_return_pct": -47.61,
        "best_rally_pct": 8.7,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 524,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-08-22",
        "signal_date": "2024-08-22",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 10.75,
        "current_price": 6.025,
        "current_return_pct": -43.95,
        "best_rally_pct": 16.28,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 522,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-08-27",
        "signal_date": "2024-08-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 11.0,
        "current_price": 6.025,
        "current_return_pct": -45.23,
        "best_rally_pct": 13.64,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 517,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-08-30",
        "signal_date": "2024-08-30",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 11.25,
        "current_price": 6.025,
        "current_return_pct": -46.44,
        "best_rally_pct": 11.11,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 514,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-09-30",
        "signal_date": "2024-09-30",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 8.0,
        "current_price": 6.025,
        "current_return_pct": -24.69,
        "best_rally_pct": 56.25,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 483,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-10-01",
        "signal_date": "2024-10-01",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 8.5,
        "current_price": 6.025,
        "current_return_pct": -29.12,
        "best_rally_pct": 47.06,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 482,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-10-04",
        "signal_date": "2024-10-04",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 8.25,
        "current_price": 6.025,
        "current_return_pct": -26.97,
        "best_rally_pct": 51.52,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 479,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-10-07",
        "signal_date": "2024-10-07",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 8.0,
        "current_price": 6.025,
        "current_return_pct": -24.69,
        "best_rally_pct": 56.25,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 476,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-10-09",
        "signal_date": "2024-10-09",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5,
        "current_price": 6.025,
        "current_return_pct": -19.67,
        "best_rally_pct": 66.67,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 474,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-10-10",
        "signal_date": "2024-10-10",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5,
        "current_price": 6.025,
        "current_return_pct": -19.67,
        "best_rally_pct": 66.67,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 473,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-10-15",
        "signal_date": "2024-10-15",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5,
        "current_price": 6.025,
        "current_return_pct": -19.67,
        "best_rally_pct": 66.67,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 468,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-10-17",
        "signal_date": "2024-10-17",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 6.025,
        "current_return_pct": -19.67,
        "best_rally_pct": 66.67,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 466,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-10-21",
        "signal_date": "2024-10-21",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 6.025,
        "current_return_pct": -19.67,
        "best_rally_pct": 66.67,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 462,
        "status": "historical"
      },
      {
        "signal_id": "RENX.L_2024-11-28",
        "signal_date": "2024-11-28",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 6.75,
        "current_price": 6.025,
        "current_return_pct": -10.74,
        "best_rally_pct": 85.19,
        "best_rally_date": "2025-01-06",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -51.8,
        "days_since_last_high": 7,
        "lock_in_reached": true,
        "age_days": 424,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 58,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 112.94,
      "median_rally_pct": 84.55,
      "best_rally_pct": 565.78,
      "worst_rally_pct": 13.23
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-02-11 20:06:35 UTC",
    "volatility": {
      "atr_normalized": 10.0,
      "stddev_20d": 0.3466
    },
    "trends": {
      "intelligence_signal": "ACCUMULATION"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 57/100 indicates strong opportunity quality",
      "Timing regime: TOO_EARLY",
      "Historical profile: 2 rallies, 85% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "RENX.L",
      "latest": [
        {
          "title": "H1 Trading update",
          "announcement_date": "11th Feb 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "Today 07:00\nRNS Number : 4996S\nRenalytix PLC\n11 February 2026\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nH1 Trading update\nLONDON and NEW YORK, 11 February 2026\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product\nkidneyintelX.dkd\n, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment in chronic diabetic kidney disease, provides a trading update for the six months ended 31 December 2025 (\"H1 FY26\").\nCurrent trading\n\u00b7\nH1 FY26 unaudited revenues of $1.6m and FY26 revenue guidance of $4m to 30 June 2026 (up 33% YoY).\n\u00b7\nThree new integrations implemented in H1 FY26, compared to one in FY25, with additional integrations expected in H2 FY26.\nRevenue acceleration in H2 FY26 from recent integrations.\n\u00b7\nN\new large-scale hospital group integration, with an initial proposed 1,000 patient pilot in 2026\n, and potential to reach over 40,000 CKD patients.\nReal World Evidence Study\n\u00b7\nRenalytix is advancing an innovative real-world evidence (RWE) study designed to further validate and expand the clinical and economic utility of\nkidneyintelX.dkd\nin kidney and cardiovascular disease management. The programme is expected to generate unique outcomes data to support broader clinical adoption, payer engagement, and strengthening the strategic positioning of\nkidneyintelX.dkd\nwithin population health and value-based care frameworks.\n\u00b7\nAs part of this study,\nkidneyintelX.dkd\nis expected to be integrated into up to five additional large healthcare organisations electronic medical record (EMR) systems, which would expand automated patient identification and testing access through deployment into routine clinical workflows.\n\u00b7\nTo support the RWE study, Renalytix is also in discussion with larger strategic partners regarding potential investment and/or logistics support, reflecting external interest in the programme and its ability to drive scalable clinical and commercial impact.\nTrading update\nH1 FY26 unaudited revenues were $1.6m. Revenue ramp-up during H1 FY26 was slower than expected due to longer lead times and complexities with larger healthcare system electronic medical record system (EMR) implementations.\nAs announced on\n12 January 2026\n, three new US healthcare provider groups have now been integrated with\nEMR\ntest ordering capabilities, with an additional three integrations on boarding in the current quarter. This additional test distribution will contribute to FY26 revenues during the second half of the financial year. FY26 full year revenues are now expected to be circa $4.0m (FY25 $3.0m). The sales pipeline that is currently being onboarded will significantly expand the EMR integrated testing footprint of\nkidneyintelX.dkd\nin 2026 and provide multiple opportunities with large healthcare systems in western and eastern United States.\nThe\nCompany is in implementation planning stage for a new large-scale integration, with an initial proposed 1,000 patient pilot in 2026 at\none of the largest regional healthcare systems in the US. When fully completed, this has the potential to be one of the larger patient populations to have access to\nkidneyintelX.dkd\n, which has full reimbursement by Medicare at $950 per reportable result. Further announcements regarding the integration and pilot study will be made as soon as practicable.\nContinued progress with Tempus AI Collaboration\nRenalytix continues to make progress with Tempus AI, Inc. (\"Tempus\") to advance EMR-integrated testing and data collection with other US healthcare providers.\nA joint working group, established as part of the previously announced\ncollaboration with Tempus AI\n, is discussing the value of combining advanced AI enabled diagnostics offering in kidney disease and cardiovascular disease. Renalytix believes this represents a unique opportunity for the partnership to take a leadership position in the Cardio-Kidney-Metabolic (CKM) health initiative, which affects up to 80% of the diabetic kidney disease population1.\nFurther operational improvements and cost savings\nDuring H1 FY26, the Company activated the relocation of its laboratory operations,\nwith the new facility to become fully operational during H2 FY26.\nThis move should significantly increase testing capacity and deliver over $1m of operating cost savings over the next five years, supporting both growth and operational efficiency.\nThe Company continues to focus on and implement cost reduction initiatives and maintained a cash balance of approximately $6 million as of 31 December 2025.\nAdditional supportive data expected before financial year end\nThe Company continues to generate and publish data on the clinical and operational value of\nkidneyintelX.dkd,\nincluding a recently\nannounced\nmanuscript in\nDiabetes Care\n. A major milestone has been reached with finalization of the two-year clinical outcome data now being prepared for submission for peer-reviewed publication. The public read-out of this is anticipated before the end of the fiscal year and is expected to be an important asset in supporting clinical adoption and informing national commercial insurance payment coverage.\nRenalytix anticipates providing an overview of the update in\nan online presentation via Investor Meet Company and will provide details in due course. The Company will\nannounce its unaudited interim results for the six months ended 31 December 2025 before the end of March 2026.\nNotes\n1\nArnold SV, Kosiborod M, Wang J et a., Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the diabetes collaborative registry. Diabetes. Obe Metab. 2018;20:2000-2003.\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering\nWalbrook PR Limited\nTel: +44 (0)20 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation,\nkidneyintelX.dkd\nis the only FDA-approved and Medicare-reimbursed prognostic tool capable of understanding a patient's risk with diabetic kidney disease early where treatment has maximal effect.\nkidneyintelX.dkd\nis now being deployed across large physician group practices and health systems in select regions of the United States.\nThe over 15,000 patients that have been tested by\nkidneyintelX.dkd\nhave produced a substantial body of real-world performance data. In patient populations where\nkidneyintelX.dkd\nhas been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded.\nkidneyintelX.dkd\nnow has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result.\nkidneyintelX.dkd\nis also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).\nKidneyIntelX\nis based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix.\nFor information about the kidneyintelX,dkd test, visit\nkidneyintelx.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTSTTMMTTMTMBTAF",
          "rns_number": "RNS Number : 4996S"
        },
        {
          "title": "Holding(s) in Company",
          "announcement_date": "21st Jan 2026",
          "release_time": "3:20 pm",
          "source": "RNS",
          "content": "Today 15:20\nRNS Number : 8356P\nRenalytix PLC\n21 January 2026\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n20 January 2026\n6.\nDate on which issuer notified (DD/MM/YYYY):\n21 January 2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.631241%\n0.000000%\n7.631241%\n33,349,947\nPosition of previous notification (if\napplicable)\n0.000000%\n0.000000%\n0.000000%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n33,349,947\n7.631241%\nSUBTOTAL 8. A\n33,349,947\n7.631241%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.631241%\n7.631241%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n21.01.2026\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFLELAILFIR",
          "rns_number": "RNS Number : 8356P"
        },
        {
          "title": "Holding(s) in Company",
          "announcement_date": "15th Jan 2026",
          "release_time": "4:51 pm",
          "source": "RNS",
          "content": "15 Jan 2026 16:51\nRNS Number : 1267P\nRenalytix PLC\n15 January 2026\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nX\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n14 January 2026\n6.\nDate on which issuer notified (DD/MM/YYYY):\n15 January 2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n0.000000%\n0.000000%\n0.000000%\n0\nPosition of previous notification (if\napplicable)\n7.742949%\n0.000000%\n7.742949%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n0\n0.000000%\nSUBTOTAL 8. A\n0\n0.000000%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nPlace of completion\nZurich, Switzerland\nDate of completion\n15.01.2026\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFERLIIELIR",
          "rns_number": "RNS Number : 1267P"
        },
        {
          "title": "Three kidneyintelX.dkd Clinical Integrations",
          "announcement_date": "12th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "12 Jan 2026 07:00\nRNS Number : 4881O\nRenalytix PLC\n12 January 2026\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nThree kidneyintelX.dkd Clinical Integrations\nLONDON and NEW YORK, 12 January 2026\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use.\nThe integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix.\nThese integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations.\nRenalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources.\nTempus AI Collaboration\nRenalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in\nSeptember 2025\n,\nto target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients.\nThe collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time.\nInvestor Engagement\nJames McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes.\nThe 44th\u00a0annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad range of healthcare and life sciences companies, including data and diagnostics partners such as Tempus.\nThe Company looks forward to updating investors on progress, corporate development and trading in February 2026.\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering\nWalbrook PR Limited\nTel: +44 (0)20 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation,\nkidneyintelX.dkd\nis the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect.\nkidneyintelX.dkd\nis now being deployed across large physician group practices and health systems in select regions of the United States.\nThe over 15,000 patients that have been tested by\nkidneyintelX.dkd\nhave produced a substantial body of real-world performance data. In patient populations where\nkidneyintelX.dkd\nhas been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded.\nkidneyintelX.dkd\nnow has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result.\nkidneyintelX.dkd\nis also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).\nKidneyIntelX\nis based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix.\nFor information about the kidneyintelX,dkd test, visit\nkidneyintelx.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCKZGMMLMNGVZM",
          "rns_number": "RNS Number : 4881O"
        },
        {
          "title": "Holding(s) in Company",
          "announcement_date": "9th Jan 2026",
          "release_time": "2:43 pm",
          "source": "RNS",
          "content": "9 Jan 2026 14:43\nRNS Number : 3877O\nRenalytix PLC\n09 January 2026\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n08 January 2026\n6.\nDate on which issuer notified (DD/MM/YYYY):\n09 January 2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.742949%\n0.000000%\n7.742949%\n33,838,133\nPosition of previous notification (if\napplicable)\n0.000000%\n0.000000%\n0.000000%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n33,838,133\n7.742949%\nSUBTOTAL 8. A\n33,838,133\n7.742949%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.742949%\n7.742949%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n09.01.2026\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFVSLAIAIIR",
          "rns_number": "RNS Number : 3877O"
        }
      ],
      "themes": [
        "funding",
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 884,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "ACCUMULATION"
    },
    "volatility": {
      "atr_normalized": 10.0,
      "stddev_20d": 0.3466
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "all_events": [
      {
        "event_id": "RNS-15th Jan 2026-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.497824Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-gtt5a7nyooqxa8r.html",
          "rns_number": "RNS Number : 1267P",
          "full_content": "15 Jan 2026 16:51\nRNS Number : 1267P\nRenalytix PLC\n15 January 2026\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nX\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n14 January 2026\n6.\nDate on which issuer notified (DD/MM/YYYY):\n15 January 2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n0.000000%\n0.000000%\n0.000000%\n0\nPosition of previous notification (if\napplicable)\n7.742949%\n0.000000%\n7.742949%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n0\n0.000000%\nSUBTOTAL 8. A\n0\n0.000000%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nPlace of completion\nZurich, Switzerland\nDate of completion\n15.01.2026\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFERLIIELIR",
          "content_length": 4642
        },
        "ingested_at": "2026-01-21T02:01:37.497866Z"
      },
      {
        "event_id": "RNS-12th Jan 2026-threekid",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.497891Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Three kidneyintelX.dkd Clinical Integrations",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/three-kidneyintelxdkd-clinical-integrations-6iaybnfi5kg3wtg.html",
          "rns_number": "RNS Number : 4881O",
          "full_content": "12 Jan 2026 07:00\nRNS Number : 4881O\nRenalytix PLC\n12 January 2026\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nThree kidneyintelX.dkd Clinical Integrations\nLONDON and NEW YORK, 12 January 2026\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use.\nThe integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix.\nThese integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations.\nRenalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources.\nTempus AI Collaboration\nRenalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in\nSeptember 2025\n,\nto target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients.\nThe collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time.\nInvestor Engagement\nJames McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes.\nThe 44th\u00a0annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad range of healthcare and life sciences companies, including data and diagnostics partners such as Tempus.\nThe Company looks forward to updating investors on progress, corporate development and trading in February 2026.\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering\nWalbrook PR Limited\nTel: +44 (0)20 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation,\nkidneyintelX.dkd\nis the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect.\nkidneyintelX.dkd\nis now being deployed across large physician group practices and health systems in select regions of the United States.\nThe over 15,000 patients that have been tested by\nkidneyintelX.dkd\nhave produced a substantial body of real-world performance data. In patient populations where\nkidneyint",
          "content_length": 6527
        },
        "ingested_at": "2026-01-21T02:01:37.497918Z"
      },
      {
        "event_id": "RNS-9th Jan 2026-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.497944Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-v1u42azi7bmztu3.html",
          "rns_number": "RNS Number : 3877O",
          "full_content": "9 Jan 2026 14:43\nRNS Number : 3877O\nRenalytix PLC\n09 January 2026\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n08 January 2026\n6.\nDate on which issuer notified (DD/MM/YYYY):\n09 January 2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.742949%\n0.000000%\n7.742949%\n33,838,133\nPosition of previous notification (if\napplicable)\n0.000000%\n0.000000%\n0.000000%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n33,838,133\n7.742949%\nSUBTOTAL 8. A\n33,838,133\n7.742949%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.742949%\n7.742949%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n09.01.2026\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFVSLAIAIIR",
          "content_length": 4520
        },
        "ingested_at": "2026-01-21T02:01:37.497962Z"
      },
      {
        "event_id": "RNS-6th Jan 2026-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.497975Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-9zw4pra5jeaq7tg.html",
          "rns_number": "RNS Number : 8776N",
          "full_content": "6 Jan 2026 16:28\nRNS Number : 8776N\nRenalytix PLC\n06 January 2026\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nX\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n05 January 2026\n6.\nDate on which issuer notified (DD/MM/YYYY):\n06 January 2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n0.000000%\n0.000000%\n0.000000%\n0\nPosition of previous notification (if\napplicable)\n7.744274%\n0.000000%\n7.744274%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n0\n0.000000%\nSUBTOTAL 8. A\n0\n0.000000%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nPlace of completion\nZurich, Switzerland\nDate of completion\n06.01.2026\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFFRLDIRIIR",
          "content_length": 4641
        },
        "ingested_at": "2026-01-21T02:01:37.497988Z"
      },
      {
        "event_id": "RNS-24th Dec 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498001Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-rt4k8778feh15ae.html",
          "rns_number": "RNS Number : 8729M",
          "full_content": "24 Dec 2025 12:56\nRNS Number : 8729M\nRenalytix PLC\n24 December 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n23 December 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n24 December 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.744274%\n0.000000%\n7.744274%\n33,843,926\nPosition of previous notification (if\napplicable)\n0.000000%\n0.000000%\n0.000000%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n33,843,926\n7.744274%\nSUBTOTAL 8. A\n33,843,926\n7.744274%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.744274%\n7.744274%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n24.12.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFEFFELSFIE",
          "content_length": 4524
        },
        "ingested_at": "2026-01-21T02:01:37.498013Z"
      },
      {
        "event_id": "RNS-24th Dec 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498026Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-5v7n8y0we0fq3h4.html",
          "rns_number": "RNS Number : 8729M",
          "full_content": "24 Dec 2025 12:56\nRNS Number : 8729M\nRenalytix PLC\n24 December 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n23 December 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n24 December 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.744274%\n0.000000%\n7.744274%\n33,843,926\nPosition of previous notification (if\napplicable)\n0.000000%\n0.000000%\n0.000000%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n33,843,926\n7.744274%\nSUBTOTAL 8. A\n33,843,926\n7.744274%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.744274%\n7.744274%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n24.12.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFEFFELSFIE",
          "content_length": 4524
        },
        "ingested_at": "2026-01-21T02:01:37.498038Z"
      },
      {
        "event_id": "RNS-23rd Dec 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498051Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-tbdlvudeedqqhd4.html",
          "rns_number": "RNS Number : 7166M",
          "full_content": "23 Dec 2025 16:13\nRNS Number : 7166M\nRenalytix PLC\n23 December 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nX\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n22 December 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n23 December 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n0.000000%\n0.000000%\n0.000000%\n0\nPosition of previous notification (if\napplicable)\n7.451844%\n0.000000%\n7.451844%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n0\n0.000000%\nSUBTOTAL 8. A\n0\n0.000000%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nPlace of completion\nZurich, Switzerland\nDate of completion\n23.12.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFLRFFLVFIE",
          "content_length": 4645
        },
        "ingested_at": "2026-01-21T02:01:37.498063Z"
      },
      {
        "event_id": "RNS-23rd Dec 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498076Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-xaj9o01ihoxqiei.html",
          "rns_number": "RNS Number : 7166M",
          "full_content": "23 Dec 2025 16:13\nRNS Number : 7166M\nRenalytix PLC\n23 December 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nX\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n22 December 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n23 December 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n0.000000%\n0.000000%\n0.000000%\n0\nPosition of previous notification (if\napplicable)\n7.451844%\n0.000000%\n7.451844%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n0\n0.000000%\nSUBTOTAL 8. A\n0\n0.000000%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nPlace of completion\nZurich, Switzerland\nDate of completion\n23.12.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFLRFFLVFIE",
          "content_length": 4645
        },
        "ingested_at": "2026-01-21T02:01:37.498088Z"
      },
      {
        "event_id": "RNS-19th Dec 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498118Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-urxkfcllehnudd9.html",
          "rns_number": "RNS Number : 3248M",
          "full_content": "19 Dec 2025 12:18\nRNS Number : 3248M\nRenalytix PLC\n19 December 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n17 December 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n19 December 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.451844%\n0.000000%\n7.451844%\n32,565,952\nPosition of previous notification (if\napplicable)\n8.000675%\n0.000000%\n8.000675%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n32,565,952\n7.451844%\nSUBTOTAL 8. A\n32,565,952\n7.451844%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.451844%\n7.451844%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n19.12.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFLFFRLALIE",
          "content_length": 4524
        },
        "ingested_at": "2026-01-21T02:01:37.498133Z"
      },
      {
        "event_id": "RNS-19th Dec 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498146Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-quptaakg5h9q3sf.html",
          "rns_number": "RNS Number : 3248M",
          "full_content": "19 Dec 2025 12:18\nRNS Number : 3248M\nRenalytix PLC\n19 December 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n17 December 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n19 December 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.451844%\n0.000000%\n7.451844%\n32,565,952\nPosition of previous notification (if\napplicable)\n8.000675%\n0.000000%\n8.000675%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n32,565,952\n7.451844%\nSUBTOTAL 8. A\n32,565,952\n7.451844%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.451844%\n7.451844%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n19.12.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFLFFRLALIE",
          "content_length": 4524
        },
        "ingested_at": "2026-01-21T02:01:37.498159Z"
      },
      {
        "event_id": "RNS-17th Dec 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498171Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-6xhd3df8zy338xt.html",
          "rns_number": "RNS Number : 9881L",
          "full_content": "17 Dec 2025 13:42\nRNS Number : 9881L\nRenalytix PLC\n17 December 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n15 December 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n17 December 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n8.000675%\n0.000000%\n8.000675%\n34,964,445\nPosition of previous notification (if\napplicable)\n7.442592%\n0.000000%\n7.442592%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n34,964,445\n8.000675%\nSUBTOTAL 8. A\n34,964,445\n8.000675%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n8.000675%\n8.000675%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n17.12.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFSVFILDLIE",
          "content_length": 4524
        },
        "ingested_at": "2026-01-21T02:01:37.498183Z"
      },
      {
        "event_id": "RNS-16th Dec 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498196Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-0hb6g54m0lzngbu.html",
          "rns_number": "RNS Number : 8070L",
          "full_content": "16 Dec 2025 13:51\nRNS Number : 8070L\nRenalytix PLC\n16 December 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n12 December 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n16 December 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.442592%\n0.000000%\n7.442592%\n32,525,518\nPosition of previous notification (if\napplicable)\n5.089787%\n0.000000%\n5.089787%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n32,525,518\n7.442592%\nSUBTOTAL 8. A\n32,525,518\n7.442592%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.442592%\n7.442592%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n16.12.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFSVFTLRLIE",
          "content_length": 4524
        },
        "ingested_at": "2026-01-21T02:01:37.498208Z"
      },
      {
        "event_id": "RNS-9th Dec 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498221Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/result-of-agm-n68l9tb64ldum1i.html",
          "rns_number": "RNS Number : 8519K",
          "full_content": "9 Dec 2025 10:57\nRNS Number : 8519K\nRenalytix PLC\n09 December 2025\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nResult of AGM\nLONDON and NEW YORK, 9 December 2025\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces\u00a0that at the Annual General Meeting (\"AGM\") held earlier today, all resolutions were duly passed.\nThe results of the AGM are detailed below:\nFor\n% voted in favour\nAgainst\n% voted against\nWithheld\nOrdinary resolutions\n1\nReceive and adopt the UK 2025 Annual Report\n196,930,280\n99.7\n587,105\n0.3\n20,878\n2\nApprove Directors' Remuneration Report\n195,421,372\n98.9\n2,073,488\n1.1\n43,403\n3\nRe-appointment of Christopher Mills as a Director\n178,267,303\n90.3\n19,130,050\n9.7\n140,910\n4\nRe-appointment of James McCullough as a Director\n194,129,345\n98.3\n3,268,008\n1.7\n140,910\n5\nRe-appointment of Fergus Fleming as a Director\n195,999,932\n99.3\n1,386,266\n0.7\n152,065\n6\nRe-appointment of Erik Lium as a Director\n177,457,676\n89.9\n19,928,522\n10.1\n152,065\n7\nRe-appointment of Julian Baines as a Director\n195,385,929\n99.3\n1,378,854\n0.7\n773,480\n8\nRe-appointment of Robert Naylor as a Director\n196,012,978\n99.3\n1,373,220\n0.7\n152,065\n9\nReappoint PKF Littlejohn LLP as Auditors\n196,188,779\n99.3\n1,276,304\n0.7\n73,180\n10\nAuthorise Board to determine auditors' remuneration\n196,927,685\n99.7\n555,598\n0.3\n54,980\n11\nAuthorise the Issue of Equity\n195,214,647\n98.9\n2,147,594\n1.1\n176,022\nSpecial resolutions\n12\nAuthorise Issue of Equity without Pre-emptive Rights\n193,317,050\n97.9\n4,042,090\n2.1\n179,123\n13\nAuthorise Market Purchase of Ordinary Shares\n195,114,033\n98.8\n2,381,796\n1.2\n18,678\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering\nWalbrook PR Limited\nTel: +44 (0)20 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation,\nkidneyintelX.dkd\nis the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect.\nkidneyintelX.dkd\nis now being deployed across large physician group practices and health systems in select regions of the United States.\nThe over 15,000 patients that have been tested by\nkidneyintelX.dkd\nhave produced a substantial body of real-world performance data. In patient populations where\nkidneyintelX.dkd\nhas been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded.\nkidneyintelX.dkd\nnow has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result.\nkidneyintelX.dkd\nis also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).\nKidneyIntelX\nis based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix.\nFor information about the kidneyintelX,dkd test, visit\nkidneyintelx.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGBGBDDUUGDGUC",
          "content_length": 4990
        },
        "ingested_at": "2026-01-21T02:01:37.498233Z"
      },
      {
        "event_id": "RNS-9th Dec 2025-agmstate",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498246Z",
        "source": "LSE_RNS",
        "data": {
          "title": "AGM Statement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/agm-statement-fxbrlnq69b3l813.html",
          "rns_number": "RNS Number : 7296K",
          "full_content": "9 Dec 2025 07:00\nRNS Number : 7296K\nRenalytix PLC\n09 December 2025\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nAGM Statement\nLONDON and NEW YORK, 9 December 2025\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, provides an update to shareholders ahead of its Annual General Meeting (\"AGM\") today at 6 Stratton Street Mayfair, London W1J 8LD at 10.00 (GMT).\nAGM Statement from Julian Baines, Executive Chairman\nI am very pleased to provide a short update for shareholders ahead of our AGM today as we continue to work towards wider adoption of the\nKidneyintelX.dkd\ntest, the first FDA-approved advanced prognostic blood test with Medicare reimbursement coverage, to identify those at-risk of progressive kidney disease and allowing\nearly interventions to improve outcomes and reduce high costs associated with chronic disease management.\nWe have made good progress in increasing testing volumes across the four target states where we have direct presence:\nFlorida, Texas, New York, and more recently Arizona. In the new financial year we recorded our first\nrevenues from Arizona, including tests ordered by one of the largest nephrology practices in the United States.\nWhilst this is encouraging, our main growth strategy is to deliver significant testing volume ramp-up through business development initiatives with important strategic partnerships that can target adoption by larger health centres across the whole of the US. To this end, in mid-September we were delighted to secure a definitive agreement with NASDAQ listed Tempus AI Inc (\"Tempus\"), which has an established network\nof healthcare institutions already utilising its precision medicine solutions. We believe this collaboration will\nallow us to significantly expand patient and clinician access to kidneyintelX and we have been encouraged by our first few months of engagement. E\nngaging with large healthcare systems presents inherent challenges, particularly due to lengthy implementation and approval processes that are often outside of our direct control, but we are satisfied that with partnerships such as Tempus and MVP Health Care, this strategy will deliver long-term value for shareholders.\nWe have also narrowed an extensive list of potential partners for our next Electronic Health Record (EHR) integration and have made significant progress with several priority targets. These targets are large healthcare systems, which we expect to generate meaningful testing volumes and become key customers for years to come.\nIn parallel, we are increasingly utilising data analytics to identify physicians with a high population of eligible patients, as well as those where a higher prevalence of eligible patients is expected. This capability enables us to provide valuable and actionable insights to clinicians and practices, complementing the clinical value of our KidneyIntelX.dkd test, while ensuring our limited commercial resources are directed toward the highest-opportunity accounts.\nFinally, we have commenced the transition to a new laboratory facility. This move is expected to significantly increase our testing capacity and deliver substantial operating cost savings over the next five years, supporting both growth and operational efficiency.\nLooking ahead, the Company is focused on converting ongoing business development activity into contracted relationships, expanded EHR integrations, and growing testing volumes. While the timing of commercial outcomes-particularly with large healthcare systems-remains difficult to predict, the Board and management are confident that the foundations being put in place today position the Company well for sustainable revenue growth, increased operating leverage, and long-term value creation for shareholders.\nThe Company will issue a trading update for the six months to 31 December 2025 by the end of January 2026.\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering\nWalbrook PR Limited\nTel: +44 (0)20 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled kidney disease remains one of th",
          "content_length": 7263
        },
        "ingested_at": "2026-01-21T02:01:37.498260Z"
      },
      {
        "event_id": "RNS-27th Nov 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498273Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-9up9o80j6xb3c0g.html",
          "rns_number": "RNS Number : 3333J",
          "full_content": "27 Nov 2025 14:39\nRNS Number : 3333J\nRenalytix PLC\n27 November 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n25 November 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n27 November 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n5.089787%\n0.000000%\n5.089787%\n22,243,319\nPosition of previous notification (if\napplicable)\n0.000000%\n0.000000%\n0.000000%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n22,243,319\n5.089787%\nSUBTOTAL 8. A\n22,243,319\n5.089787%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n5.089787%\n5.089787%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n27.11.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFVSLDLDFIE",
          "content_length": 4524
        },
        "ingested_at": "2026-01-21T02:01:37.498285Z"
      },
      {
        "event_id": "RNS-25th Nov 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498298Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-p8z4o18ybf6q2ok.html",
          "rns_number": "RNS Number : 9661I",
          "full_content": "25 Nov 2025 15:44\nRNS Number : 9661I\nRenalytix PLC\n25 November 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nX\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n24 November 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n25 November 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n0.000000%\n0.000000%\n0.000000%\n0\nPosition of previous notification (if\napplicable)\n7.986122%\n0.000000%\n7.986122%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n0\n0\nSUBTOTAL 8. A\n0\n0\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nPlace of completion\nZurich, Switzerland\nDate of completion\n25.11.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFSELVLEFIE",
          "content_length": 4629
        },
        "ingested_at": "2026-01-21T02:01:37.498310Z"
      },
      {
        "event_id": "RNS-25th Nov 2025-plantoim",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498323Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Plan to Implement ADS Ratio Change",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/plan-to-implement-ads-ratio-change-fei206y2nxnebkh.html",
          "rns_number": "RNS Number : 7856I",
          "full_content": "25 Nov 2025 07:00\nRNS Number : 7856I\nRenalytix PLC\n25 November 2025\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nRenalytix Announces Plan to Implement ADS Ratio Change\nLONDON and NEW YORK, 25 November 2025\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease,\nannounces plans to change the ratio of its American Depository Shares (\"ADSs\") to its ordinary shares from one (1)\u00a0ADS, representing two (2)\u00a0ordinary shares, to one (1)\u00a0ADS representing fifty (50) ordinary shares (the \"ADS Ratio\"). The change in the ADS Ratio is expected to become effective on or about 12 December 2025 (the \"Effective Date\").\nFor the Company's ADS holders, the change in the ADS Ratio has the same effect as a\u00a0one-for-twenty five reverse ADS split and will have no impact on an ADS holder's proportional equity interest in the Company. The change in the ADS Ratio is intended to further support the liquidity in the Company's ADSs, reduce the cost and expenses of the ADS program to the Company and its shareholders, and to provide future alternatives to regaining compliance with the U.S. listing exchanges' minimum bid price requirements. On the Effective Date, registered holders of the Company's ADSs held in certificated form will be required on a mandatory basis to surrender their certificated ADSs to Citibank, N.A., the depositary bank (the \"Depositary\"), for cancellation and will receive one (1)\u00a0new ADS in exchange for every twenty five (25)\u00a0existing ADSs surrendered. Holders of uncertificated ADSs in the Direct Registration System (DRS) and The Depository Trust Company (DTC) will have their ADSs automatically exchanged and need not take any action. The exchange of every twenty five (25)\u00a0then-held (existing) ADSs for one (1)\u00a0new ADS will occur automatically at the Effective Date, with the then-held ADSs being cancelled and new ADSs being issued by the Depositary. The Company's ADSs will continue to be traded on OTCQB under the ticker symbol \"RNLXY.\"\nNo fractional new ADSs will be issued in connection with the change in the ADS Ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary, and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes, and expenses) will be distributed to the applicable ADS holders by the Depositary.\nAs a result of the change in the ADS Ratio, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the change in the ADS Ratio will be proportionally equal to or greater than the previous ADS trading price prior to the change or that the change in the ADS Ratio will have any effect on the liquidity in the Company's ADSs.\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering\nWalbrook PR Limited\nTel: +44 (0)20 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation,\nkidneyintelX.dkd\nis the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect.\nkidneyintelX.dkd\nis now being deployed across large physician group practices and health systems in select regions of the United States.\nThe over 15,000 patients that have been tested by\nkidneyintelX.dkd\nhave produced a substantial body of real-world performance data. In patient populations where\nkidneyintelX.dkd\nhas been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded.\nkidneyintelX.dkd\nnow has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result.\nkidneyintelX.dkd\nis also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO)",
          "content_length": 6129
        },
        "ingested_at": "2026-01-21T02:01:37.498337Z"
      },
      {
        "event_id": "RNS-12th Nov 2025-pivotalk",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498351Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Pivotal kidneyintelX.dkd data published",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/pivotal-kidneyintelxdkd-data-published-o5utq8ocm7e5dme.html",
          "rns_number": "RNS Number : 1442H",
          "full_content": "12 Nov 2025 07:00\nRNS Number : 1442H\nRenalytix PLC\n12 November 2025\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nPivotal\nkidneyintelX.dkd\ndata published in Diabetes Care Journal of the American Diabetes Association\nPresentation of 3 abstacts highlighting clinical utility at American Society of Nephrology Kidney Week\nLONDON and NEW YORK, 12 November 2025\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces\na manuscript titled\n\"\nBaseline Risk and Longitudinal Changes in kidneyintelX.dkd and Its Association With Kidney Outcomes in the CANVAS and CREDENCE Trials\"\nhas been published in the highest ranked diabetes journal globally, Diabetes Care, from the American Diabetes Association.\nThe study was co-authored by global thought leaders from Europe, US and Australia and included analysis of the\nkidneyintelX.dkd\ntest in a combined cohort of 2,954 subjects from the completed CANVAS and CREDENCE clinical trials meeting the intended use of the test. Among a number of significant findings reported, are the following:\n-\nkidneyintelX.dkd\nprovides improved risk classification across all of the established risk groups as presented in the KDIGO clinical guidelines\n- Treatment with SGLT2i front line therapy in patients classified as moderate or high risk by kidneyintelX.dkd resulted in a significant risk reduction, with the high risk treated group twice as likely to reduce their\nkidneyintelX.dkd\nrisk level at 1 year compared to those not receiving treatment.\nThe authors concluded that\nkidneyintelX.dkd\nfacilitated the identification of patients most likely to respond to therapy through personalized risk assessment with the potential for monitoring in clinical practice and a role in future clinical studies.\nAssociate Professor Brendon Neuen of\nThe George Institute for Global Health, Sydney,\nwho co-authored the paper, commented:\n\"With multiple recent breakthroughs in therapies to reduce kidney function decline, the time for risk-based implementation in CKD has arrived. Incorporating novel biomarkers, as done with kidneyintelX.dkd, holds strong promise to guide risk-based care. The data published in this study provides a compelling example of how we can build on well established clinical parameters to deliver more personalized care and reduce the risk of adverse clinical outcomes.\"\nAssociate Professor Brendon Neuen is an internationally recognised expert on cardio-kidney-metabolic health. He is Program Lead, Renal and Metabolic at The George Institute for Global Health and a Staff Specialist Nephrologist and Director of Kidney Trials at Royal North Shore Hospital (full biography available below).\nThis most recent\nkidneyintelX.dkd\npublication co-incides with the presentation of three abstracts at ASN Kidney Week, held in Houston Texas from November 5-9. A summary of these abstract are as follows;\n1. PO0330: Successful Implementation of KidneyIntelX in a Large Integrated Health System for Risk-Based Management of Diabetic Kidney Disease\nThe abstract highlighted a framework for deployment of\nkidneyintelX.dkd\nand precision medicine into a large integrated health system to achieve sustained population and patient level adoption, thereby eliciting personalised improvements in care management.\n2. PO0331: Decision Impact Study of kidneyintelX.dkd on provider management and patient engagement in a community care practice environment\n87% of patients reported improved understanding of their kidney risk and 98% found the\nkidneyintelX.dkd\ntest helped in understanding their kidney and importance of overall health. 86% of physicians in this community setting reported the test result informed care management decisions.\n3. PO0332: Comparison of kidneyintelX.dkd and KFRE for Predicting Progression of Diabetic Kidney Disease\nThe\nkidneyintelX.dkd\ntest outperformed the Kidney Failure Risk Equation (KFRE) in predicting decline in kidney function or kidney failure in patients with DKD. The demonstrated improved discrimination and performance of kidneyintelX.dkd compared with the known variability in the KFRE routine clinical features, highlighted the utility of the kidneyintelX.dkd test, particularly in early stage disease.\nTaken together, these data presentations reinforce the incremental and consistent value of the\nkidneyintelX.dkd\ntest as a standard for precision medicine in CKD, and as a core element of integrated care management across multiple health care settings ultimately, driving significant improvements in patient care and health outcomes.\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Bro",
          "content_length": 10295
        },
        "ingested_at": "2026-01-21T02:01:37.498364Z"
      },
      {
        "event_id": "RNS-5th Nov 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498377Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-a3o4txuhkjnxv0d.html",
          "rns_number": "RNS Number : 3584G",
          "full_content": "5 Nov 2025 16:02\nRNS Number : 3584G\nRenalytix PLC\n05 November 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n03 November 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n04 November 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.986122%\n0.000000%\n7.986122%\n34,900,846\nPosition of previous notification (if\napplicable)\n5.169160%\n0.000000%\n5.169160%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n34,900,846\n7.986122%\nSUBTOTAL 8. A\n34,900,846\n7.986122%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.986122%\n7.986122%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n04.11.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFIRLILEIIE",
          "content_length": 4523
        },
        "ingested_at": "2026-01-21T02:01:37.498389Z"
      },
      {
        "event_id": "RNS-4th Nov 2025-publicat",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498402Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Publication of Annual Report & Notice of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/publication-of-annual-report-notice-of-agm-6lqv45txr2iccem.html",
          "rns_number": "RNS Number : 1901G",
          "full_content": "4 Nov 2025 18:05\nRNS Number : 1901G\nRenalytix PLC\n04 November 2025\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nPublication of Annual Report 2025\n&\nNotice of 2025 Annual General Meeting\nLONDON and NEW YORK, 4 November 2025\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease,\nannounces that the Annual Report for the year ended 30 June 2025 and the Notice of 2025 Annual General Meeting (\"AGM\") have now been published on the Company's website and will be posted to shareholders who have not consented to receive electronic communications tomorrow morning.\nThe Annual report is available on the Company website here:\nhttps://investors.renalytix.com/annual-half-year-reports/\nThe full Notice of AGM can be found here:\nhttps://investors.renalytix.com/documents/\nThe AGM will be held in-person on 9 December 2025 at 10.00 (GMT) at 6 Stratton Street Mayfair, London W1J 8LD.\nAny shareholder wishing to attend is required to register by contacting Walbrook PR via email at renalytix@walbrookpr.com or by telephone at +44 (0)20 7933 8780.\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering\nWalbrook PR Limited\nTel: 020 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: 07980 541 893 / 07407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation,\nkidneyintelX.dkd\nis the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect.\nkidneyintelX.dkd\nis now being deployed across large physician group practices and health systems in select regions of the United States.\nThe over 15,000 patients that have been tested by\nkidneyintelX.dkd\nhave produced a substantial body of real-world performance data. In patient populations where\nkidneyintelX.dkd\nhas been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded.\nkidneyintelX.dkd\nnow has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result.\nkidneyintelX.dkd\nis also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).\nKidneyIntelX\nis based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix.\nFor information about the kidneyintelX,dkd test, visit\nkidneyintelx.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nACSUPGPUGUPAGRC",
          "content_length": 4419
        },
        "ingested_at": "2026-01-21T02:01:37.498414Z"
      },
      {
        "event_id": "RNS-3rd Nov 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498426Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-836i1famv8g9mr2.html",
          "rns_number": "RNS Number : 9404F",
          "full_content": "3 Nov 2025 12:05\nRNS Number : 9404F\nRenalytix PLC\n03 November 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n30 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n03 November 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n5.169160%\n0.000000%\n5.169160%\n22,590,196\nPosition of previous notification (if\napplicable)\n7.997348%\n0.000000%\n7.997348%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n22,590,196\n5.169160%\nSUBTOTAL 8. A\n22,590,196\n5.169160%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n5.169160%\n5.169160%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n03.11.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFIFLSLVIIE",
          "content_length": 4522
        },
        "ingested_at": "2026-01-21T02:01:37.498438Z"
      },
      {
        "event_id": "RNS-3rd Nov 2025-auditedf",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498451Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Audited Full Year Fiscal 2025 Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/audited-full-year-fiscal-2025-results-oj618r8ux47qqen.html",
          "rns_number": "RNS Number : 8163F",
          "full_content": "3 Nov 2025 07:00\nRNS Number : 8163F\nRenalytix PLC\n03 November 2025\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nAudited Full Year Fiscal 2025 Results\nLONDON and NEW YORK, 3 November 2025\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces its\naudited financial results for the fiscal year ended 30 June 2025.\nFINANANCIAL & COMMERICAL HIGHLIGHTS\nSound financial governance and operational focus provides pathway to continued growth\n\u00b7\nTotal revenues up 30% to $3.0\u00a0million (FY24:\u00a0$2.3\u00a0million)\n\u00b7\nRevenue growth across all revenue streams, additional integration with large physician practice in NY and increased pharma services revenue from global pharma leaders\n\u00b7\nIncreased margins through testing volume build, with continued focus on improving operational efficiencies with greater scale throughout FY26\n\u00b7\n54% decrease in underlying EBITDA loss through savings in administrative expenses following operating expense reductions, delisting from NASDAQ, and regaining Foreign Private Issuer status\n\u00b7\nReceipt of more than $1million in R&D cash tax credits for claims relating to FY24 and FY23, including $0.4 million post year end\n\u00b7\nOver-subscribed, institutional led equity capital fundraise in September 2025 for \u00a36.7\u00a0million\n\u00b7\nOperational improvements resulted in a 50% reduction in laboratory test turn-around time\n\u00b7\nCollaboration agreement announced with Tempus AI to expand US national availability of kidneyintelX.dkd\nCOMMERCIAL HIGHLIGHTS\nScaling EMR integrated growth and continued real world data generation\n\u00b7\nFirst operating year with Medicare insurance reimbursement improvements in A/R turn and average unit testing price improvement\n\u00b7\nContinuing validation of benefits of electronic medical record (EMR) integration for automated at-risk patient identification and corresponding doctor alerts for testing adoption\n\u00b7\nFull integration completed with a New York based primary care physician health care network further validating business model to reach large primary care doctor treating base\n\u00b7\nAdditional health care provider networks slated for EMR integrated testing of kidneyintelX.dkd in calendar 2025\n\u00b7\nExpanded access via community nephrology: collaboration with New York Kidney & Hypertension Medicine (NYKHM) to enable testing access for 2,000+ patients in underserved NY communities\n\u00b7\nStrategic alignment of sales and operational teams with focus on key markets of New York, Texas, and Florida\n\u00b7\nPublication of data in support of kidneyintelX.dkd clinical utility including:\no\nPublished in Journal of the American Society of Nephrology (JASN) invited review highlighting the role of kidneyintelX.dkd in risk-based therapy allocation and noting inclusion in KDIGO guidelines\no\nLate breaking data presentation at National Kidney Foundation Spring meeting showing significant impact of kidneyIntelX.dkd on risk-based care when compared to a contemporary control group\no\nPivotal analyses presented at ERA 2025 (Vienna) showing kidneyIntelX.dkd enhances risk stratification across KDIGO categories and that SGLT2i therapy reduces KidneyIntelX risk levels in just 12 months, significantly slowing disease progression\nPost-period highlights\n\u00b7\nTempus AI collaboration (September 2025): Strategic partnership to integrate kidneyIntelX.dkd testing into Tempus' precision medicine platform, expanding access to providers and patients for scaled commericalisation\n\u00b7\nPartnership with MVP Health Care (August 2025): kidneyIntelX.dkd testing to be made available across all of the eligible MVP 770,000 members in New York and Vermont\n\u00b7\nExpansion into Arizona as part of our sales strategy, our fourth territory, identified for its high Medicare population\nBOARD UPDATE\n\u00b7\nThe Company also announces that Julian Baines will be transitioning from his current role as Executive Chairman to Non-Executive Chairman, with effect from 1 January 2026\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering\nWalbrook PR Limited\nTel: 020 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: 07980 541 893 / 07407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled kidney disease remains one of the largest b",
          "content_length": 69100
        },
        "ingested_at": "2026-01-21T02:01:37.498467Z"
      },
      {
        "event_id": "RNS-30th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498480Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-u4zq566ddikeq6w.html",
          "rns_number": "RNS Number : 5742F",
          "full_content": "30 Oct 2025 16:58\nRNS Number : 5742F\nRenalytix PLC\n30 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n29 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n30 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.997348%\n0.000000%\n7.997348%\n34,949,903\nPosition of previous notification (if\napplicable)\n5.172754%\n0.000000%\n5.172754%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n34,949,903\n7.997348%\nSUBTOTAL 8. A\n34,949,903\n7.997348%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.997348%\n7.997348%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n30.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFERIDLIVIE",
          "content_length": 4521
        },
        "ingested_at": "2026-01-21T02:01:37.498492Z"
      },
      {
        "event_id": "RNS-28th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498504Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-mdh611o7sd27eqb.html",
          "rns_number": "RNS Number : 1715F",
          "full_content": "28 Oct 2025 16:04\nRNS Number : 1715F\nRenalytix PLC\n28 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n27 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n28 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n5.172754%\n0.000000%\n5.172754%\n22,605,901\nPosition of previous notification (if\napplicable)\n8.002628%\n0.000000%\n8.002628%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n22,605,901\n5.172754%\nSUBTOTAL 8. A\n22,605,901\n5.172754%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n5.172754%\n5.172754%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n28.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFIRIVLTFIE",
          "content_length": 4521
        },
        "ingested_at": "2026-01-21T02:01:37.498517Z"
      },
      {
        "event_id": "RNS-27th Oct 2025-confirma",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498531Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Confirmation of receipt of \u00a3860k R&D tax credits",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/confirmation-of-receipt-of-163860k-rd-tax-credits-x2bqjth3njnzqf7.html",
          "rns_number": "RNS Number : 8354E",
          "full_content": "27 Oct 2025 07:00\nRNS Number : 8354E\nRenalytix PLC\n27 October 2025\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nConfirmation of receipt of \u00a3860k of R&D tax credits\nLONDON and NEW YORK, 27 October 2025\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, confirms the receipt of\nResearch and Development Tax Credits totalling \u00a3860k in relation to work completed in the fiscal years ended 30 June 2023 and 30 June 2024.\nThe Company received a payment of \u00a3296k in Q1 FY26, adding to the \u00a3564k payment received in Q4 FY25.\nThe Company expects a further credit to be received in early Q3 FY26 in relation to work completed in FY25.\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering\nWalbrook PR Limited\nTel: 020 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: 07980 541 893 / 07407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation,\nkidneyintelX.dkd\nis the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect.\nkidneyintelX.dkd\nis now being deployed across large physician group practices and health systems in select regions of the United States.\nThe over 15,000 patients that have been tested by\nkidneyintelX.dkd\nhave produced a substantial body of real-world performance data. In patient populations where\nkidneyintelX.dkd\nhas been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded.\nkidneyintelX.dkd\nnow has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result.\nkidneyintelX.dkd\nis also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).\nKidneyIntelX\nis based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix.\nFor information about the kidneyintelX,dkd test, visit\nkidneyintelx.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCUSUKRVKURUAA",
          "content_length": 4013
        },
        "ingested_at": "2026-01-21T02:01:37.498543Z"
      },
      {
        "event_id": "RNS-24th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498556Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-pmq92r08480teu5.html",
          "rns_number": "RNS Number : 7660E",
          "full_content": "24 Oct 2025 10:12\nRNS Number : 7660E\nRenalytix PLC\n24 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n22 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n24 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n8.002628%\n0.000000%\n8.002628%\n34,972,980\nPosition of previous notification (if\napplicable)\n0.000000%\n0.000000%\n0.000000%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n34,972,980\n8.002628%\nSUBTOTAL 8. A\n34,972,980\n8.002628%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n8.002628%\n8.002628%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n24.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFIFLAIILSFIE",
          "content_length": 4521
        },
        "ingested_at": "2026-01-21T02:01:37.498568Z"
      },
      {
        "event_id": "RNS-23rd Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498581Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-2xa68lmqmwnmkfv.html",
          "rns_number": "RNS Number : 5672E",
          "full_content": "23 Oct 2025 09:09\nRNS Number : 5672E\nRenalytix PLC\n23 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nX\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n20 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n22 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n0.000000%\n0.000000%\n0.000000%\n0\nPosition of previous notification (if\napplicable)\n7.779756%\n0.000000%\n7.779756%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n0\n0.000000%\nSUBTOTAL 8. A\n0\n0.000000%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nPlace of completion\nZurich, Switzerland\nDate of completion\n22.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFIFITIDLVFIE",
          "content_length": 4642
        },
        "ingested_at": "2026-01-21T02:01:37.498593Z"
      },
      {
        "event_id": "RNS-21st Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498605Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-l3bilum58t2cvcb.html",
          "rns_number": "RNS Number : 2179E",
          "full_content": "21 Oct 2025 10:08\nRNS Number : 2179E\nRenalytix PLC\n21 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n17 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n21 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.779756%\n0.000000%\n7.779756%\n33,998,987\nPosition of previous notification (if\napplicable)\n0.000000%\n0.000000%\n0.000000%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n33,998,987\n7.779756%\nSUBTOTAL 8. A\n33,998,987\n7.779756%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.779756%\n7.779756%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n21.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFIFIAISLLFIE",
          "content_length": 4521
        },
        "ingested_at": "2026-01-21T02:01:37.498617Z"
      },
      {
        "event_id": "RNS-17th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498629Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-9mj86a6uqg3uhmr.html",
          "rns_number": "RNS Number : 8587D",
          "full_content": "17 Oct 2025 10:26\nRNS Number : 8587D\nRenalytix PLC\n17 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify) iii: Increase in the total number of voting rights resulting in UBS' trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nX\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n15 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n16 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n0.000000%\n0.000000%\n0.000000%\n0\nPosition of previous notification (if\napplicable)\n8.324083%\n0.000000%\n8.324083%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n0\n0.000000%\nSUBTOTAL 8. A\n0\n0.000000%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nIncrease in the total number of voting rights resulting in UBS' trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nPlace of completion\nZurich, Switzerland\nDate of completion\n16.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFIFFAIELDLIE",
          "content_length": 4764
        },
        "ingested_at": "2026-01-21T02:01:37.498641Z"
      },
      {
        "event_id": "RNS-17th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498654Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-jbt8jlwyb1j1syp.html",
          "rns_number": "RNS Number : 8225D",
          "full_content": "17 Oct 2025 07:00\nRNS Number : 8225D\nRenalytix PLC\n17 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix plc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nHeights Capital Management, Inc.\nCity and country of registered office (if applicable)\nSan Francisco, California\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCVI Investments, Inc.\nCity and country of registered office (if applicable)\nCayman Islands\n5. Date on which the threshold was crossed or reached\nvi\n:\n15/10/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n15/10/2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n9.874%\n0.00%\n9.874%\n43,151,533\nPosition of previous notification (if\napplicable)\n2.96%\n0.00%\n2.96%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n43,151,533\n9.874%\nSUBTOTAL 8. A\n43,151,533\n9.874%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nHeights Capital Management, Inc.\n9.874%\n9.874%\nCVI Investments, Inc.\n9.874%\n9.874%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nNone\nPlace of completion\nLondon, United Kingdom\nDate of completion\n15.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFIFEEISLDLIE",
          "content_length": 4521
        },
        "ingested_at": "2026-01-21T02:01:37.498666Z"
      },
      {
        "event_id": "RNS-16th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498679Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-au82ze6fflmtw1v.html",
          "rns_number": "RNS Number : 7148D",
          "full_content": "16 Oct 2025 14:31\nRNS Number : 7148D\nRenalytix PLC\n16 October 2025\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nHolding(s) in Company\nLONDON and NEW YORK, 16 October 2025\u00a0-\nRenalytix plc (LSE: RENX) (OTCQB: RNLXY), announces that it has received a TR-1 notification from Harwood Capital LLP following the recent admission of ordinary shares and increase in the Company's total issued share capital (RNS 8264C: $4m balance sheet improvement with bond conversion). The resulting crossing of a threshold is due to an increase in the Company's total issued share capital, rather than any disposal or acquisition of shares. The TR-1 notification is reproduced below.\n1. Issuer Details\nISIN\nGB00BYWL4Y04\nIssuer Name\nRENALYTIX PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn event changing the breakdown of voting rights\n3. Details of person subject to the notification obligation\nName\nHarwood Capital LLP\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\nName\nCity of registered office\nCountry of registered office\nHarwood Capital Management (Gibraltar) Limited\nGibraltar\nGibraltar\nHarwood Capital LLP\nLondon\nUnited Kingdom\n4. Details of the shareholder\nName\nCity of registered office\nCountry of registered office\nNorth Atlantic Smaller Companies Investment Trust Plc\nLondon\nUnited Kingdom\nOryx International Growth Fund Limited\nGuernsey\nGuernsey\nHarwood Capital LLP\nLondon\nUnited Kingdom\n5. Date on which the threshold was crossed or reached\n15-Oct-2025\n6. Date on which Issuer notified\n15-Oct-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n3.903000\n0.000000\n3.903000\n17061345\nPosition of previous notification (if applicable)\n4.411130\n0.000000\n4.411130\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BYWL4Y04\n11500000\n2.631000\nGB00BYWL4Y04\n4800000\n1.098000\nGB00BYWL4Y04\n761345\n0.174000\nSub Total 8.A\n17061345\n3.903000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nChristopher Harwood Bernard Mills\nNorth Atlantic Smaller Companies Investment Trust Plc\n2.631000\n2.631000%\nChristopher Harwood Bernard Mills\nOryx International Growth Fund Limited\n1.098000\n1.098000%\nChristopher Harwood Bernard Mills\nHarwood Capital LLP\n0.174000\n0.174000%\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\n12. Date of Completion\n15/10/2025\n13. Place Of Completion\nLondon Stock Exchange\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering\nWalbrook PR Limited\nTel: 020 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: 07980 541 893 / 07407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United Sta",
          "content_length": 7321
        },
        "ingested_at": "2026-01-21T02:01:37.498692Z"
      },
      {
        "event_id": "RNS-16th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498705Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-luzly1qi2hf4ubp.html",
          "rns_number": "RNS Number : 7002D",
          "full_content": "16 Oct 2025 12:15\nRNS Number : 7002D\nRenalytix PLC\n16 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix plc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nUnicorn Asset Management Limited\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUnicorn AIM VCT plc\nCity and country of registered office (if applicable)\nTeignmouth, Devon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n15 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n16 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n5.90%\n5.90%\n25,797,882\nPosition of previous notification (if\napplicable)\n6.36%\n6.36%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nOrdinary shares GB00BYWL4Y04\n25,797,882\n5.90%\nSUBTOTAL 8. A\n25,797,882\n5.90%\nB 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nX\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nSee Section 4\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nFigures are based on total voting rights of 437,018,680\nPlace of completion\nUnicorn Asset Management Limited, Preachers Court, Charterhouse, Charterhouse Square, London, EC1M 6AU\nDate of completion\n16 October 2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFLLISLRLIE",
          "content_length": 4823
        },
        "ingested_at": "2026-01-21T02:01:37.498717Z"
      },
      {
        "event_id": "RNS-15th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498729Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-xkxp7nwt7fud62x.html",
          "rns_number": "RNS Number : 4819D",
          "full_content": "15 Oct 2025 09:48\nRNS Number : 4819D\nRenalytix PLC\n15 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n13 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n15 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n8.324083%\n0.000000%\n8.324083%\n33,743,222\nPosition of previous notification (if\napplicable)\n5.200990%\n0.000000%\n5.200990%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n33,743,222\n8.324083%\nSUBTOTAL 8. A\n33,743,222\n8.324083%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n8.324083%\n8.324083%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n15.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFIFSTIELELIE",
          "content_length": 4521
        },
        "ingested_at": "2026-01-21T02:01:37.498741Z"
      },
      {
        "event_id": "RNS-10th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498754Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-csg9x7k5omvns45.html",
          "rns_number": "RNS Number : 9704C",
          "full_content": "10 Oct 2025 14:34\nRNS Number : 9704C\nRenalytix PLC\n10 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n09 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n10 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n5.200990%\n0.000000%\n5.200990%\n21,083,181\nPosition of previous notification (if\napplicable)\n8.396466%\n0.000000%\n8.396466%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n21,083,181\n5.200990%\nSUBTOTAL 8. A\n21,083,181\n5.200990%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n5.200990%\n5.200990%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n10.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFVVILLILIE",
          "content_length": 4521
        },
        "ingested_at": "2026-01-21T02:01:37.498766Z"
      },
      {
        "event_id": "RNS-10th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498779Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-ik41922h8q77sdh.html",
          "rns_number": "RNS Number : 9289C",
          "full_content": "10 Oct 2025 09:56\nRNS Number : 9289C\nRenalytix PLC\n10 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n08 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n10 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n8.396466%\n0.000000%\n8.396466%\n34,036,640\nPosition of previous notification (if\napplicable)\n5.344298%\n0.000000%\n5.344298%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n34,036,640\n8.396466%\nSUBTOTAL 8. A\n34,036,640\n8.396466%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n8.396466%\n8.396466%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n10.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFIFETIELILIE",
          "content_length": 4521
        },
        "ingested_at": "2026-01-21T02:01:37.498791Z"
      },
      {
        "event_id": "RNS-10th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498804Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-6to3gk1rfoqrdwu.html",
          "rns_number": "RNS Number : 8256C",
          "full_content": "10 Oct 2025 07:01\nRNS Number : 8256C\nRenalytix PLC\n10 October 2025\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nHolding(s) in Company\nLONDON and NEW YORK, 10 October 2025\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), announces\nthat\nit has\nreceived six TR-1 notifications from Heights Capital Management Inc., covering the period 22 September 2025 to 7 October 2025, which are reproduced below with the most recent TR-1 notification first.\n(#1) TR-1: Standard form for notification of major holdings\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix plc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nHeights Capital Management, Inc.\nCity and country of registered office (if applicable)\nSan Francisco, California\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCVI Investments, Inc.\nCity and country of registered office (if applicable)\nCayman Islands\n5. Date on which the threshold was crossed or reached\nvi\n:\n07/10/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n08/10/2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n2.96%\n0.00%\n2.96%\n12,001,499\nPosition of previous notification (if\napplicable)\n3.90%\n0.00%\n3.90%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n12,001,499\n2.96%\nSUBTOTAL 8. A\n12,001,499\n2.96%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nHeights Capital Management, Inc.\n2.96%\n2.96%\nCVI Investments, Inc.\n2.96%\n2.96%\n10. In case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nNone\nPlace of completion\nLondon, United Kingdom\nDate of completion\n08.10.2025\n(#2) TR-1: Standard form for notification of major holdings\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix plc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nHeights Capital Management, Inc.\nCity and country of registered office (if applicable)\nSan Francisco, California\n4. Full name of shareholder(s)\n(if different from 3.) v\nName\nCVI Investments, Inc.\nCity and country of registered office (if applicable)\nCayman Islands\n5. Date on which the threshold was crossed or reached\nvi\n:\n02/10/2025\n6. Date on which issuer notified (DD/MM/YYYY):\n03/10/20",
          "content_length": 24938
        },
        "ingested_at": "2026-01-21T02:01:37.498817Z"
      },
      {
        "event_id": "RNS-10th Oct 2025-$4mbalan",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498831Z",
        "source": "LSE_RNS",
        "data": {
          "title": "$4m balance sheet improvement with bond conversion",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/4m-balance-sheet-improvement-with-bond-conversion-zzkm7abjespt84e.html",
          "rns_number": "RNS Number : 8264C",
          "full_content": "10 Oct 2025 07:00\nRNS Number : 8264C\nRenalytix PLC\n10 October 2025\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n$4m balance sheet improvement with bond conversion\nLONDON and NEW YORK, 10 October 2025\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, has been notified\nby a fund advised by Heights Capital Ireland LLC (\"Convertible Bond Investor\") that approximately $4m of non-amortizing senior convertible bonds (\"Convertible Bonds\") will be capitalised via the issue to the Convertible Bond Investor of 31,650,034 ordinary shares, at the recent fundraise issue price of 9.5 pence per share (\"Conversions Shares\").\nThe conversion of the Convertible Bonds will provide a significant improvement to Renalytix's balance sheet, improving the Company's net asset position by approximately $4m and saving up to $1.4m in\naccrued interest over the remaining life of the loan.\nThe conversion will also\nimprove the Company's debt to equity ratio.\nApplication will be made to the London Stock Exchange for admission of the Conversion Shares to trading on AIM (\"Admission\"). It is expected that Admission of the Conversion Shares will take place at 8.00 a.m. on 15 October 2025 and that dealings in the Conversion Shares on AIM will commence at the same time.\nTotal Voting Rights\nFollowing Admission\n, the\nCompany's total issued share capital will be\n437,018,680 Ordinary Shares o\nf\n\u00a30.0025\neach in the capital of the Company (\"Ordinary Shares\"). Each Ordinary Share carries the right to one vote at a general meeting of the Company.\nThe Company does not hold any Ordinary Shares in treasury.\nThe above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering\nWalbrook PR Limited\nTel: 020 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: 07980 541 893 / 07407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation,\nkidneyintelX.dkd\nis the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect.\nkidneyintelX.dkd\nis now being deployed across large physician group practices and health systems in select regions of the United States.\nThe over 15,000 patients that have been tested by\nkidneyintelX.dkd\nhave produced a substantial body of real-world performance data. In patient populations where\nkidneyintelX.dkd\nhas been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded.\nkidneyintelX.dkd\nnow has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result.\nkidneyintelX.dkd\nis also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).\nKidneyIntelX\nis based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix.\nFor information about the kidneyintelX,dkd test, visit\nkidneyintelx.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the",
          "content_length": 5301
        },
        "ingested_at": "2026-01-21T02:01:37.498844Z"
      },
      {
        "event_id": "RNS-9th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498857Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-l6wiywf2mjnlds9.html",
          "rns_number": "RNS Number : 8021C",
          "full_content": "9 Oct 2025 16:43\nRNS Number : 8021C\nRenalytix PLC\n09 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n07 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n09 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n5.344298%\n0.000000%\n5.344298%\n21,664,107\nPosition of previous notification (if\napplicable)\n8.636256%\n0.000000%\n8.636256%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n21,664,107\n5.344298%\nSUBTOTAL 8. A\n21,664,107\n5.344298%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n5.344298%\n5.344298%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n09.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFVEIALAIIE",
          "content_length": 4520
        },
        "ingested_at": "2026-01-21T02:01:37.498869Z"
      },
      {
        "event_id": "RNS-7th Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498882Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-j3aqzgb9uid1li2.html",
          "rns_number": "RNS Number : 4296C",
          "full_content": "7 Oct 2025 15:03\nRNS Number : 4296C\nRenalytix PLC\n07 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n03 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n07 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n8.636256%\n0.000000%\n8.636256%\n35,008,673\nPosition of previous notification (if\napplicable)\n5.779986%\n0.000000%\n5.779986%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n35,008,673\n8.636256%\nSUBTOTAL 8. A\n35,008,673\n8.636256%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n8.636256%\n8.636256%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n07.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFISILLDIIE",
          "content_length": 4520
        },
        "ingested_at": "2026-01-21T02:01:37.498894Z"
      },
      {
        "event_id": "RNS-3rd Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498906Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-4de9bttuoya970p.html",
          "rns_number": "RNS Number : 0576C",
          "full_content": "3 Oct 2025 14:32\nRNS Number : 0576C\nRenalytix PLC\n03 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n01 October 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n03 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n5.779986%\n0.000000%\n5.779986%\n23,430,252\nPosition of previous notification (if\napplicable)\n0.000000%\n0.000000%\n0.000000%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n23,430,252\n5.779986%\nSUBTOTAL 8. A\n23,430,252\n5.779986%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n5.779986%\n5.779986%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n03.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFVVILLVIIE",
          "content_length": 4520
        },
        "ingested_at": "2026-01-21T02:01:37.498918Z"
      },
      {
        "event_id": "RNS-2nd Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498931Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-hvk8fu6gy6zdhk9.html",
          "rns_number": "RNS Number : 8778B",
          "full_content": "2 Oct 2025 14:57\nRNS Number : 8778B\nRenalytix PLC\n02 October 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii: UBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nX\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n30 September 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n02 October 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n0.000000%\n0.000000%\n0.000000%\n0\nPosition of previous notification (if\napplicable)\n7.821175%\n0.000000%\n7.821175%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n0\n0.000000%\nSUBTOTAL 8. A\n0\n0.000000%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nPlace of completion\nZurich, Switzerland\nDate of completion\n02.10.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFEVISLFIIE",
          "content_length": 4643
        },
        "ingested_at": "2026-01-21T02:01:37.498943Z"
      },
      {
        "event_id": "RNS-1st Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498956Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-u4kx00z9ofgfy2z.html",
          "rns_number": "RNS Number : 6818B",
          "full_content": "1 Oct 2025 14:43\nRNS Number : 6818B\nRenalytix PLC\n01 October 2025\nS\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n1a. Identity of the issuer or the underlying issuer of existing shares:\nRenalytix PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of shares\nAn acquisition or disposal of financial instruments\nX\nAn event changing the breakdown of shares outstanding\nOther (please specify):\n3. Details of person subject to the notification obligation\nName\nPentwater Capital Management LP\nCity and country of registered office (if applicable)\nNaples\n,\nUnited States\n4. Full name of shareholder(s)\n(if different from 3.)\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached:\n30/09/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n01/10/2025\n7. Total positions of person(s) subject to the notification obligation\n% of shares outstanding (total of 8. A)\n% of\nshares outstanding through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of shares outstanding held in issuer\nResulting situation on the date on which threshold was crossed or reached\n1.427144%\n7.816294%\n9.243438%\n37,470,000.00\nPosition of previous notification (if\napplicable)\n1.427144%\n6.857097%\n8.634116%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nv\nA: Shares\nClass/type ofshares\nISIN code (if possible)\nNumber of shares outstanding\n% of shares outstanding\nDirect\nIndirect\nDirect\nIndirect\nEquity: GB00BYWL4Y04\n5,785,196.00\n1.427144%\nSUBTOTAL 8. A\n5,785,196.00\n1.427144%\nB 1: Financial Instruments as an entitlement to acquire\nType of financial instrument\nExpirationdate\nExercise/Conversion Period\nNumber shares that may be acquired if the instrument is\nexercised/converted.\n% of shares outstanding\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect\nType of financial instrument\nExpirationdate\nExercise/Conversion Period\nPhysical or cash\nsettlement\nNumber of shares\n% of shares outstanding\nSwap\nCash Settlement\n31,684,804.00\n7.816294%\nSUBTOTAL 8.B.2\n31,684,804.00\n7.816294%\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nFull\nchain of controlled undertakings through which the shares and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nX\nName\n% of shares outstanding if it equals or is higher than the notifiable threshold\n% of shares outstanding through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nMatthew Halbower\nMCH PWCM Holdings Inc.\nPentwater Capital Management LP\n1.427144%\n7.816294%\n9.243438%\n10. Additional information\nPlace of completion\nNaples\nDate of completion\n01/10/2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFSVIFLLIIE",
          "content_length": 4129
        },
        "ingested_at": "2026-01-21T02:01:37.498968Z"
      },
      {
        "event_id": "RNS-1st Oct 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.498980Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-yjg49jo15qeq2yr.html",
          "rns_number": "RNS Number : 5076B",
          "full_content": "1 Oct 2025 07:00\nRNS Number : 5076B\nRenalytix PLC\n01 October 2025\nS\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n1a. Identity of the issuer or the underlying issuer of existing shares:\nRenalytix PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of shares\nAn acquisition or disposal of financial instruments\nX\nAn event changing the breakdown of shares outstanding\nX\nOther (please specify):\n3. Details of person subject to the notification obligation\nName\nPentwater Capital Management LP\nCity and country of registered office (if applicable)\nNaples\n,\nUnited States\n4. Full name of shareholder(s)\n(if different from 3.)\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached:\n29/09/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n30/09/2025\n7. Total positions of person(s) subject to the notification obligation\n% of shares outstanding (total of 8. A)\n% of\nshares outstanding through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of shares outstanding held in issuer\nResulting situation on the date on which threshold was crossed or reached\n1.427144%\n7.206972%\n8.634116%\n35,000,000.00\nPosition of previous notification (if\napplicable)\n1.733980%\n3.645000%\n5.378980%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nv\nA: Shares\nClass/type ofshares\nISIN code (if possible)\nNumber of shares outstanding\n% of shares outstanding\nDirect\nIndirect\nDirect\nIndirect\nEquity: GB00BYWL4Y04\n5,785,196.00\n1.427144%\nSUBTOTAL 8. A\n1.427144%\nB 1: Financial Instruments as an entitlement to acquire\nType of financial instrument\nExpirationdate\nExercise/Conversion Period\nNumber shares that may be acquired if the instrument is\nexercised/converted.\n% of shares outstanding\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect\nType of financial instrument\nExpirationdate\nExercise/Conversion Period\nPhysical or cash\nsettlement\nNumber of shares\n% of shares outstanding\nSwap\nCash Settlement\n29,214,804.00\n7.206972%\nSUBTOTAL 8.B.2\n29,214,804.00\n7.206972%\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nFull\nchain of controlled undertakings through which the shares and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nX\nName\n% of shares outstanding if it equals or is higher than the notifiable threshold\n% of shares outstanding through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nMatthew Halbower\nMCH PWCM Holdings Inc.\nPentwater Capital Management LP\n1.427144%\n7.206972%\n8.634116%\n10. Additional information\nPlace of completion\nNaples\nDate of completion\n30/09/2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFFAATIIVIE",
          "content_length": 4118
        },
        "ingested_at": "2026-01-21T02:01:37.498993Z"
      },
      {
        "event_id": "RNS-1st Oct 2025-cemarkap",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.499005Z",
        "source": "LSE_RNS",
        "data": {
          "title": "CE Mark application submission",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/ce-mark-application-submission-r23jfw4xjzyndjg.html",
          "rns_number": "RNS Number : 4841B",
          "full_content": "1 Oct 2025 07:00\nRNS Number : 4841B\nRenalytix PLC\n01 October 2025\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nCE Mark application submission\nIn response to strategic partner interest in use of kidneyintelX.dkd in a clinical trial in Europe\nLONDON and NEW YORK, 1 October 2025\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces\nthat\nit has submitted an application for CE Mark certification in accordance with the European Union In-Vitro Diagnostics Regulation (IVDR) to enable clinical use and reporting of the\nkidneyintelX.dkd\u2122\ntest across the EU.\nThe\nkidneyintelX.dkd\nprognostic blood test is commercially available in the US and indicated for use as an aid in predicting level of risk (high, moderate, low) for progressive decline in kidney function in type 2 diabetes patients with diagnosed chronic kidney disease stages 1-3b.\nRenalytix is pursuing a CE mark in response to growing international strategic partner interest, having already entered in discussions with a Top 10 global pharmaceutical company on the use of the test for targeted enrollment of patients in a global clinical trial and potential use as a companion diagnostic for a novel therapy. When combined with FDA approval, the CE Mark will further embed\nkidneyintelX.dkd\nas the global precision medicine standard in Chronic Kidney Disease (CKD).\nOn successful achievement of a CE mark, expected in H1 2026, Renalytix anticipates further commercial opportunities, including international distribution partnerships, in FY26 and/or FY27.\nAccording to independently published estimates, CKD is a significant global health issue affecting nearly 850 million people globally with close to 100 million of those being European individuals.\nA diagnostic blood test requires CE mark certification which is subject to a rigorous assessment of data on safety, analytical validation, software controls and clinical performance in compliance with IVDR.\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering\nWalbrook PR Limited\nTel: 020 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: 07980 541 893 / 07407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation,\nkidneyintelX.dkd\nis the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect.\nkidneyintelX.dkd\nis now being deployed across large physician group practices and health systems in select regions of the United States.\nThe over 15,000 patients that have been tested by\nkidneyintelX.dkd\nhave produced a substantial body of real-world performance data. In patient populations where\nkidneyintelX.dkd\nhas been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded.\nkidneyintelX.dkd\nnow has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result.\nkidneyintelX.dkd\nis also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).\nKidneyIntelX\nis based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix.\nFor information about the kidneyintelX,dkd test, visit\nkidneyintelx.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage",
          "content_length": 5310
        },
        "ingested_at": "2026-01-21T02:01:37.499020Z"
      },
      {
        "event_id": "RNS-30th Sep 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.499032Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-62zzetykaj0q4z6.html",
          "rns_number": "RNS Number : 4720B",
          "full_content": "30 Sep 2025 16:02\nRNS Number : 4720B\nRenalytix PLC\n30 September 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n29 September 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n30 September 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.821175%\n0.000000%\n7.821175%\n31,704,592\nPosition of previous notification (if\napplicable)\n0.000000%\n0.000000%\n0.000000%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n31,704,592\n7.821175%\nSUBTOTAL 8. A\n31,704,592\n7.821175%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.821175%\n7.821175%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n30.09.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFIEAIIIVIE",
          "content_length": 4527
        },
        "ingested_at": "2026-01-21T02:01:37.499045Z"
      },
      {
        "event_id": "RNS-29th Sep 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.499057Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-suq2ykev20qzvy6.html",
          "rns_number": "RNS Number : 2850B",
          "full_content": "29 Sep 2025 17:18\nRNS Number : 2850B\nRenalytix PLC\n29 September 2025\nS\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n1a. Identity of the issuer or the underlying issuer of existing shares:\nRenalytix PLC\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of shares\nAn acquisition or disposal of financial instruments\nX\nAn event changing the breakdown of shares outstanding\nX\nOther (please specify):\n3. Details of person subject to the notification obligation\nName\nPentwater Capital Management LP\nCity and country of registered office (if applicable)\nNaples\n,\nUnited States\n4. Full name of shareholder(s)\n(if different from 3.)\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached:\n29/09/2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n29/09/2025\n7. Total positions of person(s) subject to the notification obligation\n% of shares outstanding (total of 8. A)\n% of\nshares outstanding through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of shares outstanding held in issuer\nResulting situation on the date on which threshold was crossed or reached\n1.427144%\n6.528577%\n7.955721%\n32,250,000.00\nPosition of previous notification (if\napplicable)\n1.733980%\n3.645000%\n5.378980%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nv\nA: Shares\nClass/type ofshares\nISIN code (if possible)\nNumber of shares outstanding\n% of shares outstanding\nDirect\nIndirect\nDirect\nIndirect\nEquity: GB00BYWL4Y04\n5,785,196\n1.427144%\nSUBTOTAL 8. A\n5,785,196\n1.427144%\nB 1: Financial Instruments as an entitlement to acquire\nType of financial instrument\nExpirationdate\nExercise/Conversion Period\nNumber shares that may be acquired if the instrument is\nexercised/converted.\n% of shares outstanding\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect\nType of financial instrument\nExpirationdate\nExercise/Conversion Period\nPhysical or cash\nsettlement\nNumber of shares\n% of shares outstanding\nSwap\nCash Settlement\n26,464,804.00\n6.528577%\nSUBTOTAL 8.B.2\n26,464,804.00\n6.528577%\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nFull\nchain of controlled undertakings through which the shares and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nX\nName\n% of shares outstanding if it equals or is higher than the notifiable threshold\n% of shares outstanding through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nMatthew Halbower\nMCH PWCM Holdings Inc.\nPentwater Capital Management LP\n1.427144%\n6.528577%\n7.955721%\n10. Additional information\nPlace of completion\nNaples\nDate of completion\n29/09/2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFLRAEIAFIE",
          "content_length": 4128
        },
        "ingested_at": "2026-01-21T02:01:37.499069Z"
      },
      {
        "event_id": "RNS-29th Sep 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.499081Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-tslpvjdj21481bq.html",
          "rns_number": "RNS Number : 2584B",
          "full_content": "29 Sep 2025 14:28\nRNS Number : 2584B\nRenalytix PLC\n29 September 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix plc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nUnicorn Asset Management Limited\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUnicorn AIM VCT plc\nCity and country of registered office (if applicable)\nTeignmouth, Devon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n29 September 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n29 September 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n6.36%\n6.36%\n25,797,882\nPosition of previous notification (if\napplicable)\n7.58%\n7.58%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nOrdinary shares GB00BYWL4Y04\n25,797,882\n6.36%\nSUBTOTAL 8. A\n25,797,882\n6.36%\nB 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nX\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nSee Section 4\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nFigures are based on total voting rights of 405,368,646\nPlace of completion\nUnicorn Asset Management Limited, Preachers Court, Charterhouse, Charterhouse Square, London, EC1M 6AU\nDate of completion\n29 September 2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFFVAEIAFIE",
          "content_length": 4831
        },
        "ingested_at": "2026-01-21T02:01:37.499094Z"
      },
      {
        "event_id": "RNS-29th Sep 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.499123Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-iry75efnxpcf04v.html",
          "rns_number": "RNS Number : 1963B",
          "full_content": "29 Sep 2025 09:32\nRNS Number : 1963B\nRenalytix PLC\n29 September 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii: UBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nX\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nCity and country of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\nvi\n:\n25 September 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n29 September 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n0.000000%\n0.000000%\n0.000000%\n0\nPosition of previous notification (if\napplicable)\n5.196433%\n0.000000%\n5.196433%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n0\n0.000000%\nSUBTOTAL 8. A\n0\n0.000000%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nUBS trading book holdings in Renalytix PLC fell below 5% and are therefore exempt from reporting.\nPlace of completion\nZurich, Switzerland\nDate of completion\n29.09.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFIFFTAAIAFIE",
          "content_length": 4648
        },
        "ingested_at": "2026-01-21T02:01:37.499136Z"
      },
      {
        "event_id": "RNS-29th Sep 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.499149Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-1g6taycpzdphyle.html",
          "rns_number": "RNS Number : 1052B",
          "full_content": "29 Sep 2025 07:00\nRNS Number : 1052B\nRenalytix PLC\n29 September 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix plc\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\nNon-UK issuer\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nX\nOther (please specify)iii:\n3. Details of person subject to the notification obligation\niv\nName\nUnicorn Asset Management Limited\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUnicorn AIM VCT plc\nCity and country of registered office (if applicable)\nTeignmouth, Devon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n26 September 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n26 September 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.58%\n7.58%\n25,797,882\nPosition of previous notification (if\napplicable)\n5.68%\n5.68%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nDirect\n(Art 9 of Directive 2004/109/EC) (DTR5.1)\nIndirect\n(Art 10 of Directive 2004/109/EC) (DTR5.2.1)\nOrdinary shares GB00BYWL4Y04\n25,797,882\n7.58%\nSUBTOTAL 8. A\n25,797,882\n7.58%\nB 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nsettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nX\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\nxiv\n(please add additional rows as necessary)\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nSee Section 4\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nFigures are based on total voting rights of 340,459,691\nPlace of completion\nUnicorn Asset Management Limited, Preachers Court, Charterhouse, Charterhouse Square, London, EC1M 6AU\nDate of completion\n26 September 2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFLSAFITFIE",
          "content_length": 4833
        },
        "ingested_at": "2026-01-21T02:01:37.499161Z"
      },
      {
        "event_id": "RNS-26th Sep 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.499173Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-28nowuiqm3reqsi.html",
          "rns_number": "RNS Number : 0487B",
          "full_content": "26 Sep 2025 12:17\nRNS Number : 0487B\nRenalytix PLC\n26 September 2025\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n24 September 2025\n6.\nDate on which issuer notified (DD/MM/YYYY):\n26 September 2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n5.196433%\n0.000000%\n5.196433%\n17,210,899\nPosition of previous notification (if\napplicable)\n0.000000%\n0.000000%\n0.000000%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n17,210,899\n5.196433%\nSUBTOTAL 8. A\n17,210,899\n5.196433%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n5.196433%\n5.196433%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n26.09.2025\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFLLARIRFIE",
          "content_length": 4527
        },
        "ingested_at": "2026-01-21T02:01:37.499186Z"
      },
      {
        "event_id": "RNS-26th Sep 2025-\u00a37.05mto",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.499201Z",
        "source": "LSE_RNS",
        "data": {
          "title": "\u00a37.05m total gross proceeds from Fundraise",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/163705m-total-gross-proceeds-from-fundraise-b2rblzsagxehcmr.html",
          "rns_number": "RNS Number : 9135A",
          "full_content": "26 Sep 2025 07:00\nRNS Number : 9135A\nRenalytix PLC\n26 September 2025\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF THE LAWS OF ENGLAND AND WALES PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"\nUK MAR\n\"). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE WITHIN THE PUBLIC DOMAIN.\nRenalytix plc\n(\"\nRenalytix\n\" or the \"\nCompany\n\")\n\u00a37.05m total gross proceeds from Fundraise\nOversubscribed WRAP Offer, combines with Placing and Subscription, and Additional Subscription\nLONDON and NEW YORK, 26 September 2025\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, confirms, further to the announcements made on 22 September, the result of its Fundraise at the Issue Price of 9.5 pence per share. The Company announces that it has raised aggregate gross proceeds of approximately \u00a30.8 million pursuant to a significantly oversubscribed WRAP Retail Offer, alongside the previously announced oversubscribed Placing, Subscription and Additional Subscription. Accordingly, the Company will issue a total of 8,421,052 new Ordinary Shares at the Issue Price pursuant to the WRAP Retail Offer (the \"Retail Offer Shares\").\nIn total, the Placing and Subscription, the Additional Subscription and the WRAP Retail Offer have raised gross proceeds of approximately \u00a37.05 million ($9.5 million) for the Company, via the Placing and Subscription of 54,741,582 Placing and Subscription Shares, 11,000,000 Additional Subscription Shares and the 8,421,052 WRAP Retail Offer Shares.\nJames McCullough, CEO of Renalytix, commented:\n\"I would like to\u00a0thank our investors for a significantly oversubscribed fundraise at both the institutional and retail investor level, at a key moment\u00a0in our commercial\u00a0growth. We all have a real opportunity\u00a0to change the course of diabetic kidney disease that causes untold suffering in millions of people\u00a0and an unsustainable social\u00a0cost burden. Over the course of coming months we will be working closely with Tempus AI to expand access to kidneyintelX.dkd advanced prognostic blood testing in the US market, along with other developing market opportunities.\"\nAdmission\nApplications have been made for the First Tranche Placing Shares, the Second Tranche Placing Shares, the Additional Subscription Shares and the Retail Offer Shares to be admitted to trading on the AIM Market of the London Stock Exchange (\"\nAdmission\n\"). Admission of the 9,253,679 First Tranche Placing Shares will become effective at 8.00 a.m. on 26 September 2025. Admission of the 45,487,903 Second Tranche Placing Shares, the 11,000,000 Additional Subscription Shares and the 8,421,052 Retail Offer Shares will become effective at 8.00 a.m.\non 29 September 2025.\nThe Retail Offer Shares will be issued free of all liens, charges and encumbrances and will, on Admission, rank\npari passu\nin all respects with the new Ordinary Shares to be issued pursuant to the Placing, the Subscription, the Additional Subscription and the Company's existing Ordinary Shares.\nDirector Shareholdings\nFollowing Admission, the percentage holdings of the Directors who participated in the Fundraise are set out in the table below:\nDirector\nShareholding prior to Fundraise\nNumber of Placing or Subscription Shares\nResulting Shareholding\nPercentage of Ordinary Share Capital held post Admission\nJulian Baines\n1,848,700\n105,263\n1,953,963\n0.48%\nChristopher Mills*\n14,561,345\n2,500,000\n17,061,345\n4.21%\nRobert Naylor\n588,055\n105,263\n693,318\n0.17%\nCatherine Coste\n279,866\n105,263\n385,129\n0.1%\n*Christopher Mills' shareholding includes shares held through North Atlantic Smaller Companies Investment Trust plc and Oryx International Growth Fund Limited. Christopher Mills is a partner and Chief Investment Officer of Harwood Capital LLP. Harwood Capital LLP is investment manager to North Atlantic Smaller Companies Investment Trust plc and investment adviser to Oryx International Growth Fund Limited.\nTotal Voting Rights\nUpon Admission, the Company's issued ordinary share capital will consist of 405,368,646 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission the total number of Ordinary Shares and voting rights in the Company will be 405,368,646 . With effect from Admission, this figure may be used by Sh",
          "content_length": 15880
        },
        "ingested_at": "2026-01-21T02:01:37.499217Z"
      },
      {
        "event_id": "RNS-24th Sep 2025-updatere",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.499230Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update Regarding Forward Guidance",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/update-regarding-forward-guidance-d7nvg6mup19d6b8.html",
          "rns_number": "RNS Number : 6757A",
          "full_content": "24 Sep 2025 14:00\nRNS Number : 6757A\nRenalytix PLC\n24 September 2025\nRenalytix plc\n(\"\nRenalytix\n\" or the \"\nCompany\n\")\nUpdate Regarding Forward Guidance\nLONDON and NEW YORK, 24 September 2025\n- Renalytix plc (LSE: RENX) a precision medicine company with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, provides a further comment regarding revenue guidance following the Company's announcement dated 23 September 2025.\nThe Company would like to clarify that the forward revenue guidance provided does not include full consideration of the implications of its recently\nannounced collaboration with Tempus AI\n, Inc. (\"Tempus\"). As it is too early to predict revenue contributions from this new relationship with Tempus, the Company expects to provide shareholders with updates in due course.\nFor further information, please contact:\nRenalytix Plc\nJames McCullough, CEO\nwww.renalytix.com\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nJeff Keating / David Hignell (Corporate Finance)\nVadim Alexandre (Corporate Broking)\nTel: 0203 470 0470\nOberon Capital (Sole Bookrunner and Joint Broker)\nMike Seabrook / Nick Lovering / Aimee McCusker\nTel: 020 3179 5300\nWalbrook PR Limited\nPaul McManus / Alice Woodings\nTel: 020 7933 8780\nor\nrenalytix@walbrookpr.com\nMob: 07980 541 893 / 07407 804 654\nThe person responsible for making this Announcement on behalf of the Company is\nJames McCullogh, Chief Executive Officer.\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation,\nkidneyintelX.dkd\nis the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect.\nkidneyintelX.dkd\nis now being deployed across large physician group practices and health systems in select regions of the United States.\nThe over 15,000 patients that have been tested by\nkidneyintelX.dkd\nhave produced a substantial body of real-world performance data. In patient populations where\nkidneyintelX.dkd\nhas been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded.\nkidneyintelX.dkd\nnow has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result.\nkidneyintelX.dkd\nis also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).\nKidneyIntelX\nis based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix.\nFor information about the kidneyintelX,dkd test, visit\nkidneyintelx.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nUPDDZGZLZDLGKZM",
          "content_length": 4235
        },
        "ingested_at": "2026-01-21T02:01:37.499242Z"
      },
      {
        "event_id": "RNS-24th Sep 2025-addition",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.499255Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Additional Subscription for 11m Shares",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/additional-subscription-for-11m-shares-s4xzviq64fdjam4.html",
          "rns_number": "RNS Number : 6328A",
          "full_content": "24 Sep 2025 10:00\nRNS Number : 6328A\nRenalytix PLC\n24 September 2025\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n24 September 2025\nRenalytix plc\n(\"\nRenalytix\n\" or the \"\nCompany\n\")\nAdditional Institutional Subscription for 11 million Shares\nRenalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that, further to the Company's announcements dated 22 September 2025 regarding the Placing and Subscription which raised gross proceeds of \u00a35.20 million, the Company has entered into an additional subscription agreement following inbound interest from a new institutional investor (the \"Additional Subscription\").\nPursuant to the terms of the Additional Subscription Agreement, ABRDN World Healthcare Fund has subscribed for 11,000,000 Subscription Shares at the Issue Price of 9.5 pence per share (the \"Additional Subscription Shares\") for an aggregate Subscription of \u00a31.045 million ($1.410 million).\nThe funds raised via the Additional Subscription will further support the Company's commercial distribution efforts, which includes the recently announced collaboration with Tempus AI, Inc. (NASDAQ: TEM).\nJames McCullough, CEO of Renalytix, commented:\n\"\nWe are particularly pleased with the strong institutional support we have received at this critical time for accelerating growth with our U.S. kidneyintelX.dkd prognostic testing and unique data accumulation program in diabetes and kidney disease\n.\"\nAdmission and Total Voting Rights\nApplication will be made to the London Stock Exchange for the Additional Subscription Shares to be admitted to trading on the AIM. It is expected that Admission of the Additional Subscription Shares will become effective and that dealings in the Additional Subscription Shares will commence at 8.00 a.m. on Monday 29 September 2025, the same day as the 45,487,903 Second Tranche Placing Shares. This will follow the Admission of the 9,253,679 First Tranche Placing Shares on Friday 26 September 2025. The Retail Offer Shares are also expected to be admitted to trading on AIM on Monday 29 September 2025.\nThe Additional Subscription Shares when issued, will be fully paid and will rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.\nA further announcement will be made regarding the Company's enlarged issued share capital and Total Voting Rights once the result of the Retail Offer has been confirmed.\nCapitalised terms used in this announcement have the meanings given to them in the Company's 'Proposed Fundraise' and 'Result of Fundraise' announcements dated 22 September 2025, unless the context provides otherwise.\nFor further information, please contact:\nRenalytix Plc\nJames McCullough, CEO\nwww.renalytix.com\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nJeff Keating / David Hignell (Corporate Finance)\nVadim Alexandre (Corporate Broking)\nTel: 0203 470 0470\nOberon Capital (Sole Bookrunner and Joint Broker)\nMike Seabrook / Nick Lovering / Aimee McCusker\nTel: 020 3179 5300\nWalbrook PR Limited\nPaul McManus / Alice Woodings\nTel: 020 7933 8780\nor\nrenalytix@walbrookpr.com\nMob: 07980 541 893 / 07407 804 654\nThe person responsible for making this Announcement on behalf of the Company is\nJames McCullogh, Chief Executive Officer.\nForward-Looking Statements\nThis Announcement includes \"forward-looking statements\" which includes all statements other than statements of historical fact, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, or any statements preceded by, followed by or that include the words \"targets\", \"believes\", \"expects\", \"aims\", \"intends\", \"will\", \"may\", \"anticipates\", \"would\", \"could\" or similar expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These and other risks are described more fully in the Company's filings with the SE",
          "content_length": 7609
        },
        "ingested_at": "2026-01-21T02:01:37.499269Z"
      },
      {
        "event_id": "RNS-23rd Sep 2025-investor",
        "event_type": "rns_announcement",
        "date": "2026-01-21T02:01:37.499282Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Investor Presentation and Revised Revenue Guidance",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/investor-presentation-and-revised-revenue-guidance-g85fmab3dv4gyq3.html",
          "rns_number": "RNS Number : 3385A",
          "full_content": "23 Sep 2025 07:00\nRNS Number : 3385A\nRenalytix PLC\n23 September 2025\nThis announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part\u00a0of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"MAR\"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nInvestor Presentation and Revised Revenue Guidance\nRevised forward guidance on expected long-term increase in revenue\nLONDON and NEW YORK, 23 September 2025\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with\nkidneyintelX.dkd\n, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that an updated corporate presentation will be available today for download from the Company's website at\nhttps://investors.renalytix.com/presentations/\n.\nThe corporate presentation includes revised forward guidance on the Company's expected revenue: $8.4m in FY26, $19.0m in FY27 and $42.0m in FY28 with the later years of FY27 and FY28 reflecting the anticipated positive revenue impact from Renalytix's recently\nannounced\ncollaboration agreement with Tempus AI, Inc. (Nasdaq: TEM) (\"Tempus\"). This revenue guidance compares to a prior outlook through FY27 calling for $8.5m in FY26, and $17.5m for FY27 as provided in the Company's Half Year Report on 18 March 2025.\nThe Board of Directors are currently considering the long-term positive impact of the Tempus collaboration and the Company will provide further updates regarding forward revenue guidance as appropriate, as the two parties execute implementation into hospital systems and other healthcare providers.\nFor further information, please contact:\nRenalytix plc\nwww.renalytix.com\nJames McCullough, CEO\nVia Walbrook PR\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nTel:\n+44 (0)20 3470 0470\nJeff Keating / David Hignell\n(Corporate Finance)\nVadim Alexandre (Corporate Broking)\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 5300\nMike Seabrook / Nick Lovering / Aimee McCusker\nWalbrook PR Limited\nTel: 020 7933 8780 or\nrenalytix@walbrookpr.com\nPaul McManus / Alice Woodings\nMob: 07980 541 893 / 07407 804 654\nAbout Renalytix\n(\nwww.renalytix.com\n)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled\nin vitro\ndiagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for\nkidneyintelX.dkd\nwhich is now offered commercially in the United States.\nUnrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation,\nkidneyintelX.dkd\nis the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect.\nkidneyintelX.dkd\nis now being deployed across large physician group practices and health systems in select regions of the United States.\nThe over 15,000 patients that have been tested by\nkidneyintelX.dkd\nhave produced a substantial body of real-world performance data. In patient populations where\nkidneyintelX.dkd\nhas been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded.\nkidneyintelX.dkd\nnow has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result.\nkidneyintelX.dkd\nis also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).\nKidneyIntelX\nis based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix.\nFor information about the kidneyintelX,dkd test, visit\nkidneyintelx.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMS",
          "content_length": 5013
        },
        "ingested_at": "2026-01-21T02:01:37.499296Z"
      },
      {
        "event_id": "RNS-21st Jan 2026-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-21T21:48:12.932718Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/holdings-in-company-z9nzgg7u4sfm1wo.html",
          "rns_number": "RNS Number : 8356P",
          "full_content": "Today 15:20\nRNS Number : 8356P\nRenalytix PLC\n21 January 2026\nTR-1: S\ntandard form for notification of major holdings\nNOTIFICATION OF MAJOR HOLDINGS\n(to be sent to the relevant issuer\nand\nto the FCA in Microsoft Word format if possible)\ni\n1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached\nii\n:\nRenalytix PLC\nGB00BYWL4Y04\n1b. Please indicate if the issuer is a non-UK issuer\n(please mark with an \"X\" if appropriate)\n2. Reason for the notification\n(please mark the appropriate box or boxes with an \"X\")\nAn acquisition or disposal of voting rights\nX\nAn acquisition or disposal of financial instruments\nAn event changing the breakdown of voting rights\nOther (please specify) iii:\n3. Details of person subject to the notification obligation\niv\nName\nUBS Group AG - Investment Bank & Global Wealth Management\nCity and country of registered office (if applicable)\nZ\n\u00fcrich\nSwitzerland\n4. Full name of shareholder(s)\n(if different from 3.)\nv\nName\nUBS AG\nCity and country of registered office (if applicable)\nLondon, United Kingdom\n5. Date on which the threshold was crossed or reached\nvi\n:\n20 January 2026\n6.\nDate on which issuer notified (DD/MM/YYYY):\n21 January 2026\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8. A)\n% of\nvoting rights through\nfinancial instruments(total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer (8.A + 8.B)\nvii\nResulting situation on the date on which threshold was crossed or reached\n7.631241%\n0.000000%\n7.631241%\n33,349,947\nPosition of previous notification (if\napplicable)\n0.000000%\n0.000000%\n0.000000%\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\nviii\nA: Voting rights attached to shares\nClass/type ofshares\nISIN code (if possible)\nNumber of voting rights\nix\n% of voting rights\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nDirect\n(DTR5.1)\nIndirect\n(DTR5.2.1)\nGB00BYWL4Y04\n33,349,947\n7.631241%\nSUBTOTAL 8. A\n33,349,947\n7.631241%\nB 1: Financial Instruments according to DTR5.3.1R (1) (a)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nNumber of voting rights that may be acquired if the instrument is\nexercised/converted.\n% of voting rights\nSUBTOTAL 8. B 1\nB 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)\nType of financial instrument\nExpirationdate\nx\nExercise/Conversion Period\nxi\nPhysical or cash\nSettlement\nxii\nNumber of voting rights\n% of voting rights\nSUBTOTAL 8.B.2\n9. Information in relation to the person subject to the notification obligation\n(please mark the\napplicable box with an \"X\")\nPerson subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer\nxiii\nFull\nchain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity\n(please add additional rows as necessary)\nxiv\nX\nName\nxv\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\nUBS Group AG\nUBS AG\n7.631241%\n7.631241%\n10.\nIn case of proxy voting, please identify:\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional information\nxvi\nPlace of completion\nZurich, Switzerland\nDate of completion\n21.01.2026\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLFLFLELAILFIR",
          "content_length": 4515
        },
        "ingested_at": "2026-01-21T21:48:12.932750Z"
      },
      {
        "event_id": "SOCIAL-16Dec20251355-MetalMan--9152754",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.307507",
        "source": "LSE_CHAT",
        "data": {
          "author": "MetalMania1",
          "content": "Great sign of confidence",
          "sentiment": 0.0,
          "engagement": "358",
          "price_at_post": "6.25",
          "thread_title": "UBS surge their holding from 5.08% to 7.44%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D0278CAD-4353-4441-AFB6-77F17FCE35E7"
        },
        "ingested_at": "2026-01-22T21:29:46.320680+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251358-Dustysla-50157366",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.307088",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Their Primary Headquarters is London, but have offices in New York and Salt Lake City. I think this has a lot going for it, those Medicaid reimbursements are going to help, but the CE mark will certainly expand from the London office. Even Today's RNS shows the confidence in its institutional backers,  there is more positives here than the negatives the SP is performing.  Interesting to see how the MVP collaboration has gone,  numbers, tests etc. Your market will expand,  but I get your gripe. Pharma companies are predominantly not that forthcoming or open to shareholder sentiments or give a lot of feedback. Its real emphasis on your own research, than feedback",
          "sentiment": 0.0,
          "engagement": "13,667",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-22T21:29:46.320659+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251405-Dustysla-83882105",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.306675",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "I also dont think viewing a US listing as being forced a negative, and getting away from Nasdaq into the OTC is a much better suit at this juncture. Too many Rules that effect listing requirements that are just not worth it,  but even a London outfit you have broken into the US Market, have multiple offices there, receiving Medicaid reimbursement and expanding reach. These are not easy to come by, even for US based companies so I wouldnt take that achievement lightly. Its a great position to be in, removing Hurdles like FDA etc. CE mark will do hopefully what FDA has done,  break and expand into other markets.",
          "sentiment": 0.0,
          "engagement": "13,667",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-22T21:29:46.320641+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251420-Mikemine-27152029",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.306260",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "I wouldn't take any notice of UBS holdings. They've been up and down for months. They'll probably go to zero holdings in the next few days.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS surge their holding from 5.08% to 7.44%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D0278CAD-4353-4441-AFB6-77F17FCE35E7"
        },
        "ingested_at": "2026-01-22T21:29:46.320623+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251512-Silverbl--7698095",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.305840",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "We will find out next month how much progress all the partnerships announcements are making on testing revenue. My fear is they will be nowhere near their H1 target. There are lots of institutional investors here besides UBS - they presumably are taking the gamble that eventually there will be a pick up in sales. No point in having an FDA approved product with the agreed reimbursement if there is no commercial market to sell into - and that has been the case so far. It has already been clarified by the company that CE is not of any importance to them in the short term - with a limited sales force the US market needs to show progress or it will start to become very difficult to secure additional funds imo. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-22T21:29:46.320606+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251251-Silverbl-83843633",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.305432",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "ADS split on OTC has now gone through - 1 UK \u00a3 share is now equivalent to 25 US $ OTC shares. Market reaction to this alongside the warnings in the AGM statement predictable. Short interest has increased significantly - this could get very messy, very quickly. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "6.25",
          "thread_title": "ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320588+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251314-Marty130-15834421",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.305008",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Presumably carried out to keep them from being expelled from the market..",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320570+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251352-Dustysla--5858771",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.304600",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Not necessarily,  the OTC doesnt have the Stringent Rules as Nasdaq surrounding Delisting. This isn't a non revenue company, Start up etc. And you shouldn't expelled wonders in entering markets in the first 12 months,  yet growth of sales has doubled each quarter. Im unsure why you see this as a bad long term investment Silverblade, I can only surmise you have bought higher and the decrease has weighed heavily on your input. Im yet to buy, as I imagined this route to profit, which takes time when reducing debt and growing in market and sales. Suppose people expect 1 year investing these days, when reality is. Takes much longer, on a gradual basis. 1 month spikes create over expectancy, and then you end up where you began, 50% down. Always better to research an investment thoroughly before entering into it. Hence what im doing",
          "sentiment": 0.0,
          "engagement": "13,667",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320552+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-Bushbat-82729259",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.304174",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bushbat",
          "content": "USB holding going up rather than the usual up 5% then down again",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "6.25",
          "thread_title": "USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-01-22T21:29:46.320535+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251434-Marty130-51020616",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.303746",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Just added hVIVO to my portfolio..  Looks undervalued, may come into it's own in 26..  A possible takeover target could see increasing share holder value.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-01-22T21:29:46.320516+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251446-Silverbl--5458194",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.303216",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dustyslay - there are minimum bid price requirements in relation to US listing exchanges - this was one of the reasons for the new ADS split. Where did you note that sales have doubled each quarter? That is simply not the case.  You also mention debt - of which there is none. You are correct I did purchase at higher prices - but so did every single PI and II here. All have lost significant sums of money. We all saw the the medium term opportunity here - however the current management team are showing a complete lack of momentum in growing the business. Yes this is still a new company but investors continue to be fed nonsense with never ending partnerships which don't deliver; revenue predictions which don't deliver; cost cutting which doesn't materialise; pay and stock options for the team which are excessive; cash burn that fritters away funds like there was no tomorrow. My input is negative because I expect better. Yet I remain invested against my better judgement. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320499+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251458-Dustysla--6689352",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.302787",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Nasdaq has listing requirements that are difficult OTC is similar to AIM, there are 3 different markets OTCQB/OTCQX and OTC pink but we can dismiss that you are in one of the the first 2. OTC Premier is stringent but that isnt listed there. 0.01 is the minimum requirement SP And a M/Cap of 10 million minimum Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus. The split has gone quite well on early judgement,  and will help consolidate liquidity as lower the SP, the higher the percentage swings and more susceptible to traders profiting on movement. Ive seen worse splits, but they are predominantly done to secure liquidity and consolidate SP",
          "sentiment": 0.0,
          "engagement": "13,667",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320481+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251506-Dustysla-60519926",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.302342",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Im not every fond of AI, or even Google AI. Never done ChatGBT etc so a lot is from memory on researching, the sales i will locate the information at some point as im a tad busy but Debt is easy to find, you would be hard pressed to find any company not still refurbishing debt after they have gone to market. The key is to see a constant, and consistent reduction per half year reports. Here is the AI, against my normal MO of real research: As of late 2025, Renalytix has reported approximately $8.21 million in total debt, a decrease from previous years. The company has actively worked to improve its balance sheet through debt restructuring and equity conversions. Key details regarding Renalytix's debt: Total Debt: The most recent figures from financial reports indicate total debt is approximately $8.21 million. Recent Reduction: Renalytix has focused on reducing its debt through strategic financial maneuvers. In October 2025, the company announced a $4 million balance sheet improvement by converting approximately $4 million of senior convertible bonds into equity, saving up to $1.4 million in future accrued interest. Debt Restructuring: A significant portion of the remaining debt is a new unsecured convertible bond issued in November 2024 (and later partially converted in Oct 2025), with a maturity date of July 2029. This bond has flexible interest payment options (cash or rolled into the principal) at the company's discretion. Historical Context: The company's total debt peaked in June 2022 at over $12 million and has generally trended downwards since then. Financial Position: The renegotiation of debts has helped the company move to a net current asset position, aiming to direct cash flows towards commercial and operational growth.",
          "sentiment": 0.0,
          "engagement": "13,667",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320463+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251529-Dustysla-33518835",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.301885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Ok, i know where i found the Sales and it took me a long time so here, more AI junk but the growth is there. Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months. Recent Revenue: For the first half of the fiscal year 2025 (H1 FY25), Renalytix reported revenues of $1.3 million. This demonstrated continued quarterly sales growth into Q3 FY25. Quarterly Growth: The company is on track to meet or exceed its target of 20% average quarter-over-quarter revenue growth. Billable Tests: For the first time, over 1,000 billable tests were processed in Q3 2025, supported by the onboarding of a large primary care network in New York and improved direct-to-physician sales. Medicare Coverage: The company has achieved FDA approval and Medicare coverage determination for its kidneyintelX.dkd test, with an established price of $950 per test. Partnerships: New collaborations, notably with Tempus AI and MVP Health Care, are expected to positively impact revenue and expand the test's reach among the 15 million people in the US with type 2 diabetes and chronic kidney disease. Future Guidance: Renalytix has provided forward revenue guidance of $3.2 million in FY25, $8.5 million in FY26, and $17.5 million in FY27. Despite recent sales growth, the company has faced financial challenges, including a decline in total annual revenue in FY24 compared to FY23, high operating losses, and a reliance on external financing to sustain operations. The company has focused on cost reductions and strategic partnerships to improve its financial position. 1000 \u00d7 $950 plus Medicaid Reimbursement in its first year. Now a new area in North America with MVP, 700 000 patients on books. You see where its going? Have some faith. And perhaps more research than whining on a forum",
          "sentiment": 0.0,
          "engagement": "13,667",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320445+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251540-Dustysla-32558175",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.301430",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade I understand all what you are saying, 2024 wouldn't have been a great year as they hadn't gone to market and thats the Pharmsma industry for you, why I dont hold any current because I feel they are run by wealthy individuals that are focused on personal wealth before Health and will fill their boots prior to any achievements and shareholders take on the dilution and the hard hold. But im kinda leaning towards this, the more i look into it because its all about timing really.  If MVP goes solid, and your market expands 2026, you should improve dramatically As for the CE mark, achieving it your correct it wont move it, but its what you do once achieved in the European markets",
          "sentiment": 0.0,
          "engagement": "13,667",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320427+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251606-Silverbl-14108767",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.300997",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "OK Dustyslay - I'll bite - here we go - my 'whining' response to your 'research' based points where real world numbers are available. 1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. The point on debt looks accurate. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320403+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251616-Dustysla-28658765",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.300564",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m OTCQB listing only says $17.98 million 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). Is this financials or Sales? Im talking about Provider to Patient sales 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). This is how it explained, a Google AI version. Id get a more accurate view, but im not not interested in doing so. 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. Ok well nothing I found in 30 mins showed they had FDA approval so the assumption is their flogging nothing. But if im wrong, and it started somewhere in 2024 fine. Small details. But Debt, well yes as you said checks out. But you said NO DEBT, quite abruptly so I got a lot closer than you in 30 minutes that you seemingly in years",
          "sentiment": 0.0,
          "engagement": "13,667",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320372+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251621-Dustysla-76121235",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.300111",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "I think your Gripe is the time spent here, and against the companies management. I get that, they are not the easiest investments as they are Crooks and useless. So I try to look at 3 things here at this juncture Revenue/Debt/Sales And Future Projected Revenue/Debt/Sales And how they will maintain a healthy cash burn in the intermediate.",
          "sentiment": 0.0,
          "engagement": "13,667",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320355+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251623-cipro-59353719",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.299665",
        "source": "LSE_CHAT",
        "data": {
          "author": "cipro",
          "content": "The trend is slowly going down with this stock did hv good potential And I hope this still has some upside however the momentum is stuttering atm Hope to get positive news in January to get the trend back up good luck all",
          "sentiment": 0.0,
          "engagement": "2,147",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-01-22T21:29:46.320337+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251751-Marty130-47827829",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.299241",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "CE marks always add value.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320319+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251146-JBCo-22370963",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.298822",
        "source": "LSE_CHAT",
        "data": {
          "author": "JBCo",
          "content": "Hopefully can hold 6p",
          "sentiment": 0.0,
          "engagement": "4,511",
          "price_at_post": "6.25",
          "thread_title": "Big seller trying to get out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=253BEB68-92E2-41AA-91A1-E5998136B1CD"
        },
        "ingested_at": "2026-01-22T21:29:46.320301+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251427-Hawker-85578031",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.298403",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Well said, SB. This is now just a waiting game, as the company has EVERYTHING they need to succeed in going to market; there are no more barriers. The only question, therefore, is whether they can sell the test into their focus regions and whether there is a market for it. So far, the jury is out. QED... Opinion:   Ho hum",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320284+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20250931-Marty130--4404237",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.297956",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "German Market is huge.. Once the CE goes through, plenty will sign up.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320266+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251241-Silverbl-13839567",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.297534",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "The jury is not only out Hawker....its leaving the courthouse! Its been another horror story in 2025 for the business which showed so much early promise. I have low expectations for the trading update in January - seems this is pretty common given the share price reaction. All time price low - makes the 9.5p raise a highlight from the management team - although the next raise could be very painful for shareholders if they cannot generate revenue and continue to burn cash. ATB to those who hold here - it continues to be a very difficult investment to justify. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "5.90",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-22T21:29:46.320248+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251644-Marty130-70975673",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:46.297083",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Down selling again.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "5.90",
          "thread_title": "UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-01-22T21:29:46.320230+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251756-tweedly-23856067",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.083553",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Right. These RNS' have been coming out for at least 6 months, no one makes sense of them so no point speculating. Merry Christmas folks",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-01-22T21:29:46.320213+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251830-Marty130-43918343",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.083140",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "U2..",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-01-22T21:29:46.320195+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251144-Mikemine--3967275",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.082725",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Merry Christmas everybody. Here's hoping for a more prosperous New year.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "5.90",
          "thread_title": "Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-22T21:29:46.320178+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251332-Marty130--6115811",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.082312",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Surely we'll get better results next year, if not a possible takeover.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-22T21:29:46.320160+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20252029-Cevodniy-65003688",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.081892",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, you are the only poster here generally and even you can't see anything positive,  except the possibility of a takeover I've just over 1.2 million at an average of 10p, I fo not expect to ever see profit.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-22T21:29:46.320142+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250037-MIKODX-77197552",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.081474",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "FY2025 was a key year for the company in establishing a solid pathway for testing adoption, life science services and strategic partnering. In July 2025, RENX announced an agreement with MVP Health Care, a U.S.-based insurer covering more than 700,000 patients. Beyond expanding physician and patient access, this agreement reinforces that Renalytix and kidneyIntelX.dkd are establishing a leadership position in chronic kidney disease management and gaining increasing recognition in the market. In September 2025, Renalytix signed an agreement with Tempus AI, Inc. (\u201cTempus\u201d), a clear leader in delivery of integrated advanced diagnostic testing and life science services in the United States. The collaboration with Tempus will enable RENX to accelerate introduction of kidneyintelX.dkd into large hospital systems and community healthcare practices across the U.S., significantly expanding distribution over the next five years. The relationship with Tempus AI has continued to develop positively, with ongoing progress in aligning commercial activities. The Balance Sheet was further improved with the conversion of an additional $4 million of convertible debt leaving outstanding long-term debt at \u00a33.1m as of October 2025. More than $1.3m in cash from backdated R&D claims and grant income, further strengthening the balance sheet. Administrative expenses decreased by more than 40% year-on-year, driven by headcount and operations optimization. RENX continue to strengthen there presence in three initial target states - Florida, Texas, and New York. In FY26, they expanded into Arizona their fourth target market which collectively represents approximately 20% of the total addressable kidneyintelX.dkd market. RENX is well positioned to deliver important and necessary change in chronic kidney disease management in the United States and globally.In the coming months and years sales will without doubt improve with the test being made more readily available in healthcare systems. Not been a bad year for the company, quite the opposite, it has been a very positive one. FY26 will see the partnerships coming to fruition with the test more widely available in the healthcare systems which will mean more sales for the company. Lots to look forward to in the coming year. I'll drink to that. Hope everyone has a merry xmas and the best of luck for the new year. With any luck we will have some good news from the parterships established, which will have a very positive affect on the SP. As we all know, this is a very volatile stock that can really take off on good news. Next year will be the year. GLA",
          "sentiment": 0.0,
          "engagement": "3,975",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-22T21:29:46.320123+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250828-Cevodniy--8921079",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.081026",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "MIKODX on the 2nd January 2025, the SP was 10.75, yesterday it was 6p. I get your optimism via your post, but obviously institutions and wealthy investors don't agree. 10p to 6p is not exactly a successful year. I hope we don't experience another 66% next year.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-22T21:29:46.320088+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251037-Marty130--1559974",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.080601",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Cevo, And don't forget the CE mark will have a transformation affect.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-22T21:29:46.320070+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251231-Marty130-65375390",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.080185",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Hopefully we will have a better year in 2026, with more announcements of higher revenues and transformational new contracts signed. The BoD badly needs pay more attention to reverse the share price trend..",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "5.90",
          "thread_title": "New contracts",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8AD3616F-3B6B-486A-8B37-36DE630CD42F"
        },
        "ingested_at": "2026-01-22T21:29:46.320052+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20251632-MIKODX--5647977",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.079762",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "It\u2019s not good watching the SP slowly slip down, but that\u2019s bound to happen with no positive news. The one consolation is the support at 5.70 is holding up well so far. Hopefully we can kick off the new year with some good news and hopefully get a good bounce from the support level all the way up past 10.",
          "sentiment": 0.0,
          "engagement": "3,975",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-22T21:29:46.320034+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251345-Silverbl--3072909",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.079349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dreadful year for investors. Trading update in January could hammer confidence further if company fails to deliver revenue targets. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-22T21:29:46.320016+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20252147-Crannog1-49640706",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.078931",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crannog12",
          "content": "You are a ray of sunshine. I take it you are invested here?",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-22T21:29:46.319998+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20260407-Cevodniy-74863110",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.078517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Ok fellow investors. Year end SP predictions. I'll start at 20p.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "5.90",
          "thread_title": "Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-22T21:29:46.319980+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261121-Marty130--8103981",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.078091",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "On receipt of the CE acceptance, which is expected h1, 18/22, on a takeover, 40/60.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-22T21:29:46.319962+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261342-Mikemine--7833742",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.077678",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "If Tempus gets going, the revenue will spike and so will the SP. Big companies like Tempus are notoriously slow to move but they've had since early September so H1 seems reasonable for them to get going. I urge anyone who has missed the RNS (15th Sept) about the collaboration agreement to read it and do a bit of research on Tempus. Apart from this ramp, I won't offer a prediction target but I do expect to multibag  from these levels. Good luck to everybody.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-22T21:29:46.319944+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20262041-Marty130-29545752",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.077267",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix said in an update on Tuesday that it was making progress in expanding the use of KidneyIntelX.dkd across the United States, reporting growing testing volumes, new state coverage and advancing commercial partnerships ahead of its annual general meeting in London. The AIM-traded company's prognostic blood test, the only FDA-approved and Medicare-reimbursed test for early-stage chronic kidney disease risk assessment, was now generating revenue from four core states - Florida, Texas, New York and, most recently, Arizona. Executive chairman Julian Baines said the first orders in Arizona included tests from one of the largest nephrology practices in the US. He emphasised that, while direct sales growth is encouraging, the company's primary strategy is to scale test adoption through major business development agreements with large healthcare systems. Renalytix signed a definitive agreement in September with Tempus AI, the Nasdaq-listed diagnostics and AI group, which Baines said has \"an established network of healthcare institutions already utilising its precision medicine solutions.\" He added that early engagement with Tempus and MVP Health Care reinforced the company's belief that its partnership-led model would \"deliver long-term value for shareholders,\" despite lengthy implementation processes common across major US providers. Renalytix said it had also narrowed potential partners for its next electronic health record integration and was working with several large healthcare systems expected to generate \"meaningful testing volumes\" over time. The company said it was increasingly using data analytics to identify physicians managing high numbers of eligible patients, helping target commercial resources where uptake prospects are strongest. Renalytix added that it had started transitioning to a new laboratory facility, a move expected to expand testing capacity and reduce operating costs over the next five years. Baines said the company was now focused on converting ongoing discussions into contracted relationships, expanding EHR integrations and accelerating test volumes. While acknowledging that timing of commercial outcomes \"remains difficult to predict,\" he said the board was confident that the company's current initiatives \"position the company well for sustainable revenue growth, increased operating leverage, and long-term value creation for shareholders.\" Renalytix said it would provide a trading update for the six months to 31 December by the end of January.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "5.90",
          "thread_title": "2026 outlook",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=30EC9492-CE10-4321-AED9-CF8B2D3F53AF"
        },
        "ingested_at": "2026-01-22T21:29:46.319926+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261649-Marty130--5069315",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.076800",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "To turn this around as the share price will continue to new lows..   Wake up BoD, pull your fingers out..",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "5.90",
          "thread_title": "Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-01-22T21:29:46.319908+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261801-oldbutno--1462956",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.076390",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "....come to those that wait.....Oh, and DEATH!",
          "sentiment": 0.0,
          "engagement": "3,317",
          "price_at_post": "5.90",
          "thread_title": "GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-22T21:29:46.319890+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261837-Silverbl-63326695",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.075964",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "New deals mean nothing without a credible commercial plan which has at its heart the means to create and service product demand in a timeous and profitable manner. Nothing to date has achieved that in any meaningful volume. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "5.90",
          "thread_title": "RE: Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-01-22T21:29:46.319873+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261839-Silverbl--4852212",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.075550",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "...well if the prognosis is kidney related oldbut i think we might be able to help out......lol. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-22T21:29:46.319854+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261935-Marty130-89659641",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.075135",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix is expected to participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, a premier global healthcare investment symposium where companies present and connect with investors, industry leaders, and innovators, focusing on new technologies like AI in healthcare, kidney disease, and strategic partnerships. While Renalytix isn't explicitly named in the top results, they are a kidney-focused company likely to attend this major event, which runs concurrently with the Biotech Showcase.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-22T21:29:46.319837+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261412-Veteran1-79753567",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.074712",
        "source": "LSE_CHAT",
        "data": {
          "author": "Veteran10",
          "content": "Bit of movement but low volume. If volumes increases, could be a momentum buy opportunity.",
          "sentiment": 0.0,
          "engagement": "4,041",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-22T21:29:46.319819+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261527-Marty130-60833688",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.074299",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "A deal may arise next week after the conference in San Francisco.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-22T21:29:46.319801+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261512-Marty130-32946676",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.073867",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "They're back in again..",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-22T21:29:46.319783+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261603-Pixels--3490341",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:43.073430",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pixels",
          "content": "How can you tell, that document shows as \"acquisition / disposal\" - is it definitely acquisition? Got to admit I struggle with reading financial type documents, I'm just a media monkey",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-22T21:29:46.319762+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261616-Marty130--7013082",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.148960",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Purchase at 7%.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-22T21:29:46.319744+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261801-Marty130-17771290",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.148555",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Upcoming Financial & Corporate Events H1 2026 Trading Update: The company is scheduled to provide a trading update for the six-month period ending December 31, 2025, by the end of January 2026.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-22T21:29:46.319726+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260710-uxm484-61794199",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.148148",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. Hopefully some new investors will jump on this month following the J.P Morgan event in the US, progress being made and undervalued at present.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-22T21:29:46.319708+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260712-morningt--6867645",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.147724",
        "source": "LSE_CHAT",
        "data": {
          "author": "mornington-oz",
          "content": "RNS  OUT",
          "sentiment": 0.0,
          "engagement": "23,497",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-22T21:29:46.319690+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260807-Marty130-47411609",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.147317",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Where? I haven't received one.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-22T21:29:46.319672+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260809-johndean--3393786",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.146899",
        "source": "LSE_CHAT",
        "data": {
          "author": "johndean",
          "content": "Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the company expects to provide further updates on progress and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "798",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-22T21:29:46.319654+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260823-Marty130-59797171",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.146487",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Results deadline missed then..  As wws due before 31st of January..",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-22T21:29:46.319636+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260838-emblaze1--5371500",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.146072",
        "source": "LSE_CHAT",
        "data": {
          "author": "emblaze1",
          "content": "LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use. The integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix. These integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations. Renalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources. Tempus AI Collaboration Renalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in September 2025, to target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients. The collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time. Investor Engagement James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. The 44th annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad rang",
          "sentiment": 0.0,
          "engagement": "917",
          "price_at_post": "6.25",
          "thread_title": "RE:Results soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=3DEB0D63-492C-4E6A-AD12-B94C142E4A0B"
        },
        "ingested_at": "2026-01-22T21:29:46.319618+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261111-Marty130-27050300",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.145630",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Enalytix plc (RENX.LN)*, Futura Medical plc (FUM.LN) Non-Independent Research; Marketing & Sales Commentary - MiFID II exempt information \u2013 see disclaimer below. Company Update: 12 January 2026 Renalytix plc (LSE: RENX, OTCQB: RNLXY)*: Three kidneyintelX.dkd clinical integration \u2013 update on Tempus collaboration Market Capitalisation: \u00a326.6m; Share Price: 6.08p \u2022 During the last quarter of 2025, Renalytix completed three additional kidney specialist healthcare provider clinical integrations in the US, in New York, Florida and Tennessee.  \u2022 Additional integrations are expected in early 2026. \u2022 Tempus collaboration is progressing well with teams from both Tempus and Renalytix working closely to target Tempus\u2019 customers with a large diabetes and kidney disease patients.  Renalytix reports that it added three new US clinical integrations in late 2025, bringing its FDAapproved kidneyintelX.dkd test into established kidney care practices in New York, Florida, and Tennessee. Testing has begun at all sites, and although initial volumes are expected to be small, the company anticipates usage to build as clinicians become familiar with the workflow. More integrations are planned for early 2026.  Renalytix states that it is working intensively with Tempus to integrate its kidney risk testing into major US health systems through Tempus' integrated electronic health records (EHR). Since the partnership began in September 2025, teams from both companies have been coordinating to target large provider networks with significant diabetes and CKD populations, aiming to streamline test ordering and strengthen data collection. The collaboration is positioned as a foundation for expanding into new clinical and geographic markets as the platform matures.  From a strategic standpoint, this fits neatly with Renalytix\u2019s strategy to have kidneyintelX.dkd test integrates into healthcare providers\u2019 EHRs, which allows quick and seamless ordering. shift toward disciplined, system-level integrations rather than chasing individual clinics. The Tempus partnership could prove far more meaningful if it unlocks access to large, data-rich health systems where adoption can scale. SP Angel acts as Nomad and Broker to the Renalytix Futura Medical plc (AIM: FUM): Positive results from WSD4000 early feasibility study Market Capitalisation: \u00a39.1m; Share Price: 1.58p \u2022 Statistically significant improvement achieved in female sexual function with WSD4000 in a study enrolling 12 women suffering from some degree of sexual dysfunction. \u2022 Results give the Company confidence to proceed to the next steps of designing a Phase III placebo-controlled trial, with results expected mid-2026 Futura reports that its WSD4000 early feasibility study in 12 women showed a clear and statistically significant improvement in sexual function, with gains on the Female Sexual Function Index (FSFI) scale well above the accepted threshold for clinical relevance. Benefits were seen across arousal",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D3CE797F-7C15-4738-8269-38EDD6CB8090"
        },
        "ingested_at": "2026-01-22T21:29:46.319600+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262236-MIKODX--6567539",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.145218",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "The company says it expects to provide a fuller trading update in February. By fuller that means they expect improvement in sales. The company is making all the right moves thus far.",
          "sentiment": 0.0,
          "engagement": "3,975",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-22T21:29:46.319582+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262252-MIKODX-76753083",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.144801",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Todays RNS means we are now seeing concrete progress on commercial rollout.This shows that Renalytix is moving towards actual deployment with multiple provider groups. Getting kidneyintelX.dkd into established clinics is a big step. It means providers see enough value in the test to integrate it into their day-to-day systems. The RNS reiterates that Renalytix and Tempus are working closely to integrate kidneyintelX.dkd into larger healthcare sytems that are already on Tempus's platform. This is very significant because a) smaller clinics alone won't generate high volumes and b) larger sytems (via Tempus) have broader patient populations and infrastucture. This will accelerate adoption more rapidly once it starts rolling through those network. Everything is starting to fall into place, the company is really now starting to see some real progression. Great RNS.",
          "sentiment": 0.0,
          "engagement": "3,975",
          "price_at_post": "6.25",
          "thread_title": "Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-22T21:29:46.319565+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261401-tweedly-34196141",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.144392",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Understandably the RNS didn't set the market alight. Waiting for hard numbers I think.",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-22T21:29:46.319547+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261535-Marty130-63564530",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.143974",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Exactly.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-22T21:29:46.319530+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261537-Hawker-56697451",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.143570",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Hope springs eternal...  Ho hum...",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-22T21:29:46.319513+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261633-Investor--5545329",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.143163",
        "source": "LSE_CHAT",
        "data": {
          "author": "Investor2025",
          "content": "Not yet..",
          "sentiment": 0.0,
          "engagement": "7",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-22T21:29:46.319495+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261836-Marty130-81086555",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.142747",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Looks like the SP is heading down, in order to boost volumes.. Let's hope the BoD release some juicy news to push it back up on healthy volumes.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-22T21:29:46.319477+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261947-Silverbl--5256466",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.142336",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Next news is likely to see share price hit all time lows - enough negative hints have been dropped recently about current trading. Statements such as \"Commercial outcomes.....remain difficult to predict\"; \"Each practice currently represents modest initial testing volumes\"; \"Engaging with large healthcare systems presents inherent challenges\" - do not fill me with short term confidence in the $8.4m 2026 revenue target - we are about to finish month 7 out of 12 in that regard. And if that revenue target is not met where does that leave the cash position? Does make you wonder what exactly the company's 11 full time sales reps are doing - door knocking physicians will not cut it here. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-22T21:29:46.319459+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262055-bluesy1--8399076",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.141911",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "This has all the hallmarks of a BOD lifestyle  funding company. FDA approval but would rather die in their own DNA.  Get out before its too late",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.15",
          "thread_title": "Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-01-22T21:29:46.319441+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262227-Marty130-74305000",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.141502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Disagree.",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.15",
          "thread_title": "RE: Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-01-22T21:29:46.319423+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261743-Mikemine--6495272",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.141086",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Looks like somebody knows something maybe?",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "6.25",
          "thread_title": "Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-01-22T21:29:46.319406+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261948-bluesy1-50869685",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.140679",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "Like what ? Minor move upwards. Lets all get excited. Tedious ...",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.25",
          "thread_title": "RE: Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-01-22T21:29:46.319388+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261120-Marty130--7679263",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.140269",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://www.proactiveinvestors.com/companies/news/1085472/renalytix-expands-us-footprint-with-three-new-clinical-partnerships-1085472.html",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-22T21:29:46.319370+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260551-Cevodniy--1573823",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.139845",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, that's great news, but nothing absolutely nothing affects the share price.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-22T21:29:46.319351+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261743-Marty130-23363848",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.139431",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Agreed",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-22T21:29:46.319329+00:00"
      },
      {
        "event_id": "SOCIAL-Today1000-Marty130-65077214",
        "event_type": "social_post",
        "date": "2026-01-22T21:29:38.138985",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Need to pull their finger out ASAP..",
          "sentiment": 0.0,
          "engagement": "1,247",
          "price_at_post": "6.25",
          "thread_title": "BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-01-22T21:29:46.319288+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20250858-uxm484-62396855",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.322439",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "That will eventually come including further deals. These are the times to add imo.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "6.75",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T21:48:32.338428+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20250905-Silverbl--5333283",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.322015",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "It\u2019s always the same here - it will be alright one day\u2026..todays statement is akin to a warning 2026 targets will be missed imo. Confirmation to come next month. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T21:48:32.338410+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20250946-unhooked--4595977",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.321606",
        "source": "LSE_CHAT",
        "data": {
          "author": "unhooked",
          "content": "Have to agree Silverblade, hopes and expectations but very little concrete to read. An exercise in stringing the market along for as long as possible...",
          "sentiment": 0.0,
          "engagement": "3,246",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T21:48:32.338392+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20250956-Paddyboy--3075847",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.321199",
        "source": "LSE_CHAT",
        "data": {
          "author": "Paddyboy",
          "content": "This was \u00a312 five years ago when people thought it was a commercial prospect. It turned out not to be and probably never will be.",
          "sentiment": 0.0,
          "engagement": "254",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T21:48:32.338375+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251014-Marty130--5608703",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.320775",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Until a major deal can be announced, don't expect any upside.. Seen this before with my investment over the years.. I was in FTC for nearly four years, take a look at how that company turned itself around...",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T21:48:32.338357+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251019-10gordon--2043997",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.320370",
        "source": "LSE_CHAT",
        "data": {
          "author": "10gordon10",
          "content": "Paddy, this was not the same product as 5 years ago, AI was just a twinkle in the eye of the world back then. This is a life changing world class  AI health care product, it has full medical approval in the USA, the biggest market in the world, and has just begun a rollout there. SOON, The rest of the world! Please short it, I love short squeezes.",
          "sentiment": 0.0,
          "engagement": "175",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T21:48:32.338339+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251131-Marty130--5397837",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.319939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "I don't understand why we never hear of any involvement with the NHS! Surely massive deal could be struck with the NHS.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "NHS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=4C62646B-A4E1-44E0-BF60-22D356FE1F5E"
        },
        "ingested_at": "2026-01-21T21:48:32.338321+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251213-Marty130--8336963",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.319532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "That went down like a bucket of sick, well done  BoD..  High time you did something to stop the rot..",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "AGM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=0601E10A-3DBB-458B-B540-F47C5BB4CC12"
        },
        "ingested_at": "2026-01-21T21:48:32.338304+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251440-Marty130-79179123",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.319121",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "10g Or China!!!",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T21:48:32.338286+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251702-Cevodniy-21734321",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.318701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Silverblade, so expect an RNS morning of the 9th prior to the AGM. Any more astute predictions?",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T21:48:32.338269+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251822-Mikemine--2828011",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.318285",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "The CEO hit the nail on the head when he referred to large companies like Tempus not being as nimble as companies like RENX and VRCI. The take their time setting up systems and incorporating new additions and there's not much that can redone about it. Tempus will offer a reach RENX could only dream of but it comes at a price and that is a slow pace. Once the new contracts start to bear fruit ball they will gather pace and I expect that to happen early next year. Frustrating though it is for us, we will have to dig deep in to our patience bucket. Thats my opinion anyway.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T21:48:32.338251+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20251920-Silverbl-23961413",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.317868",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "In the short term only the likelihood of more condescending posts from yourself cevodniya. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T21:48:32.338234+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20252013-Marty130--7907946",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.317458",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://donation.watch/en/unitedkingdom/party/REFORM/donors",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T21:48:32.338216+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20252014-Cevodniy--2496122",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.317042",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Silverblade, the reason I posted is the arrogance of your post. Expect an RNS tomorrow morning!!. That's a statement,  not a suggestion,  not anyone think there'll be a possible RNS tomorrow before the AGM. It's you making an absolute statement which was 100% incorrect. Pointing that out is condescending,  it's merely explaining your arrogance. I suppose you can us what numbers to expect in Friday's Euro lottery?",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T21:48:32.338198+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20252014-Marty130-31243970",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.316614",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Wrong link, sorry.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T21:48:32.338180+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20252015-Marty130--1180613",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.316205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix is a diagnostics company that has faced challenges getting its KidneyIntelX test validated for use within the UK's National Health Service (NHS), despite the technology being used in the US. The company's focus has primarily been on the US market where its product has FDA authorization and Medicare reimbursement. Renalytix and the NHS Limited NHS Adoption: While Renalytix is a London-based company, its commercial success and focus have been predominantly in the US healthcare system, particularly with the Mount Sinai Health System and Tempus AI. The company has reportedly missed opportunities for NHS validation. Potential but Unused: There has been discussion among investors about the potential for the KidneyIntelX test to be a cost-saving measure for the NHS, which faces significant costs from undiagnosed and uncontrolled kidney disease. NHS Technology Use: The NHS is exploring the integration of machine learning and wider datasets within its electronic health records to improve risk prediction and decision support, which aligns with the kind of technology Renalytix offers, but direct procurement has not been established. The KidneyIntelX Technology Renalytix developed KidneyIntelX, an artificial intelligence (AI)-enabled blood test for patients with type 2 diabetes and early-stage chronic kidney disease (CKD stages 1-3b). Function: The test uses AI to integrate data from blood biomarkers and electronic health records to provide a high, moderate, or low-risk score for rapid kidney function decline within five years. Purpose: This early risk assessment allows clinicians to intervene with guideline-recommended treatment sooner, potentially improving patient outcomes and reducing overall healthcare costs. In summary, as of late 2025, Renalytix's technology is not widely adopted by the NHS, with the company's business efforts centered on the US market and recent partnerships there, such as with Tempus AI and MVP Health Care.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T21:48:32.338162+00:00"
      },
      {
        "event_id": "SOCIAL-9Dec20252315-Boo-Boo-20666262",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.315750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Boo-Boo",
          "content": "Hi Marty, Apologies if this has been covered before but my understanding is that medical tests used by the NHS typically require a CE mark to show they meet necessary safety and performance standards. This mark indicates that the device can be marketed within the European Union and is compliant with relevant regulations. The RNS of 1 October details the submission of a CE application where: 'on successful achievement of a CE mark, expected in H1 2026, Renalytix anticipates further commercial opportunities, including international distribution partnerships, in FY26 and/or FY27'. My belief is that this is still bring processed and once issued should then open up new opportunities for us. BB",
          "sentiment": 0.0,
          "engagement": "10",
          "price_at_post": "6.25",
          "thread_title": "RE: Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T21:48:32.338144+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250032-Marty130-80246728",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.315318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Great post..  I forgot about the CE application.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T21:48:32.338126+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250912-Radika-87612158",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.314895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Radika",
          "content": "So does this mean not much will happen till CE marking is approved? I think placing was @9.5p and down to this6.75p",
          "sentiment": 0.0,
          "engagement": "2,855",
          "price_at_post": "6.25",
          "thread_title": "RE: Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T21:48:32.338093+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20250935-Marty130-21153368",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.314486",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Yes, i have written to the company to enquire as discover why they haven't been in discussions with the NHS. Gendrive have so why haven't renalytix?",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T21:48:32.338075+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251031-Hawker-19052578",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.314058",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "@Silverblade - I think you're 100% spot on; this feels like a prerequisite to the next disappointing, empty promises update. Ho hum.",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T21:48:32.338058+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251129-Marty130-71840793",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.313638",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Dear Sirs and Madam, I hope this message finds you well. I am writing as an investor to gain a clearer understanding of Renalytix\u2019s engagement strategy with NICE and the NHS. Given the strong potential for your diagnostic technologies within UK healthcare, and in light of Wes Streeting\u2019s recent announcement regarding the NHS\u2019s increasing adoption of AI tools, I believe there is significant opportunity for Renalytix to contribute meaningfully to national healthcare priorities while also creating value for shareholders. I have noted that companies such as Genedrive appear to have established closer relationships with NHS partners, and this has prompted me to seek further clarity on Renalytix\u2019s own plans and progress in this area. Could you please provide clarification regarding your current NHS and NICE engagement activities, as well as your broader strategy for pursuing these opportunities? I would be grateful for a response within 14 days. Thank you for your attention to this matter. Kind regards,",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "My letter to renalytix.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=AE4BEC48-D1AB-4E00-8CB8-B9FAE9E14E70"
        },
        "ingested_at": "2026-01-21T21:48:32.338040+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251130-Marty130-48827248",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.313190",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Thanks for your email. Renalytix is a US focussed business.\u00a0The product is FDA approved, and has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. They are currently only targeting test adoption in the US healthcare market - which is naturally a very large addressable market. The company has no plans to target the NHS, and do not see this as a viable commercial opportunity currently as the product is not approved for use in the UK, and the currently has only just submitted an application for CE Mark certification for use within the European Union, in response to interest from pharma partners to use in the test in clinical trials within the EU. Whilst the UK market could be a very long-term target, along with other geographic expansion - but for now the company is firmly focussed on driving shareholder value through exploiting the very large opportunity that teh US market presents. Kind regards, Paul",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.338022+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251248-Mikemine-25858598",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.312735",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "So the application for CE Mark is driven by partners not RENX and that is not for the UK market anyway. I don't blame them as it is notoriously difficult to introduce anything in to the UK medial market.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.338005+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251533-Cevodniy--7072123",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:32.312306",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Hi, seeking your expectation. I purchased my investment here in September after reading and researching for a while. What finally covinced me was a \u00a3250k purchase by I think the Finance Director at 9.61p. It was the strongest gesture I could imagine. Why would a Director invest so much money at a personal kevel to a share that was very recently oversubscribed and only alloted 70% of individuals subscription. I'm in at an average of 10p. Seriously,  does anyone have any expectation that this Company will generate revenue and actually increase its share price?",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-21T21:48:32.337987+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251817-uxm484--6977206",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.444826",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "The base is 9.5p which was based on potential. I would expect the company to sign further deals or get approvals such as the application for CE Mark certification for its kidneyintelX.dkd prognostic test under the European Union\u2019s In-Vitro Diagnostics Regulation (IVDR) or further news relating to the agreement with Tempas. I don't see this going much lower than 6p, so at this price, although one might feel nervous when they are down, it is worth being patient in my view.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-21T21:48:32.337968+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20251857-Marty130-53176628",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.444401",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "The share price of a company that gains a CE mark typically rises due to the positive market sentiment and the new access to the large European market. This increase is driven by the market's perception of improved risk/reward and potential for future revenue growth. Reasons for Share Price Movement Market Expansion: The CE mark is a certification that a product meets EU safety, health, or environmental standards, allowing it to be legally sold within the European Economic Area (EEA). This opens a significant new market for the company's products, which can lead to substantial sales growth. Increased Investor Confidence: The certification acts as an independent validation of the product's quality and compliance with rigorous standards, which can increase investor confidence in the company's management and its future prospects. Analyst Upgrades: News of a CE mark approval often leads to positive analyst ratings and upgraded target prices, further fueling investor interest and demand for the stock. Demand and Supply: Like any stock movement, the price change is ultimately a result of supply and demand. Positive news creates high demand among buyers, which can cause the price to jump. Real-World Examples Several news snippets show companies experiencing stock gains following the announcement of a CE mark: Intuitive Surgical stock gained after its DV5 system received early CE mark approval. Femasys stock rose after its FemBloc product gained the CE mark. Zimmer Biomet (ZBH) stock saw gains following the receipt of a CE mark for a knee system. In summary, obtaining a CE mark is generally a positive catalyst for a company's stock, signaling new commercial opportunities and reinforcing a positive market sentiment for the company's future performance.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "CE mark.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D885E932-8BC7-436C-AE64-90F7FEAECB05"
        },
        "ingested_at": "2026-01-21T21:48:32.337949+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20252020-Marty130-46759625",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.443928",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "CE mark could be a ground breaker... Some analysts predicting a share price at 86p could be on the money.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337789+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20252253-Radika--4094393",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.443514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Radika",
          "content": "It could take few months for CE mark to be certified",
          "sentiment": 0.0,
          "engagement": "2,855",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337772+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20252305-Cevodniy-87744757",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.443087",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Say 6 months?",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337754+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20252320-Marty130-61634496",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.442671",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "From the 1st of October 2025, so by April could be when we get the CE mark.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337736+00:00"
      },
      {
        "event_id": "SOCIAL-10Dec20252324-Marty130-12892867",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.442254",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Presumably the share price will begin rise early next year, MM usually price these in prior to an announcement.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337719+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251701-Silverbl-48879590",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.441822",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "The FD did not make any purchase cevodynia - it was an investment made by two funds where Christopher Mills is a director (he also serves on the board at Renx). Notably the CEO chose not to participate in the fund raising either - that said he was well taken care off in the form of stock options during the year. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-21T21:48:32.337701+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251707-Silverbl-21795093",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.441404",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Let's not put our hopes on the CE approval.....its not going to have any impact here in the short term. The only way to change the current direction of travel is to sell tests and create revenue - simple. Yet with 45 members of staff that seems to be beyond the current team. The timing of the 9.5p rights issue, tempus partnership and the subsequent revenue guidance updates are starting to look like another smoke screen here imo. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337684+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251830-Cevodniy--4327873",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.440954",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Silverblade,  I'm 90% in agreement with you. But one thing reassures me. Why did the FD, i think it was the Finance Director,  buy \u00a3250k of shares at 9.61p in September. Surely he knows a lot more than we do and nobody throws \u00a3250k away.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337666+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251834-Silverbl--6286853",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.440498",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Read my earlier post cevodynia. Renx FD resigned in 2024 - take from that what you will - interim in place since then. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337649+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20251919-Cevodniy--5873148",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.440043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Silverblade,  thanks for your response. It would be unusual though wouldn't it, for 2 funds to invest \u00a3250k, having obvious access to information we don't. What's your take on that and the over subscription.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337631+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20252009-Silverbl-29258722",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.439619",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "I'm not so sure about funds having access to information PI's don't - remember there was a WRAP offer the same time with the same prospectus. I get that inside info plays a role - but the primary reason Harwood (via NAS and Oryx) made their investment is the fact they have been throwing money into Renx since it was spun out of ekf 5 years ago and as a major existing shareholder if they were seen to stop it would make fund raising from others more difficult imo. The fund raise - which we were clearly told at the time of the last fundraise would not be required - was undertaken on the back of the tempus announcement and the clearly stated 3 year revenue predictions. Now we have been advised that 'Engaging with large healthcare systems presents inherent challenges, particularly due to lengthy implementation and approval processes' and the AGM avoids any update on the $8.4m 2026 target revenue - which would require an almost 200% growth from 2025's $3m. Add to that the exec chairman - who has been in post less than a year and made a number of bullish statements on his appointment - is moving into a non exec role prior to the January 2026 trading update being released. I am an investor here - and have been for many years - but despite $200m of investment into getting the test ready and approved for the market - it is proving very difficult to gain any commercial traction and with significant overheads and minimal revenue cash burn is still very high and in all likelihood will require future fund raising to ensure the company remains a going concern. all imo. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337614+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20252038-Cevodniy-15945944",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.439200",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Silverblade thank you gor your lengthy and detailed response. I think you are sceptical that i will ever see 10p per share.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337596+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20252108-Silverbl-48934573",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.438767",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "10p would equate to a market cap of \u00a345m - c.5% of the peak company valuation of c.\u00a31b. If the company achieves anywhere near its 3 year revenue targets - then the valuation will be significantly in excess of where are today - but commercial progress is essential and that remains the primary equity risk here. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337578+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20252157-Marty130--3078266",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.438352",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "SB Don't forget the CE application is due to go through in the first quarter of next year, which will lead to a significant rise in the value of the company... Assuming it does clear all hurdles.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337560+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20252159-Marty130--7740800",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.437917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix's primary product, kidneyintelX.dkd, is well-regarded and widely accepted by medical professionals, insurers, and government agencies in the United States due to strong clinical evidence and regulatory approvals.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337543+00:00"
      },
      {
        "event_id": "SOCIAL-11Dec20252202-Marty130--7219057",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.437502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Cev You will see a much higher price in the coming months, just need to hang in there.. I for one have seen my investment drop significantly.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337526+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251458-Cevodniy--9147819",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.437050",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "\u00c8",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337508+00:00"
      },
      {
        "event_id": "SOCIAL-15Dec20251500-Cevodniy--3207207",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.436635",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, i admire your confidence. As always time will tell.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337490+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250810-Dustysla-79476922",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.436213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Stock split today 1 to 25 Plan to Implement ADS Ratio Change \u00b7 Renalytix Investors https://share.google/DEduOSAnVIjIfdzLj",
          "sentiment": 0.0,
          "engagement": "13,631",
          "price_at_post": "6.25",
          "thread_title": "RNLXD (OTC listing US)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=CC0F1227-0E37-44BB-B368-C07017F8BEB9"
        },
        "ingested_at": "2026-01-21T21:48:32.337472+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250817-Dustysla-85614287",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.435777",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Halifax \u2013 Market news https://share.google/gZyQhFMRvUVgJBNds",
          "sentiment": 0.0,
          "engagement": "13,631",
          "price_at_post": "6.25",
          "thread_title": "RE: RNLXD (OTC listing US)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=CC0F1227-0E37-44BB-B368-C07017F8BEB9"
        },
        "ingested_at": "2026-01-21T21:48:32.337454+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250822-Dustysla--5331234",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.435358",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade You are treating this as a UK, AIM listed stock. Its dual listed, US based and has a predominantly large market which is growing. Drifts Occur, the US stock split should tighten up and consolidate it better but id say 10p is small potatoes if all goes to plan here. Ive seen similar stocks, in worse positions move mountains on less promise",
          "sentiment": 0.0,
          "engagement": "13,631",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337436+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251203-Cevodniy--5649567",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.434923",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Dusty, thanks for that link.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "RE: RNLXD (OTC listing US)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=CC0F1227-0E37-44BB-B368-C07017F8BEB9"
        },
        "ingested_at": "2026-01-21T21:48:32.337419+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251211-NonParti-21686959",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:27.434494",
        "source": "LSE_CHAT",
        "data": {
          "author": "NonPartisan",
          "content": "Hope so marty, i got in quite hastily and heavily at 14, so very upside down on this puppy.....",
          "sentiment": 0.0,
          "engagement": "578",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337400+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251351-Silverbl-77229279",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.341738",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dustyslay - Renalytix is a UK headquartered business listed on the UK's AIM. Its 'dual listing' on the US OTC market was forced on the business after its market cap and share price meant it no longer compiled with Nasdaq listing rules. Daily trading in the US is virtually non-existent - its hardly of interest in the UK either. I assume the recent stock split was forced on the business in similar terms to the Nasdaq issue. To say share price drift occurs given the virtual elimination of shareholder equity here in the last three years does not come close to explaining the lack of commercial progress which should have been undertaken alongside the FDA approval process. I don't disagree the current market valuation is pitiful - but that value reflects the ongoing problems the business has in convincing the medical community their test should be used more widely and the confusing updates the team provide in relation to progress. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337382+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251355-MetalMan--1761387",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.341335",
        "source": "LSE_CHAT",
        "data": {
          "author": "MetalMania1",
          "content": "Great sign of confidence",
          "sentiment": 0.0,
          "engagement": "352",
          "price_at_post": "6.25",
          "thread_title": "UBS surge their holding from 5.08% to 7.44%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D0278CAD-4353-4441-AFB6-77F17FCE35E7"
        },
        "ingested_at": "2026-01-21T21:48:32.337364+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251358-Dustysla--7749461",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.340914",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Their Primary Headquarters is London, but have offices in New York and Salt Lake City. I think this has a lot going for it, those Medicaid reimbursements are going to help, but the CE mark will certainly expand from the London office. Even Today's RNS shows the confidence in its institutional backers,  there is more positives here than the negatives the SP is performing.  Interesting to see how the MVP collaboration has gone,  numbers, tests etc. Your market will expand,  but I get your gripe. Pharma companies are predominantly not that forthcoming or open to shareholder sentiments or give a lot of feedback. Its real emphasis on your own research, than feedback",
          "sentiment": 0.0,
          "engagement": "13,631",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337346+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251405-Dustysla-29372362",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.340501",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "I also dont think viewing a US listing as being forced a negative, and getting away from Nasdaq into the OTC is a much better suit at this juncture. Too many Rules that effect listing requirements that are just not worth it,  but even a London outfit you have broken into the US Market, have multiple offices there, receiving Medicaid reimbursement and expanding reach. These are not easy to come by, even for US based companies so I wouldnt take that achievement lightly. Its a great position to be in, removing Hurdles like FDA etc. CE mark will do hopefully what FDA has done,  break and expand into other markets.",
          "sentiment": 0.0,
          "engagement": "13,631",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337329+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251420-Mikemine-29902185",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.340078",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "I wouldn't take any notice of UBS holdings. They've been up and down for months. They'll probably go to zero holdings in the next few days.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS surge their holding from 5.08% to 7.44%",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D0278CAD-4353-4441-AFB6-77F17FCE35E7"
        },
        "ingested_at": "2026-01-21T21:48:32.337311+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251512-Silverbl-17330336",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.339670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "We will find out next month how much progress all the partnerships announcements are making on testing revenue. My fear is they will be nowhere near their H1 target. There are lots of institutional investors here besides UBS - they presumably are taking the gamble that eventually there will be a pick up in sales. No point in having an FDA approved product with the agreed reimbursement if there is no commercial market to sell into - and that has been the case so far. It has already been clarified by the company that CE is not of any importance to them in the short term - with a limited sales force the US market needs to show progress or it will start to become very difficult to secure additional funds imo. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T21:48:32.337293+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251251-Silverbl--4040184",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.339257",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "ADS split on OTC has now gone through - 1 UK \u00a3 share is now equivalent to 25 US $ OTC shares. Market reaction to this alongside the warnings in the AGM statement predictable. Short interest has increased significantly - this could get very messy, very quickly. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.25",
          "thread_title": "ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.337275+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251314-Marty130--8324353",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.338834",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Presumably carried out to keep them from being expelled from the market..",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.337257+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251352-Dustysla--7413769",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.338425",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Not necessarily,  the OTC doesnt have the Stringent Rules as Nasdaq surrounding Delisting. This isn't a non revenue company, Start up etc. And you shouldn't expelled wonders in entering markets in the first 12 months,  yet growth of sales has doubled each quarter. Im unsure why you see this as a bad long term investment Silverblade, I can only surmise you have bought higher and the decrease has weighed heavily on your input. Im yet to buy, as I imagined this route to profit, which takes time when reducing debt and growing in market and sales. Suppose people expect 1 year investing these days, when reality is. Takes much longer, on a gradual basis. 1 month spikes create over expectancy, and then you end up where you began, 50% down. Always better to research an investment thoroughly before entering into it. Hence what im doing",
          "sentiment": 0.0,
          "engagement": "13,631",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.337238+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-Bushbat--9182906",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.337989",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bushbat",
          "content": "USB holding going up rather than the usual up 5% then down again",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "6.25",
          "thread_title": "USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-01-21T21:48:32.337220+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251434-Marty130--3294777",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.337580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Just added hVIVO to my portfolio..  Looks undervalued, may come into it's own in 26..  A possible takeover target could see increasing share holder value.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-01-21T21:48:32.337201+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251446-Silverbl--6922755",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.337167",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dustyslay - there are minimum bid price requirements in relation to US listing exchanges - this was one of the reasons for the new ADS split. Where did you note that sales have doubled each quarter? That is simply not the case.  You also mention debt - of which there is none. You are correct I did purchase at higher prices - but so did every single PI and II here. All have lost significant sums of money. We all saw the the medium term opportunity here - however the current management team are showing a complete lack of momentum in growing the business. Yes this is still a new company but investors continue to be fed nonsense with never ending partnerships which don't deliver; revenue predictions which don't deliver; cost cutting which doesn't materialise; pay and stock options for the team which are excessive; cash burn that fritters away funds like there was no tomorrow. My input is negative because I expect better. Yet I remain invested against my better judgement. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.337182+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251458-Dustysla-55856819",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.336719",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Nasdaq has listing requirements that are difficult OTC is similar to AIM, there are 3 different markets OTCQB/OTCQX and OTC pink but we can dismiss that you are in one of the the first 2. OTC Premier is stringent but that isnt listed there. 0.01 is the minimum requirement SP And a M/Cap of 10 million minimum Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus. The split has gone quite well on early judgement,  and will help consolidate liquidity as lower the SP, the higher the percentage swings and more susceptible to traders profiting on movement. Ive seen worse splits, but they are predominantly done to secure liquidity and consolidate SP",
          "sentiment": 0.0,
          "engagement": "13,631",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.337164+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251506-Dustysla--6728723",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.336274",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Im not every fond of AI, or even Google AI. Never done ChatGBT etc so a lot is from memory on researching, the sales i will locate the information at some point as im a tad busy but Debt is easy to find, you would be hard pressed to find any company not still refurbishing debt after they have gone to market. The key is to see a constant, and consistent reduction per half year reports. Here is the AI, against my normal MO of real research: As of late 2025, Renalytix has reported approximately $8.21 million in total debt, a decrease from previous years. The company has actively worked to improve its balance sheet through debt restructuring and equity conversions. Key details regarding Renalytix's debt: Total Debt: The most recent figures from financial reports indicate total debt is approximately $8.21 million. Recent Reduction: Renalytix has focused on reducing its debt through strategic financial maneuvers. In October 2025, the company announced a $4 million balance sheet improvement by converting approximately $4 million of senior convertible bonds into equity, saving up to $1.4 million in future accrued interest. Debt Restructuring: A significant portion of the remaining debt is a new unsecured convertible bond issued in November 2024 (and later partially converted in Oct 2025), with a maturity date of July 2029. This bond has flexible interest payment options (cash or rolled into the principal) at the company's discretion. Historical Context: The company's total debt peaked in June 2022 at over $12 million and has generally trended downwards since then. Financial Position: The renegotiation of debts has helped the company move to a net current asset position, aiming to direct cash flows towards commercial and operational growth.",
          "sentiment": 0.0,
          "engagement": "13,631",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.337146+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251529-Dustysla--2216601",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.335819",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Ok, i know where i found the Sales and it took me a long time so here, more AI junk but the growth is there. Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months. Recent Revenue: For the first half of the fiscal year 2025 (H1 FY25), Renalytix reported revenues of $1.3 million. This demonstrated continued quarterly sales growth into Q3 FY25. Quarterly Growth: The company is on track to meet or exceed its target of 20% average quarter-over-quarter revenue growth. Billable Tests: For the first time, over 1,000 billable tests were processed in Q3 2025, supported by the onboarding of a large primary care network in New York and improved direct-to-physician sales. Medicare Coverage: The company has achieved FDA approval and Medicare coverage determination for its kidneyintelX.dkd test, with an established price of $950 per test. Partnerships: New collaborations, notably with Tempus AI and MVP Health Care, are expected to positively impact revenue and expand the test's reach among the 15 million people in the US with type 2 diabetes and chronic kidney disease. Future Guidance: Renalytix has provided forward revenue guidance of $3.2 million in FY25, $8.5 million in FY26, and $17.5 million in FY27. Despite recent sales growth, the company has faced financial challenges, including a decline in total annual revenue in FY24 compared to FY23, high operating losses, and a reliance on external financing to sustain operations. The company has focused on cost reductions and strategic partnerships to improve its financial position. 1000 \u00d7 $950 plus Medicaid Reimbursement in its first year. Now a new area in North America with MVP, 700 000 patients on books. You see where its going? Have some faith. And perhaps more research than whining on a forum",
          "sentiment": 0.0,
          "engagement": "13,631",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.337128+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251540-Dustysla--7678880",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.335362",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade I understand all what you are saying, 2024 wouldn't have been a great year as they hadn't gone to market and thats the Pharmsma industry for you, why I dont hold any current because I feel they are run by wealthy individuals that are focused on personal wealth before Health and will fill their boots prior to any achievements and shareholders take on the dilution and the hard hold. But im kinda leaning towards this, the more i look into it because its all about timing really.  If MVP goes solid, and your market expands 2026, you should improve dramatically As for the CE mark, achieving it your correct it wont move it, but its what you do once achieved in the European markets",
          "sentiment": 0.0,
          "engagement": "13,631",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.337094+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251606-Silverbl--8041869",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.334935",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "OK Dustyslay - I'll bite - here we go - my 'whining' response to your 'research' based points where real world numbers are available. 1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. The point on debt looks accurate. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.337076+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251616-Dustysla--5064466",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.334499",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m OTCQB listing only says $17.98 million 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). Is this financials or Sales? Im talking about Provider to Patient sales 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). This is how it explained, a Google AI version. Id get a more accurate view, but im not not interested in doing so. 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. Ok well nothing I found in 30 mins showed they had FDA approval so the assumption is their flogging nothing. But if im wrong, and it started somewhere in 2024 fine. Small details. But Debt, well yes as you said checks out. But you said NO DEBT, quite abruptly so I got a lot closer than you in 30 minutes that you seemingly in years",
          "sentiment": 0.0,
          "engagement": "13,631",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.337058+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251621-Dustysla--6658379",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.334038",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "I think your Gripe is the time spent here, and against the companies management. I get that, they are not the easiest investments as they are Crooks and useless. So I try to look at 3 things here at this juncture Revenue/Debt/Sales And Future Projected Revenue/Debt/Sales And how they will maintain a healthy cash burn in the intermediate.",
          "sentiment": 0.0,
          "engagement": "13,631",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.337039+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251623-cipro-33465326",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.333609",
        "source": "LSE_CHAT",
        "data": {
          "author": "cipro",
          "content": "The trend is slowly going down with this stock did hv good potential And I hope this still has some upside however the momentum is stuttering atm Hope to get positive news in January to get the trend back up good luck all",
          "sentiment": 0.0,
          "engagement": "2,147",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-01-21T21:48:32.337021+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251751-Marty130-30058638",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.333180",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "CE marks always add value.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.337003+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251146-JBCo-36812746",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.332755",
        "source": "LSE_CHAT",
        "data": {
          "author": "JBCo",
          "content": "Hopefully can hold 6p",
          "sentiment": 0.0,
          "engagement": "4,502",
          "price_at_post": "6.25",
          "thread_title": "Big seller trying to get out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=253BEB68-92E2-41AA-91A1-E5998136B1CD"
        },
        "ingested_at": "2026-01-21T21:48:32.336985+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251427-Hawker--8680369",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.332343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Well said, SB. This is now just a waiting game, as the company has EVERYTHING they need to succeed in going to market; there are no more barriers. The only question, therefore, is whether they can sell the test into their focus regions and whether there is a market for it. So far, the jury is out. QED... Opinion:   Ho hum",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.336967+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20250931-Marty130-30814729",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.331888",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "German Market is huge.. Once the CE goes through, plenty will sign up.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.336949+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251241-Silverbl--8355218",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:23.331455",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "The jury is not only out Hawker....its leaving the courthouse! Its been another horror story in 2025 for the business which showed so much early promise. I have low expectations for the trading update in January - seems this is pretty common given the share price reaction. All time price low - makes the 9.5p raise a highlight from the management team - although the next raise could be very painful for shareholders if they cannot generate revenue and continue to burn cash. ATB to those who hold here - it continues to be a very difficult investment to justify. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "5.90",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-21T21:48:32.336931+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251644-Marty130-74629108",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.682304",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Down selling again.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "5.90",
          "thread_title": "UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-01-21T21:48:32.336913+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251756-tweedly--5316748",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.681889",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Right. These RNS' have been coming out for at least 6 months, no one makes sense of them so no point speculating. Merry Christmas folks",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-01-21T21:48:32.336894+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251830-Marty130-62703169",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.681479",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "U2..",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-01-21T21:48:32.336877+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251144-Mikemine-29133513",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.681062",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Merry Christmas everybody. Here's hoping for a more prosperous New year.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "5.90",
          "thread_title": "Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T21:48:32.336858+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251332-Marty130-44753408",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.680654",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Surely we'll get better results next year, if not a possible takeover.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T21:48:32.336840+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20252029-Cevodniy--2386616",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.680248",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, you are the only poster here generally and even you can't see anything positive,  except the possibility of a takeover I've just over 1.2 million at an average of 10p, I fo not expect to ever see profit.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T21:48:32.336822+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250037-MIKODX--3154878",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.679820",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "FY2025 was a key year for the company in establishing a solid pathway for testing adoption, life science services and strategic partnering. In July 2025, RENX announced an agreement with MVP Health Care, a U.S.-based insurer covering more than 700,000 patients. Beyond expanding physician and patient access, this agreement reinforces that Renalytix and kidneyIntelX.dkd are establishing a leadership position in chronic kidney disease management and gaining increasing recognition in the market. In September 2025, Renalytix signed an agreement with Tempus AI, Inc. (\u201cTempus\u201d), a clear leader in delivery of integrated advanced diagnostic testing and life science services in the United States. The collaboration with Tempus will enable RENX to accelerate introduction of kidneyintelX.dkd into large hospital systems and community healthcare practices across the U.S., significantly expanding distribution over the next five years. The relationship with Tempus AI has continued to develop positively, with ongoing progress in aligning commercial activities. The Balance Sheet was further improved with the conversion of an additional $4 million of convertible debt leaving outstanding long-term debt at \u00a33.1m as of October 2025. More than $1.3m in cash from backdated R&D claims and grant income, further strengthening the balance sheet. Administrative expenses decreased by more than 40% year-on-year, driven by headcount and operations optimization. RENX continue to strengthen there presence in three initial target states - Florida, Texas, and New York. In FY26, they expanded into Arizona their fourth target market which collectively represents approximately 20% of the total addressable kidneyintelX.dkd market. RENX is well positioned to deliver important and necessary change in chronic kidney disease management in the United States and globally.In the coming months and years sales will without doubt improve with the test being made more readily available in healthcare systems. Not been a bad year for the company, quite the opposite, it has been a very positive one. FY26 will see the partnerships coming to fruition with the test more widely available in the healthcare systems which will mean more sales for the company. Lots to look forward to in the coming year. I'll drink to that. Hope everyone has a merry xmas and the best of luck for the new year. With any luck we will have some good news from the parterships established, which will have a very positive affect on the SP. As we all know, this is a very volatile stock that can really take off on good news. Next year will be the year. GLA",
          "sentiment": 0.0,
          "engagement": "3,975",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T21:48:32.336804+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250828-Cevodniy-75807165",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.679387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "MIKODX on the 2nd January 2025, the SP was 10.75, yesterday it was 6p. I get your optimism via your post, but obviously institutions and wealthy investors don't agree. 10p to 6p is not exactly a successful year. I hope we don't experience another 66% next year.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T21:48:32.336786+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251037-Marty130--4647577",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.678956",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Cevo, And don't forget the CE mark will have a transformation affect.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T21:48:32.336768+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251231-Marty130-46146199",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.678548",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Hopefully we will have a better year in 2026, with more announcements of higher revenues and transformational new contracts signed. The BoD badly needs pay more attention to reverse the share price trend..",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "5.90",
          "thread_title": "New contracts",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8AD3616F-3B6B-486A-8B37-36DE630CD42F"
        },
        "ingested_at": "2026-01-21T21:48:32.336749+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20251632-MIKODX-83272944",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.678144",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "It\u2019s not good watching the SP slowly slip down, but that\u2019s bound to happen with no positive news. The one consolation is the support at 5.70 is holding up well so far. Hopefully we can kick off the new year with some good news and hopefully get a good bounce from the support level all the way up past 10.",
          "sentiment": 0.0,
          "engagement": "3,975",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T21:48:32.336731+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251345-Silverbl-31669721",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.677721",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dreadful year for investors. Trading update in January could hammer confidence further if company fails to deliver revenue targets. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T21:48:32.336712+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20252147-Crannog1--3344296",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.677318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crannog12",
          "content": "You are a ray of sunshine. I take it you are invested here?",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T21:48:32.336694+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20260407-Cevodniy--2412278",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.676893",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Ok fellow investors. Year end SP predictions. I'll start at 20p.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "5.90",
          "thread_title": "Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-21T21:48:32.336676+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261121-Marty130--1122836",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.676482",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "On receipt of the CE acceptance, which is expected h1, 18/22, on a takeover, 40/60.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-21T21:48:32.336658+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261342-Mikemine--4608195",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.676063",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "If Tempus gets going, the revenue will spike and so will the SP. Big companies like Tempus are notoriously slow to move but they've had since early September so H1 seems reasonable for them to get going. I urge anyone who has missed the RNS (15th Sept) about the collaboration agreement to read it and do a bit of research on Tempus. Apart from this ramp, I won't offer a prediction target but I do expect to multibag  from these levels. Good luck to everybody.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-21T21:48:32.336639+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20262041-Marty130--7625159",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.675655",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix said in an update on Tuesday that it was making progress in expanding the use of KidneyIntelX.dkd across the United States, reporting growing testing volumes, new state coverage and advancing commercial partnerships ahead of its annual general meeting in London. The AIM-traded company's prognostic blood test, the only FDA-approved and Medicare-reimbursed test for early-stage chronic kidney disease risk assessment, was now generating revenue from four core states - Florida, Texas, New York and, most recently, Arizona. Executive chairman Julian Baines said the first orders in Arizona included tests from one of the largest nephrology practices in the US. He emphasised that, while direct sales growth is encouraging, the company's primary strategy is to scale test adoption through major business development agreements with large healthcare systems. Renalytix signed a definitive agreement in September with Tempus AI, the Nasdaq-listed diagnostics and AI group, which Baines said has \"an established network of healthcare institutions already utilising its precision medicine solutions.\" He added that early engagement with Tempus and MVP Health Care reinforced the company's belief that its partnership-led model would \"deliver long-term value for shareholders,\" despite lengthy implementation processes common across major US providers. Renalytix said it had also narrowed potential partners for its next electronic health record integration and was working with several large healthcare systems expected to generate \"meaningful testing volumes\" over time. The company said it was increasingly using data analytics to identify physicians managing high numbers of eligible patients, helping target commercial resources where uptake prospects are strongest. Renalytix added that it had started transitioning to a new laboratory facility, a move expected to expand testing capacity and reduce operating costs over the next five years. Baines said the company was now focused on converting ongoing discussions into contracted relationships, expanding EHR integrations and accelerating test volumes. While acknowledging that timing of commercial outcomes \"remains difficult to predict,\" he said the board was confident that the company's current initiatives \"position the company well for sustainable revenue growth, increased operating leverage, and long-term value creation for shareholders.\" Renalytix said it would provide a trading update for the six months to 31 December by the end of January.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "5.90",
          "thread_title": "2026 outlook",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=30EC9492-CE10-4321-AED9-CF8B2D3F53AF"
        },
        "ingested_at": "2026-01-21T21:48:32.336621+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261649-Marty130-29169379",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.675202",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "To turn this around as the share price will continue to new lows..   Wake up BoD, pull your fingers out..",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "5.90",
          "thread_title": "Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-01-21T21:48:32.336604+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261801-oldbutno--5051437",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.674783",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "....come to those that wait.....Oh, and DEATH!",
          "sentiment": 0.0,
          "engagement": "3,314",
          "price_at_post": "5.90",
          "thread_title": "GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-21T21:48:32.336585+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261837-Silverbl-87228743",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.674373",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "New deals mean nothing without a credible commercial plan which has at its heart the means to create and service product demand in a timeous and profitable manner. Nothing to date has achieved that in any meaningful volume. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "5.90",
          "thread_title": "RE: Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-01-21T21:48:32.336564+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261839-Silverbl--4173916",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.673952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "...well if the prognosis is kidney related oldbut i think we might be able to help out......lol. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-21T21:48:32.336546+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261935-Marty130-89063960",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.673539",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix is expected to participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, a premier global healthcare investment symposium where companies present and connect with investors, industry leaders, and innovators, focusing on new technologies like AI in healthcare, kidney disease, and strategic partnerships. While Renalytix isn't explicitly named in the top results, they are a kidney-focused company likely to attend this major event, which runs concurrently with the Biotech Showcase.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-21T21:48:32.336528+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261412-Veteran1--5620843",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.673126",
        "source": "LSE_CHAT",
        "data": {
          "author": "Veteran10",
          "content": "Bit of movement but low volume. If volumes increases, could be a momentum buy opportunity.",
          "sentiment": 0.0,
          "engagement": "4,036",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-21T21:48:32.336510+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261527-Marty130--6777716",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.672695",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "A deal may arise next week after the conference in San Francisco.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-21T21:48:32.336492+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261512-Marty130--1671371",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:20.672262",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "They're back in again..",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-21T21:48:32.336474+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261603-Pixels-35112872",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.583481",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pixels",
          "content": "How can you tell, that document shows as \"acquisition / disposal\" - is it definitely acquisition? Got to admit I struggle with reading financial type documents, I'm just a media monkey",
          "sentiment": 0.0,
          "engagement": "181",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-21T21:48:32.336455+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261616-Marty130--7284640",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.583057",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Purchase at 7%.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-21T21:48:32.336437+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261801-Marty130--7819571",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.582651",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Upcoming Financial & Corporate Events H1 2026 Trading Update: The company is scheduled to provide a trading update for the six-month period ending December 31, 2025, by the end of January 2026.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T21:48:32.336418+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260710-uxm484-20977652",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.582239",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. Hopefully some new investors will jump on this month following the J.P Morgan event in the US, progress being made and undervalued at present.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T21:48:32.336400+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260712-morningt-83065612",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.581817",
        "source": "LSE_CHAT",
        "data": {
          "author": "mornington-oz",
          "content": "RNS  OUT",
          "sentiment": 0.0,
          "engagement": "23,490",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T21:48:32.336382+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260807-Marty130-31228280",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.581414",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Where? I haven't received one.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T21:48:32.336363+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260809-johndean-63240528",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.580994",
        "source": "LSE_CHAT",
        "data": {
          "author": "johndean",
          "content": "Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the company expects to provide further updates on progress and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "798",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T21:48:32.336345+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260823-Marty130--5362863",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.580591",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Results deadline missed then..  As wws due before 31st of January..",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T21:48:32.336326+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260838-emblaze1-72299902",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.580186",
        "source": "LSE_CHAT",
        "data": {
          "author": "emblaze1",
          "content": "LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use. The integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix. These integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations. Renalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources. Tempus AI Collaboration Renalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in September 2025, to target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients. The collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time. Investor Engagement James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. The 44th annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad rang",
          "sentiment": 0.0,
          "engagement": "917",
          "price_at_post": "6.25",
          "thread_title": "RE:Results soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=3DEB0D63-492C-4E6A-AD12-B94C142E4A0B"
        },
        "ingested_at": "2026-01-21T21:48:32.336307+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261111-Marty130-88461699",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.579729",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Enalytix plc (RENX.LN)*, Futura Medical plc (FUM.LN) Non-Independent Research; Marketing & Sales Commentary - MiFID II exempt information \u2013 see disclaimer below. Company Update: 12 January 2026 Renalytix plc (LSE: RENX, OTCQB: RNLXY)*: Three kidneyintelX.dkd clinical integration \u2013 update on Tempus collaboration Market Capitalisation: \u00a326.6m; Share Price: 6.08p \u2022 During the last quarter of 2025, Renalytix completed three additional kidney specialist healthcare provider clinical integrations in the US, in New York, Florida and Tennessee.  \u2022 Additional integrations are expected in early 2026. \u2022 Tempus collaboration is progressing well with teams from both Tempus and Renalytix working closely to target Tempus\u2019 customers with a large diabetes and kidney disease patients.  Renalytix reports that it added three new US clinical integrations in late 2025, bringing its FDAapproved kidneyintelX.dkd test into established kidney care practices in New York, Florida, and Tennessee. Testing has begun at all sites, and although initial volumes are expected to be small, the company anticipates usage to build as clinicians become familiar with the workflow. More integrations are planned for early 2026.  Renalytix states that it is working intensively with Tempus to integrate its kidney risk testing into major US health systems through Tempus' integrated electronic health records (EHR). Since the partnership began in September 2025, teams from both companies have been coordinating to target large provider networks with significant diabetes and CKD populations, aiming to streamline test ordering and strengthen data collection. The collaboration is positioned as a foundation for expanding into new clinical and geographic markets as the platform matures.  From a strategic standpoint, this fits neatly with Renalytix\u2019s strategy to have kidneyintelX.dkd test integrates into healthcare providers\u2019 EHRs, which allows quick and seamless ordering. shift toward disciplined, system-level integrations rather than chasing individual clinics. The Tempus partnership could prove far more meaningful if it unlocks access to large, data-rich health systems where adoption can scale. SP Angel acts as Nomad and Broker to the Renalytix Futura Medical plc (AIM: FUM): Positive results from WSD4000 early feasibility study Market Capitalisation: \u00a39.1m; Share Price: 1.58p \u2022 Statistically significant improvement achieved in female sexual function with WSD4000 in a study enrolling 12 women suffering from some degree of sexual dysfunction. \u2022 Results give the Company confidence to proceed to the next steps of designing a Phase III placebo-controlled trial, with results expected mid-2026 Futura reports that its WSD4000 early feasibility study in 12 women showed a clear and statistically significant improvement in sexual function, with gains on the Female Sexual Function Index (FSFI) scale well above the accepted threshold for clinical relevance. Benefits were seen across arousal",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D3CE797F-7C15-4738-8269-38EDD6CB8090"
        },
        "ingested_at": "2026-01-21T21:48:32.336278+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262236-MIKODX-29048060",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.579322",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "The company says it expects to provide a fuller trading update in February. By fuller that means they expect improvement in sales. The company is making all the right moves thus far.",
          "sentiment": 0.0,
          "engagement": "3,975",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T21:48:32.336260+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262252-MIKODX-43361102",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.578910",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Todays RNS means we are now seeing concrete progress on commercial rollout.This shows that Renalytix is moving towards actual deployment with multiple provider groups. Getting kidneyintelX.dkd into established clinics is a big step. It means providers see enough value in the test to integrate it into their day-to-day systems. The RNS reiterates that Renalytix and Tempus are working closely to integrate kidneyintelX.dkd into larger healthcare sytems that are already on Tempus's platform. This is very significant because a) smaller clinics alone won't generate high volumes and b) larger sytems (via Tempus) have broader patient populations and infrastucture. This will accelerate adoption more rapidly once it starts rolling through those network. Everything is starting to fall into place, the company is really now starting to see some real progression. Great RNS.",
          "sentiment": 0.0,
          "engagement": "3,975",
          "price_at_post": "6.25",
          "thread_title": "Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-21T21:48:32.336243+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261401-tweedly-66337664",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.578500",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Understandably the RNS didn't set the market alight. Waiting for hard numbers I think.",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-21T21:48:32.336225+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261535-Marty130-70156637",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.578081",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Exactly.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-21T21:48:32.336207+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261537-Hawker-11575841",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.577677",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Hope springs eternal...  Ho hum...",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-21T21:48:32.336190+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261633-Investor--3792991",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.577270",
        "source": "LSE_CHAT",
        "data": {
          "author": "Investor2025",
          "content": "Not yet..",
          "sentiment": 0.0,
          "engagement": "7",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-21T21:48:32.336172+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261836-Marty130--1684875",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.576854",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Looks like the SP is heading down, in order to boost volumes.. Let's hope the BoD release some juicy news to push it back up on healthy volumes.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-21T21:48:32.336154+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261947-Silverbl--8635019",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.576451",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Next news is likely to see share price hit all time lows - enough negative hints have been dropped recently about current trading. Statements such as \"Commercial outcomes.....remain difficult to predict\"; \"Each practice currently represents modest initial testing volumes\"; \"Engaging with large healthcare systems presents inherent challenges\" - do not fill me with short term confidence in the $8.4m 2026 revenue target - we are about to finish month 7 out of 12 in that regard. And if that revenue target is not met where does that leave the cash position? Does make you wonder what exactly the company's 11 full time sales reps are doing - door knocking physicians will not cut it here. SB",
          "sentiment": 0.0,
          "engagement": "1,917",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-21T21:48:32.336136+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262055-bluesy1-45867601",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.576030",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "This has all the hallmarks of a BOD lifestyle  funding company. FDA approval but would rather die in their own DNA.  Get out before its too late",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.15",
          "thread_title": "Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-01-21T21:48:32.336108+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262227-Marty130-61399458",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.575626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Disagree.",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.15",
          "thread_title": "RE: Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-01-21T21:48:32.336066+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261743-Mikemine-34215510",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.575211",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Looks like somebody knows something maybe?",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "6.25",
          "thread_title": "Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-01-21T21:48:32.336047+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261948-bluesy1--3368321",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.574793",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "Like what ? Minor move upwards. Lets all get excited. Tedious ...",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.25",
          "thread_title": "RE: Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-01-21T21:48:32.336030+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261120-Marty130--3572993",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.574388",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://www.proactiveinvestors.com/companies/news/1085472/renalytix-expands-us-footprint-with-three-new-clinical-partnerships-1085472.html",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-21T21:48:32.336011+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260551-Cevodniy--6673277",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.573965",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, that's great news, but nothing absolutely nothing affects the share price.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-21T21:48:32.335992+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261743-Marty130--1468180",
        "event_type": "social_post",
        "date": "2026-01-21T21:48:17.573538",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Agreed",
          "sentiment": 0.0,
          "engagement": "1,245",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-21T21:48:32.335970+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251144-Mikemine-27777433",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.866392",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Merry Christmas everybody. Here's hoping for a more prosperous New year.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "5.90",
          "thread_title": "Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T02:01:55.612155Z"
      },
      {
        "event_id": "SOCIAL-24Dec20251332-Marty130--1154399",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.865968",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Surely we'll get better results next year, if not a possible takeover.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T02:01:55.612127Z"
      },
      {
        "event_id": "SOCIAL-24Dec20252029-Cevodniy-86221117",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.865555",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, you are the only poster here generally and even you can't see anything positive,  except the possibility of a takeover I've just over 1.2 million at an average of 10p, I fo not expect to ever see profit.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T02:01:55.612086Z"
      },
      {
        "event_id": "SOCIAL-25Dec20250037-MIKODX-84899934",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.865133",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "FY2025 was a key year for the company in establishing a solid pathway for testing adoption, life science services and strategic partnering. In July 2025, RENX announced an agreement with MVP Health Care, a U.S.-based insurer covering more than 700,000 patients. Beyond expanding physician and patient access, this agreement reinforces that Renalytix and kidneyIntelX.dkd are establishing a leadership position in chronic kidney disease management and gaining increasing recognition in the market. In September 2025, Renalytix signed an agreement with Tempus AI, Inc. (\u201cTempus\u201d), a clear leader in delivery of integrated advanced diagnostic testing and life science services in the United States. The collaboration with Tempus will enable RENX to accelerate introduction of kidneyintelX.dkd into large hospital systems and community healthcare practices across the U.S., significantly expanding distribution over the next five years. The relationship with Tempus AI has continued to develop positively, with ongoing progress in aligning commercial activities. The Balance Sheet was further improved with the conversion of an additional $4 million of convertible debt leaving outstanding long-term debt at \u00a33.1m as of October 2025. More than $1.3m in cash from backdated R&D claims and grant income, further strengthening the balance sheet. Administrative expenses decreased by more than 40% year-on-year, driven by headcount and operations optimization. RENX continue to strengthen there presence in three initial target states - Florida, Texas, and New York. In FY26, they expanded into Arizona their fourth target market which collectively represents approximately 20% of the total addressable kidneyintelX.dkd market. RENX is well positioned to deliver important and necessary change in chronic kidney disease management in the United States and globally.In the coming months and years sales will without doubt improve with the test being made more readily available in healthcare systems. Not been a bad year for the company, quite the opposite, it has been a very positive one. FY26 will see the partnerships coming to fruition with the test more widely available in the healthcare systems which will mean more sales for the company. Lots to look forward to in the coming year. I'll drink to that. Hope everyone has a merry xmas and the best of luck for the new year. With any luck we will have some good news from the parterships established, which will have a very positive affect on the SP. As we all know, this is a very volatile stock that can really take off on good news. Next year will be the year. GLA",
          "sentiment": 0.0,
          "engagement": "3,975",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T02:01:55.612059Z"
      },
      {
        "event_id": "SOCIAL-25Dec20250828-Cevodniy-61024918",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.864688",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "MIKODX on the 2nd January 2025, the SP was 10.75, yesterday it was 6p. I get your optimism via your post, but obviously institutions and wealthy investors don't agree. 10p to 6p is not exactly a successful year. I hope we don't experience another 66% next year.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T02:01:55.612033Z"
      },
      {
        "event_id": "SOCIAL-28Dec20251037-Marty130--3183424",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.864265",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Cevo, And don't forget the CE mark will have a transformation affect.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T02:01:55.612006Z"
      },
      {
        "event_id": "SOCIAL-29Dec20251231-Marty130--9002736",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.863838",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Hopefully we will have a better year in 2026, with more announcements of higher revenues and transformational new contracts signed. The BoD badly needs pay more attention to reverse the share price trend..",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "5.90",
          "thread_title": "New contracts",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8AD3616F-3B6B-486A-8B37-36DE630CD42F"
        },
        "ingested_at": "2026-01-21T02:01:55.611979Z"
      },
      {
        "event_id": "SOCIAL-30Dec20251632-MIKODX-65416807",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.863431",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "It\u2019s not good watching the SP slowly slip down, but that\u2019s bound to happen with no positive news. The one consolation is the support at 5.70 is holding up well so far. Hopefully we can kick off the new year with some good news and hopefully get a good bounce from the support level all the way up past 10.",
          "sentiment": 0.0,
          "engagement": "3,975",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T02:01:55.611953Z"
      },
      {
        "event_id": "SOCIAL-31Dec20251345-Silverbl-51904202",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.863006",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dreadful year for investors. Trading update in January could hammer confidence further if company fails to deliver revenue targets. SB",
          "sentiment": 0.0,
          "engagement": "1,916",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T02:01:55.611926Z"
      },
      {
        "event_id": "SOCIAL-31Dec20252147-Crannog1--6427395",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.862598",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crannog12",
          "content": "You are a ray of sunshine. I take it you are invested here?",
          "sentiment": 0.0,
          "engagement": "56",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-21T02:01:55.611899Z"
      },
      {
        "event_id": "SOCIAL-1Jan20260407-Cevodniy--8700255",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.862180",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Ok fellow investors. Year end SP predictions. I'll start at 20p.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "5.90",
          "thread_title": "Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-21T02:01:55.611872Z"
      },
      {
        "event_id": "SOCIAL-1Jan20261121-Marty130-88780719",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.861757",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "On receipt of the CE acceptance, which is expected h1, 18/22, on a takeover, 40/60.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-21T02:01:55.611846Z"
      },
      {
        "event_id": "SOCIAL-1Jan20261342-Mikemine-82447924",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.861346",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "If Tempus gets going, the revenue will spike and so will the SP. Big companies like Tempus are notoriously slow to move but they've had since early September so H1 seems reasonable for them to get going. I urge anyone who has missed the RNS (15th Sept) about the collaboration agreement to read it and do a bit of research on Tempus. Apart from this ramp, I won't offer a prediction target but I do expect to multibag  from these levels. Good luck to everybody.",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-21T02:01:55.611819Z"
      },
      {
        "event_id": "SOCIAL-1Jan20262041-Marty130--8500400",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.860923",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix said in an update on Tuesday that it was making progress in expanding the use of KidneyIntelX.dkd across the United States, reporting growing testing volumes, new state coverage and advancing commercial partnerships ahead of its annual general meeting in London. The AIM-traded company's prognostic blood test, the only FDA-approved and Medicare-reimbursed test for early-stage chronic kidney disease risk assessment, was now generating revenue from four core states - Florida, Texas, New York and, most recently, Arizona. Executive chairman Julian Baines said the first orders in Arizona included tests from one of the largest nephrology practices in the US. He emphasised that, while direct sales growth is encouraging, the company's primary strategy is to scale test adoption through major business development agreements with large healthcare systems. Renalytix signed a definitive agreement in September with Tempus AI, the Nasdaq-listed diagnostics and AI group, which Baines said has \"an established network of healthcare institutions already utilising its precision medicine solutions.\" He added that early engagement with Tempus and MVP Health Care reinforced the company's belief that its partnership-led model would \"deliver long-term value for shareholders,\" despite lengthy implementation processes common across major US providers. Renalytix said it had also narrowed potential partners for its next electronic health record integration and was working with several large healthcare systems expected to generate \"meaningful testing volumes\" over time. The company said it was increasingly using data analytics to identify physicians managing high numbers of eligible patients, helping target commercial resources where uptake prospects are strongest. Renalytix added that it had started transitioning to a new laboratory facility, a move expected to expand testing capacity and reduce operating costs over the next five years. Baines said the company was now focused on converting ongoing discussions into contracted relationships, expanding EHR integrations and accelerating test volumes. While acknowledging that timing of commercial outcomes \"remains difficult to predict,\" he said the board was confident that the company's current initiatives \"position the company well for sustainable revenue growth, increased operating leverage, and long-term value creation for shareholders.\" Renalytix said it would provide a trading update for the six months to 31 December by the end of January.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "5.90",
          "thread_title": "2026 outlook",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=30EC9492-CE10-4321-AED9-CF8B2D3F53AF"
        },
        "ingested_at": "2026-01-21T02:01:55.611793Z"
      },
      {
        "event_id": "SOCIAL-6Jan20261649-Marty130--2117286",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.860471",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "To turn this around as the share price will continue to new lows..   Wake up BoD, pull your fingers out..",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "5.90",
          "thread_title": "Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-01-21T02:01:55.611766Z"
      },
      {
        "event_id": "SOCIAL-6Jan20261801-oldbutno--6570321",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.860050",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "....come to those that wait.....Oh, and DEATH!",
          "sentiment": 0.0,
          "engagement": "3,312",
          "price_at_post": "5.90",
          "thread_title": "GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-21T02:01:55.611740Z"
      },
      {
        "event_id": "SOCIAL-6Jan20261837-Silverbl--3803659",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.859636",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "New deals mean nothing without a credible commercial plan which has at its heart the means to create and service product demand in a timeous and profitable manner. Nothing to date has achieved that in any meaningful volume. SB",
          "sentiment": 0.0,
          "engagement": "1,916",
          "price_at_post": "5.90",
          "thread_title": "RE: Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-01-21T02:01:55.611713Z"
      },
      {
        "event_id": "SOCIAL-6Jan20261839-Silverbl--8416614",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.859224",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "...well if the prognosis is kidney related oldbut i think we might be able to help out......lol. SB",
          "sentiment": 0.0,
          "engagement": "1,916",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-21T02:01:55.611686Z"
      },
      {
        "event_id": "SOCIAL-6Jan20261935-Marty130--8599284",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.858799",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix is expected to participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, a premier global healthcare investment symposium where companies present and connect with investors, industry leaders, and innovators, focusing on new technologies like AI in healthcare, kidney disease, and strategic partnerships. While Renalytix isn't explicitly named in the top results, they are a kidney-focused company likely to attend this major event, which runs concurrently with the Biotech Showcase.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-21T02:01:55.611660Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261412-Veteran1-46349490",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.858387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Veteran10",
          "content": "Bit of movement but low volume. If volumes increases, could be a momentum buy opportunity.",
          "sentiment": 0.0,
          "engagement": "4,033",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-21T02:01:55.611633Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261527-Marty130--6535357",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.857950",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "A deal may arise next week after the conference in San Francisco.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-21T02:01:55.611607Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261512-Marty130--1505813",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:44.857508",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "They're back in again..",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "6.25",
          "thread_title": "UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-21T02:01:55.611580Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261603-Pixels--3632424",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.505602",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pixels",
          "content": "How can you tell, that document shows as \"acquisition / disposal\" - is it definitely acquisition? Got to admit I struggle with reading financial type documents, I'm just a media monkey",
          "sentiment": 0.0,
          "engagement": "181",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-21T02:01:55.611553Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261616-Marty130-45903464",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.505186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Purchase at 7%.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-21T02:01:55.611526Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261801-Marty130-27914573",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.504770",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Upcoming Financial & Corporate Events H1 2026 Trading Update: The company is scheduled to provide a trading update for the six-month period ending December 31, 2025, by the end of January 2026.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "6.25",
          "thread_title": "Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T02:01:55.611499Z"
      },
      {
        "event_id": "SOCIAL-12Jan20260710-uxm484-47766556",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.504359",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. Hopefully some new investors will jump on this month following the J.P Morgan event in the US, progress being made and undervalued at present.",
          "sentiment": 0.0,
          "engagement": "1,007",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T02:01:55.611472Z"
      },
      {
        "event_id": "SOCIAL-12Jan20260712-morningt--1679438",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.503933",
        "source": "LSE_CHAT",
        "data": {
          "author": "mornington-oz",
          "content": "RNS  OUT",
          "sentiment": 0.0,
          "engagement": "23,487",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T02:01:55.611445Z"
      },
      {
        "event_id": "SOCIAL-12Jan20260807-Marty130-26155465",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.503526",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Where? I haven't received one.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T02:01:55.611418Z"
      },
      {
        "event_id": "SOCIAL-12Jan20260809-johndean--1011666",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.503113",
        "source": "LSE_CHAT",
        "data": {
          "author": "johndean",
          "content": "Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the company expects to provide further updates on progress and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "798",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T02:01:55.611392Z"
      },
      {
        "event_id": "SOCIAL-12Jan20260823-Marty130--6676917",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.502698",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Results deadline missed then..  As wws due before 31st of January..",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T02:01:55.611365Z"
      },
      {
        "event_id": "SOCIAL-12Jan20260838-emblaze1--4911491",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.502291",
        "source": "LSE_CHAT",
        "data": {
          "author": "emblaze1",
          "content": "LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use. The integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix. These integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations. Renalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources. Tempus AI Collaboration Renalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in September 2025, to target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients. The collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time. Investor Engagement James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. The 44th annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad rang",
          "sentiment": 0.0,
          "engagement": "917",
          "price_at_post": "6.25",
          "thread_title": "RE:Results soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=3DEB0D63-492C-4E6A-AD12-B94C142E4A0B"
        },
        "ingested_at": "2026-01-21T02:01:55.611339Z"
      },
      {
        "event_id": "SOCIAL-12Jan20261111-Marty130--5079646",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.501832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Enalytix plc (RENX.LN)*, Futura Medical plc (FUM.LN) Non-Independent Research; Marketing & Sales Commentary - MiFID II exempt information \u2013 see disclaimer below. Company Update: 12 January 2026 Renalytix plc (LSE: RENX, OTCQB: RNLXY)*: Three kidneyintelX.dkd clinical integration \u2013 update on Tempus collaboration Market Capitalisation: \u00a326.6m; Share Price: 6.08p \u2022 During the last quarter of 2025, Renalytix completed three additional kidney specialist healthcare provider clinical integrations in the US, in New York, Florida and Tennessee.  \u2022 Additional integrations are expected in early 2026. \u2022 Tempus collaboration is progressing well with teams from both Tempus and Renalytix working closely to target Tempus\u2019 customers with a large diabetes and kidney disease patients.  Renalytix reports that it added three new US clinical integrations in late 2025, bringing its FDAapproved kidneyintelX.dkd test into established kidney care practices in New York, Florida, and Tennessee. Testing has begun at all sites, and although initial volumes are expected to be small, the company anticipates usage to build as clinicians become familiar with the workflow. More integrations are planned for early 2026.  Renalytix states that it is working intensively with Tempus to integrate its kidney risk testing into major US health systems through Tempus' integrated electronic health records (EHR). Since the partnership began in September 2025, teams from both companies have been coordinating to target large provider networks with significant diabetes and CKD populations, aiming to streamline test ordering and strengthen data collection. The collaboration is positioned as a foundation for expanding into new clinical and geographic markets as the platform matures.  From a strategic standpoint, this fits neatly with Renalytix\u2019s strategy to have kidneyintelX.dkd test integrates into healthcare providers\u2019 EHRs, which allows quick and seamless ordering. shift toward disciplined, system-level integrations rather than chasing individual clinics. The Tempus partnership could prove far more meaningful if it unlocks access to large, data-rich health systems where adoption can scale. SP Angel acts as Nomad and Broker to the Renalytix Futura Medical plc (AIM: FUM): Positive results from WSD4000 early feasibility study Market Capitalisation: \u00a39.1m; Share Price: 1.58p \u2022 Statistically significant improvement achieved in female sexual function with WSD4000 in a study enrolling 12 women suffering from some degree of sexual dysfunction. \u2022 Results give the Company confidence to proceed to the next steps of designing a Phase III placebo-controlled trial, with results expected mid-2026 Futura reports that its WSD4000 early feasibility study in 12 women showed a clear and statistically significant improvement in sexual function, with gains on the Female Sexual Function Index (FSFI) scale well above the accepted threshold for clinical relevance. Benefits were seen across arousal",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "6.25",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D3CE797F-7C15-4738-8269-38EDD6CB8090"
        },
        "ingested_at": "2026-01-21T02:01:55.611312Z"
      },
      {
        "event_id": "SOCIAL-12Jan20262236-MIKODX-47684838",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.501424",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "The company says it expects to provide a fuller trading update in February. By fuller that means they expect improvement in sales. The company is making all the right moves thus far.",
          "sentiment": 0.0,
          "engagement": "3,975",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-21T02:01:55.611285Z"
      },
      {
        "event_id": "SOCIAL-12Jan20262252-MIKODX-86480066",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.501006",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Todays RNS means we are now seeing concrete progress on commercial rollout.This shows that Renalytix is moving towards actual deployment with multiple provider groups. Getting kidneyintelX.dkd into established clinics is a big step. It means providers see enough value in the test to integrate it into their day-to-day systems. The RNS reiterates that Renalytix and Tempus are working closely to integrate kidneyintelX.dkd into larger healthcare sytems that are already on Tempus's platform. This is very significant because a) smaller clinics alone won't generate high volumes and b) larger sytems (via Tempus) have broader patient populations and infrastucture. This will accelerate adoption more rapidly once it starts rolling through those network. Everything is starting to fall into place, the company is really now starting to see some real progression. Great RNS.",
          "sentiment": 0.0,
          "engagement": "3,975",
          "price_at_post": "6.25",
          "thread_title": "Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-21T02:01:55.611258Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261401-tweedly--2434014",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.500591",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Understandably the RNS didn't set the market alight. Waiting for hard numbers I think.",
          "sentiment": 0.0,
          "engagement": "190",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-21T02:01:55.611231Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261535-Marty130-82147293",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.500182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Exactly.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-21T02:01:55.611204Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261537-Hawker--2458319",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.499765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Hope springs eternal...  Ho hum...",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-21T02:01:55.611176Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261633-Investor--5686752",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.499358",
        "source": "LSE_CHAT",
        "data": {
          "author": "Investor2025",
          "content": "Not yet..",
          "sentiment": 0.0,
          "engagement": "7",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-21T02:01:55.611149Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261836-Marty130--8909040",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.498937",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Looks like the SP is heading down, in order to boost volumes.. Let's hope the BoD release some juicy news to push it back up on healthy volumes.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-21T02:01:55.611117Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261947-Silverbl--2895068",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.498530",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Next news is likely to see share price hit all time lows - enough negative hints have been dropped recently about current trading. Statements such as \"Commercial outcomes.....remain difficult to predict\"; \"Each practice currently represents modest initial testing volumes\"; \"Engaging with large healthcare systems presents inherent challenges\" - do not fill me with short term confidence in the $8.4m 2026 revenue target - we are about to finish month 7 out of 12 in that regard. And if that revenue target is not met where does that leave the cash position? Does make you wonder what exactly the company's 11 full time sales reps are doing - door knocking physicians will not cut it here. SB",
          "sentiment": 0.0,
          "engagement": "1,916",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-21T02:01:55.611073Z"
      },
      {
        "event_id": "SOCIAL-15Jan20262055-bluesy1--2795605",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.498120",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "This has all the hallmarks of a BOD lifestyle  funding company. FDA approval but would rather die in their own DNA.  Get out before its too late",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.15",
          "thread_title": "Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-01-21T02:01:55.611046Z"
      },
      {
        "event_id": "SOCIAL-15Jan20262227-Marty130--1175599",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.497701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Disagree.",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "6.15",
          "thread_title": "RE: Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-01-21T02:01:55.611019Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261743-Mikemine--3285374",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.497287",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Looks like somebody knows something maybe?",
          "sentiment": 0.0,
          "engagement": "1,233",
          "price_at_post": "6.25",
          "thread_title": "Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-01-21T02:01:55.610992Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261948-bluesy1--4035140",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.496863",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "Like what ? Minor move upwards. Lets all get excited. Tedious ...",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.25",
          "thread_title": "RE: Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-01-21T02:01:55.610965Z"
      },
      {
        "event_id": "SOCIAL-19Jan20261120-Marty130--8732497",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.496450",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://www.proactiveinvestors.com/companies/news/1085472/renalytix-expands-us-footprint-with-three-new-clinical-partnerships-1085472.html",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "6.25",
          "thread_title": "Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-21T02:01:55.610927Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260551-Cevodniy--3738880",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.496014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, that's great news, but nothing absolutely nothing affects the share price.",
          "sentiment": 0.0,
          "engagement": "3,065",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-21T02:01:55.610876Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261743-Marty130-29204184",
        "event_type": "social_post",
        "date": "2026-01-21T02:01:42.495582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Agreed",
          "sentiment": 0.0,
          "engagement": "1,241",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-21T02:01:55.610825Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251141-Silverbl--6685368",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.381812",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "The Tempus revenue forecast issue is another example of an open goal being missed....great initial news, fundraise shortly after which benefited from the share price uplift; then the forward guidance ($8.4m, $19m, $42m) saying it reflected positive revenue impact from Tempus; then an immediate retracement saying it was too early to predict Tempus impact. Makes you wonder what went on behind closed doors (Suspect the commercial arrangement between RENX and Tempus has not been finalised). Then an update in the Annual Report referring to the Capital Markets day in 2026 which provides time to accurately assess how the Tempus collaboration will actually work - there must be a cost to RENX for accessing the Tempus clinical network. SB",
          "sentiment": 0.0,
          "engagement": "1,914",
          "price_at_post": "6.75",
          "thread_title": "RE: Performance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=7BA9E087-C666-4375-BC4A-A70E041E4E7C"
        },
        "ingested_at": "2026-01-21T02:01:55.614859Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251304-MIKODX-43198737",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.381402",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Need some good news to get the SP moving. With a higher SP only then would it make sense to do a fundraise, with dilution having minimum impact to shareholders, and add value to the company.",
          "sentiment": 0.0,
          "engagement": "3,967",
          "price_at_post": "6.75",
          "thread_title": "RE: Performance",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=7BA9E087-C666-4375-BC4A-A70E041E4E7C"
        },
        "ingested_at": "2026-01-21T02:01:55.614832Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251631-Marty130-49766486",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.380984",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Looks like UBS have cleared the decks and sold out completely.",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.75",
          "thread_title": "RNS/UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1EBE5A8E-5A88-454E-B011-E443601333AA"
        },
        "ingested_at": "2026-01-21T02:01:55.614806Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251638-Silverbl-72061208",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.380576",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Its just a reporting issue Marty as client funds are moved around within UBS. They will be sitting just below the 5% reporting threshold. They will be back over 5% soon enough. SB",
          "sentiment": 0.0,
          "engagement": "1,914",
          "price_at_post": "6.75",
          "thread_title": "RE: RNS/UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1EBE5A8E-5A88-454E-B011-E443601333AA"
        },
        "ingested_at": "2026-01-21T02:01:55.614779Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251640-Marty130-49126108",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.380163",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Sure..",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.75",
          "thread_title": "RE: RNS/UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1EBE5A8E-5A88-454E-B011-E443601333AA"
        },
        "ingested_at": "2026-01-21T02:01:55.614752Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251714-Marty130-38041954",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.379729",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "UBS selling down will probably have suppressed the stock.",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.75",
          "thread_title": "RE: RNS/UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1EBE5A8E-5A88-454E-B011-E443601333AA"
        },
        "ingested_at": "2026-01-21T02:01:55.614726Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251722-Jatw--7464764",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.379292",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jatw",
          "content": "Marty - I have changed my mind on the SP\u2026..it will be \u00a310.00 in 2026\u2026 \u2026 \u2026 (following a 50-1 consolidation to make the ADS equal one UK share)",
          "sentiment": 0.0,
          "engagement": "3,045",
          "price_at_post": "6.75",
          "thread_title": "RE: RNS/UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1EBE5A8E-5A88-454E-B011-E443601333AA"
        },
        "ingested_at": "2026-01-21T02:01:55.614699Z"
      },
      {
        "event_id": "SOCIAL-25Nov20251728-Marty130--5595674",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.378868",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Two for 1... Agreed they will probably consolidate here too..  Currently sitting close to a million shares.. Also have large investments in ATAMER..",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.75",
          "thread_title": "RE: RNS/UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1EBE5A8E-5A88-454E-B011-E443601333AA"
        },
        "ingested_at": "2026-01-21T02:01:55.614672Z"
      },
      {
        "event_id": "SOCIAL-26Nov20251156-Marty130-23378895",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.378465",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Not doing nearly enough to help bring the share price up..  We need a deal equally as good as Tempus.",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.75",
          "thread_title": "BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CBF4F8E-251E-4BA4-B627-FD96AB431889"
        },
        "ingested_at": "2026-01-21T02:01:55.614645Z"
      },
      {
        "event_id": "SOCIAL-26Nov20251942-Silverbl-36777646",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.378049",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Its not about deals. RENX has deals aplenty. In addition to having an unquantified collaboration with Tempus (so who knows if its a good deal or not), in the last two years they have signed agreements with Joslin Diabetes Centre (and associated pharma partner); Steno Diabetes Centre; US government GWAC programme; NGS (a Medicare contractor); numerous private insurance companies with tens of millions of insured patients; Vector Pharma in the middle east; Eversana; Veterans Administration - amongst others. All of these currently appear to be contributing zero (or minimum) revenue. Renx rely on 800 doctors to order a total of c.60 tests a week (or c.4 tests each a year) - that's where we are currently. Some early deals actually cost the business cash. Deals with no substance, back up or commerciality and fail to generate income to cover significant operational costs are the primary reason there is no confidence here. SB",
          "sentiment": 0.0,
          "engagement": "1,914",
          "price_at_post": "6.75",
          "thread_title": "RE: BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CBF4F8E-251E-4BA4-B627-FD96AB431889"
        },
        "ingested_at": "2026-01-21T02:01:55.614619Z"
      },
      {
        "event_id": "SOCIAL-26Nov20252218-Marty130-85811912",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.377642",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Not much hope in continuing with our investments then.  I was aware of previous agreements in place. Possibly selling some company assets then.",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.75",
          "thread_title": "RE: BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CBF4F8E-251E-4BA4-B627-FD96AB431889"
        },
        "ingested_at": "2026-01-21T02:01:55.614592Z"
      },
      {
        "event_id": "SOCIAL-27Nov20251604-10gordon-25110141",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.377232",
        "source": "LSE_CHAT",
        "data": {
          "author": "10gordon10",
          "content": "Above 5% tr-1",
          "sentiment": 0.0,
          "engagement": "172",
          "price_at_post": "6.75",
          "thread_title": "UBS back in",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=AF4FBA65-0D69-4BD0-AC28-9C19E289B3EC"
        },
        "ingested_at": "2026-01-21T02:01:55.614565Z"
      },
      {
        "event_id": "SOCIAL-27Nov20251952-Servalan--4916922",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.376818",
        "source": "LSE_CHAT",
        "data": {
          "author": "Servalan",
          "content": "So we are back to more messing around by the mystery investor who uses UBS. IR had told me in an email they were going to try and stop this endless in and out. Looks like that hasn't worked.",
          "sentiment": 0.0,
          "engagement": "103",
          "price_at_post": "6.75",
          "thread_title": "RE: UBS back in",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=AF4FBA65-0D69-4BD0-AC28-9C19E289B3EC"
        },
        "ingested_at": "2026-01-21T02:01:55.614538Z"
      },
      {
        "event_id": "SOCIAL-29Nov20252108-Silverbl-11792849",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.376408",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "UBS least of our problems here. Share price collapsed in US trading on Friday. SB",
          "sentiment": 0.0,
          "engagement": "1,914",
          "price_at_post": "6.75",
          "thread_title": "RE: UBS back in",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=AF4FBA65-0D69-4BD0-AC28-9C19E289B3EC"
        },
        "ingested_at": "2026-01-21T02:01:55.614512Z"
      },
      {
        "event_id": "SOCIAL-1Dec20251128-Veteran1--9167678",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.375987",
        "source": "LSE_CHAT",
        "data": {
          "author": "Veteran10",
          "content": "When are we expecting a Tempus progress update?",
          "sentiment": 0.0,
          "engagement": "3,966",
          "price_at_post": "6.75",
          "thread_title": "RE: UBS back in",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=AF4FBA65-0D69-4BD0-AC28-9C19E289B3EC"
        },
        "ingested_at": "2026-01-21T02:01:55.614485Z"
      },
      {
        "event_id": "SOCIAL-1Dec20251258-Silverbl--2223468",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.375584",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Hopefully some level of trading update should come out at the AGM next week - and specifically where company is in relation to its 2026 revenue target of $8.4m. Warning signs there already. Then its H1 2026 report in February - then the following was also included in FY 2025 report - \"We expect to announce additional complimentary strategic agreements in FY26 and intend to host a capital markets day in Q3-FY26 to outline our growth strategy and commercial priorities\". SB",
          "sentiment": 0.0,
          "engagement": "1,914",
          "price_at_post": "6.75",
          "thread_title": "RE: UBS back in",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=AF4FBA65-0D69-4BD0-AC28-9C19E289B3EC"
        },
        "ingested_at": "2026-01-21T02:01:55.614459Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251054-Marty130--9033527",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.375172",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix Announces Plan to Implement ADS Ratio Change LONDON and NEW YORK, 25 November 2025 \u2013 Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd , the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces plans to change the ratio of its American Depository Shares (\u201cADSs\u201d) to its ordinary shares from one (1) ADS, representing two (2) ordinary shares, to one (1) ADS representing fifty (50) ordinary shares (the \u201cADS Ratio\u201d). The change in the ADS Ratio is expected to become effective on or about 12 December 2025 (the \u201cEffective Date\u201d). For the Company\u2019s ADS holders, the change in the ADS Ratio has the same effect as a one-for-twenty five reverse ADS split and will have no impact on an ADS holder\u2019s proportional equity interest in the Company. The change in the ADS Ratio is intended to further support the liquidity in the Company\u2019s ADSs, reduce the cost and expenses of the ADS program to the Company and its shareholders, and to provide future alternatives to regaining compliance with the U.S. listing exchanges\u2019 minimum bid price requirements. On the Effective Date, registered holders of the Company\u2019s ADSs held in certificated form will be required on a mandatory basis to surrender their certificated ADSs to Citibank, N.A., the depositary bank (the \u201cDepositary\u201d), for cancellation and will receive one (1) new ADS in exchange for every twenty five (25) existing ADSs surrendered. Holders of uncertificated ADSs in the Direct Registration System (DRS) and The Depository Trust Company (DTC) will have their ADSs automatically exchanged and need not take any action. The exchange of every twenty five (25) then-held (existing) ADSs for one (1) new ADS will occur automatically at the Effective Date, with the then-held ADSs being cancelled and new ADSs being issued by the Depositary. The Company\u2019s ADSs will continue to be traded on OTCQB under the ticker symbol \u201cRNLXY.\u201d No fractional new ADSs will be issued in connection with the change in the ADS Ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary, and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes, and expenses) will be distributed to the applicable ADS holders by the Depositary. As a result of the change in the ADS Ratio, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the change in the ADS Ratio will be proportionally equal to or greater than the previous ADS trading price prior to the change or that the change in the ADS Ratio will have any effect on the liquidity in the Company\u2019s ADSs. For further information, please contact: Renalytix plc",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.75",
          "thread_title": "ADS!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=4A4B11E1-D3C4-4E8B-8FC7-F26E505497E8"
        },
        "ingested_at": "2026-01-21T02:01:55.614433Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251058-Marty130--2550761",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.374725",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Effective Date (ADS): The change in the ADS ratio is expected to become effective on or about December 15, 2025.",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.75",
          "thread_title": "RE: ADS!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=4A4B11E1-D3C4-4E8B-8FC7-F26E505497E8"
        },
        "ingested_at": "2026-01-21T02:01:55.614406Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251431-Silverbl-24798647",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.374322",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Expect an RNS in the morning ahead of the AGM tomorrow morning. Anyone's bets as to what comes out - given we are almost 6 months into FY 2026 it would be reasonable to expect some type of a trading update - i.e. in line with expectations towards the $8.4m target or sales slower than anticipated. Interesting that SP Angel (Nomad and Broker to Renx) today released a healthcare research note specifically attempting to provide some quantum on the recent Tempus deal. I can't this being unconnected to the AGM tomorrow.  The scale of the opportunity is massive - a 1% penetration of the tempus healthcare network (5000 member institutions) with each organisation purchasing 1000 tests a year (20 patients a week) adds 50,000 annual tests - $47.5m. Although this research is 'independent' it would seem reasonable to assume Renx were made aware of the content prior to its publication given SP Angels role for Renx. SB",
          "sentiment": 0.0,
          "engagement": "1,914",
          "price_at_post": "6.75",
          "thread_title": "AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.614379Z"
      },
      {
        "event_id": "SOCIAL-8Dec20251637-Marty130-77375865",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.373895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Publication of Annual Report & Notice of AGM published \u00b7 4 November 2025 18:05source \u00b7 RNS all News Releases Renalytix plc (\u201cRenalytix\u201d or the \u201cCompany\u201d) Publication of Annual Report 2025 & Notice of 2025 Annual General Meeting LONDON and NEW YORK, 4 November 2025 \u2013 Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd , the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that the Annual Report for the year ended 30 June 2025 and the Notice of 2025 Annual General Meeting (\u201cAGM\u201d) have now been published on the Company\u2019s website and will be posted to shareholders who have not consented to receive electronic communications tomorrow morning. The Annual report is available on the Company website here: https://investors.renalytix.com/annual-half-year-reports/ The full Notice of AGM can be found here: https://investors.renalytix.com/documents/ The AGM will be held in-person on 9 December 2025 at 10.00 (GMT) at 6 Stratton Street Mayfair, London W1J 8LD. Any shareholder wishing to attend is required to register by contacting Walbrook PR via email at renalytix @walbrookpr .com or by telephone at +44 (0)20 7933 8780. For further information, please contact: Renalytix plc www.renalytix.com James McCullough, CEO Via Walbrook PR SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.75",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.614352Z"
      },
      {
        "event_id": "SOCIAL-9Dec20250844-Jatw--5834922",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.373403",
        "source": "LSE_CHAT",
        "data": {
          "author": "Jatw",
          "content": "No numbers just blah blah blah\u2026.. Warm words butter no parsnips",
          "sentiment": 0.0,
          "engagement": "3,045",
          "price_at_post": "6.75",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.614325Z"
      },
      {
        "event_id": "SOCIAL-9Dec20250858-Marty130--5356790",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.372973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "We need to hear of multi million deals being signed for this to fly...",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.75",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.614299Z"
      },
      {
        "event_id": "SOCIAL-9Dec20250858-uxm484--4238625",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.372562",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "That will eventually come including further deals. These are the times to add imo.",
          "sentiment": 0.0,
          "engagement": "1,002",
          "price_at_post": "6.75",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.614273Z"
      },
      {
        "event_id": "SOCIAL-9Dec20250905-Silverbl--7258007",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.372137",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "It\u2019s always the same here - it will be alright one day\u2026..todays statement is akin to a warning 2026 targets will be missed imo. Confirmation to come next month. SB",
          "sentiment": 0.0,
          "engagement": "1,914",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.614246Z"
      },
      {
        "event_id": "SOCIAL-9Dec20250946-unhooked--2738223",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:20.371693",
        "source": "LSE_CHAT",
        "data": {
          "author": "unhooked",
          "content": "Have to agree Silverblade, hopes and expectations but very little concrete to read. An exercise in stringing the market along for as long as possible...",
          "sentiment": 0.0,
          "engagement": "3,235",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.614220Z"
      },
      {
        "event_id": "SOCIAL-9Dec20250956-Paddyboy-69415596",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.331638",
        "source": "LSE_CHAT",
        "data": {
          "author": "Paddyboy",
          "content": "This was \u00a312 five years ago when people thought it was a commercial prospect. It turned out not to be and probably never will be.",
          "sentiment": 0.0,
          "engagement": "249",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.614193Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251014-Marty130--7123615",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.331235",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Until a major deal can be announced, don't expect any upside.. Seen this before with my investment over the years.. I was in FTC for nearly four years, take a look at how that company turned itself around...",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.614166Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251019-10gordon--3091476",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.330820",
        "source": "LSE_CHAT",
        "data": {
          "author": "10gordon10",
          "content": "Paddy, this was not the same product as 5 years ago, AI was just a twinkle in the eye of the world back then. This is a life changing world class  AI health care product, it has full medical approval in the USA, the biggest market in the world, and has just begun a rollout there. SOON, The rest of the world! Please short it, I love short squeezes.",
          "sentiment": 0.0,
          "engagement": "172",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.614140Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251131-Marty130-68235526",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.330405",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "I don't understand why we never hear of any involvement with the NHS! Surely massive deal could be struck with the NHS.",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "NHS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=4C62646B-A4E1-44E0-BF60-22D356FE1F5E"
        },
        "ingested_at": "2026-01-21T02:01:55.614110Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251213-Marty130-71324406",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.329985",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "That went down like a bucket of sick, well done  BoD..  High time you did something to stop the rot..",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "AGM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=0601E10A-3DBB-458B-B540-F47C5BB4CC12"
        },
        "ingested_at": "2026-01-21T02:01:55.614076Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251440-Marty130-75152044",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.329581",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "10g Or China!!!",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.614049Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251702-Cevodniy--1734557",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.329165",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Silverblade, so expect an RNS morning of the 9th prior to the AGM. Any more astute predictions?",
          "sentiment": 0.0,
          "engagement": "3,049",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.614023Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251822-Mikemine-10804667",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.328746",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "The CEO hit the nail on the head when he referred to large companies like Tempus not being as nimble as companies like RENX and VRCI. The take their time setting up systems and incorporating new additions and there's not much that can redone about it. Tempus will offer a reach RENX could only dream of but it comes at a price and that is a slow pace. Once the new contracts start to bear fruit ball they will gather pace and I expect that to happen early next year. Frustrating though it is for us, we will have to dig deep in to our patience bucket. Thats my opinion anyway.",
          "sentiment": 0.0,
          "engagement": "1,232",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.613997Z"
      },
      {
        "event_id": "SOCIAL-9Dec20251920-Silverbl--8047480",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.328341",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "In the short term only the likelihood of more condescending posts from yourself cevodniya. SB",
          "sentiment": 0.0,
          "engagement": "1,914",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.613970Z"
      },
      {
        "event_id": "SOCIAL-9Dec20252013-Marty130-64555514",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.327926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://donation.watch/en/unitedkingdom/party/REFORM/donors",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T02:01:55.613944Z"
      },
      {
        "event_id": "SOCIAL-9Dec20252014-Cevodniy-25733426",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.327519",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Silverblade, the reason I posted is the arrogance of your post. Expect an RNS tomorrow morning!!. That's a statement,  not a suggestion,  not anyone think there'll be a possible RNS tomorrow before the AGM. It's you making an absolute statement which was 100% incorrect. Pointing that out is condescending,  it's merely explaining your arrogance. I suppose you can us what numbers to expect in Friday's Euro lottery?",
          "sentiment": 0.0,
          "engagement": "3,049",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.613917Z"
      },
      {
        "event_id": "SOCIAL-9Dec20252014-Marty130--7431228",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.327084",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Wrong link, sorry.",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "RE: Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T02:01:55.613890Z"
      },
      {
        "event_id": "SOCIAL-9Dec20252015-Marty130--6538492",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.326677",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix is a diagnostics company that has faced challenges getting its KidneyIntelX test validated for use within the UK's National Health Service (NHS), despite the technology being used in the US. The company's focus has primarily been on the US market where its product has FDA authorization and Medicare reimbursement. Renalytix and the NHS Limited NHS Adoption: While Renalytix is a London-based company, its commercial success and focus have been predominantly in the US healthcare system, particularly with the Mount Sinai Health System and Tempus AI. The company has reportedly missed opportunities for NHS validation. Potential but Unused: There has been discussion among investors about the potential for the KidneyIntelX test to be a cost-saving measure for the NHS, which faces significant costs from undiagnosed and uncontrolled kidney disease. NHS Technology Use: The NHS is exploring the integration of machine learning and wider datasets within its electronic health records to improve risk prediction and decision support, which aligns with the kind of technology Renalytix offers, but direct procurement has not been established. The KidneyIntelX Technology Renalytix developed KidneyIntelX, an artificial intelligence (AI)-enabled blood test for patients with type 2 diabetes and early-stage chronic kidney disease (CKD stages 1-3b). Function: The test uses AI to integrate data from blood biomarkers and electronic health records to provide a high, moderate, or low-risk score for rapid kidney function decline within five years. Purpose: This early risk assessment allows clinicians to intervene with guideline-recommended treatment sooner, potentially improving patient outcomes and reducing overall healthcare costs. In summary, as of late 2025, Renalytix's technology is not widely adopted by the NHS, with the company's business efforts centered on the US market and recent partnerships there, such as with Tempus AI and MVP Health Care.",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "RE: Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T02:01:55.613864Z"
      },
      {
        "event_id": "SOCIAL-9Dec20252315-Boo-Boo-65233365",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.326232",
        "source": "LSE_CHAT",
        "data": {
          "author": "Boo-Boo",
          "content": "Hi Marty, Apologies if this has been covered before but my understanding is that medical tests used by the NHS typically require a CE mark to show they meet necessary safety and performance standards. This mark indicates that the device can be marketed within the European Union and is compliant with relevant regulations. The RNS of 1 October details the submission of a CE application where: 'on successful achievement of a CE mark, expected in H1 2026, Renalytix anticipates further commercial opportunities, including international distribution partnerships, in FY26 and/or FY27'. My belief is that this is still bring processed and once issued should then open up new opportunities for us. BB",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "6.25",
          "thread_title": "RE: Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T02:01:55.613837Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250032-Marty130-23731634",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.325783",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Great post..  I forgot about the CE application.",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "RE: Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T02:01:55.613810Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250912-Radika-71364702",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.325255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Radika",
          "content": "So does this mean not much will happen till CE marking is approved? I think placing was @9.5p and down to this6.75p",
          "sentiment": 0.0,
          "engagement": "2,853",
          "price_at_post": "6.25",
          "thread_title": "RE: Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T02:01:55.613784Z"
      },
      {
        "event_id": "SOCIAL-10Dec20250935-Marty130-55067552",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.324833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Yes, i have written to the company to enquire as discover why they haven't been in discussions with the NHS. Gendrive have so why haven't renalytix?",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "RE: Renalytix should reach out to NHS.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=35F29894-0422-4B69-A0D4-35FB88E099F5"
        },
        "ingested_at": "2026-01-21T02:01:55.613758Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251031-Hawker-38277112",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.324430",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "@Silverblade - I think you're 100% spot on; this feels like a prerequisite to the next disappointing, empty promises update. Ho hum.",
          "sentiment": 0.0,
          "engagement": "299",
          "price_at_post": "6.25",
          "thread_title": "RE: AGM 9th Dec",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=566ACE39-C315-441C-8739-4770406B079C"
        },
        "ingested_at": "2026-01-21T02:01:55.613732Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251129-Marty130-29388739",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.324001",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Dear Sirs and Madam, I hope this message finds you well. I am writing as an investor to gain a clearer understanding of Renalytix\u2019s engagement strategy with NICE and the NHS. Given the strong potential for your diagnostic technologies within UK healthcare, and in light of Wes Streeting\u2019s recent announcement regarding the NHS\u2019s increasing adoption of AI tools, I believe there is significant opportunity for Renalytix to contribute meaningfully to national healthcare priorities while also creating value for shareholders. I have noted that companies such as Genedrive appear to have established closer relationships with NHS partners, and this has prompted me to seek further clarity on Renalytix\u2019s own plans and progress in this area. Could you please provide clarification regarding your current NHS and NICE engagement activities, as well as your broader strategy for pursuing these opportunities? I would be grateful for a response within 14 days. Thank you for your attention to this matter. Kind regards,",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "My letter to renalytix.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=AE4BEC48-D1AB-4E00-8CB8-B9FAE9E14E70"
        },
        "ingested_at": "2026-01-21T02:01:55.613705Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251130-Marty130-59189982",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.323562",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Thanks for your email. Renalytix is a US focussed business.\u00a0The product is FDA approved, and has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. They are currently only targeting test adoption in the US healthcare market - which is naturally a very large addressable market. The company has no plans to target the NHS, and do not see this as a viable commercial opportunity currently as the product is not approved for use in the UK, and the currently has only just submitted an application for CE Mark certification for use within the European Union, in response to interest from pharma partners to use in the test in clinical trials within the EU. Whilst the UK market could be a very long-term target, along with other geographic expansion - but for now the company is firmly focussed on driving shareholder value through exploiting the very large opportunity that teh US market presents. Kind regards, Paul",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T02:01:55.613679Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251248-Mikemine-85517160",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.323123",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "So the application for CE Mark is driven by partners not RENX and that is not for the UK market anyway. I don't blame them as it is notoriously difficult to introduce anything in to the UK medial market.",
          "sentiment": 0.0,
          "engagement": "1,232",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T02:01:55.613653Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251533-Cevodniy-41298513",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.322694",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Hi, seeking your expectation. I purchased my investment here in September after reading and researching for a while. What finally covinced me was a \u00a3250k purchase by I think the Finance Director at 9.61p. It was the strongest gesture I could imagine. Why would a Director invest so much money at a personal kevel to a share that was very recently oversubscribed and only alloted 70% of individuals subscription. I'm in at an average of 10p. Seriously,  does anyone have any expectation that this Company will generate revenue and actually increase its share price?",
          "sentiment": 0.0,
          "engagement": "3,049",
          "price_at_post": "6.25",
          "thread_title": "This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-21T02:01:55.613626Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251817-uxm484--4609826",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.322253",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "The base is 9.5p which was based on potential. I would expect the company to sign further deals or get approvals such as the application for CE Mark certification for its kidneyintelX.dkd prognostic test under the European Union\u2019s In-Vitro Diagnostics Regulation (IVDR) or further news relating to the agreement with Tempas. I don't see this going much lower than 6p, so at this price, although one might feel nervous when they are down, it is worth being patient in my view.",
          "sentiment": 0.0,
          "engagement": "1,002",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-21T02:01:55.613599Z"
      },
      {
        "event_id": "SOCIAL-10Dec20251857-Marty130-15222603",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.321807",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "The share price of a company that gains a CE mark typically rises due to the positive market sentiment and the new access to the large European market. This increase is driven by the market's perception of improved risk/reward and potential for future revenue growth. Reasons for Share Price Movement Market Expansion: The CE mark is a certification that a product meets EU safety, health, or environmental standards, allowing it to be legally sold within the European Economic Area (EEA). This opens a significant new market for the company's products, which can lead to substantial sales growth. Increased Investor Confidence: The certification acts as an independent validation of the product's quality and compliance with rigorous standards, which can increase investor confidence in the company's management and its future prospects. Analyst Upgrades: News of a CE mark approval often leads to positive analyst ratings and upgraded target prices, further fueling investor interest and demand for the stock. Demand and Supply: Like any stock movement, the price change is ultimately a result of supply and demand. Positive news creates high demand among buyers, which can cause the price to jump. Real-World Examples Several news snippets show companies experiencing stock gains following the announcement of a CE mark: Intuitive Surgical stock gained after its DV5 system received early CE mark approval. Femasys stock rose after its FemBloc product gained the CE mark. Zimmer Biomet (ZBH) stock saw gains following the receipt of a CE mark for a knee system. In summary, obtaining a CE mark is generally a positive catalyst for a company's stock, signaling new commercial opportunities and reinforcing a positive market sentiment for the company's future performance.",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "CE mark.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D885E932-8BC7-436C-AE64-90F7FEAECB05"
        },
        "ingested_at": "2026-01-21T02:01:55.613573Z"
      },
      {
        "event_id": "SOCIAL-10Dec20252020-Marty130--9913422",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:17.321325",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "CE mark could be a ground breaker... Some analysts predicting a share price at 86p could be on the money.",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T02:01:55.613546Z"
      },
      {
        "event_id": "SOCIAL-10Dec20252253-Radika--4891937",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:13.147134",
        "source": "LSE_CHAT",
        "data": {
          "author": "Radika",
          "content": "It could take few months for CE mark to be certified",
          "sentiment": 0.0,
          "engagement": "2,853",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T02:01:55.613519Z"
      },
      {
        "event_id": "SOCIAL-10Dec20252305-Cevodniy-12984440",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:13.146719",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Say 6 months?",
          "sentiment": 0.0,
          "engagement": "3,049",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T02:01:55.613492Z"
      },
      {
        "event_id": "SOCIAL-10Dec20252320-Marty130-42017305",
        "event_type": "social_post",
        "date": "2026-01-10T03:20:13.146312",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "From the 1st of October 2025, so by April could be when we get the CE mark.",
          "sentiment": 0.0,
          "engagement": "1,186",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-21T02:01:55.613464Z"
      },
      {
        "event_id": "SOCIAL-23Jan20261042-fre1-52066724",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382464",
        "source": "LSE_CHAT",
        "data": {
          "author": "fre1",
          "content": "They are starting to build up scale (thanks for link Marty130) and their collaboration with Tempus should be gaining momentum so news next month should help.",
          "sentiment": 0.0,
          "engagement": "1,886",
          "price_at_post": "6.25",
          "thread_title": "RE: BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-01-24T02:12:07.400169+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261000-Marty130-88025089",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382903",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Need to pull their finger out ASAP..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-01-24T02:12:07.400207+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261743-Marty130-48628704",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383336",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Agreed",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-24T02:12:07.400241+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260551-Cevodniy-67755467",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, that's great news, but nothing absolutely nothing affects the share price.",
          "sentiment": 0.0,
          "engagement": "3,066",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-24T02:12:07.400274+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261120-Marty130--7076872",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384173",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://www.proactiveinvestors.com/companies/news/1085472/renalytix-expands-us-footprint-with-three-new-clinical-partnerships-1085472.html",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-24T02:12:07.400308+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261948-bluesy1-40480834",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384585",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "Like what ? Minor move upwards. Lets all get excited. Tedious ...",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.25",
          "thread_title": "RE: Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-01-24T02:12:07.400335+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261743-Mikemine-72019158",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384993",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Looks like somebody knows something maybe?",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "6.25",
          "thread_title": "Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-01-24T02:12:07.400354+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262227-Marty130--2777186",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Disagree.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-01-24T02:12:07.400372+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262055-bluesy1--7151283",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385830",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "This has all the hallmarks of a BOD lifestyle  funding company. FDA approval but would rather die in their own DNA.  Get out before its too late",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.15",
          "thread_title": "Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-01-24T02:12:07.400390+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261947-Silverbl--6384547",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386254",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Next news is likely to see share price hit all time lows - enough negative hints have been dropped recently about current trading. Statements such as \"Commercial outcomes.....remain difficult to predict\"; \"Each practice currently represents modest initial testing volumes\"; \"Engaging with large healthcare systems presents inherent challenges\" - do not fill me with short term confidence in the $8.4m 2026 revenue target - we are about to finish month 7 out of 12 in that regard. And if that revenue target is not met where does that leave the cash position? Does make you wonder what exactly the company's 11 full time sales reps are doing - door knocking physicians will not cut it here. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-24T02:12:07.400409+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261836-Marty130-51017877",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386660",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Looks like the SP is heading down, in order to boost volumes.. Let's hope the BoD release some juicy news to push it back up on healthy volumes.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-24T02:12:07.400426+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261633-Investor-39683860",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387067",
        "source": "LSE_CHAT",
        "data": {
          "author": "Investor2025",
          "content": "Not yet..",
          "sentiment": 0.0,
          "engagement": "7",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-24T02:12:07.400445+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261537-Hawker-75954763",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387485",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Hope springs eternal...  Ho hum...",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-24T02:12:07.400463+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261535-Marty130--1769179",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Exactly.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-24T02:12:07.400480+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261401-tweedly-64713384",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388311",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Understandably the RNS didn't set the market alight. Waiting for hard numbers I think.",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-24T02:12:07.400498+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262252-MIKODX-65549475",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388725",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Todays RNS means we are now seeing concrete progress on commercial rollout.This shows that Renalytix is moving towards actual deployment with multiple provider groups. Getting kidneyintelX.dkd into established clinics is a big step. It means providers see enough value in the test to integrate it into their day-to-day systems. The RNS reiterates that Renalytix and Tempus are working closely to integrate kidneyintelX.dkd into larger healthcare sytems that are already on Tempus's platform. This is very significant because a) smaller clinics alone won't generate high volumes and b) larger sytems (via Tempus) have broader patient populations and infrastucture. This will accelerate adoption more rapidly once it starts rolling through those network. Everything is starting to fall into place, the company is really now starting to see some real progression. Great RNS.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-24T02:12:07.400517+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262236-MIKODX--5783307",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389141",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "The company says it expects to provide a fuller trading update in February. By fuller that means they expect improvement in sales. The company is making all the right moves thus far.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-24T02:12:07.400535+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261111-Marty130--8310710",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Enalytix plc (RENX.LN)*, Futura Medical plc (FUM.LN) Non-Independent Research; Marketing & Sales Commentary - MiFID II exempt information \u2013 see disclaimer below. Company Update: 12 January 2026 Renalytix plc (LSE: RENX, OTCQB: RNLXY)*: Three kidneyintelX.dkd clinical integration \u2013 update on Tempus collaboration Market Capitalisation: \u00a326.6m; Share Price: 6.08p \u2022 During the last quarter of 2025, Renalytix completed three additional kidney specialist healthcare provider clinical integrations in the US, in New York, Florida and Tennessee.  \u2022 Additional integrations are expected in early 2026. \u2022 Tempus collaboration is progressing well with teams from both Tempus and Renalytix working closely to target Tempus\u2019 customers with a large diabetes and kidney disease patients.  Renalytix reports that it added three new US clinical integrations in late 2025, bringing its FDAapproved kidneyintelX.dkd test into established kidney care practices in New York, Florida, and Tennessee. Testing has begun at all sites, and although initial volumes are expected to be small, the company anticipates usage to build as clinicians become familiar with the workflow. More integrations are planned for early 2026.  Renalytix states that it is working intensively with Tempus to integrate its kidney risk testing into major US health systems through Tempus' integrated electronic health records (EHR). Since the partnership began in September 2025, teams from both companies have been coordinating to target large provider networks with significant diabetes and CKD populations, aiming to streamline test ordering and strengthen data collection. The collaboration is positioned as a foundation for expanding into new clinical and geographic markets as the platform matures.  From a strategic standpoint, this fits neatly with Renalytix\u2019s strategy to have kidneyintelX.dkd test integrates into healthcare providers\u2019 EHRs, which allows quick and seamless ordering. shift toward disciplined, system-level integrations rather than chasing individual clinics. The Tempus partnership could prove far more meaningful if it unlocks access to large, data-rich health systems where adoption can scale. SP Angel acts as Nomad and Broker to the Renalytix Futura Medical plc (AIM: FUM): Positive results from WSD4000 early feasibility study Market Capitalisation: \u00a39.1m; Share Price: 1.58p \u2022 Statistically significant improvement achieved in female sexual function with WSD4000 in a study enrolling 12 women suffering from some degree of sexual dysfunction. \u2022 Results give the Company confidence to proceed to the next steps of designing a Phase III placebo-controlled trial, with results expected mid-2026 Futura reports that its WSD4000 early feasibility study in 12 women showed a clear and statistically significant improvement in sexual function, with gains on the Female Sexual Function Index (FSFI) scale well above the accepted threshold for clinical relevance. Benefits were seen across arousal",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D3CE797F-7C15-4738-8269-38EDD6CB8090"
        },
        "ingested_at": "2026-01-24T02:12:07.400553+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260838-emblaze1-73901023",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390005",
        "source": "LSE_CHAT",
        "data": {
          "author": "emblaze1",
          "content": "LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use. The integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix. These integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations. Renalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources. Tempus AI Collaboration Renalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in September 2025, to target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients. The collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time. Investor Engagement James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. The 44th annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad rang",
          "sentiment": 0.0,
          "engagement": "917",
          "price_at_post": "6.25",
          "thread_title": "RE:Results soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=3DEB0D63-492C-4E6A-AD12-B94C142E4A0B"
        },
        "ingested_at": "2026-01-24T02:12:07.400572+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260823-Marty130--4361432",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390423",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Results deadline missed then..  As wws due before 31st of January..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-24T02:12:07.400590+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260809-johndean-24388085",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390835",
        "source": "LSE_CHAT",
        "data": {
          "author": "johndean",
          "content": "Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the company expects to provide further updates on progress and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "798",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-24T02:12:07.400609+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260807-Marty130-71668093",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391262",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Where? I haven't received one.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-24T02:12:07.400627+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260712-morningt-36213582",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391677",
        "source": "LSE_CHAT",
        "data": {
          "author": "mornington-oz",
          "content": "RNS  OUT",
          "sentiment": 0.0,
          "engagement": "23,507",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-24T02:12:07.400646+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260710-uxm484--2998753",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392089",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. Hopefully some new investors will jump on this month following the J.P Morgan event in the US, progress being made and undervalued at present.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-24T02:12:07.400664+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261801-Marty130-40039356",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Upcoming Financial & Corporate Events H1 2026 Trading Update: The company is scheduled to provide a trading update for the six-month period ending December 31, 2025, by the end of January 2026.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-24T02:12:07.400683+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261516-Silverbl-73422661",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.833253",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Sounds a difficult prognosis to live with oldbut. Renx and its sister company verici were both spun out of ekf diagnostics about 5 years ago based on two unique biomarkers relating to kidney disease - renx is all about early warning and intervention through patient testing and verici focuses on pre and post kidney transplant risk monitoring (rejection).  Both company's have excellent technology and a key relationship/partnership  with Mount Sinai in New York who provide access to an extensive patient database which assists an AI driven approach to improve patient outcomes. The key issue is convincing clinicians at scale that the tests should be deployed (despite having all required regulatory approvals in place and agreed Medicare reimbursement secured). Market penetration remains slow; cash burn remains high and the market remains sceptical on the company's ability to commercialise their products - hence the low valuation here and at verici. Corporate updates expected in coming weeks. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-01-29T11:05:01.889601+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20262136-Marty130-85770980",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.834056",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Sorry..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-01-29T11:05:01.889643+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261534-oldbutno-55208172",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.834852",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "...because I have Grade 4 Kidney disease. So it won't help me but caught my interest.",
          "sentiment": 0.5,
          "engagement": "3,324",
          "price_at_post": "6.25",
          "thread_title": "Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-01-29T11:05:01.889678+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261616-Marty130--9818733",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.138786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Purchase at 7%.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-29T11:05:01.889715+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261603-Pixels-41634457",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.139331",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pixels",
          "content": "How can you tell, that document shows as \"acquisition / disposal\" - is it definitely acquisition? Got to admit I struggle with reading financial type documents, I'm just a media monkey",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-29T11:05:01.889751+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261512-Marty130-12962535",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.139866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "They're back in again..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-29T11:05:01.889786+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261527-Marty130--8616486",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.140363",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "A deal may arise next week after the conference in San Francisco.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-29T11:05:01.889823+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261412-Veteran1-25767681",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.140866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Veteran10",
          "content": "Bit of movement but low volume. If volumes increases, could be a momentum buy opportunity.",
          "sentiment": 0.0,
          "engagement": "4,077",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-29T11:05:01.889860+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261935-Marty130-51758543",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.141384",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix is expected to participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, a premier global healthcare investment symposium where companies present and connect with investors, industry leaders, and innovators, focusing on new technologies like AI in healthcare, kidney disease, and strategic partnerships. While Renalytix isn't explicitly named in the top results, they are a kidney-focused company likely to attend this major event, which runs concurrently with the Biotech Showcase.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-29T11:05:01.889893+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261839-Silverbl--4570931",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.141885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "...well if the prognosis is kidney related oldbut i think we might be able to help out......lol. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-29T11:05:01.889927+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261837-Silverbl-43955418",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.142401",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "New deals mean nothing without a credible commercial plan which has at its heart the means to create and service product demand in a timeous and profitable manner. Nothing to date has achieved that in any meaningful volume. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-01-29T11:05:01.889964+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261801-oldbutno-70058667",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.142900",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "....come to those that wait.....Oh, and DEATH!",
          "sentiment": 0.0,
          "engagement": "3,324",
          "price_at_post": "5.90",
          "thread_title": "GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-29T11:05:01.890000+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261649-Marty130--6000909",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.143434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "To turn this around as the share price will continue to new lows..   Wake up BoD, pull your fingers out..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-01-29T11:05:01.890033+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20262041-Marty130-18405859",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.144017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix said in an update on Tuesday that it was making progress in expanding the use of KidneyIntelX.dkd across the United States, reporting growing testing volumes, new state coverage and advancing commercial partnerships ahead of its annual general meeting in London. The AIM-traded company's prognostic blood test, the only FDA-approved and Medicare-reimbursed test for early-stage chronic kidney disease risk assessment, was now generating revenue from four core states - Florida, Texas, New York and, most recently, Arizona. Executive chairman Julian Baines said the first orders in Arizona included tests from one of the largest nephrology practices in the US. He emphasised that, while direct sales growth is encouraging, the company's primary strategy is to scale test adoption through major business development agreements with large healthcare systems. Renalytix signed a definitive agreement in September with Tempus AI, the Nasdaq-listed diagnostics and AI group, which Baines said has \"an established network of healthcare institutions already utilising its precision medicine solutions.\" He added that early engagement with Tempus and MVP Health Care reinforced the company's belief that its partnership-led model would \"deliver long-term value for shareholders,\" despite lengthy implementation processes common across major US providers. Renalytix said it had also narrowed potential partners for its next electronic health record integration and was working with several large healthcare systems expected to generate \"meaningful testing volumes\" over time. The company said it was increasingly using data analytics to identify physicians managing high numbers of eligible patients, helping target commercial resources where uptake prospects are strongest. Renalytix added that it had started transitioning to a new laboratory facility, a move expected to expand testing capacity and reduce operating costs over the next five years. Baines said the company was now focused on converting ongoing discussions into contracted relationships, expanding EHR integrations and accelerating test volumes. While acknowledging that timing of commercial outcomes \"remains difficult to predict,\" he said the board was confident that the company's current initiatives \"position the company well for sustainable revenue growth, increased operating leverage, and long-term value creation for shareholders.\" Renalytix said it would provide a trading update for the six months to 31 December by the end of January.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "2026 outlook",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=30EC9492-CE10-4321-AED9-CF8B2D3F53AF"
        },
        "ingested_at": "2026-01-29T11:05:01.890053+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261342-Mikemine--5585369",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.144538",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "If Tempus gets going, the revenue will spike and so will the SP. Big companies like Tempus are notoriously slow to move but they've had since early September so H1 seems reasonable for them to get going. I urge anyone who has missed the RNS (15th Sept) about the collaboration agreement to read it and do a bit of research on Tempus. Apart from this ramp, I won't offer a prediction target but I do expect to multibag  from these levels. Good luck to everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-29T11:05:01.890072+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261121-Marty130--5207517",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.145043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "On receipt of the CE acceptance, which is expected h1, 18/22, on a takeover, 40/60.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-29T11:05:01.890090+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20260407-Cevodniy--8601483",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.145565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Ok fellow investors. Year end SP predictions. I'll start at 20p.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-29T11:05:01.890136+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20252147-Crannog1--6445196",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.146063",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crannog12",
          "content": "You are a ray of sunshine. I take it you are invested here?",
          "sentiment": 0.0,
          "engagement": "57",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-29T11:05:01.890154+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251345-Silverbl--4213465",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.146588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dreadful year for investors. Trading update in January could hammer confidence further if company fails to deliver revenue targets. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-29T11:05:01.890173+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20251632-MIKODX-54204226",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147014",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "It\u2019s not good watching the SP slowly slip down, but that\u2019s bound to happen with no positive news. The one consolation is the support at 5.70 is holding up well so far. Hopefully we can kick off the new year with some good news and hopefully get a good bounce from the support level all the way up past 10.",
          "sentiment": 0.0,
          "engagement": "3,977",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-29T11:05:01.890191+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251231-Marty130-51582426",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Hopefully we will have a better year in 2026, with more announcements of higher revenues and transformational new contracts signed. The BoD badly needs pay more attention to reverse the share price trend..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "New contracts",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8AD3616F-3B6B-486A-8B37-36DE630CD42F"
        },
        "ingested_at": "2026-01-29T11:05:01.890209+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251037-Marty130--3012143",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147873",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Cevo, And don't forget the CE mark will have a transformation affect.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-29T11:05:01.890233+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250828-Cevodniy--4827603",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.148323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "MIKODX on the 2nd January 2025, the SP was 10.75, yesterday it was 6p. I get your optimism via your post, but obviously institutions and wealthy investors don't agree. 10p to 6p is not exactly a successful year. I hope we don't experience another 66% next year.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-29T11:05:01.890251+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250037-MIKODX-35454589",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.148764",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "FY2025 was a key year for the company in establishing a solid pathway for testing adoption, life science services and strategic partnering. In July 2025, RENX announced an agreement with MVP Health Care, a U.S.-based insurer covering more than 700,000 patients. Beyond expanding physician and patient access, this agreement reinforces that Renalytix and kidneyIntelX.dkd are establishing a leadership position in chronic kidney disease management and gaining increasing recognition in the market. In September 2025, Renalytix signed an agreement with Tempus AI, Inc. (\u201cTempus\u201d), a clear leader in delivery of integrated advanced diagnostic testing and life science services in the United States. The collaboration with Tempus will enable RENX to accelerate introduction of kidneyintelX.dkd into large hospital systems and community healthcare practices across the U.S., significantly expanding distribution over the next five years. The relationship with Tempus AI has continued to develop positively, with ongoing progress in aligning commercial activities. The Balance Sheet was further improved with the conversion of an additional $4 million of convertible debt leaving outstanding long-term debt at \u00a33.1m as of October 2025. More than $1.3m in cash from backdated R&D claims and grant income, further strengthening the balance sheet. Administrative expenses decreased by more than 40% year-on-year, driven by headcount and operations optimization. RENX continue to strengthen there presence in three initial target states - Florida, Texas, and New York. In FY26, they expanded into Arizona their fourth target market which collectively represents approximately 20% of the total addressable kidneyintelX.dkd market. RENX is well positioned to deliver important and necessary change in chronic kidney disease management in the United States and globally.In the coming months and years sales will without doubt improve with the test being made more readily available in healthcare systems. Not been a bad year for the company, quite the opposite, it has been a very positive one. FY26 will see the partnerships coming to fruition with the test more widely available in the healthcare systems which will mean more sales for the company. Lots to look forward to in the coming year. I'll drink to that. Hope everyone has a merry xmas and the best of luck for the new year. With any luck we will have some good news from the parterships established, which will have a very positive affect on the SP. As we all know, this is a very volatile stock that can really take off on good news. Next year will be the year. GLA",
          "sentiment": 0.0,
          "engagement": "3,977",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-29T11:05:01.890270+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20252029-Cevodniy--6422055",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.149203",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, you are the only poster here generally and even you can't see anything positive,  except the possibility of a takeover I've just over 1.2 million at an average of 10p, I fo not expect to ever see profit.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-29T11:05:01.890288+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251332-Marty130-16032028",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.866496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Surely we'll get better results next year, if not a possible takeover.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-29T11:05:01.890307+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251144-Mikemine--4990737",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.866939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Merry Christmas everybody. Here's hoping for a more prosperous New year.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "5.90",
          "thread_title": "Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-29T11:05:01.890326+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251830-Marty130--4629724",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.867379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "U2..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-01-29T11:05:01.890344+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251756-tweedly-21312350",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.867802",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Right. These RNS' have been coming out for at least 6 months, no one makes sense of them so no point speculating. Merry Christmas folks",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-01-29T11:05:01.890363+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251644-Marty130--4640952",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.868233",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Down selling again.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-01-29T11:05:01.890382+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251241-Silverbl--4155256",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.868652",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "The jury is not only out Hawker....its leaving the courthouse! Its been another horror story in 2025 for the business which showed so much early promise. I have low expectations for the trading update in January - seems this is pretty common given the share price reaction. All time price low - makes the 9.5p raise a highlight from the management team - although the next raise could be very painful for shareholders if they cannot generate revenue and continue to burn cash. ATB to those who hold here - it continues to be a very difficult investment to justify. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890401+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20250931-Marty130--3168870",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "German Market is huge.. Once the CE goes through, plenty will sign up.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890420+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251427-Hawker--8292263",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Well said, SB. This is now just a waiting game, as the company has EVERYTHING they need to succeed in going to market; there are no more barriers. The only question, therefore, is whether they can sell the test into their focus regions and whether there is a market for it. So far, the jury is out. QED... Opinion:   Ho hum",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890438+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251146-JBCo--3614025",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869928",
        "source": "LSE_CHAT",
        "data": {
          "author": "JBCo",
          "content": "Hopefully can hold 6p",
          "sentiment": 0.0,
          "engagement": "4,545",
          "price_at_post": "6.25",
          "thread_title": "Big seller trying to get out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=253BEB68-92E2-41AA-91A1-E5998136B1CD"
        },
        "ingested_at": "2026-01-29T11:05:01.890457+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251751-Marty130-25397832",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.870350",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "CE marks always add value.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890476+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251623-cipro--4814350",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.870772",
        "source": "LSE_CHAT",
        "data": {
          "author": "cipro",
          "content": "The trend is slowly going down with this stock did hv good potential And I hope this still has some upside however the momentum is stuttering atm Hope to get positive news in January to get the trend back up good luck all",
          "sentiment": 0.0,
          "engagement": "2,148",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-01-29T11:05:01.890506+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251621-Dustysla--2493419",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.871231",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "I think your Gripe is the time spent here, and against the companies management. I get that, they are not the easiest investments as they are Crooks and useless. So I try to look at 3 things here at this juncture Revenue/Debt/Sales And Future Projected Revenue/Debt/Sales And how they will maintain a healthy cash burn in the intermediate.",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890540+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251616-Dustysla-11674566",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.871686",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m OTCQB listing only says $17.98 million 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). Is this financials or Sales? Im talking about Provider to Patient sales 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). This is how it explained, a Google AI version. Id get a more accurate view, but im not not interested in doing so. 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. Ok well nothing I found in 30 mins showed they had FDA approval so the assumption is their flogging nothing. But if im wrong, and it started somewhere in 2024 fine. Small details. But Debt, well yes as you said checks out. But you said NO DEBT, quite abruptly so I got a lot closer than you in 30 minutes that you seemingly in years",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890575+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251606-Silverbl--3415289",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.872134",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "OK Dustyslay - I'll bite - here we go - my 'whining' response to your 'research' based points where real world numbers are available. 1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. The point on debt looks accurate. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890608+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251540-Dustysla-12799160",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.872558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade I understand all what you are saying, 2024 wouldn't have been a great year as they hadn't gone to market and thats the Pharmsma industry for you, why I dont hold any current because I feel they are run by wealthy individuals that are focused on personal wealth before Health and will fill their boots prior to any achievements and shareholders take on the dilution and the hard hold. But im kinda leaning towards this, the more i look into it because its all about timing really.  If MVP goes solid, and your market expands 2026, you should improve dramatically As for the CE mark, achieving it your correct it wont move it, but its what you do once achieved in the European markets",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890641+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251529-Dustysla-54737034",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Ok, i know where i found the Sales and it took me a long time so here, more AI junk but the growth is there. Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months. Recent Revenue: For the first half of the fiscal year 2025 (H1 FY25), Renalytix reported revenues of $1.3 million. This demonstrated continued quarterly sales growth into Q3 FY25. Quarterly Growth: The company is on track to meet or exceed its target of 20% average quarter-over-quarter revenue growth. Billable Tests: For the first time, over 1,000 billable tests were processed in Q3 2025, supported by the onboarding of a large primary care network in New York and improved direct-to-physician sales. Medicare Coverage: The company has achieved FDA approval and Medicare coverage determination for its kidneyintelX.dkd test, with an established price of $950 per test. Partnerships: New collaborations, notably with Tempus AI and MVP Health Care, are expected to positively impact revenue and expand the test's reach among the 15 million people in the US with type 2 diabetes and chronic kidney disease. Future Guidance: Renalytix has provided forward revenue guidance of $3.2 million in FY25, $8.5 million in FY26, and $17.5 million in FY27. Despite recent sales growth, the company has faced financial challenges, including a decline in total annual revenue in FY24 compared to FY23, high operating losses, and a reliance on external financing to sustain operations. The company has focused on cost reductions and strategic partnerships to improve its financial position. 1000 \u00d7 $950 plus Medicaid Reimbursement in its first year. Now a new area in North America with MVP, 700 000 patients on books. You see where its going? Have some faith. And perhaps more research than whining on a forum",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890674+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251506-Dustysla--5759805",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873471",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Im not every fond of AI, or even Google AI. Never done ChatGBT etc so a lot is from memory on researching, the sales i will locate the information at some point as im a tad busy but Debt is easy to find, you would be hard pressed to find any company not still refurbishing debt after they have gone to market. The key is to see a constant, and consistent reduction per half year reports. Here is the AI, against my normal MO of real research: As of late 2025, Renalytix has reported approximately $8.21 million in total debt, a decrease from previous years. The company has actively worked to improve its balance sheet through debt restructuring and equity conversions. Key details regarding Renalytix's debt: Total Debt: The most recent figures from financial reports indicate total debt is approximately $8.21 million. Recent Reduction: Renalytix has focused on reducing its debt through strategic financial maneuvers. In October 2025, the company announced a $4 million balance sheet improvement by converting approximately $4 million of senior convertible bonds into equity, saving up to $1.4 million in future accrued interest. Debt Restructuring: A significant portion of the remaining debt is a new unsecured convertible bond issued in November 2024 (and later partially converted in Oct 2025), with a maturity date of July 2029. This bond has flexible interest payment options (cash or rolled into the principal) at the company's discretion. Historical Context: The company's total debt peaked in June 2022 at over $12 million and has generally trended downwards since then. Financial Position: The renegotiation of debts has helped the company move to a net current asset position, aiming to direct cash flows towards commercial and operational growth.",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890705+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251458-Dustysla--4131879",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Nasdaq has listing requirements that are difficult OTC is similar to AIM, there are 3 different markets OTCQB/OTCQX and OTC pink but we can dismiss that you are in one of the the first 2. OTC Premier is stringent but that isnt listed there. 0.01 is the minimum requirement SP And a M/Cap of 10 million minimum Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus. The split has gone quite well on early judgement,  and will help consolidate liquidity as lower the SP, the higher the percentage swings and more susceptible to traders profiting on movement. Ive seen worse splits, but they are predominantly done to secure liquidity and consolidate SP",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890740+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251446-Silverbl--4521824",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.874343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dustyslay - there are minimum bid price requirements in relation to US listing exchanges - this was one of the reasons for the new ADS split. Where did you note that sales have doubled each quarter? That is simply not the case.  You also mention debt - of which there is none. You are correct I did purchase at higher prices - but so did every single PI and II here. All have lost significant sums of money. We all saw the the medium term opportunity here - however the current management team are showing a complete lack of momentum in growing the business. Yes this is still a new company but investors continue to be fed nonsense with never ending partnerships which don't deliver; revenue predictions which don't deliver; cost cutting which doesn't materialise; pay and stock options for the team which are excessive; cash burn that fritters away funds like there was no tomorrow. My input is negative because I expect better. Yet I remain invested against my better judgement. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890773+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251434-Marty130-42000970",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.874751",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Just added hVIVO to my portfolio..  Looks undervalued, may come into it's own in 26..  A possible takeover target could see increasing share holder value.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-01-29T11:05:01.890806+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-Bushbat--6738741",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.875218",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bushbat",
          "content": "USB holding going up rather than the usual up 5% then down again",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "6.25",
          "thread_title": "USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-01-29T11:05:01.890839+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251352-Dustysla--4834144",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.875653",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Not necessarily,  the OTC doesnt have the Stringent Rules as Nasdaq surrounding Delisting. This isn't a non revenue company, Start up etc. And you shouldn't expelled wonders in entering markets in the first 12 months,  yet growth of sales has doubled each quarter. Im unsure why you see this as a bad long term investment Silverblade, I can only surmise you have bought higher and the decrease has weighed heavily on your input. Im yet to buy, as I imagined this route to profit, which takes time when reducing debt and growing in market and sales. Suppose people expect 1 year investing these days, when reality is. Takes much longer, on a gradual basis. 1 month spikes create over expectancy, and then you end up where you began, 50% down. Always better to research an investment thoroughly before entering into it. Hence what im doing",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890872+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251314-Marty130-60224205",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876066",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Presumably carried out to keep them from being expelled from the market..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890905+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251251-Silverbl--7001531",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876510",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "ADS split on OTC has now gone through - 1 UK \u00a3 share is now equivalent to 25 US $ OTC shares. Market reaction to this alongside the warnings in the AGM statement predictable. Short interest has increased significantly - this could get very messy, very quickly. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-29T11:05:01.890936+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251512-Silverbl-86809389",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "We will find out next month how much progress all the partnerships announcements are making on testing revenue. My fear is they will be nowhere near their H1 target. There are lots of institutional investors here besides UBS - they presumably are taking the gamble that eventually there will be a pick up in sales. No point in having an FDA approved product with the agreed reimbursement if there is no commercial market to sell into - and that has been the case so far. It has already been clarified by the company that CE is not of any importance to them in the short term - with a limited sales force the US market needs to show progress or it will start to become very difficult to secure additional funds imo. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-29T11:05:01.890967+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261042-fre1--3091234",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382464",
        "source": "LSE_CHAT",
        "data": {
          "author": "fre1",
          "content": "They are starting to build up scale (thanks for link Marty130) and their collaboration with Tempus should be gaining momentum so news next month should help.",
          "sentiment": 0.0,
          "engagement": "1,886",
          "price_at_post": "6.25",
          "thread_title": "RE: BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-01-29T11:05:01.891000+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261000-Marty130--5431620",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382903",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Need to pull their finger out ASAP..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-01-29T11:05:01.891025+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261743-Marty130--4812762",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383336",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Agreed",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-29T11:05:01.891044+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260551-Cevodniy--7739349",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, that's great news, but nothing absolutely nothing affects the share price.",
          "sentiment": 0.0,
          "engagement": "3,066",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-29T11:05:01.891064+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261120-Marty130-71432821",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384173",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://www.proactiveinvestors.com/companies/news/1085472/renalytix-expands-us-footprint-with-three-new-clinical-partnerships-1085472.html",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-29T11:05:01.891083+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261948-bluesy1--4733568",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384585",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "Like what ? Minor move upwards. Lets all get excited. Tedious ...",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.25",
          "thread_title": "RE: Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-01-29T11:05:01.891122+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261743-Mikemine-54750796",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384993",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Looks like somebody knows something maybe?",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "6.25",
          "thread_title": "Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-01-29T11:05:01.891144+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262227-Marty130-18372583",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Disagree.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-01-29T11:05:01.891162+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262055-bluesy1-64387275",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385830",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "This has all the hallmarks of a BOD lifestyle  funding company. FDA approval but would rather die in their own DNA.  Get out before its too late",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.15",
          "thread_title": "Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-01-29T11:05:01.891181+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261947-Silverbl--1770613",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386254",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Next news is likely to see share price hit all time lows - enough negative hints have been dropped recently about current trading. Statements such as \"Commercial outcomes.....remain difficult to predict\"; \"Each practice currently represents modest initial testing volumes\"; \"Engaging with large healthcare systems presents inherent challenges\" - do not fill me with short term confidence in the $8.4m 2026 revenue target - we are about to finish month 7 out of 12 in that regard. And if that revenue target is not met where does that leave the cash position? Does make you wonder what exactly the company's 11 full time sales reps are doing - door knocking physicians will not cut it here. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-29T11:05:01.891200+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261836-Marty130--1722109",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386660",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Looks like the SP is heading down, in order to boost volumes.. Let's hope the BoD release some juicy news to push it back up on healthy volumes.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-29T11:05:01.891219+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261633-Investor-21341048",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387067",
        "source": "LSE_CHAT",
        "data": {
          "author": "Investor2025",
          "content": "Not yet..",
          "sentiment": 0.0,
          "engagement": "7",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-29T11:05:01.891238+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261537-Hawker-36616709",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387485",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Hope springs eternal...  Ho hum...",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-29T11:05:01.891257+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261535-Marty130--4736780",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Exactly.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-29T11:05:01.891276+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261401-tweedly-50085950",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388311",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Understandably the RNS didn't set the market alight. Waiting for hard numbers I think.",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-29T11:05:01.891295+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262252-MIKODX-68229782",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388725",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Todays RNS means we are now seeing concrete progress on commercial rollout.This shows that Renalytix is moving towards actual deployment with multiple provider groups. Getting kidneyintelX.dkd into established clinics is a big step. It means providers see enough value in the test to integrate it into their day-to-day systems. The RNS reiterates that Renalytix and Tempus are working closely to integrate kidneyintelX.dkd into larger healthcare sytems that are already on Tempus's platform. This is very significant because a) smaller clinics alone won't generate high volumes and b) larger sytems (via Tempus) have broader patient populations and infrastucture. This will accelerate adoption more rapidly once it starts rolling through those network. Everything is starting to fall into place, the company is really now starting to see some real progression. Great RNS.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-29T11:05:01.891313+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262236-MIKODX-16532436",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389141",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "The company says it expects to provide a fuller trading update in February. By fuller that means they expect improvement in sales. The company is making all the right moves thus far.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-29T11:05:01.891332+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261111-Marty130-39459671",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Enalytix plc (RENX.LN)*, Futura Medical plc (FUM.LN) Non-Independent Research; Marketing & Sales Commentary - MiFID II exempt information \u2013 see disclaimer below. Company Update: 12 January 2026 Renalytix plc (LSE: RENX, OTCQB: RNLXY)*: Three kidneyintelX.dkd clinical integration \u2013 update on Tempus collaboration Market Capitalisation: \u00a326.6m; Share Price: 6.08p \u2022 During the last quarter of 2025, Renalytix completed three additional kidney specialist healthcare provider clinical integrations in the US, in New York, Florida and Tennessee.  \u2022 Additional integrations are expected in early 2026. \u2022 Tempus collaboration is progressing well with teams from both Tempus and Renalytix working closely to target Tempus\u2019 customers with a large diabetes and kidney disease patients.  Renalytix reports that it added three new US clinical integrations in late 2025, bringing its FDAapproved kidneyintelX.dkd test into established kidney care practices in New York, Florida, and Tennessee. Testing has begun at all sites, and although initial volumes are expected to be small, the company anticipates usage to build as clinicians become familiar with the workflow. More integrations are planned for early 2026.  Renalytix states that it is working intensively with Tempus to integrate its kidney risk testing into major US health systems through Tempus' integrated electronic health records (EHR). Since the partnership began in September 2025, teams from both companies have been coordinating to target large provider networks with significant diabetes and CKD populations, aiming to streamline test ordering and strengthen data collection. The collaboration is positioned as a foundation for expanding into new clinical and geographic markets as the platform matures.  From a strategic standpoint, this fits neatly with Renalytix\u2019s strategy to have kidneyintelX.dkd test integrates into healthcare providers\u2019 EHRs, which allows quick and seamless ordering. shift toward disciplined, system-level integrations rather than chasing individual clinics. The Tempus partnership could prove far more meaningful if it unlocks access to large, data-rich health systems where adoption can scale. SP Angel acts as Nomad and Broker to the Renalytix Futura Medical plc (AIM: FUM): Positive results from WSD4000 early feasibility study Market Capitalisation: \u00a39.1m; Share Price: 1.58p \u2022 Statistically significant improvement achieved in female sexual function with WSD4000 in a study enrolling 12 women suffering from some degree of sexual dysfunction. \u2022 Results give the Company confidence to proceed to the next steps of designing a Phase III placebo-controlled trial, with results expected mid-2026 Futura reports that its WSD4000 early feasibility study in 12 women showed a clear and statistically significant improvement in sexual function, with gains on the Female Sexual Function Index (FSFI) scale well above the accepted threshold for clinical relevance. Benefits were seen across arousal",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D3CE797F-7C15-4738-8269-38EDD6CB8090"
        },
        "ingested_at": "2026-01-29T11:05:01.891351+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260838-emblaze1--3803261",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390005",
        "source": "LSE_CHAT",
        "data": {
          "author": "emblaze1",
          "content": "LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use. The integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix. These integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations. Renalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources. Tempus AI Collaboration Renalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in September 2025, to target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients. The collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time. Investor Engagement James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. The 44th annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad rang",
          "sentiment": 0.0,
          "engagement": "917",
          "price_at_post": "6.25",
          "thread_title": "RE:Results soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=3DEB0D63-492C-4E6A-AD12-B94C142E4A0B"
        },
        "ingested_at": "2026-01-29T11:05:01.891370+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260823-Marty130-14865967",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390423",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Results deadline missed then..  As wws due before 31st of January..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-29T11:05:01.891388+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260809-johndean--6705860",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390835",
        "source": "LSE_CHAT",
        "data": {
          "author": "johndean",
          "content": "Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the company expects to provide further updates on progress and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "798",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-29T11:05:01.891422+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260807-Marty130--3255427",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391262",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Where? I haven't received one.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-29T11:05:01.891449+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260712-morningt--8103874",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391677",
        "source": "LSE_CHAT",
        "data": {
          "author": "mornington-oz",
          "content": "RNS  OUT",
          "sentiment": 0.0,
          "engagement": "23,507",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-29T11:05:01.891469+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260710-uxm484-31114142",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392089",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. Hopefully some new investors will jump on this month following the J.P Morgan event in the US, progress being made and undervalued at present.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-29T11:05:01.891488+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261801-Marty130-85242921",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Upcoming Financial & Corporate Events H1 2026 Trading Update: The company is scheduled to provide a trading update for the six-month period ending December 31, 2025, by the end of January 2026.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-29T11:05:01.891508+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261515-Dustysla-40728712",
        "event_type": "social_post",
        "date": "2026-01-30T23:32:44.764676",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Marty Great news, these outcomes wont be felt or showcased in SP appreciation till you start seeing the sales,  and financials from this growing customer base Cev. But its 100% positive reinforcement that its growing its clientele one state at a time,  and in this case 3 more states. A continous trend of the whole US market, state by state is the goal here. Stick with it Cev",
          "sentiment": 0.0,
          "engagement": "13,821",
          "price_at_post": "5.90",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-30T23:32:52.124478+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261516-Silverbl--2705110",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.833253",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Sounds a difficult prognosis to live with oldbut. Renx and its sister company verici were both spun out of ekf diagnostics about 5 years ago based on two unique biomarkers relating to kidney disease - renx is all about early warning and intervention through patient testing and verici focuses on pre and post kidney transplant risk monitoring (rejection).  Both company's have excellent technology and a key relationship/partnership  with Mount Sinai in New York who provide access to an extensive patient database which assists an AI driven approach to improve patient outcomes. The key issue is convincing clinicians at scale that the tests should be deployed (despite having all required regulatory approvals in place and agreed Medicare reimbursement secured). Market penetration remains slow; cash burn remains high and the market remains sceptical on the company's ability to commercialise their products - hence the low valuation here and at verici. Corporate updates expected in coming weeks. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-01-30T23:32:52.124501+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20262136-Marty130-73106100",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.834056",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Sorry..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-01-30T23:32:52.124526+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261534-oldbutno-73677185",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.834852",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "...because I have Grade 4 Kidney disease. So it won't help me but caught my interest.",
          "sentiment": 0.5,
          "engagement": "3,324",
          "price_at_post": "6.25",
          "thread_title": "Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-01-30T23:32:52.124545+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261616-Marty130-65043930",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.138786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Purchase at 7%.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-30T23:32:52.124564+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261603-Pixels-31975486",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.139331",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pixels",
          "content": "How can you tell, that document shows as \"acquisition / disposal\" - is it definitely acquisition? Got to admit I struggle with reading financial type documents, I'm just a media monkey",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-30T23:32:52.124582+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261512-Marty130-11280619",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.139866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "They're back in again..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-01-30T23:32:52.124601+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261527-Marty130-68502794",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.140363",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "A deal may arise next week after the conference in San Francisco.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-30T23:32:52.124619+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261412-Veteran1--7200061",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.140866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Veteran10",
          "content": "Bit of movement but low volume. If volumes increases, could be a momentum buy opportunity.",
          "sentiment": 0.0,
          "engagement": "4,077",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-30T23:32:52.124638+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261935-Marty130--2766876",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.141384",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix is expected to participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, a premier global healthcare investment symposium where companies present and connect with investors, industry leaders, and innovators, focusing on new technologies like AI in healthcare, kidney disease, and strategic partnerships. While Renalytix isn't explicitly named in the top results, they are a kidney-focused company likely to attend this major event, which runs concurrently with the Biotech Showcase.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-30T23:32:52.124656+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261839-Silverbl-25147388",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.141885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "...well if the prognosis is kidney related oldbut i think we might be able to help out......lol. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-30T23:32:52.124674+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261837-Silverbl--8771669",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.142401",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "New deals mean nothing without a credible commercial plan which has at its heart the means to create and service product demand in a timeous and profitable manner. Nothing to date has achieved that in any meaningful volume. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-01-30T23:32:52.124692+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261801-oldbutno--4939038",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.142900",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "....come to those that wait.....Oh, and DEATH!",
          "sentiment": 0.0,
          "engagement": "3,324",
          "price_at_post": "5.90",
          "thread_title": "GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-01-30T23:32:52.124710+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261649-Marty130-57298195",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.143434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "To turn this around as the share price will continue to new lows..   Wake up BoD, pull your fingers out..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-01-30T23:32:52.124728+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20262041-Marty130-46161664",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.144017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix said in an update on Tuesday that it was making progress in expanding the use of KidneyIntelX.dkd across the United States, reporting growing testing volumes, new state coverage and advancing commercial partnerships ahead of its annual general meeting in London. The AIM-traded company's prognostic blood test, the only FDA-approved and Medicare-reimbursed test for early-stage chronic kidney disease risk assessment, was now generating revenue from four core states - Florida, Texas, New York and, most recently, Arizona. Executive chairman Julian Baines said the first orders in Arizona included tests from one of the largest nephrology practices in the US. He emphasised that, while direct sales growth is encouraging, the company's primary strategy is to scale test adoption through major business development agreements with large healthcare systems. Renalytix signed a definitive agreement in September with Tempus AI, the Nasdaq-listed diagnostics and AI group, which Baines said has \"an established network of healthcare institutions already utilising its precision medicine solutions.\" He added that early engagement with Tempus and MVP Health Care reinforced the company's belief that its partnership-led model would \"deliver long-term value for shareholders,\" despite lengthy implementation processes common across major US providers. Renalytix said it had also narrowed potential partners for its next electronic health record integration and was working with several large healthcare systems expected to generate \"meaningful testing volumes\" over time. The company said it was increasingly using data analytics to identify physicians managing high numbers of eligible patients, helping target commercial resources where uptake prospects are strongest. Renalytix added that it had started transitioning to a new laboratory facility, a move expected to expand testing capacity and reduce operating costs over the next five years. Baines said the company was now focused on converting ongoing discussions into contracted relationships, expanding EHR integrations and accelerating test volumes. While acknowledging that timing of commercial outcomes \"remains difficult to predict,\" he said the board was confident that the company's current initiatives \"position the company well for sustainable revenue growth, increased operating leverage, and long-term value creation for shareholders.\" Renalytix said it would provide a trading update for the six months to 31 December by the end of January.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "2026 outlook",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=30EC9492-CE10-4321-AED9-CF8B2D3F53AF"
        },
        "ingested_at": "2026-01-30T23:32:52.124746+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261342-Mikemine--6171016",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.144538",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "If Tempus gets going, the revenue will spike and so will the SP. Big companies like Tempus are notoriously slow to move but they've had since early September so H1 seems reasonable for them to get going. I urge anyone who has missed the RNS (15th Sept) about the collaboration agreement to read it and do a bit of research on Tempus. Apart from this ramp, I won't offer a prediction target but I do expect to multibag  from these levels. Good luck to everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-30T23:32:52.124764+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261121-Marty130--8272690",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.145043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "On receipt of the CE acceptance, which is expected h1, 18/22, on a takeover, 40/60.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-30T23:32:52.124782+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20260407-Cevodniy--3599786",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.145565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Ok fellow investors. Year end SP predictions. I'll start at 20p.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-01-30T23:32:52.124801+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20252147-Crannog1-31165154",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.146063",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crannog12",
          "content": "You are a ray of sunshine. I take it you are invested here?",
          "sentiment": 0.0,
          "engagement": "57",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-30T23:32:52.124819+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251345-Silverbl--3351781",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.146588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dreadful year for investors. Trading update in January could hammer confidence further if company fails to deliver revenue targets. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-30T23:32:52.124837+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20251632-MIKODX--5274244",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147014",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "It\u2019s not good watching the SP slowly slip down, but that\u2019s bound to happen with no positive news. The one consolation is the support at 5.70 is holding up well so far. Hopefully we can kick off the new year with some good news and hopefully get a good bounce from the support level all the way up past 10.",
          "sentiment": 0.0,
          "engagement": "3,977",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-30T23:32:52.124855+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251231-Marty130--3636099",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Hopefully we will have a better year in 2026, with more announcements of higher revenues and transformational new contracts signed. The BoD badly needs pay more attention to reverse the share price trend..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "New contracts",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8AD3616F-3B6B-486A-8B37-36DE630CD42F"
        },
        "ingested_at": "2026-01-30T23:32:52.124873+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251037-Marty130--5408808",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147873",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Cevo, And don't forget the CE mark will have a transformation affect.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-30T23:32:52.124891+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250828-Cevodniy-20790392",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.148323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "MIKODX on the 2nd January 2025, the SP was 10.75, yesterday it was 6p. I get your optimism via your post, but obviously institutions and wealthy investors don't agree. 10p to 6p is not exactly a successful year. I hope we don't experience another 66% next year.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-30T23:32:52.124909+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250037-MIKODX--9826289",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.148764",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "FY2025 was a key year for the company in establishing a solid pathway for testing adoption, life science services and strategic partnering. In July 2025, RENX announced an agreement with MVP Health Care, a U.S.-based insurer covering more than 700,000 patients. Beyond expanding physician and patient access, this agreement reinforces that Renalytix and kidneyIntelX.dkd are establishing a leadership position in chronic kidney disease management and gaining increasing recognition in the market. In September 2025, Renalytix signed an agreement with Tempus AI, Inc. (\u201cTempus\u201d), a clear leader in delivery of integrated advanced diagnostic testing and life science services in the United States. The collaboration with Tempus will enable RENX to accelerate introduction of kidneyintelX.dkd into large hospital systems and community healthcare practices across the U.S., significantly expanding distribution over the next five years. The relationship with Tempus AI has continued to develop positively, with ongoing progress in aligning commercial activities. The Balance Sheet was further improved with the conversion of an additional $4 million of convertible debt leaving outstanding long-term debt at \u00a33.1m as of October 2025. More than $1.3m in cash from backdated R&D claims and grant income, further strengthening the balance sheet. Administrative expenses decreased by more than 40% year-on-year, driven by headcount and operations optimization. RENX continue to strengthen there presence in three initial target states - Florida, Texas, and New York. In FY26, they expanded into Arizona their fourth target market which collectively represents approximately 20% of the total addressable kidneyintelX.dkd market. RENX is well positioned to deliver important and necessary change in chronic kidney disease management in the United States and globally.In the coming months and years sales will without doubt improve with the test being made more readily available in healthcare systems. Not been a bad year for the company, quite the opposite, it has been a very positive one. FY26 will see the partnerships coming to fruition with the test more widely available in the healthcare systems which will mean more sales for the company. Lots to look forward to in the coming year. I'll drink to that. Hope everyone has a merry xmas and the best of luck for the new year. With any luck we will have some good news from the parterships established, which will have a very positive affect on the SP. As we all know, this is a very volatile stock that can really take off on good news. Next year will be the year. GLA",
          "sentiment": 0.0,
          "engagement": "3,977",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-30T23:32:52.124928+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20252029-Cevodniy-62887022",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.149203",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, you are the only poster here generally and even you can't see anything positive,  except the possibility of a takeover I've just over 1.2 million at an average of 10p, I fo not expect to ever see profit.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-30T23:32:52.124946+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251332-Marty130--6650467",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.866496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Surely we'll get better results next year, if not a possible takeover.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-30T23:32:52.124964+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251144-Mikemine--1348431",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.866939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Merry Christmas everybody. Here's hoping for a more prosperous New year.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "5.90",
          "thread_title": "Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-01-30T23:32:52.124982+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251830-Marty130--9203557",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.867379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "U2..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-01-30T23:32:52.124999+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251756-tweedly--7798819",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.867802",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Right. These RNS' have been coming out for at least 6 months, no one makes sense of them so no point speculating. Merry Christmas folks",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-01-30T23:32:52.125017+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251644-Marty130--4374702",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.868233",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Down selling again.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-01-30T23:32:52.125035+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251241-Silverbl-41251972",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.868652",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "The jury is not only out Hawker....its leaving the courthouse! Its been another horror story in 2025 for the business which showed so much early promise. I have low expectations for the trading update in January - seems this is pretty common given the share price reaction. All time price low - makes the 9.5p raise a highlight from the management team - although the next raise could be very painful for shareholders if they cannot generate revenue and continue to burn cash. ATB to those who hold here - it continues to be a very difficult investment to justify. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125053+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20250931-Marty130--5375332",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "German Market is huge.. Once the CE goes through, plenty will sign up.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125070+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251427-Hawker-10652219",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Well said, SB. This is now just a waiting game, as the company has EVERYTHING they need to succeed in going to market; there are no more barriers. The only question, therefore, is whether they can sell the test into their focus regions and whether there is a market for it. So far, the jury is out. QED... Opinion:   Ho hum",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125088+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251146-JBCo--6390340",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869928",
        "source": "LSE_CHAT",
        "data": {
          "author": "JBCo",
          "content": "Hopefully can hold 6p",
          "sentiment": 0.0,
          "engagement": "4,545",
          "price_at_post": "6.25",
          "thread_title": "Big seller trying to get out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=253BEB68-92E2-41AA-91A1-E5998136B1CD"
        },
        "ingested_at": "2026-01-30T23:32:52.125117+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251751-Marty130--7151502",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.870350",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "CE marks always add value.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125136+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251623-cipro--8974832",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.870772",
        "source": "LSE_CHAT",
        "data": {
          "author": "cipro",
          "content": "The trend is slowly going down with this stock did hv good potential And I hope this still has some upside however the momentum is stuttering atm Hope to get positive news in January to get the trend back up good luck all",
          "sentiment": 0.0,
          "engagement": "2,148",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-01-30T23:32:52.125154+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251621-Dustysla--4740566",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.871231",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "I think your Gripe is the time spent here, and against the companies management. I get that, they are not the easiest investments as they are Crooks and useless. So I try to look at 3 things here at this juncture Revenue/Debt/Sales And Future Projected Revenue/Debt/Sales And how they will maintain a healthy cash burn in the intermediate.",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125172+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251616-Dustysla--4368160",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.871686",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m OTCQB listing only says $17.98 million 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). Is this financials or Sales? Im talking about Provider to Patient sales 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). This is how it explained, a Google AI version. Id get a more accurate view, but im not not interested in doing so. 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. Ok well nothing I found in 30 mins showed they had FDA approval so the assumption is their flogging nothing. But if im wrong, and it started somewhere in 2024 fine. Small details. But Debt, well yes as you said checks out. But you said NO DEBT, quite abruptly so I got a lot closer than you in 30 minutes that you seemingly in years",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125190+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251606-Silverbl--8301614",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.872134",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "OK Dustyslay - I'll bite - here we go - my 'whining' response to your 'research' based points where real world numbers are available. 1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. The point on debt looks accurate. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125208+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251540-Dustysla-82747524",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.872558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade I understand all what you are saying, 2024 wouldn't have been a great year as they hadn't gone to market and thats the Pharmsma industry for you, why I dont hold any current because I feel they are run by wealthy individuals that are focused on personal wealth before Health and will fill their boots prior to any achievements and shareholders take on the dilution and the hard hold. But im kinda leaning towards this, the more i look into it because its all about timing really.  If MVP goes solid, and your market expands 2026, you should improve dramatically As for the CE mark, achieving it your correct it wont move it, but its what you do once achieved in the European markets",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125226+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251529-Dustysla--5559809",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Ok, i know where i found the Sales and it took me a long time so here, more AI junk but the growth is there. Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months. Recent Revenue: For the first half of the fiscal year 2025 (H1 FY25), Renalytix reported revenues of $1.3 million. This demonstrated continued quarterly sales growth into Q3 FY25. Quarterly Growth: The company is on track to meet or exceed its target of 20% average quarter-over-quarter revenue growth. Billable Tests: For the first time, over 1,000 billable tests were processed in Q3 2025, supported by the onboarding of a large primary care network in New York and improved direct-to-physician sales. Medicare Coverage: The company has achieved FDA approval and Medicare coverage determination for its kidneyintelX.dkd test, with an established price of $950 per test. Partnerships: New collaborations, notably with Tempus AI and MVP Health Care, are expected to positively impact revenue and expand the test's reach among the 15 million people in the US with type 2 diabetes and chronic kidney disease. Future Guidance: Renalytix has provided forward revenue guidance of $3.2 million in FY25, $8.5 million in FY26, and $17.5 million in FY27. Despite recent sales growth, the company has faced financial challenges, including a decline in total annual revenue in FY24 compared to FY23, high operating losses, and a reliance on external financing to sustain operations. The company has focused on cost reductions and strategic partnerships to improve its financial position. 1000 \u00d7 $950 plus Medicaid Reimbursement in its first year. Now a new area in North America with MVP, 700 000 patients on books. You see where its going? Have some faith. And perhaps more research than whining on a forum",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125245+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251506-Dustysla-15856764",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873471",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Im not every fond of AI, or even Google AI. Never done ChatGBT etc so a lot is from memory on researching, the sales i will locate the information at some point as im a tad busy but Debt is easy to find, you would be hard pressed to find any company not still refurbishing debt after they have gone to market. The key is to see a constant, and consistent reduction per half year reports. Here is the AI, against my normal MO of real research: As of late 2025, Renalytix has reported approximately $8.21 million in total debt, a decrease from previous years. The company has actively worked to improve its balance sheet through debt restructuring and equity conversions. Key details regarding Renalytix's debt: Total Debt: The most recent figures from financial reports indicate total debt is approximately $8.21 million. Recent Reduction: Renalytix has focused on reducing its debt through strategic financial maneuvers. In October 2025, the company announced a $4 million balance sheet improvement by converting approximately $4 million of senior convertible bonds into equity, saving up to $1.4 million in future accrued interest. Debt Restructuring: A significant portion of the remaining debt is a new unsecured convertible bond issued in November 2024 (and later partially converted in Oct 2025), with a maturity date of July 2029. This bond has flexible interest payment options (cash or rolled into the principal) at the company's discretion. Historical Context: The company's total debt peaked in June 2022 at over $12 million and has generally trended downwards since then. Financial Position: The renegotiation of debts has helped the company move to a net current asset position, aiming to direct cash flows towards commercial and operational growth.",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125263+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251458-Dustysla--6721094",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Nasdaq has listing requirements that are difficult OTC is similar to AIM, there are 3 different markets OTCQB/OTCQX and OTC pink but we can dismiss that you are in one of the the first 2. OTC Premier is stringent but that isnt listed there. 0.01 is the minimum requirement SP And a M/Cap of 10 million minimum Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus. The split has gone quite well on early judgement,  and will help consolidate liquidity as lower the SP, the higher the percentage swings and more susceptible to traders profiting on movement. Ive seen worse splits, but they are predominantly done to secure liquidity and consolidate SP",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125282+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251446-Silverbl--3470147",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.874343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dustyslay - there are minimum bid price requirements in relation to US listing exchanges - this was one of the reasons for the new ADS split. Where did you note that sales have doubled each quarter? That is simply not the case.  You also mention debt - of which there is none. You are correct I did purchase at higher prices - but so did every single PI and II here. All have lost significant sums of money. We all saw the the medium term opportunity here - however the current management team are showing a complete lack of momentum in growing the business. Yes this is still a new company but investors continue to be fed nonsense with never ending partnerships which don't deliver; revenue predictions which don't deliver; cost cutting which doesn't materialise; pay and stock options for the team which are excessive; cash burn that fritters away funds like there was no tomorrow. My input is negative because I expect better. Yet I remain invested against my better judgement. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125300+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251434-Marty130--8149095",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.874751",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Just added hVIVO to my portfolio..  Looks undervalued, may come into it's own in 26..  A possible takeover target could see increasing share holder value.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-01-30T23:32:52.125319+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-Bushbat--5226810",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.875218",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bushbat",
          "content": "USB holding going up rather than the usual up 5% then down again",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "6.25",
          "thread_title": "USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-01-30T23:32:52.125337+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251352-Dustysla-18557859",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.875653",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Not necessarily,  the OTC doesnt have the Stringent Rules as Nasdaq surrounding Delisting. This isn't a non revenue company, Start up etc. And you shouldn't expelled wonders in entering markets in the first 12 months,  yet growth of sales has doubled each quarter. Im unsure why you see this as a bad long term investment Silverblade, I can only surmise you have bought higher and the decrease has weighed heavily on your input. Im yet to buy, as I imagined this route to profit, which takes time when reducing debt and growing in market and sales. Suppose people expect 1 year investing these days, when reality is. Takes much longer, on a gradual basis. 1 month spikes create over expectancy, and then you end up where you began, 50% down. Always better to research an investment thoroughly before entering into it. Hence what im doing",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125356+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251314-Marty130-53602599",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876066",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Presumably carried out to keep them from being expelled from the market..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125374+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251251-Silverbl--9033971",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876510",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "ADS split on OTC has now gone through - 1 UK \u00a3 share is now equivalent to 25 US $ OTC shares. Market reaction to this alongside the warnings in the AGM statement predictable. Short interest has increased significantly - this could get very messy, very quickly. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-01-30T23:32:52.125392+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251512-Silverbl--6620235",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "We will find out next month how much progress all the partnerships announcements are making on testing revenue. My fear is they will be nowhere near their H1 target. There are lots of institutional investors here besides UBS - they presumably are taking the gamble that eventually there will be a pick up in sales. No point in having an FDA approved product with the agreed reimbursement if there is no commercial market to sell into - and that has been the case so far. It has already been clarified by the company that CE is not of any importance to them in the short term - with a limited sales force the US market needs to show progress or it will start to become very difficult to secure additional funds imo. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-01-30T23:32:52.125411+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261042-fre1--6352621",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382464",
        "source": "LSE_CHAT",
        "data": {
          "author": "fre1",
          "content": "They are starting to build up scale (thanks for link Marty130) and their collaboration with Tempus should be gaining momentum so news next month should help.",
          "sentiment": 0.0,
          "engagement": "1,886",
          "price_at_post": "6.25",
          "thread_title": "RE: BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-01-30T23:32:52.125429+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261000-Marty130--2988180",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382903",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Need to pull their finger out ASAP..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-01-30T23:32:52.125447+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261743-Marty130-12293567",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383336",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Agreed",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-30T23:32:52.125465+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260551-Cevodniy-40426199",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, that's great news, but nothing absolutely nothing affects the share price.",
          "sentiment": 0.0,
          "engagement": "3,066",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-30T23:32:52.125483+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261120-Marty130-14433576",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384173",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://www.proactiveinvestors.com/companies/news/1085472/renalytix-expands-us-footprint-with-three-new-clinical-partnerships-1085472.html",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-01-30T23:32:52.125501+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261948-bluesy1--2625930",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384585",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "Like what ? Minor move upwards. Lets all get excited. Tedious ...",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.25",
          "thread_title": "RE: Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-01-30T23:32:52.125519+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261743-Mikemine-45841865",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384993",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Looks like somebody knows something maybe?",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "6.25",
          "thread_title": "Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-01-30T23:32:52.125538+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262227-Marty130-22633562",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Disagree.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-01-30T23:32:52.125555+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262055-bluesy1--7218926",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385830",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "This has all the hallmarks of a BOD lifestyle  funding company. FDA approval but would rather die in their own DNA.  Get out before its too late",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.15",
          "thread_title": "Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-01-30T23:32:52.125574+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261947-Silverbl--1715225",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386254",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Next news is likely to see share price hit all time lows - enough negative hints have been dropped recently about current trading. Statements such as \"Commercial outcomes.....remain difficult to predict\"; \"Each practice currently represents modest initial testing volumes\"; \"Engaging with large healthcare systems presents inherent challenges\" - do not fill me with short term confidence in the $8.4m 2026 revenue target - we are about to finish month 7 out of 12 in that regard. And if that revenue target is not met where does that leave the cash position? Does make you wonder what exactly the company's 11 full time sales reps are doing - door knocking physicians will not cut it here. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-30T23:32:52.125592+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261836-Marty130--3872778",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386660",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Looks like the SP is heading down, in order to boost volumes.. Let's hope the BoD release some juicy news to push it back up on healthy volumes.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-30T23:32:52.125610+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261633-Investor--4732782",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387067",
        "source": "LSE_CHAT",
        "data": {
          "author": "Investor2025",
          "content": "Not yet..",
          "sentiment": 0.0,
          "engagement": "7",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-01-30T23:32:52.125629+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261537-Hawker-40939401",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387485",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Hope springs eternal...  Ho hum...",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-30T23:32:52.125647+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261535-Marty130-50406597",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Exactly.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-30T23:32:52.125665+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261401-tweedly-23406648",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388311",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Understandably the RNS didn't set the market alight. Waiting for hard numbers I think.",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-30T23:32:52.125683+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262252-MIKODX-39943051",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388725",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Todays RNS means we are now seeing concrete progress on commercial rollout.This shows that Renalytix is moving towards actual deployment with multiple provider groups. Getting kidneyintelX.dkd into established clinics is a big step. It means providers see enough value in the test to integrate it into their day-to-day systems. The RNS reiterates that Renalytix and Tempus are working closely to integrate kidneyintelX.dkd into larger healthcare sytems that are already on Tempus's platform. This is very significant because a) smaller clinics alone won't generate high volumes and b) larger sytems (via Tempus) have broader patient populations and infrastucture. This will accelerate adoption more rapidly once it starts rolling through those network. Everything is starting to fall into place, the company is really now starting to see some real progression. Great RNS.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-01-30T23:32:52.125704+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262236-MIKODX-61797372",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389141",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "The company says it expects to provide a fuller trading update in February. By fuller that means they expect improvement in sales. The company is making all the right moves thus far.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-30T23:32:52.125722+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261111-Marty130--7706434",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Enalytix plc (RENX.LN)*, Futura Medical plc (FUM.LN) Non-Independent Research; Marketing & Sales Commentary - MiFID II exempt information \u2013 see disclaimer below. Company Update: 12 January 2026 Renalytix plc (LSE: RENX, OTCQB: RNLXY)*: Three kidneyintelX.dkd clinical integration \u2013 update on Tempus collaboration Market Capitalisation: \u00a326.6m; Share Price: 6.08p \u2022 During the last quarter of 2025, Renalytix completed three additional kidney specialist healthcare provider clinical integrations in the US, in New York, Florida and Tennessee.  \u2022 Additional integrations are expected in early 2026. \u2022 Tempus collaboration is progressing well with teams from both Tempus and Renalytix working closely to target Tempus\u2019 customers with a large diabetes and kidney disease patients.  Renalytix reports that it added three new US clinical integrations in late 2025, bringing its FDAapproved kidneyintelX.dkd test into established kidney care practices in New York, Florida, and Tennessee. Testing has begun at all sites, and although initial volumes are expected to be small, the company anticipates usage to build as clinicians become familiar with the workflow. More integrations are planned for early 2026.  Renalytix states that it is working intensively with Tempus to integrate its kidney risk testing into major US health systems through Tempus' integrated electronic health records (EHR). Since the partnership began in September 2025, teams from both companies have been coordinating to target large provider networks with significant diabetes and CKD populations, aiming to streamline test ordering and strengthen data collection. The collaboration is positioned as a foundation for expanding into new clinical and geographic markets as the platform matures.  From a strategic standpoint, this fits neatly with Renalytix\u2019s strategy to have kidneyintelX.dkd test integrates into healthcare providers\u2019 EHRs, which allows quick and seamless ordering. shift toward disciplined, system-level integrations rather than chasing individual clinics. The Tempus partnership could prove far more meaningful if it unlocks access to large, data-rich health systems where adoption can scale. SP Angel acts as Nomad and Broker to the Renalytix Futura Medical plc (AIM: FUM): Positive results from WSD4000 early feasibility study Market Capitalisation: \u00a39.1m; Share Price: 1.58p \u2022 Statistically significant improvement achieved in female sexual function with WSD4000 in a study enrolling 12 women suffering from some degree of sexual dysfunction. \u2022 Results give the Company confidence to proceed to the next steps of designing a Phase III placebo-controlled trial, with results expected mid-2026 Futura reports that its WSD4000 early feasibility study in 12 women showed a clear and statistically significant improvement in sexual function, with gains on the Female Sexual Function Index (FSFI) scale well above the accepted threshold for clinical relevance. Benefits were seen across arousal",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D3CE797F-7C15-4738-8269-38EDD6CB8090"
        },
        "ingested_at": "2026-01-30T23:32:52.125740+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260838-emblaze1--4858583",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390005",
        "source": "LSE_CHAT",
        "data": {
          "author": "emblaze1",
          "content": "LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use. The integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix. These integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations. Renalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources. Tempus AI Collaboration Renalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in September 2025, to target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients. The collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time. Investor Engagement James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. The 44th annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad rang",
          "sentiment": 0.0,
          "engagement": "917",
          "price_at_post": "6.25",
          "thread_title": "RE:Results soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=3DEB0D63-492C-4E6A-AD12-B94C142E4A0B"
        },
        "ingested_at": "2026-01-30T23:32:52.125758+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260823-Marty130-51074367",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390423",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Results deadline missed then..  As wws due before 31st of January..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-30T23:32:52.125776+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260809-johndean--7184333",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390835",
        "source": "LSE_CHAT",
        "data": {
          "author": "johndean",
          "content": "Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the company expects to provide further updates on progress and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "798",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-30T23:32:52.125794+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260807-Marty130-33160427",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391262",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Where? I haven't received one.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-30T23:32:52.125812+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260712-morningt-21497177",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391677",
        "source": "LSE_CHAT",
        "data": {
          "author": "mornington-oz",
          "content": "RNS  OUT",
          "sentiment": 0.0,
          "engagement": "23,507",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-30T23:32:52.125830+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260710-uxm484--4187522",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392089",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. Hopefully some new investors will jump on this month following the J.P Morgan event in the US, progress being made and undervalued at present.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-30T23:32:52.125848+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261801-Marty130--7414103",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Upcoming Financial & Corporate Events H1 2026 Trading Update: The company is scheduled to provide a trading update for the six-month period ending December 31, 2025, by the end of January 2026.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-01-30T23:32:52.125867+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261126-uxm484--1576156",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.747673",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Bad news already priced in by the looks of it given this has dropped from 10p but in reality the update is likely going to be positive. Should be hitting further deal news soon, Tempus update, CE Mark soon and operational update. Expecting a move back to 10p in the next 2 months so a good buy at these prices. Appears to be decent time to average down or buy in.",
          "sentiment": 0.5,
          "engagement": "1,012",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-06T23:35:14.343366+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261039-Marty130--7341586",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.748119",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "The Company looks forward to updating investors on progress, corporate development and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "1,318",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-06T23:35:14.343404+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261548-Silverbl-26384873",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.748540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Renx no longer post quarterly updates. Looks like the imminent trading update is going to hit hard. All time share price low today. Market bracing itself for bad news - history just repeating itself here unfortunately. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "5.40",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-06T23:35:14.343437+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261500-Stuartrm--2788202",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.748951",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stuartrm",
          "content": "Please ignore the reference to Nasdaq compliance in my last post. The information, which I got from AI, muddled Renalytix (the first two dates) with a different Renx. Sorry about that. I only realised once I started to delve further.",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "5.40",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-06T23:35:14.343472+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261452-Stuartrm-46522334",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.749529",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stuartrm",
          "content": "Upcoming Financial Calendar Trading Update: Expected February 2026. Quarterly Earnings Release: Scheduled for 26 March 2026 (covering the period ending December 2025). Nasdaq Compliance Deadline: 27 July 2026. Renalytix has until this date to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "5.40",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-06T23:35:14.343504+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261330-MIKODX-57908296",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.750132",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Need some good news and soon, must be some type of update on how things are progressing with Tempus. Any good news on that front should get the SP up a few ticks.",
          "sentiment": 0.0,
          "engagement": "3,987",
          "price_at_post": "5.25",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-06T23:35:14.343523+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261244-warrior1-86538981",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.750545",
        "source": "LSE_CHAT",
        "data": {
          "author": "warrior1066",
          "content": "Not overdue, in last RNS they said February",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-06T23:35:14.343541+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261110-handybro-45955784",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.750950",
        "source": "LSE_CHAT",
        "data": {
          "author": "handybrownone",
          "content": "Agree - was just checking 27 Jan last year. Generally not a good sign, Suspect they're waiting for something good to day to help us digest some bad news",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.75",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-06T23:35:14.343559+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261708-Marty130--6834878",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.751369",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Trading update is overdue..",
          "sentiment": 0.0,
          "engagement": "1,318",
          "price_at_post": "5.75",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-06T23:35:14.343577+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261515-Dustysla-12891068",
        "event_type": "social_post",
        "date": "2026-01-30T23:32:44.764676",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Marty Great news, these outcomes wont be felt or showcased in SP appreciation till you start seeing the sales,  and financials from this growing customer base Cev. But its 100% positive reinforcement that its growing its clientele one state at a time,  and in this case 3 more states. A continous trend of the whole US market, state by state is the goal here. Stick with it Cev",
          "sentiment": 0.0,
          "engagement": "13,821",
          "price_at_post": "5.90",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-06T23:35:14.343596+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261516-Silverbl--4273647",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.833253",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Sounds a difficult prognosis to live with oldbut. Renx and its sister company verici were both spun out of ekf diagnostics about 5 years ago based on two unique biomarkers relating to kidney disease - renx is all about early warning and intervention through patient testing and verici focuses on pre and post kidney transplant risk monitoring (rejection).  Both company's have excellent technology and a key relationship/partnership  with Mount Sinai in New York who provide access to an extensive patient database which assists an AI driven approach to improve patient outcomes. The key issue is convincing clinicians at scale that the tests should be deployed (despite having all required regulatory approvals in place and agreed Medicare reimbursement secured). Market penetration remains slow; cash burn remains high and the market remains sceptical on the company's ability to commercialise their products - hence the low valuation here and at verici. Corporate updates expected in coming weeks. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-06T23:35:14.343614+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20262136-Marty130-33877140",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.834056",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Sorry..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-06T23:35:14.343632+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261534-oldbutno-61092378",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.834852",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "...because I have Grade 4 Kidney disease. So it won't help me but caught my interest.",
          "sentiment": 0.5,
          "engagement": "3,324",
          "price_at_post": "6.25",
          "thread_title": "Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-06T23:35:14.343650+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261616-Marty130--4821577",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.138786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Purchase at 7%.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-02-06T23:35:14.343669+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261603-Pixels-71326933",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.139331",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pixels",
          "content": "How can you tell, that document shows as \"acquisition / disposal\" - is it definitely acquisition? Got to admit I struggle with reading financial type documents, I'm just a media monkey",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-02-06T23:35:14.343688+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261512-Marty130-87237492",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.139866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "They're back in again..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-02-06T23:35:14.343706+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261527-Marty130-51067472",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.140363",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "A deal may arise next week after the conference in San Francisco.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-06T23:35:14.343724+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261412-Veteran1--2516226",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.140866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Veteran10",
          "content": "Bit of movement but low volume. If volumes increases, could be a momentum buy opportunity.",
          "sentiment": 0.0,
          "engagement": "4,077",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-06T23:35:14.343742+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261935-Marty130-57317511",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.141384",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix is expected to participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, a premier global healthcare investment symposium where companies present and connect with investors, industry leaders, and innovators, focusing on new technologies like AI in healthcare, kidney disease, and strategic partnerships. While Renalytix isn't explicitly named in the top results, they are a kidney-focused company likely to attend this major event, which runs concurrently with the Biotech Showcase.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-06T23:35:14.343760+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261839-Silverbl--2365293",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.141885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "...well if the prognosis is kidney related oldbut i think we might be able to help out......lol. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-06T23:35:14.343778+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261837-Silverbl-83256764",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.142401",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "New deals mean nothing without a credible commercial plan which has at its heart the means to create and service product demand in a timeous and profitable manner. Nothing to date has achieved that in any meaningful volume. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-02-06T23:35:14.343795+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261801-oldbutno-28979605",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.142900",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "....come to those that wait.....Oh, and DEATH!",
          "sentiment": 0.0,
          "engagement": "3,324",
          "price_at_post": "5.90",
          "thread_title": "GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-06T23:35:14.343813+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261649-Marty130-41701126",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.143434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "To turn this around as the share price will continue to new lows..   Wake up BoD, pull your fingers out..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-02-06T23:35:14.343831+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20262041-Marty130--1347619",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.144017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix said in an update on Tuesday that it was making progress in expanding the use of KidneyIntelX.dkd across the United States, reporting growing testing volumes, new state coverage and advancing commercial partnerships ahead of its annual general meeting in London. The AIM-traded company's prognostic blood test, the only FDA-approved and Medicare-reimbursed test for early-stage chronic kidney disease risk assessment, was now generating revenue from four core states - Florida, Texas, New York and, most recently, Arizona. Executive chairman Julian Baines said the first orders in Arizona included tests from one of the largest nephrology practices in the US. He emphasised that, while direct sales growth is encouraging, the company's primary strategy is to scale test adoption through major business development agreements with large healthcare systems. Renalytix signed a definitive agreement in September with Tempus AI, the Nasdaq-listed diagnostics and AI group, which Baines said has \"an established network of healthcare institutions already utilising its precision medicine solutions.\" He added that early engagement with Tempus and MVP Health Care reinforced the company's belief that its partnership-led model would \"deliver long-term value for shareholders,\" despite lengthy implementation processes common across major US providers. Renalytix said it had also narrowed potential partners for its next electronic health record integration and was working with several large healthcare systems expected to generate \"meaningful testing volumes\" over time. The company said it was increasingly using data analytics to identify physicians managing high numbers of eligible patients, helping target commercial resources where uptake prospects are strongest. Renalytix added that it had started transitioning to a new laboratory facility, a move expected to expand testing capacity and reduce operating costs over the next five years. Baines said the company was now focused on converting ongoing discussions into contracted relationships, expanding EHR integrations and accelerating test volumes. While acknowledging that timing of commercial outcomes \"remains difficult to predict,\" he said the board was confident that the company's current initiatives \"position the company well for sustainable revenue growth, increased operating leverage, and long-term value creation for shareholders.\" Renalytix said it would provide a trading update for the six months to 31 December by the end of January.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "2026 outlook",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=30EC9492-CE10-4321-AED9-CF8B2D3F53AF"
        },
        "ingested_at": "2026-02-06T23:35:14.343849+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261342-Mikemine--3426828",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.144538",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "If Tempus gets going, the revenue will spike and so will the SP. Big companies like Tempus are notoriously slow to move but they've had since early September so H1 seems reasonable for them to get going. I urge anyone who has missed the RNS (15th Sept) about the collaboration agreement to read it and do a bit of research on Tempus. Apart from this ramp, I won't offer a prediction target but I do expect to multibag  from these levels. Good luck to everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-02-06T23:35:14.343867+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261121-Marty130-11166796",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.145043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "On receipt of the CE acceptance, which is expected h1, 18/22, on a takeover, 40/60.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-02-06T23:35:14.343885+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20260407-Cevodniy--4647564",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.145565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Ok fellow investors. Year end SP predictions. I'll start at 20p.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-02-06T23:35:14.343903+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20252147-Crannog1--8000450",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.146063",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crannog12",
          "content": "You are a ray of sunshine. I take it you are invested here?",
          "sentiment": 0.0,
          "engagement": "57",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-06T23:35:14.343920+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251345-Silverbl--8657940",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.146588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dreadful year for investors. Trading update in January could hammer confidence further if company fails to deliver revenue targets. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-06T23:35:14.343938+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20251632-MIKODX--4944618",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147014",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "It\u2019s not good watching the SP slowly slip down, but that\u2019s bound to happen with no positive news. The one consolation is the support at 5.70 is holding up well so far. Hopefully we can kick off the new year with some good news and hopefully get a good bounce from the support level all the way up past 10.",
          "sentiment": 0.0,
          "engagement": "3,977",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-06T23:35:14.343956+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251231-Marty130-33707531",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Hopefully we will have a better year in 2026, with more announcements of higher revenues and transformational new contracts signed. The BoD badly needs pay more attention to reverse the share price trend..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "New contracts",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8AD3616F-3B6B-486A-8B37-36DE630CD42F"
        },
        "ingested_at": "2026-02-06T23:35:14.343973+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251037-Marty130--2899636",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147873",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Cevo, And don't forget the CE mark will have a transformation affect.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-06T23:35:14.343991+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250828-Cevodniy-68374097",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.148323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "MIKODX on the 2nd January 2025, the SP was 10.75, yesterday it was 6p. I get your optimism via your post, but obviously institutions and wealthy investors don't agree. 10p to 6p is not exactly a successful year. I hope we don't experience another 66% next year.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-06T23:35:14.344009+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250037-MIKODX-10398169",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.148764",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "FY2025 was a key year for the company in establishing a solid pathway for testing adoption, life science services and strategic partnering. In July 2025, RENX announced an agreement with MVP Health Care, a U.S.-based insurer covering more than 700,000 patients. Beyond expanding physician and patient access, this agreement reinforces that Renalytix and kidneyIntelX.dkd are establishing a leadership position in chronic kidney disease management and gaining increasing recognition in the market. In September 2025, Renalytix signed an agreement with Tempus AI, Inc. (\u201cTempus\u201d), a clear leader in delivery of integrated advanced diagnostic testing and life science services in the United States. The collaboration with Tempus will enable RENX to accelerate introduction of kidneyintelX.dkd into large hospital systems and community healthcare practices across the U.S., significantly expanding distribution over the next five years. The relationship with Tempus AI has continued to develop positively, with ongoing progress in aligning commercial activities. The Balance Sheet was further improved with the conversion of an additional $4 million of convertible debt leaving outstanding long-term debt at \u00a33.1m as of October 2025. More than $1.3m in cash from backdated R&D claims and grant income, further strengthening the balance sheet. Administrative expenses decreased by more than 40% year-on-year, driven by headcount and operations optimization. RENX continue to strengthen there presence in three initial target states - Florida, Texas, and New York. In FY26, they expanded into Arizona their fourth target market which collectively represents approximately 20% of the total addressable kidneyintelX.dkd market. RENX is well positioned to deliver important and necessary change in chronic kidney disease management in the United States and globally.In the coming months and years sales will without doubt improve with the test being made more readily available in healthcare systems. Not been a bad year for the company, quite the opposite, it has been a very positive one. FY26 will see the partnerships coming to fruition with the test more widely available in the healthcare systems which will mean more sales for the company. Lots to look forward to in the coming year. I'll drink to that. Hope everyone has a merry xmas and the best of luck for the new year. With any luck we will have some good news from the parterships established, which will have a very positive affect on the SP. As we all know, this is a very volatile stock that can really take off on good news. Next year will be the year. GLA",
          "sentiment": 0.0,
          "engagement": "3,977",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-06T23:35:14.344027+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20252029-Cevodniy--3669326",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.149203",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, you are the only poster here generally and even you can't see anything positive,  except the possibility of a takeover I've just over 1.2 million at an average of 10p, I fo not expect to ever see profit.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-06T23:35:14.344045+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251332-Marty130--3240972",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.866496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Surely we'll get better results next year, if not a possible takeover.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-06T23:35:14.344062+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251144-Mikemine--9946479",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.866939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Merry Christmas everybody. Here's hoping for a more prosperous New year.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "5.90",
          "thread_title": "Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-06T23:35:14.344080+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251830-Marty130--6379187",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.867379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "U2..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-02-06T23:35:14.344111+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251756-tweedly--4420050",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.867802",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Right. These RNS' have been coming out for at least 6 months, no one makes sense of them so no point speculating. Merry Christmas folks",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-02-06T23:35:14.344133+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251644-Marty130--5923936",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.868233",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Down selling again.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-02-06T23:35:14.344151+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251241-Silverbl-37877625",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.868652",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "The jury is not only out Hawker....its leaving the courthouse! Its been another horror story in 2025 for the business which showed so much early promise. I have low expectations for the trading update in January - seems this is pretty common given the share price reaction. All time price low - makes the 9.5p raise a highlight from the management team - although the next raise could be very painful for shareholders if they cannot generate revenue and continue to burn cash. ATB to those who hold here - it continues to be a very difficult investment to justify. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344169+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20250931-Marty130-32817266",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "German Market is huge.. Once the CE goes through, plenty will sign up.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344188+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251427-Hawker--4096252",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Well said, SB. This is now just a waiting game, as the company has EVERYTHING they need to succeed in going to market; there are no more barriers. The only question, therefore, is whether they can sell the test into their focus regions and whether there is a market for it. So far, the jury is out. QED... Opinion:   Ho hum",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344206+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251146-JBCo--4496100",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869928",
        "source": "LSE_CHAT",
        "data": {
          "author": "JBCo",
          "content": "Hopefully can hold 6p",
          "sentiment": 0.0,
          "engagement": "4,545",
          "price_at_post": "6.25",
          "thread_title": "Big seller trying to get out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=253BEB68-92E2-41AA-91A1-E5998136B1CD"
        },
        "ingested_at": "2026-02-06T23:35:14.344224+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251751-Marty130--2364859",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.870350",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "CE marks always add value.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344242+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251623-cipro--8095185",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.870772",
        "source": "LSE_CHAT",
        "data": {
          "author": "cipro",
          "content": "The trend is slowly going down with this stock did hv good potential And I hope this still has some upside however the momentum is stuttering atm Hope to get positive news in January to get the trend back up good luck all",
          "sentiment": 0.0,
          "engagement": "2,148",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-02-06T23:35:14.344261+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251621-Dustysla-58885817",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.871231",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "I think your Gripe is the time spent here, and against the companies management. I get that, they are not the easiest investments as they are Crooks and useless. So I try to look at 3 things here at this juncture Revenue/Debt/Sales And Future Projected Revenue/Debt/Sales And how they will maintain a healthy cash burn in the intermediate.",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344279+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251616-Dustysla--7710103",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.871686",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m OTCQB listing only says $17.98 million 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). Is this financials or Sales? Im talking about Provider to Patient sales 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). This is how it explained, a Google AI version. Id get a more accurate view, but im not not interested in doing so. 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. Ok well nothing I found in 30 mins showed they had FDA approval so the assumption is their flogging nothing. But if im wrong, and it started somewhere in 2024 fine. Small details. But Debt, well yes as you said checks out. But you said NO DEBT, quite abruptly so I got a lot closer than you in 30 minutes that you seemingly in years",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344298+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251606-Silverbl--8623010",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.872134",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "OK Dustyslay - I'll bite - here we go - my 'whining' response to your 'research' based points where real world numbers are available. 1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. The point on debt looks accurate. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344316+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251540-Dustysla-62773852",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.872558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade I understand all what you are saying, 2024 wouldn't have been a great year as they hadn't gone to market and thats the Pharmsma industry for you, why I dont hold any current because I feel they are run by wealthy individuals that are focused on personal wealth before Health and will fill their boots prior to any achievements and shareholders take on the dilution and the hard hold. But im kinda leaning towards this, the more i look into it because its all about timing really.  If MVP goes solid, and your market expands 2026, you should improve dramatically As for the CE mark, achieving it your correct it wont move it, but its what you do once achieved in the European markets",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344334+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251529-Dustysla-55190673",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Ok, i know where i found the Sales and it took me a long time so here, more AI junk but the growth is there. Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months. Recent Revenue: For the first half of the fiscal year 2025 (H1 FY25), Renalytix reported revenues of $1.3 million. This demonstrated continued quarterly sales growth into Q3 FY25. Quarterly Growth: The company is on track to meet or exceed its target of 20% average quarter-over-quarter revenue growth. Billable Tests: For the first time, over 1,000 billable tests were processed in Q3 2025, supported by the onboarding of a large primary care network in New York and improved direct-to-physician sales. Medicare Coverage: The company has achieved FDA approval and Medicare coverage determination for its kidneyintelX.dkd test, with an established price of $950 per test. Partnerships: New collaborations, notably with Tempus AI and MVP Health Care, are expected to positively impact revenue and expand the test's reach among the 15 million people in the US with type 2 diabetes and chronic kidney disease. Future Guidance: Renalytix has provided forward revenue guidance of $3.2 million in FY25, $8.5 million in FY26, and $17.5 million in FY27. Despite recent sales growth, the company has faced financial challenges, including a decline in total annual revenue in FY24 compared to FY23, high operating losses, and a reliance on external financing to sustain operations. The company has focused on cost reductions and strategic partnerships to improve its financial position. 1000 \u00d7 $950 plus Medicaid Reimbursement in its first year. Now a new area in North America with MVP, 700 000 patients on books. You see where its going? Have some faith. And perhaps more research than whining on a forum",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344353+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251506-Dustysla-31889270",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873471",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Im not every fond of AI, or even Google AI. Never done ChatGBT etc so a lot is from memory on researching, the sales i will locate the information at some point as im a tad busy but Debt is easy to find, you would be hard pressed to find any company not still refurbishing debt after they have gone to market. The key is to see a constant, and consistent reduction per half year reports. Here is the AI, against my normal MO of real research: As of late 2025, Renalytix has reported approximately $8.21 million in total debt, a decrease from previous years. The company has actively worked to improve its balance sheet through debt restructuring and equity conversions. Key details regarding Renalytix's debt: Total Debt: The most recent figures from financial reports indicate total debt is approximately $8.21 million. Recent Reduction: Renalytix has focused on reducing its debt through strategic financial maneuvers. In October 2025, the company announced a $4 million balance sheet improvement by converting approximately $4 million of senior convertible bonds into equity, saving up to $1.4 million in future accrued interest. Debt Restructuring: A significant portion of the remaining debt is a new unsecured convertible bond issued in November 2024 (and later partially converted in Oct 2025), with a maturity date of July 2029. This bond has flexible interest payment options (cash or rolled into the principal) at the company's discretion. Historical Context: The company's total debt peaked in June 2022 at over $12 million and has generally trended downwards since then. Financial Position: The renegotiation of debts has helped the company move to a net current asset position, aiming to direct cash flows towards commercial and operational growth.",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344371+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251458-Dustysla-64002353",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Nasdaq has listing requirements that are difficult OTC is similar to AIM, there are 3 different markets OTCQB/OTCQX and OTC pink but we can dismiss that you are in one of the the first 2. OTC Premier is stringent but that isnt listed there. 0.01 is the minimum requirement SP And a M/Cap of 10 million minimum Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus. The split has gone quite well on early judgement,  and will help consolidate liquidity as lower the SP, the higher the percentage swings and more susceptible to traders profiting on movement. Ive seen worse splits, but they are predominantly done to secure liquidity and consolidate SP",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344389+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251446-Silverbl--7000308",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.874343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dustyslay - there are minimum bid price requirements in relation to US listing exchanges - this was one of the reasons for the new ADS split. Where did you note that sales have doubled each quarter? That is simply not the case.  You also mention debt - of which there is none. You are correct I did purchase at higher prices - but so did every single PI and II here. All have lost significant sums of money. We all saw the the medium term opportunity here - however the current management team are showing a complete lack of momentum in growing the business. Yes this is still a new company but investors continue to be fed nonsense with never ending partnerships which don't deliver; revenue predictions which don't deliver; cost cutting which doesn't materialise; pay and stock options for the team which are excessive; cash burn that fritters away funds like there was no tomorrow. My input is negative because I expect better. Yet I remain invested against my better judgement. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344408+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251434-Marty130--8370615",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.874751",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Just added hVIVO to my portfolio..  Looks undervalued, may come into it's own in 26..  A possible takeover target could see increasing share holder value.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-02-06T23:35:14.344426+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-Bushbat--7590066",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.875218",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bushbat",
          "content": "USB holding going up rather than the usual up 5% then down again",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "6.25",
          "thread_title": "USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-02-06T23:35:14.344445+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251352-Dustysla--2116960",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.875653",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Not necessarily,  the OTC doesnt have the Stringent Rules as Nasdaq surrounding Delisting. This isn't a non revenue company, Start up etc. And you shouldn't expelled wonders in entering markets in the first 12 months,  yet growth of sales has doubled each quarter. Im unsure why you see this as a bad long term investment Silverblade, I can only surmise you have bought higher and the decrease has weighed heavily on your input. Im yet to buy, as I imagined this route to profit, which takes time when reducing debt and growing in market and sales. Suppose people expect 1 year investing these days, when reality is. Takes much longer, on a gradual basis. 1 month spikes create over expectancy, and then you end up where you began, 50% down. Always better to research an investment thoroughly before entering into it. Hence what im doing",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344463+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251314-Marty130-19335983",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876066",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Presumably carried out to keep them from being expelled from the market..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344481+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251251-Silverbl--8590864",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876510",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "ADS split on OTC has now gone through - 1 UK \u00a3 share is now equivalent to 25 US $ OTC shares. Market reaction to this alongside the warnings in the AGM statement predictable. Short interest has increased significantly - this could get very messy, very quickly. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-06T23:35:14.344499+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251512-Silverbl-40812158",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "We will find out next month how much progress all the partnerships announcements are making on testing revenue. My fear is they will be nowhere near their H1 target. There are lots of institutional investors here besides UBS - they presumably are taking the gamble that eventually there will be a pick up in sales. No point in having an FDA approved product with the agreed reimbursement if there is no commercial market to sell into - and that has been the case so far. It has already been clarified by the company that CE is not of any importance to them in the short term - with a limited sales force the US market needs to show progress or it will start to become very difficult to secure additional funds imo. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-02-06T23:35:14.344517+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261042-fre1-34322974",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382464",
        "source": "LSE_CHAT",
        "data": {
          "author": "fre1",
          "content": "They are starting to build up scale (thanks for link Marty130) and their collaboration with Tempus should be gaining momentum so news next month should help.",
          "sentiment": 0.0,
          "engagement": "1,886",
          "price_at_post": "6.25",
          "thread_title": "RE: BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-02-06T23:35:14.344535+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261000-Marty130--6812833",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382903",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Need to pull their finger out ASAP..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-02-06T23:35:14.344552+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261743-Marty130-75863488",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383336",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Agreed",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-06T23:35:14.344576+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260551-Cevodniy--5542785",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, that's great news, but nothing absolutely nothing affects the share price.",
          "sentiment": 0.0,
          "engagement": "3,066",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-06T23:35:14.344594+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261120-Marty130-71377711",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384173",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://www.proactiveinvestors.com/companies/news/1085472/renalytix-expands-us-footprint-with-three-new-clinical-partnerships-1085472.html",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-06T23:35:14.344612+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261948-bluesy1-74013475",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384585",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "Like what ? Minor move upwards. Lets all get excited. Tedious ...",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.25",
          "thread_title": "RE: Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-02-06T23:35:14.344631+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261743-Mikemine--1416846",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384993",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Looks like somebody knows something maybe?",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "6.25",
          "thread_title": "Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-02-06T23:35:14.344649+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262227-Marty130--5090141",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Disagree.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-02-06T23:35:14.344667+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262055-bluesy1--1519480",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385830",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "This has all the hallmarks of a BOD lifestyle  funding company. FDA approval but would rather die in their own DNA.  Get out before its too late",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.15",
          "thread_title": "Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-02-06T23:35:14.344685+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261947-Silverbl--8519161",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386254",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Next news is likely to see share price hit all time lows - enough negative hints have been dropped recently about current trading. Statements such as \"Commercial outcomes.....remain difficult to predict\"; \"Each practice currently represents modest initial testing volumes\"; \"Engaging with large healthcare systems presents inherent challenges\" - do not fill me with short term confidence in the $8.4m 2026 revenue target - we are about to finish month 7 out of 12 in that regard. And if that revenue target is not met where does that leave the cash position? Does make you wonder what exactly the company's 11 full time sales reps are doing - door knocking physicians will not cut it here. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-02-06T23:35:14.344704+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261836-Marty130--4007970",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386660",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Looks like the SP is heading down, in order to boost volumes.. Let's hope the BoD release some juicy news to push it back up on healthy volumes.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-02-06T23:35:14.344722+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261633-Investor-43216130",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387067",
        "source": "LSE_CHAT",
        "data": {
          "author": "Investor2025",
          "content": "Not yet..",
          "sentiment": 0.0,
          "engagement": "7",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-02-06T23:35:14.344740+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261537-Hawker--3811833",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387485",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Hope springs eternal...  Ho hum...",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-06T23:35:14.344758+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261535-Marty130--6698606",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Exactly.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-06T23:35:14.344776+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261401-tweedly--8585313",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388311",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Understandably the RNS didn't set the market alight. Waiting for hard numbers I think.",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-06T23:35:14.344794+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262252-MIKODX--1470324",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388725",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Todays RNS means we are now seeing concrete progress on commercial rollout.This shows that Renalytix is moving towards actual deployment with multiple provider groups. Getting kidneyintelX.dkd into established clinics is a big step. It means providers see enough value in the test to integrate it into their day-to-day systems. The RNS reiterates that Renalytix and Tempus are working closely to integrate kidneyintelX.dkd into larger healthcare sytems that are already on Tempus's platform. This is very significant because a) smaller clinics alone won't generate high volumes and b) larger sytems (via Tempus) have broader patient populations and infrastucture. This will accelerate adoption more rapidly once it starts rolling through those network. Everything is starting to fall into place, the company is really now starting to see some real progression. Great RNS.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-06T23:35:14.344812+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262236-MIKODX--3862792",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389141",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "The company says it expects to provide a fuller trading update in February. By fuller that means they expect improvement in sales. The company is making all the right moves thus far.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-06T23:35:14.344830+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261111-Marty130-92727651",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Enalytix plc (RENX.LN)*, Futura Medical plc (FUM.LN) Non-Independent Research; Marketing & Sales Commentary - MiFID II exempt information \u2013 see disclaimer below. Company Update: 12 January 2026 Renalytix plc (LSE: RENX, OTCQB: RNLXY)*: Three kidneyintelX.dkd clinical integration \u2013 update on Tempus collaboration Market Capitalisation: \u00a326.6m; Share Price: 6.08p \u2022 During the last quarter of 2025, Renalytix completed three additional kidney specialist healthcare provider clinical integrations in the US, in New York, Florida and Tennessee.  \u2022 Additional integrations are expected in early 2026. \u2022 Tempus collaboration is progressing well with teams from both Tempus and Renalytix working closely to target Tempus\u2019 customers with a large diabetes and kidney disease patients.  Renalytix reports that it added three new US clinical integrations in late 2025, bringing its FDAapproved kidneyintelX.dkd test into established kidney care practices in New York, Florida, and Tennessee. Testing has begun at all sites, and although initial volumes are expected to be small, the company anticipates usage to build as clinicians become familiar with the workflow. More integrations are planned for early 2026.  Renalytix states that it is working intensively with Tempus to integrate its kidney risk testing into major US health systems through Tempus' integrated electronic health records (EHR). Since the partnership began in September 2025, teams from both companies have been coordinating to target large provider networks with significant diabetes and CKD populations, aiming to streamline test ordering and strengthen data collection. The collaboration is positioned as a foundation for expanding into new clinical and geographic markets as the platform matures.  From a strategic standpoint, this fits neatly with Renalytix\u2019s strategy to have kidneyintelX.dkd test integrates into healthcare providers\u2019 EHRs, which allows quick and seamless ordering. shift toward disciplined, system-level integrations rather than chasing individual clinics. The Tempus partnership could prove far more meaningful if it unlocks access to large, data-rich health systems where adoption can scale. SP Angel acts as Nomad and Broker to the Renalytix Futura Medical plc (AIM: FUM): Positive results from WSD4000 early feasibility study Market Capitalisation: \u00a39.1m; Share Price: 1.58p \u2022 Statistically significant improvement achieved in female sexual function with WSD4000 in a study enrolling 12 women suffering from some degree of sexual dysfunction. \u2022 Results give the Company confidence to proceed to the next steps of designing a Phase III placebo-controlled trial, with results expected mid-2026 Futura reports that its WSD4000 early feasibility study in 12 women showed a clear and statistically significant improvement in sexual function, with gains on the Female Sexual Function Index (FSFI) scale well above the accepted threshold for clinical relevance. Benefits were seen across arousal",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D3CE797F-7C15-4738-8269-38EDD6CB8090"
        },
        "ingested_at": "2026-02-06T23:35:14.344848+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260838-emblaze1-91422131",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390005",
        "source": "LSE_CHAT",
        "data": {
          "author": "emblaze1",
          "content": "LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use. The integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix. These integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations. Renalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources. Tempus AI Collaboration Renalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in September 2025, to target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients. The collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time. Investor Engagement James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. The 44th annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad rang",
          "sentiment": 0.0,
          "engagement": "917",
          "price_at_post": "6.25",
          "thread_title": "RE:Results soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=3DEB0D63-492C-4E6A-AD12-B94C142E4A0B"
        },
        "ingested_at": "2026-02-06T23:35:14.344866+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260823-Marty130-76626898",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390423",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Results deadline missed then..  As wws due before 31st of January..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-06T23:35:14.344884+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260809-johndean--8382932",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390835",
        "source": "LSE_CHAT",
        "data": {
          "author": "johndean",
          "content": "Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the company expects to provide further updates on progress and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "798",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-06T23:35:14.344902+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260807-Marty130-30871438",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391262",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Where? I haven't received one.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-06T23:35:14.344920+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260712-morningt-83142064",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391677",
        "source": "LSE_CHAT",
        "data": {
          "author": "mornington-oz",
          "content": "RNS  OUT",
          "sentiment": 0.0,
          "engagement": "23,507",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-06T23:35:14.344938+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260710-uxm484-64975725",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392089",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. Hopefully some new investors will jump on this month following the J.P Morgan event in the US, progress being made and undervalued at present.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-06T23:35:14.344956+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261801-Marty130-39895349",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Upcoming Financial & Corporate Events H1 2026 Trading Update: The company is scheduled to provide a trading update for the six-month period ending December 31, 2025, by the end of January 2026.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-06T23:35:14.344975+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261345-MIKODX-23777033",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.763333",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Stuartrm - Just to confirm, the American depositories have already been downgraded to the OTCQB market, so the minimum $1 doesn\u2019t apply.",
          "sentiment": 0.0,
          "engagement": "3,994",
          "price_at_post": "5.80",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T00:05:18.914775+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261108-Marty130--5303492",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.764111",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Ignore previous post LOB.",
          "sentiment": 0.0,
          "engagement": "1,324",
          "price_at_post": "5.80",
          "thread_title": "RE: News from mover the pond.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=4BC7AB33-708C-4ECC-B3BB-CDC7404BE190"
        },
        "ingested_at": "2026-02-10T00:05:18.914813+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261105-Marty130-38192394",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.766252",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2025 RENX ENTERPRISES CORP. (Exact Name of Registrant as Specified in its Charter) Delaware\t \t001-41581\t \t87-1375590 (State or Other Jurisdiction of Incorporation)\t \t(Commission File Number)\t \t(I.R.S. Employer Identification Number) 100 Biscayne Blvd., #1201 Miami, FL 33132 (Address of Principal Executive Offices, Zip Code) Registrant\u2019s telephone number, including area code: 646-240-4235 (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: \u2610\tWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) \u2610\tSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) \u2610\tPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) \u2610\tPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class\t \tTrading Symbol(s)\t \tName of Each Exchange on Which Registered Common Stock, par value $0.001\t \tRENX\t \tThe Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (\u00a7230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (\u00a7240.12b-2 of this chapter). Emerging growth company \u2612 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \u2610 Item 1.01. Entry Into a Material Definitive Agreement. Effective December 30, 2025, Resource Group LLC (\u201cResource Group\u201d), a wholly owned subsidiary of RenX Enterprises Corp. (the \u201cCompany\u201d), entered into a Negotiable Promissory Note and Security Agreement in the principal amount of $1,507,658 (the \u201cFirst Note\u201d) and Negotiable Promissory Note and Security Agreement in the principal amount of $1,047,528 (the \u201cSecond Note\u201d; and together with the First Note, the \u201cNotes\u201d) with Commercial Credit Group (the \u201cLender\u201d) to finance the purchase of a Komptech Crambo shredder and a Diamond Z horizontal grinder for approximately $2.54 million with a 30% down payment of approximately $700,000 that had previously been deployed under a rental arrangement. The First Note is payable as follows: the first installment of $265,266 was due on 12/30/2025 followed by 48 monthly installments of $25,879. The Second Note is payable as follows: the firs",
          "sentiment": 0.0,
          "engagement": "1,324",
          "price_at_post": "5.80",
          "thread_title": "News from mover the pond.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=4BC7AB33-708C-4ECC-B3BB-CDC7404BE190"
        },
        "ingested_at": "2026-02-10T00:05:18.914850+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260758-Marty130-41344902",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.767052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Long overdue..",
          "sentiment": 0.0,
          "engagement": "1,324",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T00:05:18.914886+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260001-MIKODX--5616967",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.767767",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "An update should drop anytime now. Hopefully  the news will be good, with more tests being churned out especiallwith the addition of the three new locations in USA.  Coupled with that we should have enough funds to see us through until at least the end of the year. I would say we will see steady progress being made and the company in a more  healthy condition financiallly. Looking forward to good news that will hopefully get the SP moving in the right direction.",
          "sentiment": 0.0,
          "engagement": "3,994",
          "price_at_post": "5.80",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T00:05:18.914907+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261219-Bushbat--7857444",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.768670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bushbat",
          "content": "The overall consensus recommendation for Renalytix is Strong Buy",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "5.80",
          "thread_title": "From Stockopedia",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=9646FDEC-1EFA-48E9-A3AF-808CB92E83EB"
        },
        "ingested_at": "2026-02-10T00:05:18.914925+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261126-uxm484--3941512",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.747673",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Bad news already priced in by the looks of it given this has dropped from 10p but in reality the update is likely going to be positive. Should be hitting further deal news soon, Tempus update, CE Mark soon and operational update. Expecting a move back to 10p in the next 2 months so a good buy at these prices. Appears to be decent time to average down or buy in.",
          "sentiment": 0.5,
          "engagement": "1,012",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T00:05:18.914945+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261039-Marty130--6484559",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.748119",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "The Company looks forward to updating investors on progress, corporate development and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "1,318",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T00:05:18.914963+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261548-Silverbl-79243841",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.748540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Renx no longer post quarterly updates. Looks like the imminent trading update is going to hit hard. All time share price low today. Market bracing itself for bad news - history just repeating itself here unfortunately. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "5.40",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T00:05:18.914982+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261500-Stuartrm--7796809",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.748951",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stuartrm",
          "content": "Please ignore the reference to Nasdaq compliance in my last post. The information, which I got from AI, muddled Renalytix (the first two dates) with a different Renx. Sorry about that. I only realised once I started to delve further.",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "5.40",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T00:05:18.915000+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261452-Stuartrm-28876649",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.749529",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stuartrm",
          "content": "Upcoming Financial Calendar Trading Update: Expected February 2026. Quarterly Earnings Release: Scheduled for 26 March 2026 (covering the period ending December 2025). Nasdaq Compliance Deadline: 27 July 2026. Renalytix has until this date to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "5.40",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T00:05:18.915017+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261330-MIKODX-61388041",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.750132",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Need some good news and soon, must be some type of update on how things are progressing with Tempus. Any good news on that front should get the SP up a few ticks.",
          "sentiment": 0.0,
          "engagement": "3,987",
          "price_at_post": "5.25",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-10T00:05:18.915035+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261244-warrior1--9221850",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.750545",
        "source": "LSE_CHAT",
        "data": {
          "author": "warrior1066",
          "content": "Not overdue, in last RNS they said February",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T00:05:18.915053+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261110-handybro--6652620",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.750950",
        "source": "LSE_CHAT",
        "data": {
          "author": "handybrownone",
          "content": "Agree - was just checking 27 Jan last year. Generally not a good sign, Suspect they're waiting for something good to day to help us digest some bad news",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.75",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T00:05:18.915071+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261708-Marty130-29394328",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.751369",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Trading update is overdue..",
          "sentiment": 0.0,
          "engagement": "1,318",
          "price_at_post": "5.75",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T00:05:18.915090+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261515-Dustysla-46761685",
        "event_type": "social_post",
        "date": "2026-01-30T23:32:44.764676",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Marty Great news, these outcomes wont be felt or showcased in SP appreciation till you start seeing the sales,  and financials from this growing customer base Cev. But its 100% positive reinforcement that its growing its clientele one state at a time,  and in this case 3 more states. A continous trend of the whole US market, state by state is the goal here. Stick with it Cev",
          "sentiment": 0.0,
          "engagement": "13,821",
          "price_at_post": "5.90",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-10T00:05:18.915136+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261516-Silverbl--4619584",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.833253",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Sounds a difficult prognosis to live with oldbut. Renx and its sister company verici were both spun out of ekf diagnostics about 5 years ago based on two unique biomarkers relating to kidney disease - renx is all about early warning and intervention through patient testing and verici focuses on pre and post kidney transplant risk monitoring (rejection).  Both company's have excellent technology and a key relationship/partnership  with Mount Sinai in New York who provide access to an extensive patient database which assists an AI driven approach to improve patient outcomes. The key issue is convincing clinicians at scale that the tests should be deployed (despite having all required regulatory approvals in place and agreed Medicare reimbursement secured). Market penetration remains slow; cash burn remains high and the market remains sceptical on the company's ability to commercialise their products - hence the low valuation here and at verici. Corporate updates expected in coming weeks. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-10T00:05:18.915155+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20262136-Marty130-56546256",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.834056",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Sorry..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-10T00:05:18.915173+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261534-oldbutno--4303206",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.834852",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "...because I have Grade 4 Kidney disease. So it won't help me but caught my interest.",
          "sentiment": 0.5,
          "engagement": "3,324",
          "price_at_post": "6.25",
          "thread_title": "Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-10T00:05:18.915192+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261616-Marty130--5369945",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.138786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Purchase at 7%.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-02-10T00:05:18.915210+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261603-Pixels--6807114",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.139331",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pixels",
          "content": "How can you tell, that document shows as \"acquisition / disposal\" - is it definitely acquisition? Got to admit I struggle with reading financial type documents, I'm just a media monkey",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-02-10T00:05:18.915228+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261512-Marty130--4348404",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.139866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "They're back in again..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-02-10T00:05:18.915246+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261527-Marty130-31280060",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.140363",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "A deal may arise next week after the conference in San Francisco.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-10T00:05:18.915264+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261412-Veteran1-89224471",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.140866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Veteran10",
          "content": "Bit of movement but low volume. If volumes increases, could be a momentum buy opportunity.",
          "sentiment": 0.0,
          "engagement": "4,077",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-10T00:05:18.915282+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261935-Marty130-39041183",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.141384",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix is expected to participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, a premier global healthcare investment symposium where companies present and connect with investors, industry leaders, and innovators, focusing on new technologies like AI in healthcare, kidney disease, and strategic partnerships. While Renalytix isn't explicitly named in the top results, they are a kidney-focused company likely to attend this major event, which runs concurrently with the Biotech Showcase.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-10T00:05:18.915300+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261839-Silverbl--5840196",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.141885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "...well if the prognosis is kidney related oldbut i think we might be able to help out......lol. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-10T00:05:18.915318+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261837-Silverbl--6589996",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.142401",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "New deals mean nothing without a credible commercial plan which has at its heart the means to create and service product demand in a timeous and profitable manner. Nothing to date has achieved that in any meaningful volume. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-02-10T00:05:18.915336+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261801-oldbutno-81752258",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.142900",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "....come to those that wait.....Oh, and DEATH!",
          "sentiment": 0.0,
          "engagement": "3,324",
          "price_at_post": "5.90",
          "thread_title": "GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-10T00:05:18.915354+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261649-Marty130-14549744",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.143434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "To turn this around as the share price will continue to new lows..   Wake up BoD, pull your fingers out..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-02-10T00:05:18.915372+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20262041-Marty130-15848233",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.144017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix said in an update on Tuesday that it was making progress in expanding the use of KidneyIntelX.dkd across the United States, reporting growing testing volumes, new state coverage and advancing commercial partnerships ahead of its annual general meeting in London. The AIM-traded company's prognostic blood test, the only FDA-approved and Medicare-reimbursed test for early-stage chronic kidney disease risk assessment, was now generating revenue from four core states - Florida, Texas, New York and, most recently, Arizona. Executive chairman Julian Baines said the first orders in Arizona included tests from one of the largest nephrology practices in the US. He emphasised that, while direct sales growth is encouraging, the company's primary strategy is to scale test adoption through major business development agreements with large healthcare systems. Renalytix signed a definitive agreement in September with Tempus AI, the Nasdaq-listed diagnostics and AI group, which Baines said has \"an established network of healthcare institutions already utilising its precision medicine solutions.\" He added that early engagement with Tempus and MVP Health Care reinforced the company's belief that its partnership-led model would \"deliver long-term value for shareholders,\" despite lengthy implementation processes common across major US providers. Renalytix said it had also narrowed potential partners for its next electronic health record integration and was working with several large healthcare systems expected to generate \"meaningful testing volumes\" over time. The company said it was increasingly using data analytics to identify physicians managing high numbers of eligible patients, helping target commercial resources where uptake prospects are strongest. Renalytix added that it had started transitioning to a new laboratory facility, a move expected to expand testing capacity and reduce operating costs over the next five years. Baines said the company was now focused on converting ongoing discussions into contracted relationships, expanding EHR integrations and accelerating test volumes. While acknowledging that timing of commercial outcomes \"remains difficult to predict,\" he said the board was confident that the company's current initiatives \"position the company well for sustainable revenue growth, increased operating leverage, and long-term value creation for shareholders.\" Renalytix said it would provide a trading update for the six months to 31 December by the end of January.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "2026 outlook",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=30EC9492-CE10-4321-AED9-CF8B2D3F53AF"
        },
        "ingested_at": "2026-02-10T00:05:18.915390+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261342-Mikemine-40629997",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.144538",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "If Tempus gets going, the revenue will spike and so will the SP. Big companies like Tempus are notoriously slow to move but they've had since early September so H1 seems reasonable for them to get going. I urge anyone who has missed the RNS (15th Sept) about the collaboration agreement to read it and do a bit of research on Tempus. Apart from this ramp, I won't offer a prediction target but I do expect to multibag  from these levels. Good luck to everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-02-10T00:05:18.915408+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261121-Marty130-39134034",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.145043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "On receipt of the CE acceptance, which is expected h1, 18/22, on a takeover, 40/60.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-02-10T00:05:18.915425+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20260407-Cevodniy-89517134",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.145565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Ok fellow investors. Year end SP predictions. I'll start at 20p.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-02-10T00:05:18.915443+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20252147-Crannog1--2985613",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.146063",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crannog12",
          "content": "You are a ray of sunshine. I take it you are invested here?",
          "sentiment": 0.0,
          "engagement": "57",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T00:05:18.915461+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251345-Silverbl--3972291",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.146588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dreadful year for investors. Trading update in January could hammer confidence further if company fails to deliver revenue targets. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T00:05:18.915479+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20251632-MIKODX-21750541",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147014",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "It\u2019s not good watching the SP slowly slip down, but that\u2019s bound to happen with no positive news. The one consolation is the support at 5.70 is holding up well so far. Hopefully we can kick off the new year with some good news and hopefully get a good bounce from the support level all the way up past 10.",
          "sentiment": 0.0,
          "engagement": "3,977",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T00:05:18.915497+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251231-Marty130--5439877",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Hopefully we will have a better year in 2026, with more announcements of higher revenues and transformational new contracts signed. The BoD badly needs pay more attention to reverse the share price trend..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "New contracts",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8AD3616F-3B6B-486A-8B37-36DE630CD42F"
        },
        "ingested_at": "2026-02-10T00:05:18.915515+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251037-Marty130--3828276",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147873",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Cevo, And don't forget the CE mark will have a transformation affect.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T00:05:18.915533+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250828-Cevodniy-36451925",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.148323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "MIKODX on the 2nd January 2025, the SP was 10.75, yesterday it was 6p. I get your optimism via your post, but obviously institutions and wealthy investors don't agree. 10p to 6p is not exactly a successful year. I hope we don't experience another 66% next year.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T00:05:18.915550+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250037-MIKODX-47403126",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.148764",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "FY2025 was a key year for the company in establishing a solid pathway for testing adoption, life science services and strategic partnering. In July 2025, RENX announced an agreement with MVP Health Care, a U.S.-based insurer covering more than 700,000 patients. Beyond expanding physician and patient access, this agreement reinforces that Renalytix and kidneyIntelX.dkd are establishing a leadership position in chronic kidney disease management and gaining increasing recognition in the market. In September 2025, Renalytix signed an agreement with Tempus AI, Inc. (\u201cTempus\u201d), a clear leader in delivery of integrated advanced diagnostic testing and life science services in the United States. The collaboration with Tempus will enable RENX to accelerate introduction of kidneyintelX.dkd into large hospital systems and community healthcare practices across the U.S., significantly expanding distribution over the next five years. The relationship with Tempus AI has continued to develop positively, with ongoing progress in aligning commercial activities. The Balance Sheet was further improved with the conversion of an additional $4 million of convertible debt leaving outstanding long-term debt at \u00a33.1m as of October 2025. More than $1.3m in cash from backdated R&D claims and grant income, further strengthening the balance sheet. Administrative expenses decreased by more than 40% year-on-year, driven by headcount and operations optimization. RENX continue to strengthen there presence in three initial target states - Florida, Texas, and New York. In FY26, they expanded into Arizona their fourth target market which collectively represents approximately 20% of the total addressable kidneyintelX.dkd market. RENX is well positioned to deliver important and necessary change in chronic kidney disease management in the United States and globally.In the coming months and years sales will without doubt improve with the test being made more readily available in healthcare systems. Not been a bad year for the company, quite the opposite, it has been a very positive one. FY26 will see the partnerships coming to fruition with the test more widely available in the healthcare systems which will mean more sales for the company. Lots to look forward to in the coming year. I'll drink to that. Hope everyone has a merry xmas and the best of luck for the new year. With any luck we will have some good news from the parterships established, which will have a very positive affect on the SP. As we all know, this is a very volatile stock that can really take off on good news. Next year will be the year. GLA",
          "sentiment": 0.0,
          "engagement": "3,977",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T00:05:18.915568+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20252029-Cevodniy--4500023",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.149203",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, you are the only poster here generally and even you can't see anything positive,  except the possibility of a takeover I've just over 1.2 million at an average of 10p, I fo not expect to ever see profit.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T00:05:18.915586+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251332-Marty130-13426992",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.866496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Surely we'll get better results next year, if not a possible takeover.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T00:05:18.915605+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251144-Mikemine-37238723",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.866939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Merry Christmas everybody. Here's hoping for a more prosperous New year.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "5.90",
          "thread_title": "Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T00:05:18.915624+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251830-Marty130-35386548",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.867379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "U2..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-02-10T00:05:18.915642+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251756-tweedly--1031194",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.867802",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Right. These RNS' have been coming out for at least 6 months, no one makes sense of them so no point speculating. Merry Christmas folks",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-02-10T00:05:18.915660+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251644-Marty130-58505705",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.868233",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Down selling again.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-02-10T00:05:18.915680+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251241-Silverbl--8570678",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.868652",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "The jury is not only out Hawker....its leaving the courthouse! Its been another horror story in 2025 for the business which showed so much early promise. I have low expectations for the trading update in January - seems this is pretty common given the share price reaction. All time price low - makes the 9.5p raise a highlight from the management team - although the next raise could be very painful for shareholders if they cannot generate revenue and continue to burn cash. ATB to those who hold here - it continues to be a very difficult investment to justify. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915698+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20250931-Marty130--4937993",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "German Market is huge.. Once the CE goes through, plenty will sign up.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915716+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251427-Hawker--8550324",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Well said, SB. This is now just a waiting game, as the company has EVERYTHING they need to succeed in going to market; there are no more barriers. The only question, therefore, is whether they can sell the test into their focus regions and whether there is a market for it. So far, the jury is out. QED... Opinion:   Ho hum",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915734+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251146-JBCo--5323830",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869928",
        "source": "LSE_CHAT",
        "data": {
          "author": "JBCo",
          "content": "Hopefully can hold 6p",
          "sentiment": 0.0,
          "engagement": "4,545",
          "price_at_post": "6.25",
          "thread_title": "Big seller trying to get out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=253BEB68-92E2-41AA-91A1-E5998136B1CD"
        },
        "ingested_at": "2026-02-10T00:05:18.915752+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251751-Marty130-61173902",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.870350",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "CE marks always add value.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915771+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251623-cipro-51997229",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.870772",
        "source": "LSE_CHAT",
        "data": {
          "author": "cipro",
          "content": "The trend is slowly going down with this stock did hv good potential And I hope this still has some upside however the momentum is stuttering atm Hope to get positive news in January to get the trend back up good luck all",
          "sentiment": 0.0,
          "engagement": "2,148",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-02-10T00:05:18.915789+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251621-Dustysla--8244423",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.871231",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "I think your Gripe is the time spent here, and against the companies management. I get that, they are not the easiest investments as they are Crooks and useless. So I try to look at 3 things here at this juncture Revenue/Debt/Sales And Future Projected Revenue/Debt/Sales And how they will maintain a healthy cash burn in the intermediate.",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915808+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251616-Dustysla-40304573",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.871686",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m OTCQB listing only says $17.98 million 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). Is this financials or Sales? Im talking about Provider to Patient sales 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). This is how it explained, a Google AI version. Id get a more accurate view, but im not not interested in doing so. 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. Ok well nothing I found in 30 mins showed they had FDA approval so the assumption is their flogging nothing. But if im wrong, and it started somewhere in 2024 fine. Small details. But Debt, well yes as you said checks out. But you said NO DEBT, quite abruptly so I got a lot closer than you in 30 minutes that you seemingly in years",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915827+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251606-Silverbl-41088563",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.872134",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "OK Dustyslay - I'll bite - here we go - my 'whining' response to your 'research' based points where real world numbers are available. 1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. The point on debt looks accurate. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915845+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251540-Dustysla-17090867",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.872558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade I understand all what you are saying, 2024 wouldn't have been a great year as they hadn't gone to market and thats the Pharmsma industry for you, why I dont hold any current because I feel they are run by wealthy individuals that are focused on personal wealth before Health and will fill their boots prior to any achievements and shareholders take on the dilution and the hard hold. But im kinda leaning towards this, the more i look into it because its all about timing really.  If MVP goes solid, and your market expands 2026, you should improve dramatically As for the CE mark, achieving it your correct it wont move it, but its what you do once achieved in the European markets",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915863+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251529-Dustysla--5232471",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Ok, i know where i found the Sales and it took me a long time so here, more AI junk but the growth is there. Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months. Recent Revenue: For the first half of the fiscal year 2025 (H1 FY25), Renalytix reported revenues of $1.3 million. This demonstrated continued quarterly sales growth into Q3 FY25. Quarterly Growth: The company is on track to meet or exceed its target of 20% average quarter-over-quarter revenue growth. Billable Tests: For the first time, over 1,000 billable tests were processed in Q3 2025, supported by the onboarding of a large primary care network in New York and improved direct-to-physician sales. Medicare Coverage: The company has achieved FDA approval and Medicare coverage determination for its kidneyintelX.dkd test, with an established price of $950 per test. Partnerships: New collaborations, notably with Tempus AI and MVP Health Care, are expected to positively impact revenue and expand the test's reach among the 15 million people in the US with type 2 diabetes and chronic kidney disease. Future Guidance: Renalytix has provided forward revenue guidance of $3.2 million in FY25, $8.5 million in FY26, and $17.5 million in FY27. Despite recent sales growth, the company has faced financial challenges, including a decline in total annual revenue in FY24 compared to FY23, high operating losses, and a reliance on external financing to sustain operations. The company has focused on cost reductions and strategic partnerships to improve its financial position. 1000 \u00d7 $950 plus Medicaid Reimbursement in its first year. Now a new area in North America with MVP, 700 000 patients on books. You see where its going? Have some faith. And perhaps more research than whining on a forum",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915882+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251506-Dustysla--3989102",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873471",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Im not every fond of AI, or even Google AI. Never done ChatGBT etc so a lot is from memory on researching, the sales i will locate the information at some point as im a tad busy but Debt is easy to find, you would be hard pressed to find any company not still refurbishing debt after they have gone to market. The key is to see a constant, and consistent reduction per half year reports. Here is the AI, against my normal MO of real research: As of late 2025, Renalytix has reported approximately $8.21 million in total debt, a decrease from previous years. The company has actively worked to improve its balance sheet through debt restructuring and equity conversions. Key details regarding Renalytix's debt: Total Debt: The most recent figures from financial reports indicate total debt is approximately $8.21 million. Recent Reduction: Renalytix has focused on reducing its debt through strategic financial maneuvers. In October 2025, the company announced a $4 million balance sheet improvement by converting approximately $4 million of senior convertible bonds into equity, saving up to $1.4 million in future accrued interest. Debt Restructuring: A significant portion of the remaining debt is a new unsecured convertible bond issued in November 2024 (and later partially converted in Oct 2025), with a maturity date of July 2029. This bond has flexible interest payment options (cash or rolled into the principal) at the company's discretion. Historical Context: The company's total debt peaked in June 2022 at over $12 million and has generally trended downwards since then. Financial Position: The renegotiation of debts has helped the company move to a net current asset position, aiming to direct cash flows towards commercial and operational growth.",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915906+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251458-Dustysla-63179151",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Nasdaq has listing requirements that are difficult OTC is similar to AIM, there are 3 different markets OTCQB/OTCQX and OTC pink but we can dismiss that you are in one of the the first 2. OTC Premier is stringent but that isnt listed there. 0.01 is the minimum requirement SP And a M/Cap of 10 million minimum Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus. The split has gone quite well on early judgement,  and will help consolidate liquidity as lower the SP, the higher the percentage swings and more susceptible to traders profiting on movement. Ive seen worse splits, but they are predominantly done to secure liquidity and consolidate SP",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915924+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251446-Silverbl--8043781",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.874343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dustyslay - there are minimum bid price requirements in relation to US listing exchanges - this was one of the reasons for the new ADS split. Where did you note that sales have doubled each quarter? That is simply not the case.  You also mention debt - of which there is none. You are correct I did purchase at higher prices - but so did every single PI and II here. All have lost significant sums of money. We all saw the the medium term opportunity here - however the current management team are showing a complete lack of momentum in growing the business. Yes this is still a new company but investors continue to be fed nonsense with never ending partnerships which don't deliver; revenue predictions which don't deliver; cost cutting which doesn't materialise; pay and stock options for the team which are excessive; cash burn that fritters away funds like there was no tomorrow. My input is negative because I expect better. Yet I remain invested against my better judgement. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915943+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251434-Marty130--4056920",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.874751",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Just added hVIVO to my portfolio..  Looks undervalued, may come into it's own in 26..  A possible takeover target could see increasing share holder value.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-02-10T00:05:18.915962+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-Bushbat--9694795",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.875218",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bushbat",
          "content": "USB holding going up rather than the usual up 5% then down again",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "6.25",
          "thread_title": "USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-02-10T00:05:18.915981+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251352-Dustysla--3101439",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.875653",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Not necessarily,  the OTC doesnt have the Stringent Rules as Nasdaq surrounding Delisting. This isn't a non revenue company, Start up etc. And you shouldn't expelled wonders in entering markets in the first 12 months,  yet growth of sales has doubled each quarter. Im unsure why you see this as a bad long term investment Silverblade, I can only surmise you have bought higher and the decrease has weighed heavily on your input. Im yet to buy, as I imagined this route to profit, which takes time when reducing debt and growing in market and sales. Suppose people expect 1 year investing these days, when reality is. Takes much longer, on a gradual basis. 1 month spikes create over expectancy, and then you end up where you began, 50% down. Always better to research an investment thoroughly before entering into it. Hence what im doing",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.915999+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251314-Marty130--5848899",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876066",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Presumably carried out to keep them from being expelled from the market..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.916018+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251251-Silverbl-34841694",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876510",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "ADS split on OTC has now gone through - 1 UK \u00a3 share is now equivalent to 25 US $ OTC shares. Market reaction to this alongside the warnings in the AGM statement predictable. Short interest has increased significantly - this could get very messy, very quickly. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T00:05:18.916036+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251512-Silverbl--6477658",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "We will find out next month how much progress all the partnerships announcements are making on testing revenue. My fear is they will be nowhere near their H1 target. There are lots of institutional investors here besides UBS - they presumably are taking the gamble that eventually there will be a pick up in sales. No point in having an FDA approved product with the agreed reimbursement if there is no commercial market to sell into - and that has been the case so far. It has already been clarified by the company that CE is not of any importance to them in the short term - with a limited sales force the US market needs to show progress or it will start to become very difficult to secure additional funds imo. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-02-10T00:05:18.916054+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261042-fre1--5015227",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382464",
        "source": "LSE_CHAT",
        "data": {
          "author": "fre1",
          "content": "They are starting to build up scale (thanks for link Marty130) and their collaboration with Tempus should be gaining momentum so news next month should help.",
          "sentiment": 0.0,
          "engagement": "1,886",
          "price_at_post": "6.25",
          "thread_title": "RE: BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-02-10T00:05:18.916072+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261000-Marty130-40718141",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382903",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Need to pull their finger out ASAP..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-02-10T00:05:18.916091+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261743-Marty130--7993955",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383336",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Agreed",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-10T00:05:18.916126+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260551-Cevodniy--1317467",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, that's great news, but nothing absolutely nothing affects the share price.",
          "sentiment": 0.0,
          "engagement": "3,066",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-10T00:05:18.916145+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261120-Marty130--7053799",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384173",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://www.proactiveinvestors.com/companies/news/1085472/renalytix-expands-us-footprint-with-three-new-clinical-partnerships-1085472.html",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-10T00:05:18.916164+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261948-bluesy1-55050451",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384585",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "Like what ? Minor move upwards. Lets all get excited. Tedious ...",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.25",
          "thread_title": "RE: Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-02-10T00:05:18.916182+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261743-Mikemine--7679626",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384993",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Looks like somebody knows something maybe?",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "6.25",
          "thread_title": "Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-02-10T00:05:18.916201+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262227-Marty130--5005204",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Disagree.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-02-10T00:05:18.916219+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262055-bluesy1--8858319",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385830",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "This has all the hallmarks of a BOD lifestyle  funding company. FDA approval but would rather die in their own DNA.  Get out before its too late",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.15",
          "thread_title": "Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-02-10T00:05:18.916237+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261947-Silverbl--4867643",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386254",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Next news is likely to see share price hit all time lows - enough negative hints have been dropped recently about current trading. Statements such as \"Commercial outcomes.....remain difficult to predict\"; \"Each practice currently represents modest initial testing volumes\"; \"Engaging with large healthcare systems presents inherent challenges\" - do not fill me with short term confidence in the $8.4m 2026 revenue target - we are about to finish month 7 out of 12 in that regard. And if that revenue target is not met where does that leave the cash position? Does make you wonder what exactly the company's 11 full time sales reps are doing - door knocking physicians will not cut it here. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-02-10T00:05:18.916255+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261836-Marty130--7230292",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386660",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Looks like the SP is heading down, in order to boost volumes.. Let's hope the BoD release some juicy news to push it back up on healthy volumes.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-02-10T00:05:18.916273+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261633-Investor--7882149",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387067",
        "source": "LSE_CHAT",
        "data": {
          "author": "Investor2025",
          "content": "Not yet..",
          "sentiment": 0.0,
          "engagement": "7",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-02-10T00:05:18.916291+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261537-Hawker-33521909",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387485",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Hope springs eternal...  Ho hum...",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-10T00:05:18.916309+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261535-Marty130--3969775",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Exactly.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-10T00:05:18.916328+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261401-tweedly-68202312",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388311",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Understandably the RNS didn't set the market alight. Waiting for hard numbers I think.",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-10T00:05:18.916346+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262252-MIKODX-30811286",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388725",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Todays RNS means we are now seeing concrete progress on commercial rollout.This shows that Renalytix is moving towards actual deployment with multiple provider groups. Getting kidneyintelX.dkd into established clinics is a big step. It means providers see enough value in the test to integrate it into their day-to-day systems. The RNS reiterates that Renalytix and Tempus are working closely to integrate kidneyintelX.dkd into larger healthcare sytems that are already on Tempus's platform. This is very significant because a) smaller clinics alone won't generate high volumes and b) larger sytems (via Tempus) have broader patient populations and infrastucture. This will accelerate adoption more rapidly once it starts rolling through those network. Everything is starting to fall into place, the company is really now starting to see some real progression. Great RNS.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-10T00:05:18.916364+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262236-MIKODX-77463264",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389141",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "The company says it expects to provide a fuller trading update in February. By fuller that means they expect improvement in sales. The company is making all the right moves thus far.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T00:05:18.916382+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261111-Marty130--8919554",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Enalytix plc (RENX.LN)*, Futura Medical plc (FUM.LN) Non-Independent Research; Marketing & Sales Commentary - MiFID II exempt information \u2013 see disclaimer below. Company Update: 12 January 2026 Renalytix plc (LSE: RENX, OTCQB: RNLXY)*: Three kidneyintelX.dkd clinical integration \u2013 update on Tempus collaboration Market Capitalisation: \u00a326.6m; Share Price: 6.08p \u2022 During the last quarter of 2025, Renalytix completed three additional kidney specialist healthcare provider clinical integrations in the US, in New York, Florida and Tennessee.  \u2022 Additional integrations are expected in early 2026. \u2022 Tempus collaboration is progressing well with teams from both Tempus and Renalytix working closely to target Tempus\u2019 customers with a large diabetes and kidney disease patients.  Renalytix reports that it added three new US clinical integrations in late 2025, bringing its FDAapproved kidneyintelX.dkd test into established kidney care practices in New York, Florida, and Tennessee. Testing has begun at all sites, and although initial volumes are expected to be small, the company anticipates usage to build as clinicians become familiar with the workflow. More integrations are planned for early 2026.  Renalytix states that it is working intensively with Tempus to integrate its kidney risk testing into major US health systems through Tempus' integrated electronic health records (EHR). Since the partnership began in September 2025, teams from both companies have been coordinating to target large provider networks with significant diabetes and CKD populations, aiming to streamline test ordering and strengthen data collection. The collaboration is positioned as a foundation for expanding into new clinical and geographic markets as the platform matures.  From a strategic standpoint, this fits neatly with Renalytix\u2019s strategy to have kidneyintelX.dkd test integrates into healthcare providers\u2019 EHRs, which allows quick and seamless ordering. shift toward disciplined, system-level integrations rather than chasing individual clinics. The Tempus partnership could prove far more meaningful if it unlocks access to large, data-rich health systems where adoption can scale. SP Angel acts as Nomad and Broker to the Renalytix Futura Medical plc (AIM: FUM): Positive results from WSD4000 early feasibility study Market Capitalisation: \u00a39.1m; Share Price: 1.58p \u2022 Statistically significant improvement achieved in female sexual function with WSD4000 in a study enrolling 12 women suffering from some degree of sexual dysfunction. \u2022 Results give the Company confidence to proceed to the next steps of designing a Phase III placebo-controlled trial, with results expected mid-2026 Futura reports that its WSD4000 early feasibility study in 12 women showed a clear and statistically significant improvement in sexual function, with gains on the Female Sexual Function Index (FSFI) scale well above the accepted threshold for clinical relevance. Benefits were seen across arousal",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D3CE797F-7C15-4738-8269-38EDD6CB8090"
        },
        "ingested_at": "2026-02-10T00:05:18.916400+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260838-emblaze1-41008373",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390005",
        "source": "LSE_CHAT",
        "data": {
          "author": "emblaze1",
          "content": "LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use. The integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix. These integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations. Renalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources. Tempus AI Collaboration Renalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in September 2025, to target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients. The collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time. Investor Engagement James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. The 44th annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad rang",
          "sentiment": 0.0,
          "engagement": "917",
          "price_at_post": "6.25",
          "thread_title": "RE:Results soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=3DEB0D63-492C-4E6A-AD12-B94C142E4A0B"
        },
        "ingested_at": "2026-02-10T00:05:18.916418+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260823-Marty130-68265651",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390423",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Results deadline missed then..  As wws due before 31st of January..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T00:05:18.916437+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260809-johndean-54112938",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390835",
        "source": "LSE_CHAT",
        "data": {
          "author": "johndean",
          "content": "Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the company expects to provide further updates on progress and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "798",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T00:05:18.916455+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260807-Marty130-38837099",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391262",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Where? I haven't received one.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T00:05:18.916474+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260712-morningt-36520324",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391677",
        "source": "LSE_CHAT",
        "data": {
          "author": "mornington-oz",
          "content": "RNS  OUT",
          "sentiment": 0.0,
          "engagement": "23,507",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T00:05:18.916492+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260710-uxm484-63940538",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392089",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. Hopefully some new investors will jump on this month following the J.P Morgan event in the US, progress being made and undervalued at present.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T00:05:18.916510+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261801-Marty130--2938835",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Upcoming Financial & Corporate Events H1 2026 Trading Update: The company is scheduled to provide a trading update for the six-month period ending December 31, 2025, by the end of January 2026.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T00:05:18.916528+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261345-MIKODX--3412603",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.763333",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Stuartrm - Just to confirm, the American depositories have already been downgraded to the OTCQB market, so the minimum $1 doesn\u2019t apply.",
          "sentiment": 0.0,
          "engagement": "3,994",
          "price_at_post": "5.80",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T23:28:50.911671+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261108-Marty130--5400041",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.764111",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Ignore previous post LOB.",
          "sentiment": 0.0,
          "engagement": "1,324",
          "price_at_post": "5.80",
          "thread_title": "RE: News from mover the pond.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=4BC7AB33-708C-4ECC-B3BB-CDC7404BE190"
        },
        "ingested_at": "2026-02-10T23:28:50.911699+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261105-Marty130--6909256",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.766252",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2025 RENX ENTERPRISES CORP. (Exact Name of Registrant as Specified in its Charter) Delaware\t \t001-41581\t \t87-1375590 (State or Other Jurisdiction of Incorporation)\t \t(Commission File Number)\t \t(I.R.S. Employer Identification Number) 100 Biscayne Blvd., #1201 Miami, FL 33132 (Address of Principal Executive Offices, Zip Code) Registrant\u2019s telephone number, including area code: 646-240-4235 (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: \u2610\tWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) \u2610\tSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) \u2610\tPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) \u2610\tPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class\t \tTrading Symbol(s)\t \tName of Each Exchange on Which Registered Common Stock, par value $0.001\t \tRENX\t \tThe Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (\u00a7230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (\u00a7240.12b-2 of this chapter). Emerging growth company \u2612 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \u2610 Item 1.01. Entry Into a Material Definitive Agreement. Effective December 30, 2025, Resource Group LLC (\u201cResource Group\u201d), a wholly owned subsidiary of RenX Enterprises Corp. (the \u201cCompany\u201d), entered into a Negotiable Promissory Note and Security Agreement in the principal amount of $1,507,658 (the \u201cFirst Note\u201d) and Negotiable Promissory Note and Security Agreement in the principal amount of $1,047,528 (the \u201cSecond Note\u201d; and together with the First Note, the \u201cNotes\u201d) with Commercial Credit Group (the \u201cLender\u201d) to finance the purchase of a Komptech Crambo shredder and a Diamond Z horizontal grinder for approximately $2.54 million with a 30% down payment of approximately $700,000 that had previously been deployed under a rental arrangement. The First Note is payable as follows: the first installment of $265,266 was due on 12/30/2025 followed by 48 monthly installments of $25,879. The Second Note is payable as follows: the firs",
          "sentiment": 0.0,
          "engagement": "1,324",
          "price_at_post": "5.80",
          "thread_title": "News from mover the pond.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=4BC7AB33-708C-4ECC-B3BB-CDC7404BE190"
        },
        "ingested_at": "2026-02-10T23:28:50.911719+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260758-Marty130--1172689",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.767052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Long overdue..",
          "sentiment": 0.0,
          "engagement": "1,324",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T23:28:50.911738+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260001-MIKODX--3687991",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.767767",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "An update should drop anytime now. Hopefully  the news will be good, with more tests being churned out especiallwith the addition of the three new locations in USA.  Coupled with that we should have enough funds to see us through until at least the end of the year. I would say we will see steady progress being made and the company in a more  healthy condition financiallly. Looking forward to good news that will hopefully get the SP moving in the right direction.",
          "sentiment": 0.0,
          "engagement": "3,994",
          "price_at_post": "5.80",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T23:28:50.911757+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261219-Bushbat--2612708",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.768670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bushbat",
          "content": "The overall consensus recommendation for Renalytix is Strong Buy",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "5.80",
          "thread_title": "From Stockopedia",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=9646FDEC-1EFA-48E9-A3AF-808CB92E83EB"
        },
        "ingested_at": "2026-02-10T23:28:50.911775+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261126-uxm484-21342953",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.747673",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Bad news already priced in by the looks of it given this has dropped from 10p but in reality the update is likely going to be positive. Should be hitting further deal news soon, Tempus update, CE Mark soon and operational update. Expecting a move back to 10p in the next 2 months so a good buy at these prices. Appears to be decent time to average down or buy in.",
          "sentiment": 0.5,
          "engagement": "1,012",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T23:28:50.911793+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261039-Marty130-11716995",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.748119",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "The Company looks forward to updating investors on progress, corporate development and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "1,318",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T23:28:50.911812+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261548-Silverbl-71962844",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.748540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Renx no longer post quarterly updates. Looks like the imminent trading update is going to hit hard. All time share price low today. Market bracing itself for bad news - history just repeating itself here unfortunately. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "5.40",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T23:28:50.911831+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261500-Stuartrm-17799988",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.748951",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stuartrm",
          "content": "Please ignore the reference to Nasdaq compliance in my last post. The information, which I got from AI, muddled Renalytix (the first two dates) with a different Renx. Sorry about that. I only realised once I started to delve further.",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "5.40",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T23:28:50.911849+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261452-Stuartrm--7238090",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.749529",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stuartrm",
          "content": "Upcoming Financial Calendar Trading Update: Expected February 2026. Quarterly Earnings Release: Scheduled for 26 March 2026 (covering the period ending December 2025). Nasdaq Compliance Deadline: 27 July 2026. Renalytix has until this date to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "5.40",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T23:28:50.911867+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261330-MIKODX--2928990",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.750132",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Need some good news and soon, must be some type of update on how things are progressing with Tempus. Any good news on that front should get the SP up a few ticks.",
          "sentiment": 0.0,
          "engagement": "3,987",
          "price_at_post": "5.25",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-10T23:28:50.911885+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261244-warrior1-15355897",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.750545",
        "source": "LSE_CHAT",
        "data": {
          "author": "warrior1066",
          "content": "Not overdue, in last RNS they said February",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T23:28:50.911903+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261110-handybro--3846859",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.750950",
        "source": "LSE_CHAT",
        "data": {
          "author": "handybrownone",
          "content": "Agree - was just checking 27 Jan last year. Generally not a good sign, Suspect they're waiting for something good to day to help us digest some bad news",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.75",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T23:28:50.911921+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261708-Marty130--1285137",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.751369",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Trading update is overdue..",
          "sentiment": 0.0,
          "engagement": "1,318",
          "price_at_post": "5.75",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-10T23:28:50.911939+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261515-Dustysla-20679990",
        "event_type": "social_post",
        "date": "2026-01-30T23:32:44.764676",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Marty Great news, these outcomes wont be felt or showcased in SP appreciation till you start seeing the sales,  and financials from this growing customer base Cev. But its 100% positive reinforcement that its growing its clientele one state at a time,  and in this case 3 more states. A continous trend of the whole US market, state by state is the goal here. Stick with it Cev",
          "sentiment": 0.0,
          "engagement": "13,821",
          "price_at_post": "5.90",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-10T23:28:50.911958+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261516-Silverbl--5076418",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.833253",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Sounds a difficult prognosis to live with oldbut. Renx and its sister company verici were both spun out of ekf diagnostics about 5 years ago based on two unique biomarkers relating to kidney disease - renx is all about early warning and intervention through patient testing and verici focuses on pre and post kidney transplant risk monitoring (rejection).  Both company's have excellent technology and a key relationship/partnership  with Mount Sinai in New York who provide access to an extensive patient database which assists an AI driven approach to improve patient outcomes. The key issue is convincing clinicians at scale that the tests should be deployed (despite having all required regulatory approvals in place and agreed Medicare reimbursement secured). Market penetration remains slow; cash burn remains high and the market remains sceptical on the company's ability to commercialise their products - hence the low valuation here and at verici. Corporate updates expected in coming weeks. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-10T23:28:50.911976+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20262136-Marty130-38567719",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.834056",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Sorry..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-10T23:28:50.911994+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261534-oldbutno-17849293",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.834852",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "...because I have Grade 4 Kidney disease. So it won't help me but caught my interest.",
          "sentiment": 0.5,
          "engagement": "3,324",
          "price_at_post": "6.25",
          "thread_title": "Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-10T23:28:50.912013+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261616-Marty130-46939909",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.138786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Purchase at 7%.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-02-10T23:28:50.912031+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261603-Pixels--1046693",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.139331",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pixels",
          "content": "How can you tell, that document shows as \"acquisition / disposal\" - is it definitely acquisition? Got to admit I struggle with reading financial type documents, I'm just a media monkey",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-02-10T23:28:50.912050+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261512-Marty130--4359344",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.139866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "They're back in again..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-02-10T23:28:50.912068+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261527-Marty130-26902326",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.140363",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "A deal may arise next week after the conference in San Francisco.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-10T23:28:50.912086+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261412-Veteran1--1118076",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.140866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Veteran10",
          "content": "Bit of movement but low volume. If volumes increases, could be a momentum buy opportunity.",
          "sentiment": 0.0,
          "engagement": "4,077",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-10T23:28:50.912124+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261935-Marty130--4228830",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.141384",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix is expected to participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, a premier global healthcare investment symposium where companies present and connect with investors, industry leaders, and innovators, focusing on new technologies like AI in healthcare, kidney disease, and strategic partnerships. While Renalytix isn't explicitly named in the top results, they are a kidney-focused company likely to attend this major event, which runs concurrently with the Biotech Showcase.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-10T23:28:50.912145+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261839-Silverbl--5226506",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.141885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "...well if the prognosis is kidney related oldbut i think we might be able to help out......lol. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-10T23:28:50.912163+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261837-Silverbl--9248313",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.142401",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "New deals mean nothing without a credible commercial plan which has at its heart the means to create and service product demand in a timeous and profitable manner. Nothing to date has achieved that in any meaningful volume. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-02-10T23:28:50.912182+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261801-oldbutno--3915237",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.142900",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "....come to those that wait.....Oh, and DEATH!",
          "sentiment": 0.0,
          "engagement": "3,324",
          "price_at_post": "5.90",
          "thread_title": "GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-10T23:28:50.912200+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261649-Marty130--4641274",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.143434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "To turn this around as the share price will continue to new lows..   Wake up BoD, pull your fingers out..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-02-10T23:28:50.912218+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20262041-Marty130--1240261",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.144017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix said in an update on Tuesday that it was making progress in expanding the use of KidneyIntelX.dkd across the United States, reporting growing testing volumes, new state coverage and advancing commercial partnerships ahead of its annual general meeting in London. The AIM-traded company's prognostic blood test, the only FDA-approved and Medicare-reimbursed test for early-stage chronic kidney disease risk assessment, was now generating revenue from four core states - Florida, Texas, New York and, most recently, Arizona. Executive chairman Julian Baines said the first orders in Arizona included tests from one of the largest nephrology practices in the US. He emphasised that, while direct sales growth is encouraging, the company's primary strategy is to scale test adoption through major business development agreements with large healthcare systems. Renalytix signed a definitive agreement in September with Tempus AI, the Nasdaq-listed diagnostics and AI group, which Baines said has \"an established network of healthcare institutions already utilising its precision medicine solutions.\" He added that early engagement with Tempus and MVP Health Care reinforced the company's belief that its partnership-led model would \"deliver long-term value for shareholders,\" despite lengthy implementation processes common across major US providers. Renalytix said it had also narrowed potential partners for its next electronic health record integration and was working with several large healthcare systems expected to generate \"meaningful testing volumes\" over time. The company said it was increasingly using data analytics to identify physicians managing high numbers of eligible patients, helping target commercial resources where uptake prospects are strongest. Renalytix added that it had started transitioning to a new laboratory facility, a move expected to expand testing capacity and reduce operating costs over the next five years. Baines said the company was now focused on converting ongoing discussions into contracted relationships, expanding EHR integrations and accelerating test volumes. While acknowledging that timing of commercial outcomes \"remains difficult to predict,\" he said the board was confident that the company's current initiatives \"position the company well for sustainable revenue growth, increased operating leverage, and long-term value creation for shareholders.\" Renalytix said it would provide a trading update for the six months to 31 December by the end of January.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "2026 outlook",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=30EC9492-CE10-4321-AED9-CF8B2D3F53AF"
        },
        "ingested_at": "2026-02-10T23:28:50.912236+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261342-Mikemine--6689176",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.144538",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "If Tempus gets going, the revenue will spike and so will the SP. Big companies like Tempus are notoriously slow to move but they've had since early September so H1 seems reasonable for them to get going. I urge anyone who has missed the RNS (15th Sept) about the collaboration agreement to read it and do a bit of research on Tempus. Apart from this ramp, I won't offer a prediction target but I do expect to multibag  from these levels. Good luck to everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-02-10T23:28:50.912254+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261121-Marty130-12812311",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.145043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "On receipt of the CE acceptance, which is expected h1, 18/22, on a takeover, 40/60.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-02-10T23:28:50.912272+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20260407-Cevodniy-27622927",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.145565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Ok fellow investors. Year end SP predictions. I'll start at 20p.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-02-10T23:28:50.912290+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20252147-Crannog1--1512997",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.146063",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crannog12",
          "content": "You are a ray of sunshine. I take it you are invested here?",
          "sentiment": 0.0,
          "engagement": "57",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T23:28:50.912308+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251345-Silverbl-90744344",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.146588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dreadful year for investors. Trading update in January could hammer confidence further if company fails to deliver revenue targets. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T23:28:50.912326+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20251632-MIKODX-29721418",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147014",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "It\u2019s not good watching the SP slowly slip down, but that\u2019s bound to happen with no positive news. The one consolation is the support at 5.70 is holding up well so far. Hopefully we can kick off the new year with some good news and hopefully get a good bounce from the support level all the way up past 10.",
          "sentiment": 0.0,
          "engagement": "3,977",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T23:28:50.912345+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251231-Marty130--8330831",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Hopefully we will have a better year in 2026, with more announcements of higher revenues and transformational new contracts signed. The BoD badly needs pay more attention to reverse the share price trend..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "New contracts",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8AD3616F-3B6B-486A-8B37-36DE630CD42F"
        },
        "ingested_at": "2026-02-10T23:28:50.912363+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251037-Marty130--1473770",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147873",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Cevo, And don't forget the CE mark will have a transformation affect.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T23:28:50.912381+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250828-Cevodniy-18397833",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.148323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "MIKODX on the 2nd January 2025, the SP was 10.75, yesterday it was 6p. I get your optimism via your post, but obviously institutions and wealthy investors don't agree. 10p to 6p is not exactly a successful year. I hope we don't experience another 66% next year.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T23:28:50.912399+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250037-MIKODX-10602169",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.148764",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "FY2025 was a key year for the company in establishing a solid pathway for testing adoption, life science services and strategic partnering. In July 2025, RENX announced an agreement with MVP Health Care, a U.S.-based insurer covering more than 700,000 patients. Beyond expanding physician and patient access, this agreement reinforces that Renalytix and kidneyIntelX.dkd are establishing a leadership position in chronic kidney disease management and gaining increasing recognition in the market. In September 2025, Renalytix signed an agreement with Tempus AI, Inc. (\u201cTempus\u201d), a clear leader in delivery of integrated advanced diagnostic testing and life science services in the United States. The collaboration with Tempus will enable RENX to accelerate introduction of kidneyintelX.dkd into large hospital systems and community healthcare practices across the U.S., significantly expanding distribution over the next five years. The relationship with Tempus AI has continued to develop positively, with ongoing progress in aligning commercial activities. The Balance Sheet was further improved with the conversion of an additional $4 million of convertible debt leaving outstanding long-term debt at \u00a33.1m as of October 2025. More than $1.3m in cash from backdated R&D claims and grant income, further strengthening the balance sheet. Administrative expenses decreased by more than 40% year-on-year, driven by headcount and operations optimization. RENX continue to strengthen there presence in three initial target states - Florida, Texas, and New York. In FY26, they expanded into Arizona their fourth target market which collectively represents approximately 20% of the total addressable kidneyintelX.dkd market. RENX is well positioned to deliver important and necessary change in chronic kidney disease management in the United States and globally.In the coming months and years sales will without doubt improve with the test being made more readily available in healthcare systems. Not been a bad year for the company, quite the opposite, it has been a very positive one. FY26 will see the partnerships coming to fruition with the test more widely available in the healthcare systems which will mean more sales for the company. Lots to look forward to in the coming year. I'll drink to that. Hope everyone has a merry xmas and the best of luck for the new year. With any luck we will have some good news from the parterships established, which will have a very positive affect on the SP. As we all know, this is a very volatile stock that can really take off on good news. Next year will be the year. GLA",
          "sentiment": 0.0,
          "engagement": "3,977",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T23:28:50.912417+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20252029-Cevodniy--2104183",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.149203",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, you are the only poster here generally and even you can't see anything positive,  except the possibility of a takeover I've just over 1.2 million at an average of 10p, I fo not expect to ever see profit.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T23:28:50.912435+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251332-Marty130--3535544",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.866496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Surely we'll get better results next year, if not a possible takeover.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T23:28:50.912454+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251144-Mikemine-28944036",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.866939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Merry Christmas everybody. Here's hoping for a more prosperous New year.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "5.90",
          "thread_title": "Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-10T23:28:50.912473+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251830-Marty130-63018149",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.867379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "U2..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-02-10T23:28:50.912491+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251756-tweedly--4128835",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.867802",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Right. These RNS' have been coming out for at least 6 months, no one makes sense of them so no point speculating. Merry Christmas folks",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-02-10T23:28:50.912510+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251644-Marty130-22642575",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.868233",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Down selling again.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-02-10T23:28:50.912528+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251241-Silverbl-55782682",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.868652",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "The jury is not only out Hawker....its leaving the courthouse! Its been another horror story in 2025 for the business which showed so much early promise. I have low expectations for the trading update in January - seems this is pretty common given the share price reaction. All time price low - makes the 9.5p raise a highlight from the management team - although the next raise could be very painful for shareholders if they cannot generate revenue and continue to burn cash. ATB to those who hold here - it continues to be a very difficult investment to justify. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912547+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20250931-Marty130-64973218",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "German Market is huge.. Once the CE goes through, plenty will sign up.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912565+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251427-Hawker-84509247",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Well said, SB. This is now just a waiting game, as the company has EVERYTHING they need to succeed in going to market; there are no more barriers. The only question, therefore, is whether they can sell the test into their focus regions and whether there is a market for it. So far, the jury is out. QED... Opinion:   Ho hum",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912583+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251146-JBCo--7841174",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869928",
        "source": "LSE_CHAT",
        "data": {
          "author": "JBCo",
          "content": "Hopefully can hold 6p",
          "sentiment": 0.0,
          "engagement": "4,545",
          "price_at_post": "6.25",
          "thread_title": "Big seller trying to get out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=253BEB68-92E2-41AA-91A1-E5998136B1CD"
        },
        "ingested_at": "2026-02-10T23:28:50.912602+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251751-Marty130--6174797",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.870350",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "CE marks always add value.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912620+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251623-cipro--7865579",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.870772",
        "source": "LSE_CHAT",
        "data": {
          "author": "cipro",
          "content": "The trend is slowly going down with this stock did hv good potential And I hope this still has some upside however the momentum is stuttering atm Hope to get positive news in January to get the trend back up good luck all",
          "sentiment": 0.0,
          "engagement": "2,148",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-02-10T23:28:50.912639+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251621-Dustysla-87102117",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.871231",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "I think your Gripe is the time spent here, and against the companies management. I get that, they are not the easiest investments as they are Crooks and useless. So I try to look at 3 things here at this juncture Revenue/Debt/Sales And Future Projected Revenue/Debt/Sales And how they will maintain a healthy cash burn in the intermediate.",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912657+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251616-Dustysla--5845032",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.871686",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m OTCQB listing only says $17.98 million 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). Is this financials or Sales? Im talking about Provider to Patient sales 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). This is how it explained, a Google AI version. Id get a more accurate view, but im not not interested in doing so. 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. Ok well nothing I found in 30 mins showed they had FDA approval so the assumption is their flogging nothing. But if im wrong, and it started somewhere in 2024 fine. Small details. But Debt, well yes as you said checks out. But you said NO DEBT, quite abruptly so I got a lot closer than you in 30 minutes that you seemingly in years",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912676+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251606-Silverbl--8397467",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.872134",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "OK Dustyslay - I'll bite - here we go - my 'whining' response to your 'research' based points where real world numbers are available. 1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. The point on debt looks accurate. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912700+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251540-Dustysla--3674318",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.872558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade I understand all what you are saying, 2024 wouldn't have been a great year as they hadn't gone to market and thats the Pharmsma industry for you, why I dont hold any current because I feel they are run by wealthy individuals that are focused on personal wealth before Health and will fill their boots prior to any achievements and shareholders take on the dilution and the hard hold. But im kinda leaning towards this, the more i look into it because its all about timing really.  If MVP goes solid, and your market expands 2026, you should improve dramatically As for the CE mark, achieving it your correct it wont move it, but its what you do once achieved in the European markets",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912718+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251529-Dustysla--6144090",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Ok, i know where i found the Sales and it took me a long time so here, more AI junk but the growth is there. Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months. Recent Revenue: For the first half of the fiscal year 2025 (H1 FY25), Renalytix reported revenues of $1.3 million. This demonstrated continued quarterly sales growth into Q3 FY25. Quarterly Growth: The company is on track to meet or exceed its target of 20% average quarter-over-quarter revenue growth. Billable Tests: For the first time, over 1,000 billable tests were processed in Q3 2025, supported by the onboarding of a large primary care network in New York and improved direct-to-physician sales. Medicare Coverage: The company has achieved FDA approval and Medicare coverage determination for its kidneyintelX.dkd test, with an established price of $950 per test. Partnerships: New collaborations, notably with Tempus AI and MVP Health Care, are expected to positively impact revenue and expand the test's reach among the 15 million people in the US with type 2 diabetes and chronic kidney disease. Future Guidance: Renalytix has provided forward revenue guidance of $3.2 million in FY25, $8.5 million in FY26, and $17.5 million in FY27. Despite recent sales growth, the company has faced financial challenges, including a decline in total annual revenue in FY24 compared to FY23, high operating losses, and a reliance on external financing to sustain operations. The company has focused on cost reductions and strategic partnerships to improve its financial position. 1000 \u00d7 $950 plus Medicaid Reimbursement in its first year. Now a new area in North America with MVP, 700 000 patients on books. You see where its going? Have some faith. And perhaps more research than whining on a forum",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912737+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251506-Dustysla--8141747",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873471",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Im not every fond of AI, or even Google AI. Never done ChatGBT etc so a lot is from memory on researching, the sales i will locate the information at some point as im a tad busy but Debt is easy to find, you would be hard pressed to find any company not still refurbishing debt after they have gone to market. The key is to see a constant, and consistent reduction per half year reports. Here is the AI, against my normal MO of real research: As of late 2025, Renalytix has reported approximately $8.21 million in total debt, a decrease from previous years. The company has actively worked to improve its balance sheet through debt restructuring and equity conversions. Key details regarding Renalytix's debt: Total Debt: The most recent figures from financial reports indicate total debt is approximately $8.21 million. Recent Reduction: Renalytix has focused on reducing its debt through strategic financial maneuvers. In October 2025, the company announced a $4 million balance sheet improvement by converting approximately $4 million of senior convertible bonds into equity, saving up to $1.4 million in future accrued interest. Debt Restructuring: A significant portion of the remaining debt is a new unsecured convertible bond issued in November 2024 (and later partially converted in Oct 2025), with a maturity date of July 2029. This bond has flexible interest payment options (cash or rolled into the principal) at the company's discretion. Historical Context: The company's total debt peaked in June 2022 at over $12 million and has generally trended downwards since then. Financial Position: The renegotiation of debts has helped the company move to a net current asset position, aiming to direct cash flows towards commercial and operational growth.",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912755+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251458-Dustysla-61284207",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Nasdaq has listing requirements that are difficult OTC is similar to AIM, there are 3 different markets OTCQB/OTCQX and OTC pink but we can dismiss that you are in one of the the first 2. OTC Premier is stringent but that isnt listed there. 0.01 is the minimum requirement SP And a M/Cap of 10 million minimum Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus. The split has gone quite well on early judgement,  and will help consolidate liquidity as lower the SP, the higher the percentage swings and more susceptible to traders profiting on movement. Ive seen worse splits, but they are predominantly done to secure liquidity and consolidate SP",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912774+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251446-Silverbl--4189473",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.874343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dustyslay - there are minimum bid price requirements in relation to US listing exchanges - this was one of the reasons for the new ADS split. Where did you note that sales have doubled each quarter? That is simply not the case.  You also mention debt - of which there is none. You are correct I did purchase at higher prices - but so did every single PI and II here. All have lost significant sums of money. We all saw the the medium term opportunity here - however the current management team are showing a complete lack of momentum in growing the business. Yes this is still a new company but investors continue to be fed nonsense with never ending partnerships which don't deliver; revenue predictions which don't deliver; cost cutting which doesn't materialise; pay and stock options for the team which are excessive; cash burn that fritters away funds like there was no tomorrow. My input is negative because I expect better. Yet I remain invested against my better judgement. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912793+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251434-Marty130-49013062",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.874751",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Just added hVIVO to my portfolio..  Looks undervalued, may come into it's own in 26..  A possible takeover target could see increasing share holder value.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-02-10T23:28:50.912811+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-Bushbat--8688025",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.875218",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bushbat",
          "content": "USB holding going up rather than the usual up 5% then down again",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "6.25",
          "thread_title": "USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-02-10T23:28:50.912830+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251352-Dustysla-21467538",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.875653",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Not necessarily,  the OTC doesnt have the Stringent Rules as Nasdaq surrounding Delisting. This isn't a non revenue company, Start up etc. And you shouldn't expelled wonders in entering markets in the first 12 months,  yet growth of sales has doubled each quarter. Im unsure why you see this as a bad long term investment Silverblade, I can only surmise you have bought higher and the decrease has weighed heavily on your input. Im yet to buy, as I imagined this route to profit, which takes time when reducing debt and growing in market and sales. Suppose people expect 1 year investing these days, when reality is. Takes much longer, on a gradual basis. 1 month spikes create over expectancy, and then you end up where you began, 50% down. Always better to research an investment thoroughly before entering into it. Hence what im doing",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912848+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251314-Marty130-91353839",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876066",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Presumably carried out to keep them from being expelled from the market..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912866+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251251-Silverbl--3862879",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876510",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "ADS split on OTC has now gone through - 1 UK \u00a3 share is now equivalent to 25 US $ OTC shares. Market reaction to this alongside the warnings in the AGM statement predictable. Short interest has increased significantly - this could get very messy, very quickly. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-10T23:28:50.912885+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251512-Silverbl-19185236",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "We will find out next month how much progress all the partnerships announcements are making on testing revenue. My fear is they will be nowhere near their H1 target. There are lots of institutional investors here besides UBS - they presumably are taking the gamble that eventually there will be a pick up in sales. No point in having an FDA approved product with the agreed reimbursement if there is no commercial market to sell into - and that has been the case so far. It has already been clarified by the company that CE is not of any importance to them in the short term - with a limited sales force the US market needs to show progress or it will start to become very difficult to secure additional funds imo. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-02-10T23:28:50.912903+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261042-fre1-16861912",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382464",
        "source": "LSE_CHAT",
        "data": {
          "author": "fre1",
          "content": "They are starting to build up scale (thanks for link Marty130) and their collaboration with Tempus should be gaining momentum so news next month should help.",
          "sentiment": 0.0,
          "engagement": "1,886",
          "price_at_post": "6.25",
          "thread_title": "RE: BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-02-10T23:28:50.912921+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261000-Marty130-74621260",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382903",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Need to pull their finger out ASAP..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-02-10T23:28:50.912940+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261743-Marty130--5388878",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383336",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Agreed",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-10T23:28:50.912958+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260551-Cevodniy--4679556",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, that's great news, but nothing absolutely nothing affects the share price.",
          "sentiment": 0.0,
          "engagement": "3,066",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-10T23:28:50.912977+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261120-Marty130--1823044",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384173",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://www.proactiveinvestors.com/companies/news/1085472/renalytix-expands-us-footprint-with-three-new-clinical-partnerships-1085472.html",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-10T23:28:50.912995+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261948-bluesy1--3589472",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384585",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "Like what ? Minor move upwards. Lets all get excited. Tedious ...",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.25",
          "thread_title": "RE: Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-02-10T23:28:50.913013+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261743-Mikemine--7681353",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384993",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Looks like somebody knows something maybe?",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "6.25",
          "thread_title": "Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-02-10T23:28:50.913032+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262227-Marty130-28447568",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Disagree.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-02-10T23:28:50.913050+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262055-bluesy1--8099761",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385830",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "This has all the hallmarks of a BOD lifestyle  funding company. FDA approval but would rather die in their own DNA.  Get out before its too late",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.15",
          "thread_title": "Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-02-10T23:28:50.913068+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261947-Silverbl-92104297",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386254",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Next news is likely to see share price hit all time lows - enough negative hints have been dropped recently about current trading. Statements such as \"Commercial outcomes.....remain difficult to predict\"; \"Each practice currently represents modest initial testing volumes\"; \"Engaging with large healthcare systems presents inherent challenges\" - do not fill me with short term confidence in the $8.4m 2026 revenue target - we are about to finish month 7 out of 12 in that regard. And if that revenue target is not met where does that leave the cash position? Does make you wonder what exactly the company's 11 full time sales reps are doing - door knocking physicians will not cut it here. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-02-10T23:28:50.913086+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261836-Marty130--6229394",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386660",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Looks like the SP is heading down, in order to boost volumes.. Let's hope the BoD release some juicy news to push it back up on healthy volumes.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-02-10T23:28:50.913121+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261633-Investor--2918259",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387067",
        "source": "LSE_CHAT",
        "data": {
          "author": "Investor2025",
          "content": "Not yet..",
          "sentiment": 0.0,
          "engagement": "7",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-02-10T23:28:50.913141+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261537-Hawker--4890989",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387485",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Hope springs eternal...  Ho hum...",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-10T23:28:50.913159+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261535-Marty130--8392729",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Exactly.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-10T23:28:50.913177+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261401-tweedly--6615110",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388311",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Understandably the RNS didn't set the market alight. Waiting for hard numbers I think.",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-10T23:28:50.913196+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262252-MIKODX-14705222",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388725",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Todays RNS means we are now seeing concrete progress on commercial rollout.This shows that Renalytix is moving towards actual deployment with multiple provider groups. Getting kidneyintelX.dkd into established clinics is a big step. It means providers see enough value in the test to integrate it into their day-to-day systems. The RNS reiterates that Renalytix and Tempus are working closely to integrate kidneyintelX.dkd into larger healthcare sytems that are already on Tempus's platform. This is very significant because a) smaller clinics alone won't generate high volumes and b) larger sytems (via Tempus) have broader patient populations and infrastucture. This will accelerate adoption more rapidly once it starts rolling through those network. Everything is starting to fall into place, the company is really now starting to see some real progression. Great RNS.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-10T23:28:50.913214+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262236-MIKODX-13080799",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389141",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "The company says it expects to provide a fuller trading update in February. By fuller that means they expect improvement in sales. The company is making all the right moves thus far.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T23:28:50.913232+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261111-Marty130--5198124",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Enalytix plc (RENX.LN)*, Futura Medical plc (FUM.LN) Non-Independent Research; Marketing & Sales Commentary - MiFID II exempt information \u2013 see disclaimer below. Company Update: 12 January 2026 Renalytix plc (LSE: RENX, OTCQB: RNLXY)*: Three kidneyintelX.dkd clinical integration \u2013 update on Tempus collaboration Market Capitalisation: \u00a326.6m; Share Price: 6.08p \u2022 During the last quarter of 2025, Renalytix completed three additional kidney specialist healthcare provider clinical integrations in the US, in New York, Florida and Tennessee.  \u2022 Additional integrations are expected in early 2026. \u2022 Tempus collaboration is progressing well with teams from both Tempus and Renalytix working closely to target Tempus\u2019 customers with a large diabetes and kidney disease patients.  Renalytix reports that it added three new US clinical integrations in late 2025, bringing its FDAapproved kidneyintelX.dkd test into established kidney care practices in New York, Florida, and Tennessee. Testing has begun at all sites, and although initial volumes are expected to be small, the company anticipates usage to build as clinicians become familiar with the workflow. More integrations are planned for early 2026.  Renalytix states that it is working intensively with Tempus to integrate its kidney risk testing into major US health systems through Tempus' integrated electronic health records (EHR). Since the partnership began in September 2025, teams from both companies have been coordinating to target large provider networks with significant diabetes and CKD populations, aiming to streamline test ordering and strengthen data collection. The collaboration is positioned as a foundation for expanding into new clinical and geographic markets as the platform matures.  From a strategic standpoint, this fits neatly with Renalytix\u2019s strategy to have kidneyintelX.dkd test integrates into healthcare providers\u2019 EHRs, which allows quick and seamless ordering. shift toward disciplined, system-level integrations rather than chasing individual clinics. The Tempus partnership could prove far more meaningful if it unlocks access to large, data-rich health systems where adoption can scale. SP Angel acts as Nomad and Broker to the Renalytix Futura Medical plc (AIM: FUM): Positive results from WSD4000 early feasibility study Market Capitalisation: \u00a39.1m; Share Price: 1.58p \u2022 Statistically significant improvement achieved in female sexual function with WSD4000 in a study enrolling 12 women suffering from some degree of sexual dysfunction. \u2022 Results give the Company confidence to proceed to the next steps of designing a Phase III placebo-controlled trial, with results expected mid-2026 Futura reports that its WSD4000 early feasibility study in 12 women showed a clear and statistically significant improvement in sexual function, with gains on the Female Sexual Function Index (FSFI) scale well above the accepted threshold for clinical relevance. Benefits were seen across arousal",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D3CE797F-7C15-4738-8269-38EDD6CB8090"
        },
        "ingested_at": "2026-02-10T23:28:50.913250+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260838-emblaze1--9609415",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390005",
        "source": "LSE_CHAT",
        "data": {
          "author": "emblaze1",
          "content": "LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use. The integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix. These integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations. Renalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources. Tempus AI Collaboration Renalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in September 2025, to target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients. The collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time. Investor Engagement James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. The 44th annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad rang",
          "sentiment": 0.0,
          "engagement": "917",
          "price_at_post": "6.25",
          "thread_title": "RE:Results soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=3DEB0D63-492C-4E6A-AD12-B94C142E4A0B"
        },
        "ingested_at": "2026-02-10T23:28:50.913269+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260823-Marty130-61291252",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390423",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Results deadline missed then..  As wws due before 31st of January..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T23:28:50.913287+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260809-johndean-74368502",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390835",
        "source": "LSE_CHAT",
        "data": {
          "author": "johndean",
          "content": "Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the company expects to provide further updates on progress and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "798",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T23:28:50.913305+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260807-Marty130-13648462",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391262",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Where? I haven't received one.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T23:28:50.913324+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260712-morningt-53686631",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391677",
        "source": "LSE_CHAT",
        "data": {
          "author": "mornington-oz",
          "content": "RNS  OUT",
          "sentiment": 0.0,
          "engagement": "23,507",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T23:28:50.913342+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260710-uxm484--8691883",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392089",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. Hopefully some new investors will jump on this month following the J.P Morgan event in the US, progress being made and undervalued at present.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T23:28:50.913360+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261801-Marty130--5894701",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Upcoming Financial & Corporate Events H1 2026 Trading Update: The company is scheduled to provide a trading update for the six-month period ending December 31, 2025, by the end of January 2026.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-10T23:28:50.913378+00:00"
      },
      {
        "event_id": "RNS-11th Feb 2026-h1tradin",
        "event_type": "rns_announcement",
        "date": "2026-02-11T16:55:05.656543Z",
        "source": "LSE_RNS",
        "data": {
          "title": "H1 Trading update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/RENX/h1-trading-update-53t2fwdkjxl1c00.html",
          "rns_number": "RNS Number : 4996S",
          "full_content": "Today 07:00\nRNS Number : 4996S\nRenalytix PLC\n11 February 2026\nTHE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\nH1 Trading update\nLONDON and NEW YORK, 11 February 2026\n- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product\nkidneyintelX.dkd\n, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment in chronic diabetic kidney disease, provides a trading update for the six months ended 31 December 2025 (\"H1 FY26\").\nCurrent trading\n\u00b7\nH1 FY26 unaudited revenues of $1.6m and FY26 revenue guidance of $4m to 30 June 2026 (up 33% YoY).\n\u00b7\nThree new integrations implemented in H1 FY26, compared to one in FY25, with additional integrations expected in H2 FY26.\nRevenue acceleration in H2 FY26 from recent integrations.\n\u00b7\nN\new large-scale hospital group integration, with an initial proposed 1,000 patient pilot in 2026\n, and potential to reach over 40,000 CKD patients.\nReal World Evidence Study\n\u00b7\nRenalytix is advancing an innovative real-world evidence (RWE) study designed to further validate and expand the clinical and economic utility of\nkidneyintelX.dkd\nin kidney and cardiovascular disease management. The programme is expected to generate unique outcomes data to support broader clinical adoption, payer engagement, and strengthening the strategic positioning of\nkidneyintelX.dkd\nwithin population health and value-based care frameworks.\n\u00b7\nAs part of this study,\nkidneyintelX.dkd\nis expected to be integrated into up to five additional large healthcare organisations electronic medical record (EMR) systems, which would expand automated patient identification and testing access through deployment into routine clinical workflows.\n\u00b7\nTo support the RWE study, Renalytix is also in discussion with larger strategic partners regarding potential investment and/or logistics support, reflecting external interest in the programme and its ability to drive scalable clinical and commercial impact.\nTrading update\nH1 FY26 unaudited revenues were $1.6m. Revenue ramp-up during H1 FY26 was slower than expected due to longer lead times and complexities with larger healthcare system electronic medical record system (EMR) implementations.\nAs announced on\n12 January 2026\n, three new US healthcare provider groups have now been integrated with\nEMR\ntest ordering capabilities, with an additional three integrations on boarding in the current quarter. This additional test distribution will contribute to FY26 revenues during the second half of the financial year. FY26 full year revenues are now expected to be circa $4.0m (FY25 $3.0m). The sales pipeline that is currently being onboarded will significantly expand the EMR integrated testing footprint of\nkidneyintelX.dkd\nin 2026 and provide multiple opportunities with large healthcare systems in western and eastern United States.\nThe\nCompany is in implementation planning stage for a new large-scale integration, with an initial proposed 1,000 patient pilot in 2026 at\none of the largest regional healthcare systems in the US. When fully completed, this has the potential to be one of the larger patient populations to have access to\nkidneyintelX.dkd\n, which has full reimbursement by Medicare at $950 per reportable result. Further announcements regarding the integration and pilot study will be made as soon as practicable.\nContinued progress with Tempus AI Collaboration\nRenalytix continues to make progress with Tempus AI, Inc. (\"Tempus\") to advance EMR-integrated testing and data collection with other US healthcare providers.\nA joint working group, established as part of the previously announced\ncollaboration with Tempus AI\n, is discussing the value of combining advanced AI enabled diagnostics offering in kidney disease and cardiovascular disease. Renalytix believes this represents a unique opportunity for the partnership to take a leadership position in the Cardio-Kidney-Metabolic (CKM) health initiative, which affects up to 80% of the diabetic kidney disease population1.\nFurther operational improvements and cost savings\nDuring H1 FY26, the Company activated the relocation of its laboratory operations,\nwith the new facility to become fully operational during H2 FY26.\nThis move should significantly increase testing capacity and deliver over $1m of operating cost savings over the next five years, supporting both growth and operational efficiency.\nThe Company continues to focus on and implement cost reduction initiatives and maintained a cash balance of approximately $6 million as of 31 December 2025.\nAdditional supportive data expected before financial year end\nThe Company",
          "content_length": 9257
        },
        "ingested_at": "2026-02-11T16:55:05.656586Z"
      },
      {
        "event_id": "SOCIAL-Today1611-Rellik-39031956",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.262325",
        "source": "LSE_CHAT",
        "data": {
          "author": "Rellik",
          "content": "Marti , that is a modular building co and nothing to do with this co .",
          "sentiment": 0.0,
          "engagement": "502",
          "price_at_post": "4.125",
          "thread_title": "RE: Renx USA",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=AB4E428A-AE89-45F7-9520-420199A35342"
        },
        "ingested_at": "2026-02-11T16:55:18.208458+00:00"
      },
      {
        "event_id": "SOCIAL-Today1603-Marty130--4940709",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.262879",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://www.barchart.com/stocks/quotes/RENX/overview",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "4.125",
          "thread_title": "Renx USA",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=AB4E428A-AE89-45F7-9520-420199A35342"
        },
        "ingested_at": "2026-02-11T16:55:18.208503+00:00"
      },
      {
        "event_id": "SOCIAL-Today1559-Marty130--4289546",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.263306",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renx is up in the usa.",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "4.125",
          "thread_title": "RENX usa",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=AE33B833-5EDC-424F-8202-188FA1FFAB6C"
        },
        "ingested_at": "2026-02-11T16:55:18.208553+00:00"
      },
      {
        "event_id": "SOCIAL-Today1529-MIKODX-50096544",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.263716",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Https://www.londonstockexchange.com/news-article/RENX/h1-trading-update/17455460",
          "sentiment": 0.0,
          "engagement": "4,002",
          "price_at_post": "4.125",
          "thread_title": "RE: Not a sausage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=20722DED-5CEB-4989-B058-562819DF3C60"
        },
        "ingested_at": "2026-02-11T16:55:18.208576+00:00"
      },
      {
        "event_id": "SOCIAL-Today1457-david777-78188257",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.264125",
        "source": "LSE_CHAT",
        "data": {
          "author": "david777",
          "content": "Go to  london  stock exchange and put in renx and it is shown there",
          "sentiment": 0.0,
          "engagement": "152",
          "price_at_post": "4.125",
          "thread_title": "RE: Not a sausage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=20722DED-5CEB-4989-B058-562819DF3C60"
        },
        "ingested_at": "2026-02-11T16:55:18.208594+00:00"
      },
      {
        "event_id": "SOCIAL-Today1450-Stuartrm--4281775",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.264523",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stuartrm",
          "content": "I have just looked on the Renalytix webpage under news and RNS and there is nothing.  Where has the information discussed been published?",
          "sentiment": 0.0,
          "engagement": "321",
          "price_at_post": "4.125",
          "thread_title": "Not a sausage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=20722DED-5CEB-4989-B058-562819DF3C60"
        },
        "ingested_at": "2026-02-11T16:55:18.208612+00:00"
      },
      {
        "event_id": "SOCIAL-Today1445-MIKODX-43604087",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.264922",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "It really has actually. Over 4M shares traded so far today, a lot higher than the daily average. This should start to creep back up. It was an opportunity to get the shares cheap. That boat will soon be gone.",
          "sentiment": 0.0,
          "engagement": "4,002",
          "price_at_post": "4.125",
          "thread_title": "RE: Volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=84142563-B6EC-48F3-83D9-64792B55FF43"
        },
        "ingested_at": "2026-02-11T16:55:18.208630+00:00"
      },
      {
        "event_id": "SOCIAL-Today1235-katstran--6486405",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.265334",
        "source": "LSE_CHAT",
        "data": {
          "author": "katstrangler",
          "content": "But a terrible rns for an mcap of\u00a327mill... which is why it lost 25% today.  and if they're still only talking with  Tempus then how long is it going to take to see them contribute to revenue?  i'm thinking minimum, Q3 or 4.",
          "sentiment": 0.0,
          "engagement": "10,634",
          "price_at_post": "4.125",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8D3EA9AC-BB50-488D-BFBB-CE9D6DA31304"
        },
        "ingested_at": "2026-02-11T16:55:18.208648+00:00"
      },
      {
        "event_id": "SOCIAL-Today1230-katstran-77555111",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.265735",
        "source": "LSE_CHAT",
        "data": {
          "author": "katstrangler",
          "content": "It really hasn't!  put the pom poms away... we're losing 30 - zero.",
          "sentiment": 0.0,
          "engagement": "10,634",
          "price_at_post": "4.125",
          "thread_title": "RE: Volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=84142563-B6EC-48F3-83D9-64792B55FF43"
        },
        "ingested_at": "2026-02-11T16:55:18.208665+00:00"
      },
      {
        "event_id": "SOCIAL-Today1227-Marty130-88609794",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.266139",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "One thing for sure, lowering the price has brought the buyers back..",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "4.125",
          "thread_title": "Volumes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=84142563-B6EC-48F3-83D9-64792B55FF43"
        },
        "ingested_at": "2026-02-11T16:55:18.208683+00:00"
      },
      {
        "event_id": "SOCIAL-Today1152-MIKODX-19496649",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.266537",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "4.12 with a MCAP of \u00a318M? What a ridiculous overreaction from the market. With the fundamentals this company has, and with revenue increasing year on year, the shares are badly undervalued. This is bargain basement prices. This is a great opportunity for investors at this price. I would buy some more but I've invested enough so far. Cant see it staying at these levels for long. In fact I see the reverse. If sales continue to increase we should be way past 10p in very soon. Holding firmly.",
          "sentiment": 0.0,
          "engagement": "4,002",
          "price_at_post": "4.125",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8D3EA9AC-BB50-488D-BFBB-CE9D6DA31304"
        },
        "ingested_at": "2026-02-11T16:55:18.208700+00:00"
      },
      {
        "event_id": "SOCIAL-Today1143-MIKODX-53094472",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.266933",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "After going through todays RNS, it actually isn't that bad. In fact, it's quite good. Distribution is progressing and has improved. Maybe not to the forecasted numbers but improvements all the same. Doesn't make sense why it has dipped.",
          "sentiment": 0.0,
          "engagement": "4,002",
          "price_at_post": "4.125",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8D3EA9AC-BB50-488D-BFBB-CE9D6DA31304"
        },
        "ingested_at": "2026-02-11T16:55:18.208717+00:00"
      },
      {
        "event_id": "SOCIAL-Today1141-Sandyman--5025496",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.267379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sandyman",
          "content": "What a load of insane people live in this world! For me, even a placing of 1p would be expensive!",
          "sentiment": 0.0,
          "engagement": "1,070",
          "price_at_post": "4.125",
          "thread_title": "To think the share placing was at 9.5p!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=0AC53EF0-BF58-4090-B92A-4E894C0A3A44"
        },
        "ingested_at": "2026-02-11T16:55:18.208735+00:00"
      },
      {
        "event_id": "SOCIAL-Today1124-Marty130--6719852",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.267778",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Manipulation!! Surely we'll see a bounce after the Dow opens.",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "4.125",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8D3EA9AC-BB50-488D-BFBB-CE9D6DA31304"
        },
        "ingested_at": "2026-02-11T16:55:18.208752+00:00"
      },
      {
        "event_id": "SOCIAL-Today1117-Bline59--3715490",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.268189",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bline59",
          "content": "It actually is a Very Good RNS.....Why the SP has dropped 30% is due to market manipulation. The fundamentals are great, the framework for major expansion remain in place, and the number of outlets and patients who need and are getting the treatment is increasing.  The SP fall makes no sense at all to any honest person.",
          "sentiment": 0.0,
          "engagement": "2,824",
          "price_at_post": "4.125",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8D3EA9AC-BB50-488D-BFBB-CE9D6DA31304"
        },
        "ingested_at": "2026-02-11T16:55:18.208770+00:00"
      },
      {
        "event_id": "SOCIAL-Today1116-Marty130-83942075",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.268583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Was badly handled! Perhaps the Americans may see it in better light, when they open.",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "4.125",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8D3EA9AC-BB50-488D-BFBB-CE9D6DA31304"
        },
        "ingested_at": "2026-02-11T16:55:18.208787+00:00"
      },
      {
        "event_id": "SOCIAL-Today1113-MIKODX-91801757",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.268982",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Seems like there has been an RNS today, but its not showing on this website. Not a good RNS either, no wonder the SP has fallen. https://www.proactiveinvestors.co.uk/companies/news/1087169/renalytix-shares-fall-25-as-revenues-miss-expectations-1087169.html",
          "sentiment": 0.0,
          "engagement": "4,002",
          "price_at_post": "4.125",
          "thread_title": "Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8D3EA9AC-BB50-488D-BFBB-CE9D6DA31304"
        },
        "ingested_at": "2026-02-11T16:55:18.208804+00:00"
      },
      {
        "event_id": "SOCIAL-Today1112-Silverbl--1912856",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.269389",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "8 years to get here Hawker.....not good. Honestly between this and verici :-( SB",
          "sentiment": 0.0,
          "engagement": "1,930",
          "price_at_post": "4.125",
          "thread_title": "RE: Trust",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=CC5B0E59-BB40-47BD-98F2-5DE73991F286"
        },
        "ingested_at": "2026-02-11T16:55:18.208821+00:00"
      },
      {
        "event_id": "SOCIAL-Today1111-katstran-17166336",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.269786",
        "source": "LSE_CHAT",
        "data": {
          "author": "katstrangler",
          "content": "See what happens over the next few days...",
          "sentiment": 0.0,
          "engagement": "10,634",
          "price_at_post": "4.125",
          "thread_title": "Knowing in advance the results, they must already have placing sort...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=A04AD1FE-93DF-48DE-87D3-9B4CC4DA8704"
        },
        "ingested_at": "2026-02-11T16:55:18.208839+00:00"
      },
      {
        "event_id": "SOCIAL-Today1053-Hawker-12626767",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.270198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Can\u2019t disagree with any of that, SB.  I think you\u2019re spot on. Groundhog Day continues at RENX, until something material changes.",
          "sentiment": 0.0,
          "engagement": "309",
          "price_at_post": "4.125",
          "thread_title": "RE: Trust",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=CC5B0E59-BB40-47BD-98F2-5DE73991F286"
        },
        "ingested_at": "2026-02-11T16:55:18.208856+00:00"
      },
      {
        "event_id": "SOCIAL-Today1031-Silverbl--4733049",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.270599",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Once again, Renalytix has shown a complete lack of transparency to its shareholders - including those institutions who have funded the company since 2018 with more than \u00a3200m in capital provided to a company now worth less than \u00a320m. Setting and failing targets is a simple way to erode any trust the market place has in the management team. Its an own goal. Rather than a positive (yes a very small one) saying they are looking at a 30% YOY growth, the shock at a 100% revenue downgrade has caused fear and uncertainty on the company's commercial viability. How on earth are such forecasts allowed to be made without evidence they are achievable. It was only four months ago - when they must have know Q1 was poor. II's who supported the business at 9p must be livid. SB",
          "sentiment": 0.0,
          "engagement": "1,930",
          "price_at_post": "4.375",
          "thread_title": "Trust",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=CC5B0E59-BB40-47BD-98F2-5DE73991F286"
        },
        "ingested_at": "2026-02-11T16:55:18.208874+00:00"
      },
      {
        "event_id": "SOCIAL-Today0957-UserStev-21020646",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.271007",
        "source": "LSE_CHAT",
        "data": {
          "author": "UserSteve",
          "content": "Yes, very frequent problems with this London South East platform. - Sometimes RNSs simply do not appear for all companies, as has happened today - Sometimes every RNS appears twice, as happened on 31 Dec 2025 (they *still* have not fixed this issue) - Sometimes the share prices for US stocks just stop updating, and the Intraday Share Chart displays a flat line for a long period of time",
          "sentiment": 0.0,
          "engagement": "2,605",
          "price_at_post": "4.375",
          "thread_title": "RE: Takes the biscuit",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D1204625-3BE8-462B-B8BC-421934621FE4"
        },
        "ingested_at": "2026-02-11T16:55:18.208891+00:00"
      },
      {
        "event_id": "SOCIAL-Today0956-Marty130--2095651",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.271411",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "I didn't say that, I  was reflecting on what happened during the a previous takeover bid in 2023.",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "4.375",
          "thread_title": "RE: Takes the biscuit",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D1204625-3BE8-462B-B8BC-421934621FE4"
        },
        "ingested_at": "2026-02-11T16:55:18.208908+00:00"
      },
      {
        "event_id": "SOCIAL-Today0955-Hawker-77169932",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.271815",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Renalytix has again fallen far short of its own narrative, cutting FY26 guidance from roughly USD 8.4\u20138.5m of revenue to about USD 4m, a halving that underlines the persistent execution and adoption challenges and makes the current 33% year\u2011on\u2011year growth rate deeply underwhelming for what was pitched as a high\u2011growth disruptor. However, the company is still growing from a very low base, has continued to expand EMR integrations and ordering access, and retains a potentially valuable, FDA\u2011cleared and reimbursed prognostic test in a very large diabetic kidney disease market, such that \u2013 while this has been a serial disappointment and now represents a binary\u2011ish, survival\u2011dependent option rather than a clean growth story \u2013 I remain invested on the basis that any meaningful inflection in utilisation or successful delivery on even a fraction of the longer\u2011term revenue aspirations (USD 19m in FY27, USD 42m in FY28) could still yield significant upside from today\u2019s levels if the company can fund itself and stay alive long enough to execute. DYOR & GLA.",
          "sentiment": 0.0,
          "engagement": "309",
          "price_at_post": "4.375",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.208926+00:00"
      },
      {
        "event_id": "SOCIAL-Today0955-katstran-16797151",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:09.272220",
        "source": "LSE_CHAT",
        "data": {
          "author": "katstrangler",
          "content": "Total nonsense.  barely any revenue and you think there's a 40p offer in the wings?  i suspect you're just trying to cheer yourself up!",
          "sentiment": 0.0,
          "engagement": "10,634",
          "price_at_post": "4.375",
          "thread_title": "RE: Takes the biscuit",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D1204625-3BE8-462B-B8BC-421934621FE4"
        },
        "ingested_at": "2026-02-11T16:55:18.208944+00:00"
      },
      {
        "event_id": "SOCIAL-Today0955-Marty130--2722642",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.857013",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Agreed",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "4.375",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.208962+00:00"
      },
      {
        "event_id": "SOCIAL-Today0954-katstran--7584789",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.857459",
        "source": "LSE_CHAT",
        "data": {
          "author": "katstrangler",
          "content": "What 'games' are being played?  sellers not wanting to wait another year before possible good news? 3.5million shares traded this morning, buys and sells.  fund managers are going to wait for the placing to buy as there'll be a lot more than 3.5million shares created...",
          "sentiment": 0.0,
          "engagement": "10,634",
          "price_at_post": "4.375",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.208980+00:00"
      },
      {
        "event_id": "SOCIAL-Today0954-Marty130--1157864",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.857868",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "May get an offer as has previously taken place.. SP peaked at 40p..",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "4.375",
          "thread_title": "RE: Takes the biscuit",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D1204625-3BE8-462B-B8BC-421934621FE4"
        },
        "ingested_at": "2026-02-11T16:55:18.208997+00:00"
      },
      {
        "event_id": "SOCIAL-Today0949-Mommur--8526835",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.858283",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mommur",
          "content": "Yes I am also a long suffering shareholder. I wish I had never considered RENX when it was part of the NAS investment trust holdings. Having made considerable gains elsewhere over the last 2 years I have been offsetting against CGT. I now have only 15k of losses to go before I can fully forget this share that led my heart due to its great concept that appears to be non marketable.   Perhaps a software purchase by someone sometime.",
          "sentiment": 0.0,
          "engagement": "1,297",
          "price_at_post": "4.375",
          "thread_title": "RE: Takes the biscuit",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D1204625-3BE8-462B-B8BC-421934621FE4"
        },
        "ingested_at": "2026-02-11T16:55:18.209015+00:00"
      },
      {
        "event_id": "SOCIAL-Today0947-tweedly-71988930",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.858688",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Https://www.londonstockexchange.com/news?tab=news-explorer&namecode=RENX ADVFN/LSE do seem to have a consistent issue where they don't pick up RNS'",
          "sentiment": 0.0,
          "engagement": "193",
          "price_at_post": "4.375",
          "thread_title": "RE: Takes the biscuit",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D1204625-3BE8-462B-B8BC-421934621FE4"
        },
        "ingested_at": "2026-02-11T16:55:18.209033+00:00"
      },
      {
        "event_id": "SOCIAL-Today0936-Marty130--8762115",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.859092",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Games are possibly being played, yes it worked, the share price reduced, enabling big funds to buy in at lower prices, possibly with confidence for the future.",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "4.25",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209051+00:00"
      },
      {
        "event_id": "SOCIAL-Today0931-MIKODX--6391927",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.859503",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Down into the 4s, the lowest I\u2019ve ever seen this share. That\u2019s what happens when the company stays silent and has no positive news. The delay in the trading update announcement has had a negative affect on the SP. Those results need to be announced now, otherwise this will slide further.",
          "sentiment": 0.0,
          "engagement": "4,002",
          "price_at_post": "4.25",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209068+00:00"
      },
      {
        "event_id": "SOCIAL-Today0923-unhooked--8377434",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.859899",
        "source": "LSE_CHAT",
        "data": {
          "author": "unhooked",
          "content": "I'm a long-suffering shareholder.  Clearly a poor update has been released, but I can't even read it because I can't find the damn thing in  any of the usual places.  Keep up the good work boys. Fleecers!",
          "sentiment": 0.0,
          "engagement": "3,274",
          "price_at_post": "4.25",
          "thread_title": "Takes the biscuit",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D1204625-3BE8-462B-B8BC-421934621FE4"
        },
        "ingested_at": "2026-02-11T16:55:18.209086+00:00"
      },
      {
        "event_id": "SOCIAL-Today0915-Marty130-21265319",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.860308",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "I am way down too, but find holding out works for me..  RENX have still to receive the CE mark and presumably the EU deals will follow..",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "4.10",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209121+00:00"
      },
      {
        "event_id": "SOCIAL-Today0904-MammaC--8803834",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.860715",
        "source": "LSE_CHAT",
        "data": {
          "author": "MammaC",
          "content": "Im afraid I am done here. I lost \u00a330k in Renx 2024 and managed to offset it on this years tax return against some gains elsewhere. I then bought back in several months ago in the hope the finances/revenue were improving. They clearly are not.",
          "sentiment": 0.0,
          "engagement": "743",
          "price_at_post": "4.10",
          "thread_title": "Renx",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=5B49813D-0822-4A43-8617-3012CBC24952"
        },
        "ingested_at": "2026-02-11T16:55:18.209141+00:00"
      },
      {
        "event_id": "SOCIAL-Today0850-katstran-85040481",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.861125",
        "source": "LSE_CHAT",
        "data": {
          "author": "katstrangler",
          "content": "It was less than a nothingburger.  it was just thin bread... halved expected revenue for the year... Tempus produced nothing but talk... sorry, but i seriously doubt the placing will be at a premium, just because the last placing was at 9p... the funders of the next placing will need them to see guaranteed profit... and they won't see it at a 6p raise.  they're not interested in being 'investors'... they want to sell into a spiked rns to be rid of the shares.",
          "sentiment": 0.0,
          "engagement": "10,634",
          "price_at_post": "4.00",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209159+00:00"
      },
      {
        "event_id": "SOCIAL-Today0850-oogleflu-66484540",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.861524",
        "source": "LSE_CHAT",
        "data": {
          "author": "oogleflugal",
          "content": "Doesn\u2019t actually look like this is their fault. However not informing the market sooner is",
          "sentiment": 0.0,
          "engagement": "5,483",
          "price_at_post": "4.00",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209178+00:00"
      },
      {
        "event_id": "SOCIAL-Today0841-UserStev--2183748",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.861944",
        "source": "LSE_CHAT",
        "data": {
          "author": "UserSteve",
          "content": "Silverblade, you are quite right. The 23 Sep 2025 RNS stated \"The corporate presentation includes revised forward guidance on the Company's expected revenue: $8.4m in FY26\" https://www.lse.co.uk/rns/RENX/investor-presentation-and-revised-revenue-guidance-g85fmab3dv4gyq3.html But todays RNS has slashed that guidance by more than half: \"FY26 revenue guidance of $4m\" https://www.londonstockexchange.com/news-article/RENX/h1-trading-update/17455460 Does the company give investors any explanation for this catastrophic miss?",
          "sentiment": 0.0,
          "engagement": "2,605",
          "price_at_post": "4.00",
          "thread_title": "RE: Wow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BC8C3BD0-25D4-45F1-8BFA-39FEAADCE804"
        },
        "ingested_at": "2026-02-11T16:55:18.209196+00:00"
      },
      {
        "event_id": "SOCIAL-Today0833-uxm484-66311325",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.862357",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "I doubt it would be this soon maybe at the end of the year. Plenty of institutional support so I would think 6p plus and at a premium price given the last one was well supported at 9p. Slow revenue is expected and it should start to pick up nicely. Plenty of value at these prices.",
          "sentiment": 0.0,
          "engagement": "1,014",
          "price_at_post": "4.00",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209214+00:00"
      },
      {
        "event_id": "SOCIAL-Today0831-Marty130-80390033",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.862756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "The RNS was a nothing \ud83c\udf54 burger..",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "4.00",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209232+00:00"
      },
      {
        "event_id": "SOCIAL-Today0826-katstran--1232063",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.863167",
        "source": "LSE_CHAT",
        "data": {
          "author": "katstrangler",
          "content": "Some punt buys at 4.20 but as Tempus just hasn't delivered anything yet and the revenue is adrift by \u00a34million, expecting a placing now... 4- 3.5ish...",
          "sentiment": 0.0,
          "engagement": "10,634",
          "price_at_post": "4.00",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209249+00:00"
      },
      {
        "event_id": "SOCIAL-Today0826-Marty130-49693455",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.863566",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix plc reported unaudited revenues of $1.6 million for the first half of fiscal year 2026, with full-year revenue guidance now projected at approximately $4 million, representing a 33% year-over-year increase",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "4.00",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209267+00:00"
      },
      {
        "event_id": "SOCIAL-Today0823-Marty130-32820653",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.863962",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Where's the rns?",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "3.80",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209284+00:00"
      },
      {
        "event_id": "SOCIAL-Today0821-BeardedD-14443087",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.864366",
        "source": "LSE_CHAT",
        "data": {
          "author": "BeardedDragon",
          "content": "So much for the \"Excellent RNS\"...look at the SP collapse on the news.",
          "sentiment": 0.0,
          "engagement": "4,300",
          "price_at_post": "3.80",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209302+00:00"
      },
      {
        "event_id": "SOCIAL-Today0819-katstran--6082421",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.864764",
        "source": "LSE_CHAT",
        "data": {
          "author": "katstrangler",
          "content": "Gla.",
          "sentiment": 0.0,
          "engagement": "10,634",
          "price_at_post": "3.80",
          "thread_title": "Revenue looks like going to halved this year.  placing coming...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=36B00031-7A2E-4109-B414-DB9135F40B15"
        },
        "ingested_at": "2026-02-11T16:55:18.209320+00:00"
      },
      {
        "event_id": "SOCIAL-Today0749-uxm484-62607276",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.865176",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Looking good from here. Revenues will increase and plenty of deals to come. Our base is still 9p.",
          "sentiment": 0.5,
          "engagement": "1,014",
          "price_at_post": "5.60",
          "thread_title": "RE: Wow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BC8C3BD0-25D4-45F1-8BFA-39FEAADCE804"
        },
        "ingested_at": "2026-02-11T16:55:18.209338+00:00"
      },
      {
        "event_id": "SOCIAL-Today0726-Silverbl--1300077",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.865580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Disaster. From $8.4m 2026 target to $4m, completely unacceptable. No wonder Baines bailed out. Staggering incompetency. SB",
          "sentiment": 0.0,
          "engagement": "1,930",
          "price_at_post": "5.60",
          "thread_title": "Wow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BC8C3BD0-25D4-45F1-8BFA-39FEAADCE804"
        },
        "ingested_at": "2026-02-11T16:55:18.209356+00:00"
      },
      {
        "event_id": "SOCIAL-Today0722-johndean-61006389",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.865982",
        "source": "LSE_CHAT",
        "data": {
          "author": "johndean",
          "content": "Close X Renalytix plc reported unaudited revenues of $1.6 million for the first half of fiscal year 2026, with full-year revenue guidance now projected at approximately $4 million, representing a 33% year-over-year increase. The company successfully implemented three new electronic medical record integrations in the first half, with more expected in the second half, and is planning a large-scale hospital group integration involving a 1,000-patient pilot. Renalytix is also advancing a real-world evidence study to validate and expand the utility of its kidneyintelX.dkd product, which is expected to be integrated into up to five additional healthcare organizations' EMR systems. Furthermore, the relocation of laboratory operations is anticipated to deliver over $1 million in operating cost savings over five years, while the company maintained a cash balance of approximately $6 million as of December 31, 2025.",
          "sentiment": 0.0,
          "engagement": "800",
          "price_at_post": "5.60",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209374+00:00"
      },
      {
        "event_id": "SOCIAL-Today0722-WESTCCOU-39589436",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.866392",
        "source": "LSE_CHAT",
        "data": {
          "author": "WESTCCOUNTRYBO",
          "content": "Would you post it as it\u2019s not visible here yet\u2026 thanks",
          "sentiment": 0.0,
          "engagement": "1,874",
          "price_at_post": "5.60",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209392+00:00"
      },
      {
        "event_id": "SOCIAL-Today0712-morningt-63679820",
        "event_type": "social_post",
        "date": "2026-02-11T16:55:13.866785",
        "source": "LSE_CHAT",
        "data": {
          "author": "mornington-oz",
          "content": "Excellent RNS, about time this got back to 10p +",
          "sentiment": 0.0,
          "engagement": "23,688",
          "price_at_post": "5.60",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209410+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261345-MIKODX-47960577",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.763333",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Stuartrm - Just to confirm, the American depositories have already been downgraded to the OTCQB market, so the minimum $1 doesn\u2019t apply.",
          "sentiment": 0.0,
          "engagement": "3,994",
          "price_at_post": "5.80",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209430+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261108-Marty130--1715640",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.764111",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Ignore previous post LOB.",
          "sentiment": 0.0,
          "engagement": "1,324",
          "price_at_post": "5.80",
          "thread_title": "RE: News from mover the pond.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=4BC7AB33-708C-4ECC-B3BB-CDC7404BE190"
        },
        "ingested_at": "2026-02-11T16:55:18.209449+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261105-Marty130-10794030",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.766252",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2025 RENX ENTERPRISES CORP. (Exact Name of Registrant as Specified in its Charter) Delaware\t \t001-41581\t \t87-1375590 (State or Other Jurisdiction of Incorporation)\t \t(Commission File Number)\t \t(I.R.S. Employer Identification Number) 100 Biscayne Blvd., #1201 Miami, FL 33132 (Address of Principal Executive Offices, Zip Code) Registrant\u2019s telephone number, including area code: 646-240-4235 (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: \u2610\tWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) \u2610\tSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) \u2610\tPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) \u2610\tPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class\t \tTrading Symbol(s)\t \tName of Each Exchange on Which Registered Common Stock, par value $0.001\t \tRENX\t \tThe Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (\u00a7230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (\u00a7240.12b-2 of this chapter). Emerging growth company \u2612 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \u2610 Item 1.01. Entry Into a Material Definitive Agreement. Effective December 30, 2025, Resource Group LLC (\u201cResource Group\u201d), a wholly owned subsidiary of RenX Enterprises Corp. (the \u201cCompany\u201d), entered into a Negotiable Promissory Note and Security Agreement in the principal amount of $1,507,658 (the \u201cFirst Note\u201d) and Negotiable Promissory Note and Security Agreement in the principal amount of $1,047,528 (the \u201cSecond Note\u201d; and together with the First Note, the \u201cNotes\u201d) with Commercial Credit Group (the \u201cLender\u201d) to finance the purchase of a Komptech Crambo shredder and a Diamond Z horizontal grinder for approximately $2.54 million with a 30% down payment of approximately $700,000 that had previously been deployed under a rental arrangement. The First Note is payable as follows: the first installment of $265,266 was due on 12/30/2025 followed by 48 monthly installments of $25,879. The Second Note is payable as follows: the firs",
          "sentiment": 0.0,
          "engagement": "1,324",
          "price_at_post": "5.80",
          "thread_title": "News from mover the pond.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=4BC7AB33-708C-4ECC-B3BB-CDC7404BE190"
        },
        "ingested_at": "2026-02-11T16:55:18.209468+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260758-Marty130-81530077",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.767052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Long overdue..",
          "sentiment": 0.0,
          "engagement": "1,324",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209487+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260001-MIKODX--1399477",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.767767",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "An update should drop anytime now. Hopefully  the news will be good, with more tests being churned out especiallwith the addition of the three new locations in USA.  Coupled with that we should have enough funds to see us through until at least the end of the year. I would say we will see steady progress being made and the company in a more  healthy condition financiallly. Looking forward to good news that will hopefully get the SP moving in the right direction.",
          "sentiment": 0.0,
          "engagement": "3,994",
          "price_at_post": "5.80",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209505+00:00"
      },
      {
        "event_id": "SOCIAL-7Feb20261219-Bushbat--1697805",
        "event_type": "social_post",
        "date": "2026-02-10T00:05:10.768670",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bushbat",
          "content": "The overall consensus recommendation for Renalytix is Strong Buy",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "5.80",
          "thread_title": "From Stockopedia",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=9646FDEC-1EFA-48E9-A3AF-808CB92E83EB"
        },
        "ingested_at": "2026-02-11T16:55:18.209524+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261126-uxm484-22141154",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.747673",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "Bad news already priced in by the looks of it given this has dropped from 10p but in reality the update is likely going to be positive. Should be hitting further deal news soon, Tempus update, CE Mark soon and operational update. Expecting a move back to 10p in the next 2 months so a good buy at these prices. Appears to be decent time to average down or buy in.",
          "sentiment": 0.5,
          "engagement": "1,012",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209542+00:00"
      },
      {
        "event_id": "SOCIAL-4Feb20261039-Marty130-20050314",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.748119",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "The Company looks forward to updating investors on progress, corporate development and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "1,318",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209560+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261548-Silverbl--8510279",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.748540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Renx no longer post quarterly updates. Looks like the imminent trading update is going to hit hard. All time share price low today. Market bracing itself for bad news - history just repeating itself here unfortunately. SB",
          "sentiment": 0.0,
          "engagement": "1,926",
          "price_at_post": "5.40",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209578+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261500-Stuartrm--6940098",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.748951",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stuartrm",
          "content": "Please ignore the reference to Nasdaq compliance in my last post. The information, which I got from AI, muddled Renalytix (the first two dates) with a different Renx. Sorry about that. I only realised once I started to delve further.",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "5.40",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209596+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261452-Stuartrm-57395754",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.749529",
        "source": "LSE_CHAT",
        "data": {
          "author": "Stuartrm",
          "content": "Upcoming Financial Calendar Trading Update: Expected February 2026. Quarterly Earnings Release: Scheduled for 26 March 2026 (covering the period ending December 2025). Nasdaq Compliance Deadline: 27 July 2026. Renalytix has until this date to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.",
          "sentiment": 0.0,
          "engagement": "319",
          "price_at_post": "5.40",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209615+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261330-MIKODX-18719235",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.750132",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Need some good news and soon, must be some type of update on how things are progressing with Tempus. Any good news on that front should get the SP up a few ticks.",
          "sentiment": 0.0,
          "engagement": "3,987",
          "price_at_post": "5.25",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-11T16:55:18.209632+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261244-warrior1-26224937",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.750545",
        "source": "LSE_CHAT",
        "data": {
          "author": "warrior1066",
          "content": "Not overdue, in last RNS they said February",
          "sentiment": 0.0,
          "engagement": "360",
          "price_at_post": "5.50",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209657+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261110-handybro-26248556",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.750950",
        "source": "LSE_CHAT",
        "data": {
          "author": "handybrownone",
          "content": "Agree - was just checking 27 Jan last year. Generally not a good sign, Suspect they're waiting for something good to day to help us digest some bad news",
          "sentiment": 0.0,
          "engagement": "501",
          "price_at_post": "5.75",
          "thread_title": "RE: Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209675+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20261708-Marty130-92045867",
        "event_type": "social_post",
        "date": "2026-02-06T23:35:07.751369",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Trading update is overdue..",
          "sentiment": 0.0,
          "engagement": "1,318",
          "price_at_post": "5.75",
          "thread_title": "Trading update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1688AE27-B60A-42D4-9F28-66C6BDC17A1B"
        },
        "ingested_at": "2026-02-11T16:55:18.209694+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261515-Dustysla--4819076",
        "event_type": "social_post",
        "date": "2026-01-30T23:32:44.764676",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Marty Great news, these outcomes wont be felt or showcased in SP appreciation till you start seeing the sales,  and financials from this growing customer base Cev. But its 100% positive reinforcement that its growing its clientele one state at a time,  and in this case 3 more states. A continous trend of the whole US market, state by state is the goal here. Stick with it Cev",
          "sentiment": 0.0,
          "engagement": "13,821",
          "price_at_post": "5.90",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-11T16:55:18.209712+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261516-Silverbl--5953807",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.833253",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Sounds a difficult prognosis to live with oldbut. Renx and its sister company verici were both spun out of ekf diagnostics about 5 years ago based on two unique biomarkers relating to kidney disease - renx is all about early warning and intervention through patient testing and verici focuses on pre and post kidney transplant risk monitoring (rejection).  Both company's have excellent technology and a key relationship/partnership  with Mount Sinai in New York who provide access to an extensive patient database which assists an AI driven approach to improve patient outcomes. The key issue is convincing clinicians at scale that the tests should be deployed (despite having all required regulatory approvals in place and agreed Medicare reimbursement secured). Market penetration remains slow; cash burn remains high and the market remains sceptical on the company's ability to commercialise their products - hence the low valuation here and at verici. Corporate updates expected in coming weeks. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-11T16:55:18.209731+00:00"
      },
      {
        "event_id": "SOCIAL-25Jan20262136-Marty130-64176569",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.834056",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Sorry..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-11T16:55:18.209749+00:00"
      },
      {
        "event_id": "SOCIAL-24Jan20261534-oldbutno--4779567",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:54.834852",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "...because I have Grade 4 Kidney disease. So it won't help me but caught my interest.",
          "sentiment": 0.5,
          "engagement": "3,324",
          "price_at_post": "6.25",
          "thread_title": "Bought after watching.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC9C759A-31CA-46EA-A4FB-1818AC30EDF0"
        },
        "ingested_at": "2026-02-11T16:55:18.209767+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261616-Marty130--7263819",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.138786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Purchase at 7%.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-02-11T16:55:18.209786+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261603-Pixels-60973988",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.139331",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pixels",
          "content": "How can you tell, that document shows as \"acquisition / disposal\" - is it definitely acquisition? Got to admit I struggle with reading financial type documents, I'm just a media monkey",
          "sentiment": 0.0,
          "engagement": "196",
          "price_at_post": "6.25",
          "thread_title": "RE: UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-02-11T16:55:18.209803+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261512-Marty130--6527593",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.139866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "They're back in again..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "UBS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8D546EE7-B8E8-4E60-963B-73375F769E61"
        },
        "ingested_at": "2026-02-11T16:55:18.209821+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261527-Marty130-66008833",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.140363",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "A deal may arise next week after the conference in San Francisco.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-11T16:55:18.209838+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261412-Veteran1--7005687",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.140866",
        "source": "LSE_CHAT",
        "data": {
          "author": "Veteran10",
          "content": "Bit of movement but low volume. If volumes increases, could be a momentum buy opportunity.",
          "sentiment": 0.0,
          "engagement": "4,077",
          "price_at_post": "6.25",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-11T16:55:18.209857+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261935-Marty130-86609497",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.141384",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix is expected to participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, a premier global healthcare investment symposium where companies present and connect with investors, industry leaders, and innovators, focusing on new technologies like AI in healthcare, kidney disease, and strategic partnerships. While Renalytix isn't explicitly named in the top results, they are a kidney-focused company likely to attend this major event, which runs concurrently with the Biotech Showcase.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-11T16:55:18.209875+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261839-Silverbl-20813143",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.141885",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "...well if the prognosis is kidney related oldbut i think we might be able to help out......lol. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-11T16:55:18.209893+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261837-Silverbl-77660646",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.142401",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "New deals mean nothing without a credible commercial plan which has at its heart the means to create and service product demand in a timeous and profitable manner. Nothing to date has achieved that in any meaningful volume. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-02-11T16:55:18.209910+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261801-oldbutno-37214449",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.142900",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldbutnowisa",
          "content": "....come to those that wait.....Oh, and DEATH!",
          "sentiment": 0.0,
          "engagement": "3,324",
          "price_at_post": "5.90",
          "thread_title": "GOOD things.....",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=56221F99-C44C-4F1E-AD07-DC93F77ABE11"
        },
        "ingested_at": "2026-02-11T16:55:18.209928+00:00"
      },
      {
        "event_id": "SOCIAL-6Jan20261649-Marty130-43241155",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.143434",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "To turn this around as the share price will continue to new lows..   Wake up BoD, pull your fingers out..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "Need a mega deal",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=92C35C7D-379C-4AFE-B3EF-48A99DD540AC"
        },
        "ingested_at": "2026-02-11T16:55:18.209946+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20262041-Marty130-43500994",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.144017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Renalytix said in an update on Tuesday that it was making progress in expanding the use of KidneyIntelX.dkd across the United States, reporting growing testing volumes, new state coverage and advancing commercial partnerships ahead of its annual general meeting in London. The AIM-traded company's prognostic blood test, the only FDA-approved and Medicare-reimbursed test for early-stage chronic kidney disease risk assessment, was now generating revenue from four core states - Florida, Texas, New York and, most recently, Arizona. Executive chairman Julian Baines said the first orders in Arizona included tests from one of the largest nephrology practices in the US. He emphasised that, while direct sales growth is encouraging, the company's primary strategy is to scale test adoption through major business development agreements with large healthcare systems. Renalytix signed a definitive agreement in September with Tempus AI, the Nasdaq-listed diagnostics and AI group, which Baines said has \"an established network of healthcare institutions already utilising its precision medicine solutions.\" He added that early engagement with Tempus and MVP Health Care reinforced the company's belief that its partnership-led model would \"deliver long-term value for shareholders,\" despite lengthy implementation processes common across major US providers. Renalytix said it had also narrowed potential partners for its next electronic health record integration and was working with several large healthcare systems expected to generate \"meaningful testing volumes\" over time. The company said it was increasingly using data analytics to identify physicians managing high numbers of eligible patients, helping target commercial resources where uptake prospects are strongest. Renalytix added that it had started transitioning to a new laboratory facility, a move expected to expand testing capacity and reduce operating costs over the next five years. Baines said the company was now focused on converting ongoing discussions into contracted relationships, expanding EHR integrations and accelerating test volumes. While acknowledging that timing of commercial outcomes \"remains difficult to predict,\" he said the board was confident that the company's current initiatives \"position the company well for sustainable revenue growth, increased operating leverage, and long-term value creation for shareholders.\" Renalytix said it would provide a trading update for the six months to 31 December by the end of January.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "2026 outlook",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=30EC9492-CE10-4321-AED9-CF8B2D3F53AF"
        },
        "ingested_at": "2026-02-11T16:55:18.209964+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261342-Mikemine--1539248",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.144538",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "If Tempus gets going, the revenue will spike and so will the SP. Big companies like Tempus are notoriously slow to move but they've had since early September so H1 seems reasonable for them to get going. I urge anyone who has missed the RNS (15th Sept) about the collaboration agreement to read it and do a bit of research on Tempus. Apart from this ramp, I won't offer a prediction target but I do expect to multibag  from these levels. Good luck to everybody.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-02-11T16:55:18.209982+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20261121-Marty130--3736233",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.145043",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "On receipt of the CE acceptance, which is expected h1, 18/22, on a takeover, 40/60.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-02-11T16:55:18.210000+00:00"
      },
      {
        "event_id": "SOCIAL-1Jan20260407-Cevodniy-18848217",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.145565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Ok fellow investors. Year end SP predictions. I'll start at 20p.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "Year end December 31st 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=EC904B8B-55AE-471E-B525-730DCCAEAE5E"
        },
        "ingested_at": "2026-02-11T16:55:18.210019+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20252147-Crannog1--6254885",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.146063",
        "source": "LSE_CHAT",
        "data": {
          "author": "Crannog12",
          "content": "You are a ray of sunshine. I take it you are invested here?",
          "sentiment": 0.0,
          "engagement": "57",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-11T16:55:18.210037+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251345-Silverbl--2063291",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.146588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dreadful year for investors. Trading update in January could hammer confidence further if company fails to deliver revenue targets. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-11T16:55:18.210055+00:00"
      },
      {
        "event_id": "SOCIAL-30Dec20251632-MIKODX--8859547",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147014",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "It\u2019s not good watching the SP slowly slip down, but that\u2019s bound to happen with no positive news. The one consolation is the support at 5.70 is holding up well so far. Hopefully we can kick off the new year with some good news and hopefully get a good bounce from the support level all the way up past 10.",
          "sentiment": 0.0,
          "engagement": "3,977",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-11T16:55:18.210073+00:00"
      },
      {
        "event_id": "SOCIAL-29Dec20251231-Marty130--6005747",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147452",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Hopefully we will have a better year in 2026, with more announcements of higher revenues and transformational new contracts signed. The BoD badly needs pay more attention to reverse the share price trend..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "New contracts",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=8AD3616F-3B6B-486A-8B37-36DE630CD42F"
        },
        "ingested_at": "2026-02-11T16:55:18.210091+00:00"
      },
      {
        "event_id": "SOCIAL-28Dec20251037-Marty130-87228233",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.147873",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Cevo, And don't forget the CE mark will have a transformation affect.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-11T16:55:18.210141+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250828-Cevodniy--6880680",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.148323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "MIKODX on the 2nd January 2025, the SP was 10.75, yesterday it was 6p. I get your optimism via your post, but obviously institutions and wealthy investors don't agree. 10p to 6p is not exactly a successful year. I hope we don't experience another 66% next year.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-11T16:55:18.210159+00:00"
      },
      {
        "event_id": "SOCIAL-25Dec20250037-MIKODX--5452253",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.148764",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "FY2025 was a key year for the company in establishing a solid pathway for testing adoption, life science services and strategic partnering. In July 2025, RENX announced an agreement with MVP Health Care, a U.S.-based insurer covering more than 700,000 patients. Beyond expanding physician and patient access, this agreement reinforces that Renalytix and kidneyIntelX.dkd are establishing a leadership position in chronic kidney disease management and gaining increasing recognition in the market. In September 2025, Renalytix signed an agreement with Tempus AI, Inc. (\u201cTempus\u201d), a clear leader in delivery of integrated advanced diagnostic testing and life science services in the United States. The collaboration with Tempus will enable RENX to accelerate introduction of kidneyintelX.dkd into large hospital systems and community healthcare practices across the U.S., significantly expanding distribution over the next five years. The relationship with Tempus AI has continued to develop positively, with ongoing progress in aligning commercial activities. The Balance Sheet was further improved with the conversion of an additional $4 million of convertible debt leaving outstanding long-term debt at \u00a33.1m as of October 2025. More than $1.3m in cash from backdated R&D claims and grant income, further strengthening the balance sheet. Administrative expenses decreased by more than 40% year-on-year, driven by headcount and operations optimization. RENX continue to strengthen there presence in three initial target states - Florida, Texas, and New York. In FY26, they expanded into Arizona their fourth target market which collectively represents approximately 20% of the total addressable kidneyintelX.dkd market. RENX is well positioned to deliver important and necessary change in chronic kidney disease management in the United States and globally.In the coming months and years sales will without doubt improve with the test being made more readily available in healthcare systems. Not been a bad year for the company, quite the opposite, it has been a very positive one. FY26 will see the partnerships coming to fruition with the test more widely available in the healthcare systems which will mean more sales for the company. Lots to look forward to in the coming year. I'll drink to that. Hope everyone has a merry xmas and the best of luck for the new year. With any luck we will have some good news from the parterships established, which will have a very positive affect on the SP. As we all know, this is a very volatile stock that can really take off on good news. Next year will be the year. GLA",
          "sentiment": 0.0,
          "engagement": "3,977",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-11T16:55:18.210177+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20252029-Cevodniy-16819329",
        "event_type": "social_post",
        "date": "2026-01-29T11:04:58.149203",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, you are the only poster here generally and even you can't see anything positive,  except the possibility of a takeover I've just over 1.2 million at an average of 10p, I fo not expect to ever see profit.",
          "sentiment": 0.0,
          "engagement": "3,077",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-11T16:55:18.210195+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251332-Marty130-57509305",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.866496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Surely we'll get better results next year, if not a possible takeover.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-11T16:55:18.210213+00:00"
      },
      {
        "event_id": "SOCIAL-24Dec20251144-Mikemine-23974536",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.866939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Merry Christmas everybody. Here's hoping for a more prosperous New year.",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "5.90",
          "thread_title": "Merry Christmas",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=1590BCFB-39CF-41BE-8B6A-672FEA4A8DDC"
        },
        "ingested_at": "2026-02-11T16:55:18.210231+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251830-Marty130--1188270",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.867379",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "U2..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-02-11T16:55:18.210249+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251756-tweedly--7630538",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.867802",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Right. These RNS' have been coming out for at least 6 months, no one makes sense of them so no point speculating. Merry Christmas folks",
          "sentiment": 0.0,
          "engagement": "192",
          "price_at_post": "5.90",
          "thread_title": "RE: UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-02-11T16:55:18.210267+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251644-Marty130--1883578",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.868233",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Down selling again.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "5.90",
          "thread_title": "UBS rns",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=070670C2-5541-4652-A088-9C6C957AA4E4"
        },
        "ingested_at": "2026-02-11T16:55:18.210285+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251241-Silverbl--1214353",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.868652",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "The jury is not only out Hawker....its leaving the courthouse! Its been another horror story in 2025 for the business which showed so much early promise. I have low expectations for the trading update in January - seems this is pretty common given the share price reaction. All time price low - makes the 9.5p raise a highlight from the management team - although the next raise could be very painful for shareholders if they cannot generate revenue and continue to burn cash. ATB to those who hold here - it continues to be a very difficult investment to justify. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "5.90",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210303+00:00"
      },
      {
        "event_id": "SOCIAL-21Dec20250931-Marty130-65965250",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869064",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "German Market is huge.. Once the CE goes through, plenty will sign up.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210321+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251427-Hawker-42162622",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Well said, SB. This is now just a waiting game, as the company has EVERYTHING they need to succeed in going to market; there are no more barriers. The only question, therefore, is whether they can sell the test into their focus regions and whether there is a market for it. So far, the jury is out. QED... Opinion:   Ho hum",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210339+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251146-JBCo-82371127",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.869928",
        "source": "LSE_CHAT",
        "data": {
          "author": "JBCo",
          "content": "Hopefully can hold 6p",
          "sentiment": 0.0,
          "engagement": "4,545",
          "price_at_post": "6.25",
          "thread_title": "Big seller trying to get out",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=253BEB68-92E2-41AA-91A1-E5998136B1CD"
        },
        "ingested_at": "2026-02-11T16:55:18.210358+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251751-Marty130--6828049",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.870350",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "CE marks always add value.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210375+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251623-cipro-97254447",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.870772",
        "source": "LSE_CHAT",
        "data": {
          "author": "cipro",
          "content": "The trend is slowly going down with this stock did hv good potential And I hope this still has some upside however the momentum is stuttering atm Hope to get positive news in January to get the trend back up good luck all",
          "sentiment": 0.0,
          "engagement": "2,148",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-02-11T16:55:18.210393+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251621-Dustysla--6558456",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.871231",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "I think your Gripe is the time spent here, and against the companies management. I get that, they are not the easiest investments as they are Crooks and useless. So I try to look at 3 things here at this juncture Revenue/Debt/Sales And Future Projected Revenue/Debt/Sales And how they will maintain a healthy cash burn in the intermediate.",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210412+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251616-Dustysla-35626391",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.871686",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m OTCQB listing only says $17.98 million 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). Is this financials or Sales? Im talking about Provider to Patient sales 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). This is how it explained, a Google AI version. Id get a more accurate view, but im not not interested in doing so. 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. Ok well nothing I found in 30 mins showed they had FDA approval so the assumption is their flogging nothing. But if im wrong, and it started somewhere in 2024 fine. Small details. But Debt, well yes as you said checks out. But you said NO DEBT, quite abruptly so I got a lot closer than you in 30 minutes that you seemingly in years",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210429+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251606-Silverbl-54817335",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.872134",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "OK Dustyslay - I'll bite - here we go - my 'whining' response to your 'research' based points where real world numbers are available. 1. \" Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus.\". Wrong. Renx market cap is \u00a328m; or $37.5m 2. \" Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months.\". Wrong. Q1 2025 $520K; Q2 2025 $780k; Q3 2025 $950k; Q4 2025 $750K. (Note the quarterly decline). 3. \" a decline in total annual revenue in FY24 compared to FY23\". Wrong. 2023 Revenue $2.3m. 2024 $3.0m (missed its own $3.2m guidance). 4. \" 2024 wouldn't have been a great year as they hadn't gone to market\". Wrong. See point above which clearly indicates trading in prior years. The point on debt looks accurate. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210447+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251540-Dustysla--2917258",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.872558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade I understand all what you are saying, 2024 wouldn't have been a great year as they hadn't gone to market and thats the Pharmsma industry for you, why I dont hold any current because I feel they are run by wealthy individuals that are focused on personal wealth before Health and will fill their boots prior to any achievements and shareholders take on the dilution and the hard hold. But im kinda leaning towards this, the more i look into it because its all about timing really.  If MVP goes solid, and your market expands 2026, you should improve dramatically As for the CE mark, achieving it your correct it wont move it, but its what you do once achieved in the European markets",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210465+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251529-Dustysla--1037221",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873014",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Ok, i know where i found the Sales and it took me a long time so here, more AI junk but the growth is there. Each Quarter ive seen the sales had only risen, but doubled almost 6 months to 6 months. Recent Revenue: For the first half of the fiscal year 2025 (H1 FY25), Renalytix reported revenues of $1.3 million. This demonstrated continued quarterly sales growth into Q3 FY25. Quarterly Growth: The company is on track to meet or exceed its target of 20% average quarter-over-quarter revenue growth. Billable Tests: For the first time, over 1,000 billable tests were processed in Q3 2025, supported by the onboarding of a large primary care network in New York and improved direct-to-physician sales. Medicare Coverage: The company has achieved FDA approval and Medicare coverage determination for its kidneyintelX.dkd test, with an established price of $950 per test. Partnerships: New collaborations, notably with Tempus AI and MVP Health Care, are expected to positively impact revenue and expand the test's reach among the 15 million people in the US with type 2 diabetes and chronic kidney disease. Future Guidance: Renalytix has provided forward revenue guidance of $3.2 million in FY25, $8.5 million in FY26, and $17.5 million in FY27. Despite recent sales growth, the company has faced financial challenges, including a decline in total annual revenue in FY24 compared to FY23, high operating losses, and a reliance on external financing to sustain operations. The company has focused on cost reductions and strategic partnerships to improve its financial position. 1000 \u00d7 $950 plus Medicaid Reimbursement in its first year. Now a new area in North America with MVP, 700 000 patients on books. You see where its going? Have some faith. And perhaps more research than whining on a forum",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210482+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251506-Dustysla-36004400",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873471",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Im not every fond of AI, or even Google AI. Never done ChatGBT etc so a lot is from memory on researching, the sales i will locate the information at some point as im a tad busy but Debt is easy to find, you would be hard pressed to find any company not still refurbishing debt after they have gone to market. The key is to see a constant, and consistent reduction per half year reports. Here is the AI, against my normal MO of real research: As of late 2025, Renalytix has reported approximately $8.21 million in total debt, a decrease from previous years. The company has actively worked to improve its balance sheet through debt restructuring and equity conversions. Key details regarding Renalytix's debt: Total Debt: The most recent figures from financial reports indicate total debt is approximately $8.21 million. Recent Reduction: Renalytix has focused on reducing its debt through strategic financial maneuvers. In October 2025, the company announced a $4 million balance sheet improvement by converting approximately $4 million of senior convertible bonds into equity, saving up to $1.4 million in future accrued interest. Debt Restructuring: A significant portion of the remaining debt is a new unsecured convertible bond issued in November 2024 (and later partially converted in Oct 2025), with a maturity date of July 2029. This bond has flexible interest payment options (cash or rolled into the principal) at the company's discretion. Historical Context: The company's total debt peaked in June 2022 at over $12 million and has generally trended downwards since then. Financial Position: The renegotiation of debts has helped the company move to a net current asset position, aiming to direct cash flows towards commercial and operational growth.",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210500+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251458-Dustysla-22206270",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.873917",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Silverblade Nasdaq has listing requirements that are difficult OTC is similar to AIM, there are 3 different markets OTCQB/OTCQX and OTC pink but we can dismiss that you are in one of the the first 2. OTC Premier is stringent but that isnt listed there. 0.01 is the minimum requirement SP And a M/Cap of 10 million minimum Your SP is now up 9% today at $4.05 and has an M/Cap of $17 million plus. The split has gone quite well on early judgement,  and will help consolidate liquidity as lower the SP, the higher the percentage swings and more susceptible to traders profiting on movement. Ive seen worse splits, but they are predominantly done to secure liquidity and consolidate SP",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210518+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251446-Silverbl--3771780",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.874343",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Dustyslay - there are minimum bid price requirements in relation to US listing exchanges - this was one of the reasons for the new ADS split. Where did you note that sales have doubled each quarter? That is simply not the case.  You also mention debt - of which there is none. You are correct I did purchase at higher prices - but so did every single PI and II here. All have lost significant sums of money. We all saw the the medium term opportunity here - however the current management team are showing a complete lack of momentum in growing the business. Yes this is still a new company but investors continue to be fed nonsense with never ending partnerships which don't deliver; revenue predictions which don't deliver; cost cutting which doesn't materialise; pay and stock options for the team which are excessive; cash burn that fritters away funds like there was no tomorrow. My input is negative because I expect better. Yet I remain invested against my better judgement. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210535+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251434-Marty130--5994119",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.874751",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Just added hVIVO to my portfolio..  Looks undervalued, may come into it's own in 26..  A possible takeover target could see increasing share holder value.",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-02-11T16:55:18.210553+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251407-Bushbat-16091729",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.875218",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bushbat",
          "content": "USB holding going up rather than the usual up 5% then down again",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "6.25",
          "thread_title": "USB holding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=D80DB965-E0FB-4A19-8DF3-5FCE8FF33AA3"
        },
        "ingested_at": "2026-02-11T16:55:18.210571+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251352-Dustysla--5902016",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.875653",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dustyslay",
          "content": "Not necessarily,  the OTC doesnt have the Stringent Rules as Nasdaq surrounding Delisting. This isn't a non revenue company, Start up etc. And you shouldn't expelled wonders in entering markets in the first 12 months,  yet growth of sales has doubled each quarter. Im unsure why you see this as a bad long term investment Silverblade, I can only surmise you have bought higher and the decrease has weighed heavily on your input. Im yet to buy, as I imagined this route to profit, which takes time when reducing debt and growing in market and sales. Suppose people expect 1 year investing these days, when reality is. Takes much longer, on a gradual basis. 1 month spikes create over expectancy, and then you end up where you began, 50% down. Always better to research an investment thoroughly before entering into it. Hence what im doing",
          "sentiment": 0.0,
          "engagement": "13,799",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210589+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251314-Marty130--8172555",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876066",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Presumably carried out to keep them from being expelled from the market..",
          "sentiment": 0.0,
          "engagement": "1,284",
          "price_at_post": "6.25",
          "thread_title": "RE: ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210606+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251251-Silverbl-56371645",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876510",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "ADS split on OTC has now gone through - 1 UK \u00a3 share is now equivalent to 25 US $ OTC shares. Market reaction to this alongside the warnings in the AGM statement predictable. Short interest has increased significantly - this could get very messy, very quickly. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "ADS Split",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=6CE6229A-63DB-4726-ACBE-F5B858BA3094"
        },
        "ingested_at": "2026-02-11T16:55:18.210624+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20251512-Silverbl--3731439",
        "event_type": "social_post",
        "date": "2026-01-29T11:05:01.876973",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "We will find out next month how much progress all the partnerships announcements are making on testing revenue. My fear is they will be nowhere near their H1 target. There are lots of institutional investors here besides UBS - they presumably are taking the gamble that eventually there will be a pick up in sales. No point in having an FDA approved product with the agreed reimbursement if there is no commercial market to sell into - and that has been the case so far. It has already been clarified by the company that CE is not of any importance to them in the short term - with a limited sales force the US market needs to show progress or it will start to become very difficult to secure additional funds imo. SB",
          "sentiment": 0.0,
          "engagement": "1,922",
          "price_at_post": "6.25",
          "thread_title": "RE: Their response.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&share=RENX&thread=BF9E5572-08CC-420C-AC4A-D459C051D7B1"
        },
        "ingested_at": "2026-02-11T16:55:18.210641+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261042-fre1--7965217",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382464",
        "source": "LSE_CHAT",
        "data": {
          "author": "fre1",
          "content": "They are starting to build up scale (thanks for link Marty130) and their collaboration with Tempus should be gaining momentum so news next month should help.",
          "sentiment": 0.0,
          "engagement": "1,886",
          "price_at_post": "6.25",
          "thread_title": "RE: BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-02-11T16:55:18.210659+00:00"
      },
      {
        "event_id": "SOCIAL-22Jan20261000-Marty130--1442451",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.382903",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Need to pull their finger out ASAP..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "BoD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=311400AE-9A19-4839-9524-4AF98AEDEA24"
        },
        "ingested_at": "2026-02-11T16:55:18.210677+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261743-Marty130--2722642",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383336",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Agreed",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-11T16:55:18.210695+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260551-Cevodniy-29078114",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.383750",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cevodniya",
          "content": "Marty, that's great news, but nothing absolutely nothing affects the share price.",
          "sentiment": 0.0,
          "engagement": "3,066",
          "price_at_post": "6.25",
          "thread_title": "RE: Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-11T16:55:18.210713+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20261120-Marty130--4219537",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384173",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Https://www.proactiveinvestors.com/companies/news/1085472/renalytix-expands-us-footprint-with-three-new-clinical-partnerships-1085472.html",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Announcements",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=77A47FF9-8458-4A41-B76B-142DFC1A4AC3"
        },
        "ingested_at": "2026-02-11T16:55:18.210730+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261948-bluesy1--6051709",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384585",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "Like what ? Minor move upwards. Lets all get excited. Tedious ...",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.25",
          "thread_title": "RE: Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-02-11T16:55:18.210748+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261743-Mikemine-49098791",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.384993",
        "source": "LSE_CHAT",
        "data": {
          "author": "Mikemine",
          "content": "Looks like somebody knows something maybe?",
          "sentiment": 0.0,
          "engagement": "1,234",
          "price_at_post": "6.25",
          "thread_title": "Large trade",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=1C5E6F3B-5A9B-45FF-BFCB-17F6F0169981"
        },
        "ingested_at": "2026-02-11T16:55:18.210767+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262227-Marty130-48372034",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Disagree.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-02-11T16:55:18.210784+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20262055-bluesy1--3454096",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.385830",
        "source": "LSE_CHAT",
        "data": {
          "author": "bluesy1",
          "content": "This has all the hallmarks of a BOD lifestyle  funding company. FDA approval but would rather die in their own DNA.  Get out before its too late",
          "sentiment": 0.0,
          "engagement": "130",
          "price_at_post": "6.15",
          "thread_title": "Lifestyle BODS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=2C3F1884-FB09-4809-B948-CE927E2F85FA"
        },
        "ingested_at": "2026-02-11T16:55:18.210802+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261947-Silverbl--5436818",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386254",
        "source": "LSE_CHAT",
        "data": {
          "author": "Silverblade",
          "content": "Next news is likely to see share price hit all time lows - enough negative hints have been dropped recently about current trading. Statements such as \"Commercial outcomes.....remain difficult to predict\"; \"Each practice currently represents modest initial testing volumes\"; \"Engaging with large healthcare systems presents inherent challenges\" - do not fill me with short term confidence in the $8.4m 2026 revenue target - we are about to finish month 7 out of 12 in that regard. And if that revenue target is not met where does that leave the cash position? Does make you wonder what exactly the company's 11 full time sales reps are doing - door knocking physicians will not cut it here. SB",
          "sentiment": 0.0,
          "engagement": "1,918",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-02-11T16:55:18.210820+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261836-Marty130-21589145",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.386660",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Looks like the SP is heading down, in order to boost volumes.. Let's hope the BoD release some juicy news to push it back up on healthy volumes.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.15",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-02-11T16:55:18.210837+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261633-Investor--6125326",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387067",
        "source": "LSE_CHAT",
        "data": {
          "author": "Investor2025",
          "content": "Not yet..",
          "sentiment": 0.0,
          "engagement": "7",
          "price_at_post": "6.25",
          "thread_title": "RE: This company",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=FC4E718F-5492-4FD0-BE03-1E0F7D51071E"
        },
        "ingested_at": "2026-02-11T16:55:18.210855+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261537-Hawker-14129164",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387485",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hawker",
          "content": "Hope springs eternal...  Ho hum...",
          "sentiment": 0.0,
          "engagement": "300",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-11T16:55:18.210872+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261535-Marty130-14614083",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.387895",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Exactly.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-11T16:55:18.210890+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261401-tweedly-55656044",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388311",
        "source": "LSE_CHAT",
        "data": {
          "author": "tweedly",
          "content": "Understandably the RNS didn't set the market alight. Waiting for hard numbers I think.",
          "sentiment": 0.0,
          "engagement": "191",
          "price_at_post": "6.25",
          "thread_title": "RE: Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-11T16:55:18.210908+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262252-MIKODX-91435102",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.388725",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "Todays RNS means we are now seeing concrete progress on commercial rollout.This shows that Renalytix is moving towards actual deployment with multiple provider groups. Getting kidneyintelX.dkd into established clinics is a big step. It means providers see enough value in the test to integrate it into their day-to-day systems. The RNS reiterates that Renalytix and Tempus are working closely to integrate kidneyintelX.dkd into larger healthcare sytems that are already on Tempus's platform. This is very significant because a) smaller clinics alone won't generate high volumes and b) larger sytems (via Tempus) have broader patient populations and infrastucture. This will accelerate adoption more rapidly once it starts rolling through those network. Everything is starting to fall into place, the company is really now starting to see some real progression. Great RNS.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "Todays RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=8687A37B-A54F-452F-BECE-7EC785D5C673"
        },
        "ingested_at": "2026-02-11T16:55:18.210925+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20262236-MIKODX--7857991",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389141",
        "source": "LSE_CHAT",
        "data": {
          "author": "MIKODX",
          "content": "The company says it expects to provide a fuller trading update in February. By fuller that means they expect improvement in sales. The company is making all the right moves thus far.",
          "sentiment": 0.0,
          "engagement": "3,976",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-11T16:55:18.210943+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20261111-Marty130--6696964",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.389558",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Enalytix plc (RENX.LN)*, Futura Medical plc (FUM.LN) Non-Independent Research; Marketing & Sales Commentary - MiFID II exempt information \u2013 see disclaimer below. Company Update: 12 January 2026 Renalytix plc (LSE: RENX, OTCQB: RNLXY)*: Three kidneyintelX.dkd clinical integration \u2013 update on Tempus collaboration Market Capitalisation: \u00a326.6m; Share Price: 6.08p \u2022 During the last quarter of 2025, Renalytix completed three additional kidney specialist healthcare provider clinical integrations in the US, in New York, Florida and Tennessee.  \u2022 Additional integrations are expected in early 2026. \u2022 Tempus collaboration is progressing well with teams from both Tempus and Renalytix working closely to target Tempus\u2019 customers with a large diabetes and kidney disease patients.  Renalytix reports that it added three new US clinical integrations in late 2025, bringing its FDAapproved kidneyintelX.dkd test into established kidney care practices in New York, Florida, and Tennessee. Testing has begun at all sites, and although initial volumes are expected to be small, the company anticipates usage to build as clinicians become familiar with the workflow. More integrations are planned for early 2026.  Renalytix states that it is working intensively with Tempus to integrate its kidney risk testing into major US health systems through Tempus' integrated electronic health records (EHR). Since the partnership began in September 2025, teams from both companies have been coordinating to target large provider networks with significant diabetes and CKD populations, aiming to streamline test ordering and strengthen data collection. The collaboration is positioned as a foundation for expanding into new clinical and geographic markets as the platform matures.  From a strategic standpoint, this fits neatly with Renalytix\u2019s strategy to have kidneyintelX.dkd test integrates into healthcare providers\u2019 EHRs, which allows quick and seamless ordering. shift toward disciplined, system-level integrations rather than chasing individual clinics. The Tempus partnership could prove far more meaningful if it unlocks access to large, data-rich health systems where adoption can scale. SP Angel acts as Nomad and Broker to the Renalytix Futura Medical plc (AIM: FUM): Positive results from WSD4000 early feasibility study Market Capitalisation: \u00a39.1m; Share Price: 1.58p \u2022 Statistically significant improvement achieved in female sexual function with WSD4000 in a study enrolling 12 women suffering from some degree of sexual dysfunction. \u2022 Results give the Company confidence to proceed to the next steps of designing a Phase III placebo-controlled trial, with results expected mid-2026 Futura reports that its WSD4000 early feasibility study in 12 women showed a clear and statistically significant improvement in sexual function, with gains on the Female Sexual Function Index (FSFI) scale well above the accepted threshold for clinical relevance. Benefits were seen across arousal",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=D3CE797F-7C15-4738-8269-38EDD6CB8090"
        },
        "ingested_at": "2026-02-11T16:55:18.210960+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260838-emblaze1-21481889",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390005",
        "source": "LSE_CHAT",
        "data": {
          "author": "emblaze1",
          "content": "LONDON and NEW YORK, 12 January 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that during the last quarter of 2025 it successfully completed three additional health care provider clinical integrations in the United States. Initial testing volumes have now commenced across all sites. The Company continues to expand its electronic health care integrated testing with one-click ordering for ease of physician use. The integrations were completed with Joseph P. Addabbo Family Health Center in New York, Central Florida Kidney Specialists in Florida and The Kidney Experts PLLC in Tennessee. All three sites are established regional kidney care providers and the integrations were implemented directly by Renalytix. These integrations enable the use of Renalytix's kidney disease testing solutions within each practice's existing clinical workflow. While each practice currently represents modest initial testing volumes, the Company anticipates growing utilisation over time as adoption expands across their respective patient populations. Renalytix continues to focus on disciplined expansion of its clinical footprint and expects to complete additional integrations with healthcare providers in early calendar year 2026. The Company believes this measured approach supports scalable growth in test utilisation, while maintaining efficient deployment of internal resources. Tempus AI Collaboration Renalytix continues to work closely with Tempus AI, Inc. (\"Tempus\") to advance electronic health record integrated testing and data collection with major US healthcare providers in alignment with its longer-term goal of data-driven kidney disease solutions. Personnel from Tempus and Renalytix has been working closely together since this key collaboration was announced in September 2025, to target the healthcare customers integrated with Tempus that have large, costly populations of diabetes and kidney disease patients. The collaboration with Tempus will support the development of solutions to enable future expansion into additional clinical and geographic markets over time. Investor Engagement James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. The 44th annual conference is the largest healthcare investment symposium in the industry, which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community from the USA and the wider international investment community. The conference is attended by a broad rang",
          "sentiment": 0.0,
          "engagement": "917",
          "price_at_post": "6.25",
          "thread_title": "RE:Results soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=3DEB0D63-492C-4E6A-AD12-B94C142E4A0B"
        },
        "ingested_at": "2026-02-11T16:55:18.210978+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260823-Marty130--2481631",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390423",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Results deadline missed then..  As wws due before 31st of January..",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-11T16:55:18.210995+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260809-johndean-72022595",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.390835",
        "source": "LSE_CHAT",
        "data": {
          "author": "johndean",
          "content": "Renalytix plc announced the successful completion of three new kidneyintelX.dkd clinical integrations in the United States during the last quarter of 2025, with initial testing volumes now active at these sites. The company is also advancing its collaboration with Tempus AI, Inc. to enhance electronic health record integration and data collection, aiming for future data-driven kidney disease solutions. The CEO is attending the J.P. Morgan Healthcare Conference to engage with investors, and the company expects to provide further updates on progress and trading in February 2026.",
          "sentiment": 0.0,
          "engagement": "798",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-11T16:55:18.211013+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260807-Marty130-71572507",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391262",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Where? I haven't received one.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-11T16:55:18.211030+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260712-morningt-85234861",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.391677",
        "source": "LSE_CHAT",
        "data": {
          "author": "mornington-oz",
          "content": "RNS  OUT",
          "sentiment": 0.0,
          "engagement": "23,507",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-11T16:55:18.211048+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260710-uxm484-19764073",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392089",
        "source": "LSE_CHAT",
        "data": {
          "author": "uxm484",
          "content": "James McCullough, Chief Executive Officer, is attending the J.P. Morgan Healthcare Conference in the US this week, where Renalytix will engage with existing and prospective investors and stakeholders as part of its ongoing corporate development and investor relations programmes. Hopefully some new investors will jump on this month following the J.P Morgan event in the US, progress being made and undervalued at present.",
          "sentiment": 0.0,
          "engagement": "1,009",
          "price_at_post": "6.25",
          "thread_title": "RE: Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-11T16:55:18.211066+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261801-Marty130--8314740",
        "event_type": "social_post",
        "date": "2026-01-24T02:12:07.392515",
        "source": "LSE_CHAT",
        "data": {
          "author": "Marty130",
          "content": "Upcoming Financial & Corporate Events H1 2026 Trading Update: The company is scheduled to provide a trading update for the six-month period ending December 31, 2025, by the end of January 2026.",
          "sentiment": 0.0,
          "engagement": "1,248",
          "price_at_post": "6.25",
          "thread_title": "Results soon.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=RENX&thread=09B879FD-C70F-4CCA-AE63-A05E7ABA7F09"
        },
        "ingested_at": "2026-02-11T16:55:18.211083+00:00"
      }
    ],
    "catalyst_dates": {
      "proxy_date": "2025-01-06"
    }
  },
  "ai_insights": {
    "key_insights": [],
    "hidden_patterns": [],
    "contrarian_signals": [],
    "risk_warnings": [],
    "opportunity_flags": [],
    "narrative_summary": "RENX.L presents a standard crash recovery setup without unusual patterns detected. Monitor for catalyst developments and trend shifts.",
    "_is_real": false,
    "_selected_rns": []
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Patent expiry or IP challenges"
      ],
      "relevant_rns_count": 1,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 70.5,
      "signal": "HIGH_PANIC",
      "interpretation": "\ud83d\udfe0 Fear dominant - watch for reversal signs",
      "breakdown": {
        "price_destruction": 36.5,
        "volume_death": 18,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": true,
      "opportunity_reason": "\u26a0\ufe0f HIGH PANIC + Early timing = Potential accumulation phase"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udc94 Price destruction: 36/40 points",
        "\ud83d\udcc9 Volume death: 18/20 points"
      ],
      "facts_points": [],
      "verdict": "\ud83c\udfaf CONTRARIAN OPPORTUNITY - Fear dominates but facts support recovery potential"
    },
    "crashhunter_signals": [
      {
        "type": "HIGH_PANIC",
        "icon": "\ud83d\udfe0",
        "text": "Fear 70/100",
        "color": "#f59e0b"
      },
      {
        "type": "EARLY",
        "icon": "\u23f0",
        "text": "Too Early",
        "color": "#3b82f6"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 57",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "H1 Trading update",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Three kidneyintelX.dkd Clinical Integrations",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Holding(s) in Company",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "BUY",
      "reason": "\ud83c\udfaf CrashHunter Signal: \u26a0\ufe0f HIGH PANIC + Early timing = Potential accumulation phase",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "70/100",
          "pass": true,
          "icon": "\ud83d\udd34"
        },
        {
          "criterion": "Timing Regime",
          "value": "TOO_EARLY",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "57/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "40/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "3 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "5/5"
    },
    "contrarian_panic": {
      "total_score": 63,
      "band": "\ud83d\udfe0 HIGH COMPRESSION (Top 15% - STRONG OPPORTUNITY)",
      "components": {
        "compression": {
          "score": 25,
          "max": 40,
          "signals_30d": 1,
          "signals_60d": 10,
          "signals_90d": 11,
          "signals_per_week": 0.85,
          "total_signals": 58,
          "rsi_extreme_count": 8,
          "rsi_ultra_count": 3,
          "escalation_count": 2,
          "density_score": 8,
          "rsi_score": 10,
          "escalation_score": 7,
          "description": "0.8 signals/week | 8 RSI<20 | 2 escalations | \u26a1 HIGH COMPRESSION"
        },
        "intensification": {
          "score": 20,
          "max": 20,
          "recent_types": [
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM",
            "EXTREME CRASH BOTTOM"
          ],
          "escalating": true,
          "sustained": false,
          "current_intensity": 3,
          "pattern": "ESCALATING TO EXTREME - Fear building!"
        },
        "volume_death": {
          "score": 8,
          "max": 15,
          "relative_volume": 3.11,
          "description": "High volume - Panic spike or interest"
        },
        "pop_potential": {
          "score": 10,
          "max": 15,
          "best_historical_rally": 348.0,
          "avg_rally": 83.8,
          "signal_count": 58,
          "description": "SOLID MOVER - Historical 3x+ (348%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation detected"
        }
      },
      "ticker": "RENX.L",
      "signal_date": "2024-11-28",
      "total_signals_history": 58
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +16 (AI_Technical_Score=13.0/20)",
      "Drawdown reversion potential: +18 (Drawdown_Pct=91.0%)",
      "Volume confirmation: +10 (Relative_Volume=3.1)",
      "Pattern reliability: +5 (Rally_Count=2.0)",
      "Upside history: +8 (best_rally_pct=85%)"
    ],
    "technical_score": {
      "points": 16,
      "ai_score": 13.0,
      "reason": "AI Technical Score 13.0/20 translates to 16/25 points"
    },
    "drawdown_score": {
      "points": 18,
      "drawdown_pct": 90.99,
      "reason": "Drawdown of 91.0% gives 18/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 3.11,
      "reason": "Relative volume 3.11x gives 10 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 2.0,
      "reason": "2.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 8,
      "best_rally_pct": 85.19,
      "reason": "Best rally of 85% gives 8/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=TOO_EARLY",
          "current_return_pct=-10.7%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2024-11-28"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "TOO_EARLY",
    "run_multiple": -0.13,
    "current_run_pct": -10.74,
    "avg_historical_run_pct": 85.19
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows TOO_EARLY timing with 57/100 APEX score. Historical data shows 2 rallies averaging 85% upside. Current position: -10.7%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "TOO_EARLY means you can get chopped before real move"
    ],
    "timing_translation": "It might be starting, but not proven yet. Wait for base + volume + catalysts.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  },
  "report_version": "5.0",
  "comprehensive_apex": {
    "score": 57,
    "rating": "MODERATE",
    "color": "#f59e0b",
    "calculation": "APEX Score: 57/100",
    "components": {
      "setup": {
        "score": 64,
        "weight": 0.25
      },
      "trust": {
        "score": 40,
        "weight": 0.2
      },
      "panic": {
        "score": 70.5,
        "weight": 0.3
      },
      "compression": {
        "score": 63,
        "weight": 0.25
      }
    },
    "timing": {
      "regime": "TOO_EARLY",
      "multiplier": 1.0
    }
  }
};</script>
  <script src="../../apex_trust_panel.js"></script>
</body>
</html>
